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Tras preguntas y más preguntas y miedo y nervios y ansiedad y más ansiedad 
y bloqueos y periodos depresivos y tristeza y mucha, pero mucha, mierda… 
acabas. Tarde y reventado, pero acabas. Y lo único que quieres es pasar 
página y que esto no te pase más nunca. 
¿Y? 
Pues que te surgen más preguntas y más miedo y más nervios…. Y te das 
cuenta de que vives en un puto bucle científico que se está comiendo tu vida.  
¿Y? 
No lo sé, estoy en ello. Terapia y medicación, supongo. Aunque la 
autodestrucción y los realities son muy apetecibles. 
 
 
En primer lugar, las formalidades. 
Gracias Jordi por dejarme que trabajara en la UGM. A estas alturas, creo que 
los dos nos habremos planteado muchas veces si fue una buena decisión, 
pero ya da igual. 
 
 
A continuación, el momento pasteleo, aunque si no sé dar un abrazo, no 
penséis que esto me va a salir fluido. Y menos aún, estando sobrio. Y que no 
se me enfade nadie si no he puesto su nombre o si no he escrito un parrafazo 
lacrimógeno y azucarado exaltando la belleza de nuestra relación. Si dejo que 
leas esto, significa que también eres importante para mí. 
Lo mejor de todo este tiempo sois, de calle, vosotros y vosotras:  
Bea, Carolina, Eva, Fer, LauraA, LauraG, María, Marta, Pili, Silvia, 
Vicente/Andreu y VicenteH. Mis amig@s, con l@s que he vivido, he sentido y 
he crecido…. y me he desafasao, sí, que seguro que estáis pensando en el 
dragón y/o en otros momentazos. Lo mejor de la UGM era su gente. 
 
 
Ali, Isa, Lou, Elena, Manoli, Sole, Nuria, l@s narrativ@s... y muchas más. 
Personas maravillosas que forman parte de mi vida, lo cual no es fácil. 
 
 
Y para acabar los agradecimientos: 
Les doy las gracias a mis padres y a mi hermana, porque son los tres pilares 
fundamentales de mi vida. Son mi refugio (literalmente en estos últimos 
meses). 
 
 
 
Esta tesis me la dedico a mí. Sí, a mí. Por lo malo, por los errores, por crecer, 
por saber perder, por aguantar, por terminar y por intentar aprender durante 
este largo camino tanto a nivel personal como profesional todo lo que he 
podido.  
 
 
 
Hasta aquí llega la parte suculenta, donde enseño y escondo, como siempre. 
Ahora llega la ciencia, a la que, aunque tenga mis dudas, creo que tengo algo 
que aportar, y de la que quiero vivir trabajando con dignidad. 
 
 
P.D. Negaré tener cualquier relación con este texto; tengo una fachada que 
mantener.  
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ABBREVIATIONS. 
 
 
 
   
ᴥ 5mC: 5-methylcytosine. 
ᴥ 6-OHDA: 6-hydroxidopamine. 
ᴥ AD: Alzheimer´s disease. 
ᴥ ALS: amyotrophic lateral sclerosis. 
ᴥ Syn: -synuclein. 
ᴥ CBD: corticobasal degeneration. 
ᴥ CI: confidence interval. 
ᴥ C.I.: cognitive impairment. 
ᴥ CMA: chaperone-mediated autophagy. 
ᴥ df: degrees of freedom. 
ᴥ DLB: dementia with Lewy bodies. 
ᴥ ER: endoplasmic reticulum. 
ᴥ FTD: frontotemporal dementia. 
ᴥ FTLD: frontotemporal lobar degeneration. 
ᴥ GD: Gaucher disease. 
ᴥ GWAS: genome-wide association study. 
ᴥ Hcy: homocysteine. 
ᴥ HD: Huntington´s disease. 
ᴥ HWE: Hardy-Weinberg equilibrium. 
ᴥ LB: Lewy bodies. 
ᴥ LD: linkage disequilibrium. 
ᴥ L-dopa: levodopa. 
ᴥ M.C.I.: mild cognitive impairment. 
ᴥ MPTP: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. 
ᴥ N.C.: normal cognition. 
 
 
ᴥ NE: nuclear envelope. 
ᴥ OR: odds ratio. 
ᴥ PD: Parkinson´s disease. 
ᴥ PSP: progressive supranuclear palsy. 
ᴥ ROS: reactive oxygen species. 
ᴥ SN: substantia nigra. 
ᴥ SNpc: substantia nigra pars compacta. 
ᴥ SNpr: substantia nigra pars reticulata. 
ᴥ TSS: transcription start site. 
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“…the unhappy sufferer has considered                                                                       
it has an evil, from the domination of                                                                                               
which he had no prospect of escape.” 
(James Parkinson, 1817) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In 1817, the British surgeon James Parkinson published “An essay on the 
shaking palsy” [1]. He described an unknown malady (“it has not yet obtained a 
place in the classification of nosologists”) that he observed in 6 people. The 
features of the disease (“tremor at rest, bradykinesia, tendency to fall…”) were 
so recognizable that he was sure all patients were suffering from shaking palsy, 
even when they weren´t anatomically examined and were perhaps at different 
stages of the disease. 
James Parkinson thought that, due to the parts of the body involved in 
the disease, there was a disordered state in some part of the medulla. He was 
wrong. However, almost two-hundred years after the publication of his book, 
most part of the reflections he pointed out are still useful: 
“So slight and nearly imperceptible are the first inroads of this malady, 
and so extremely slow is its progress, that it rarely happens, that the patient can 
form any recollection of the precise period of its commencement. The first 
symptoms perceived are, a slight sense of weakness, with a proneness to 
trembling in some particular part; sometimes in the head, but most commonly 
in one of the hands and arms.” 
 
There are previous descriptions in literature of a disease similar to 
shaking palsy. Nevertheless, after the studies that the French neurologist Jean-
Martin Charcot carried out between 1868 and 1881, the name shaking palsy (or 
paralysis agitans) changed to Parkinson´s disease (PD) on behalf of James 
Parkinson. 
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I.1. Definition of PD.  
Parkinson´s disease is a progressive neurodegenerative disorder  
 anatomopathologically defined by nigral degeneration and presence of 
numerous Lewy bodies1 in surviving neurons [2], 
 clinically defined by postural instability, tremor at rest, bradykinesia and 
rigidity. 
 
PD can also be called primary parkinsonism2. There are other 
parkinsonisms: 
 Secondary parkinsonism is due to environmental factors (drugs, toxins, 
head trauma, brain tumors…). 
 In parkinsonism-plus syndromes (multiple system atrophy, progressive 
supranuclear palsy, diffuse Lewy body disease3…) there is parkinsonism 
plus other motoric neurologic features. 
 In heredodegenerative disorders, parkinsonism is only one feature of a 
hereditary degenerative disorder: Alzheimer´s disease, Huntington´s 
disease, frontotemporal dementia… [3, 4]  
                                                          
1
 Lewy bodies are abnormal filamentous intracytoplasmic protein inclusions with -synuclein 
as their major component. Other components are ubiquitin, phosphorylated neurofilaments, 
molecular chaperons… 
 These deposits are the predominant lesions in PD, dementia with Lewy bodies (DLB) and 
multiple system atrophy (MSA) although they can also be present in other diseases like 
Alzheimer´s disease, prion diseases… as secondary lesions. 
2
 The term parkinsonism refers to a clinical syndrome comprising combinations of motor 
problems: postural instability, tremor at rest, bradykinesia, rigidity, flexed posture and the 
freezing phenomenon. 
3
 Diffuse Lewy body disease is also called dementia with Lewy bodies (DLB). 
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Fig. 1. Frontal section of a human brain.  
Basal ganglia are formed by five different interconnected nuclei: substantia nigra, subthalamic 
nucleus, globus pallidus, putamen and caudate nucleus. Caudate nucleus and putamen form 
the striatum (neostriatum). 
I.2. Anatomical perspective. 
Modified from [5]   
 
The substantia nigra (SN) is a large midbrain structure which can be 
divided into two different parts: the substantia nigra pars compacta (SNpc) and 
the substantia nigra pars reticulata (SNpr). 
SNpc is a densely populated area formed by neurons that contain 
dopamine and neuromelanin (this pigment gives the characteristic dark color 
to the region); whereas SNpr is a cell-sparse portion, located ventrally to the 
SNpc and formed by GABAergic neurons.  
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SN, as a component of basal ganglia, takes part in the circuits that link 
the five nuclei shown in Figure 1 to the cortex and thalamus to control 
voluntary movement execution by influencing its planning and initiation. SNpc 
and SNpr have very different connections and functions in that process. It is 
called the direct and indirect pathway model. 
 
How does it work in normal conditions (healthy people)? 
The striatum, the main input nucleus of the circuit, transmits the flow of 
information received from the cortex to the output nuclei (SNpr and internal 
globus pallidus, GPi). The transmission is mediated by two different groups of 
striatal neurons that express either the D1 dopamine receptor (direct pathway) 
or the D2 dopamine receptor (indirect pathway). In the direct pathway, 
GABAergic striatal neurons project to SNpr and GPi, whereas in the indirect 
pathway, the route is more complicated and D2-expressing neurons project to 
the external globus pallidus (GPe), which sends GABAergic projections to the 
subthalamic nucleus that, on its turn, sends its glutamatergic efferents to 
GPi/SNpr. The loop is closed via the GABAergic projections that connect the 
output nuclei to the ventral lateral and ventral anterior nuclei of the motor 
thalamus which finally sends its glutamatergic efferents to the cortex [6] 
(Figure 2). 
The striatum receives dopamine from the SNpc. This dopamine has 
opposite effects in D1 and D2-expressing neurons: 
I. INTRODUCTION.  I.2. Anatomical perspective. 
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Fig. 2. Direct and indirect pathway model in healthy people. 
Excitatory projections are depicted as thick black arrows and + symbols, and inhibitory 
projections as thin black arrows and - symbols. GPe: external globus pallidus; GPi: internal 
globus pallidus; SNc: substantia nigra pars compacta; SNr: substantia nigra pars reticulata; 
STN: subthalamic nucleus; VA/VL Thal: ventral anterior and ventrolateral nuclei of the 
thalamus; D1: dopaminergic receptor type 1; D2: dopaminergic receptor type 2; dopa: 
dopamine; glu: glutamate; GABA: gamma-aminobutyric acid. 
o striatal D1 receptors are activated by dopamine and, 
consequently, the GABAergic transmission to the output nuclei 
via the direct pathway is increased: GPi/SNpr are less active via 
the direct pathway. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Modified from [7] 
o striatal D2 receptors are inhibited by dopamine and, therefore, 
the GABAergic transmission to GPe decreases. Being less 
inhibited, GPe transmits more GABA to the subthalamic nucleus 
which is inhibited and decreases its glutamatergic transport to 
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the output nuclei: GPi/SNpr are less active via the indirect 
pathway. 
 
Both mechanisms have the same consequence, the output nuclei is less 
active and, as a consequence, there is disinhibition of the thalamus and 
activation of the cortex. That means that movement is initiated. 
 
 
What happens in PD patients? 
However, in Parkinson´s disease there is loss of dopamine-containing 
neurons in the substantia nigra pars compacta. Due to that fact, the output 
nuclei become hyperactive and such hyperactivity is sustained by the enhanced 
glutamatergic inputs that GPi/SNpr receive from the subthalamic nucleus. 
Therefore, the ventral lateral and ventral anterior nuclei of the motor thalamus 
are inhibited and, thus, motor cortex and prefrontal cortex are less active 
(Figure 3). As a result, PD patients lose their ability to control voluntary 
movements.  
 
Although the profound changes in the circuit basal ganglia-thalamus-
cortex explain the difficulty to initiate movements, the cause for the tremor 
and rigidity is less clear. 
 
I. INTRODUCTION.  I.2. Anatomical perspective. 
6 
 
 
 
 
 
 
 
 
 
 
 
 
 
Modified from [7] 
 SNpc can be subdivided into different areas, although the definition 
and terminology of these subregions vary considerably. Based on [8], [9] and 
[10],  [11] split the substantia nigra pars compacta in four main regions (Figure 
4): 
 A small pars medialis (medioventral group). 
 A small pars lateralis (nigrosome 3). 
 A large dorsal tier (nigrosomes 4 and 5 and the matrix). 
 A large ventral tier (nigrosomes 1 and 2). 
Fig. 3. Direct and indirect pathway model in a PD patient. 
Now, excitatory projections are depicted by + symbol, and inhibitory projections by - symbol.  The 
width of the arrow does not mean either excitatory or inhibitory. Increased transmissions are 
illustrated by thick blue arrows whereas decreased transmissions are illustrated by dashed blue 
arrows. GPe: external globus pallidus; GPi: internal globus pallidus; SNc: substantia nigra pars 
compacta; SNr: substantia nigra pars reticulata; STN: subthalamic nucleus; VA/VL Thal: ventral 
anterior and ventrolateral nuclei of the thalamus; D1: dopaminergic receptor type 1; D2: 
dopaminergic receptor type 2; dopa: dopamine; glu: glutamate; GABA: gamma-aminobutyric acid. 
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Taken from [8] 
 
 
The terms nigrosome and matrix are defined in [9] and [10] using 
calbindin D28K immunostaining. SNpc shows two nigral compartments: the 
matrix, which is a wide calbindin-rich region and contains the 60% of dopamine-
containing neurons, and the nigrosomes, which are small invaginated calbindin-
poor pockets embedded in the matrix, that contain the remaining 40%. 
In PD patients nigral death follows a strict order, beginning in nigrosome 
1 and spreading to nigrosomes 2, 4, 3, 5 and finally to the matrix. Depletion 
begins in the main pocket (nigrosome 1) and then goes to other nigrosomes 
and the matrix along rostral, medial and dorsal axes of progression.  
For this reason, the ventral tier (70-90% of neuronal loss) is considerably 
more affected than the dorsal tier (25-70% of neuronal loss) (Figure 5) [11]. This 
neuronal pattern of death in Parkinson´s disease is completely opposite to the 
observed in aging, where the dorsal tier is more affected than the ventral tier.  
 
 
Fig. 4. Substantia nigra tiers.          
Sagittal representation of the 
substantia nigra. PR = pars 
reticulata (dots).          vPC ventral 
tier pars compacta (black). dPC 
dorsal tier pars compacta 
(crosses). 
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Taken from [11]. 
Despite this great loss, initially, there is an increased efficiency of 
residual dopamine-containing neurons which results in an increased release of 
dopamine at the striatal level that mask PD symptoms in an early phase of the 
disease. There are no clinical signs until the percentage of nigral death is 
superior to 50% and the loss of striatal dopamine reaches the 80% [6, 8].  
 The loss of dopamine-containing neurons in SNpc is spatially driven and 
increases with the duration in PD. Nevertheless, there are other factors than 
nigral location that control neuronal survival because, after decades of 
degeneration, there still are neurons alive in the substantia nigra pars 
compacta and other basal ganglia and brain areas are affected too.  
Fig. 5. Schematic representation of the variability within the SN in the susceptibility to 
degeneration. 
Schematic representation of the position of the dorsal (SNd) and ventral (SNv) tiers of the human 
SN (left) and the variable degree of neurodegeneration in these tiers in patients with Parkinson’s 
disease (right) (cp = cerebral peduncle, IP = interpeduncular nucleus, red nucleus, exiting 3rd 
nerve fibres and periaqueductal grey are highlighted). 
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I.3. Clinical perspective. 
The four main clinical features in Parkinson´s disease are motor 
symptoms: 
 Postural instability; the loss of balance makes the individual feel 
unsteady. 
 
 Tremor, defined as involuntary movements that are rhythmic or 
fairly rhythmic, whether of large amplitude or barely visible. This 
tremor is only present at rest, i.e. it is reduced or eliminated by 
movement. It is distal and in one or more planes and it is present in 
hands, legs, tongue, lips and lightly closed eyes. 
 
 Rigidity appears throughout the full range of movement in limbs, 
trunk and neck.  
 
 Bradykinesia (slowness of movement). It encompasses difficulties 
with planning, initiating and executing movement and with 
performing sequential and simultaneous tasks. As a consequence, 
affected people show: 
 Hypomimia (reduced degree of facial expression) and 
reduced blinking. 
 Dysarthria (poorly articulated speech, with quiet and 
monotonous voices).  
 Dysphagia (difficulty in swallowing). 
 Shuffling and slow gait (reduced arm swing while walking). 
I. INTRODUCTION.  I.3. Clinical perspective. 
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 Problems to do some fine tasks like buttoning, using utensils 
or writing. In this respect, micrographia, handwriting that 
decreases in size from normal to minute, is common. 
Tremor is the most embarrassing trait for PD patients although rigidity 
and bradykinesia are more disabling. Any of these features may occur in 
isolation or in any combination and their onset can be unilateral or bilateral 
(symmetric or asymmetric) [12]. It is noteworthy that neuronal loss occurs 
contralaterally to the affected body side. 
There are other clinical signs that can also be present in PD patients. 
These signs can be divided in: 
 Secondary motor symptoms, as for example: 
 Sialorrhoea (excessive secretion of saliva). 
 Festination (involuntary tendency to increase speed of gait). 
 Freezing (sudden and transient inability to move; it is a 
common cause of fall). 
 Dystonia. 
 
 Non-motor symptoms, which can be classified into different 
categories: 
 Sleep disorders: vivid dreams where PD patients kick, grab, 
swear or punch while sleeping, daytime drowsiness, sleep 
fragmentation, REM behavior disorder… 
 Sensory abnormalities: pain, anosmia (loss of sense of smell), 
paresthesias (sensation of tingling, burning, pricking or 
I. INTRODUCTION.  I.3. Clinical perspective. 
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numbness of a person´s skin with no apparent physical 
effect)… 
 Cognitive/neurobehavioral abnormalities: cognitive 
impairment, bradyphrenia (slowness of thinking), word 
finding difficulties (tip-of-the-tongue phenomenon), 
depression, apathy, anhedonia (loss of sensation of pleasure), 
dementia, obsessive-compulsive disorders (like punding, an 
intense fascination with repetitive handling and examining of 
mechanical objects)... 
 Autonomic dysfunctions: constipation, urinary and sexual 
dysfunction, abnormal sweating, seborrhea, weight loss... [13] 
Non-motor symptoms are very common. In fact, up to 60% of patients 
suffer from more than one, and 25% have four or more. They can be due to the 
progression of the disease itself that affects other parts of the brain or to its 
treatment [14]. 
If the onset of the disease is unilateral, the initial body side commonly 
remains more affected than the later-involved side. In addition, it has been 
shown that there are also differences in the cognitive and perceptual functions 
of PD patients due to this differential beginning. The hemispheres of the brain 
are specialized in different tasks, being the right hemisphere, that controls the 
left body side, related to visuospatial function, and the left hemisphere, that 
controls the right body side, related to verbally-based actions. Therefore, PD 
patients will show different impairment on visual memory or poorer verbal 
memory performance depending on where the disease started [15].  
I. INTRODUCTION.  I.4. Diagnosis. 
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I.4. Diagnosis. 
There is no conclusive test for diagnosis in Parkinson´s disease. The only 
“definite” way to demonstrate that a person is suffering from Parkinson´s 
disease is a post-mortem analysis of the brain to determine nigral degeneration 
and Lewy body presence. 
Despite this, the presence of a combination of some typical motor 
symptoms is the common way to identify PD. Although it will not be definite, its 
accuracy will improve with time and repeated assessments. 
The diagnosis follows some steps: 
 Step 1: Diagnosis of parkinsonian syndrome. 
There is bradykinesia and at least one of the following: muscular rigidity, 
tremor at rest or postural instability not caused by primary visual, 
vestibular, cerebellar or proprioceptive dysfunction. 
 Step 2: Exclusion criteria for Parkinson´s disease. 
The presence of any of the following implies that the disease is not PD: 
history of repeated strokes with stepwise progression of parkinsonian 
features, history of repeated head injury, history of definite encephalitis, 
sustained remission, strictly unilateral features after 3 years, 
supranuclear gaze palsy, cerebellar signs, early severe autonomic 
involvement, early severe dementia, presence of a cerebral tumour, 
MPTP exposure or negative response to large doses of L-dopa (if 
malabsorption excluded). 
 Step 3: Supportive prospective positive criteria of Parkinson´s 
disease. 
I. INTRODUCTION.  I.4. Diagnosis. 
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When the patient has three or more of the following, it is more probable 
that it is suffering PD: tremor at rest, unilateral onset, progressive 
disorder, hyposmia, visual hallucination, L-dopa response for 5 years or 
more, persistent asymmetry affecting the side onset most, clinical 
course of 10 years or more [16]. 
 
Based upon the analysis of brain tissue from patients at different stages 
of the disease, [17] proposed the most suitable scheme at the present time to 
explain the onset and the evolution of symptoms in PD patients. Nevertheless, 
it might be taken into account that at least 15% of PD patients do not follow it. 
In this model, known as Braak stages, neuronal damage follows a 
predetermined sequence (Table 1, Figure 6). 
Taken from [17] 
Stage 1 
 
medulla 
oblongata 
Lesions in the dorsal IX/X motor nucleus and/or 
intermediate reticular zone and, frequently, in the anterior 
olfactory nucleus. 
Stage 2 medulla 
oblongata and 
pontine 
tegmentum 
Pathology of stage 1 plus lesions in caudal raphe nuclei, 
gigantocellular reticular nucleus, and coeruleus–
subcoeruleus complex. 
Stage 3  
 
midbrain Pathology of stage 2 plus midbrain lesions, in particular in 
the pars compacta of the substantia nigra. 
Stage 4 
 
basal 
prosencephalon 
and mesocortex 
Pathology of stage 3 plus prosencephalic lesions. Cortical 
involvement is confined to the temporal mesocortex 
(transentorhinal region) and allocortex (CA2-plexus). 
Stage 5  
 
neocortex Pathology of stage 4 plus lesions in high order sensory 
association areas of the neocortex and prefrontal 
neocortex. 
Stage 6  
 
neocortex Pathology of stage 5 plus lesions in first order sensory 
association areas of the neocortex and premotor areas, 
occasionally mild changes in primary sensory areas and the 
primary motor field. 
Table 1. Stages in the evolution of PD-related pathology. 
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Modified from [17] 
The current clinical diagnosis identifies the malady once it has evolved 
to, at least, stage 3, when there is damage in the substantia nigra and the 
motor symptoms begin. It would be very useful to identify the disease in its 
presymptomatic phase, stages 1 and 2, which is characterized by hyposmia, 
depression and sleep disorders. The identification of this silent phase is one of 
the most challenging aspects of the malady because if it could be recognized, 
there would be the possibility to administer a neuroprotective therapy to PD 
patients to delay the beginning of motor symptoms. Although there have been 
some attempts to find biomarkers4 [18], those assessed do not add relevant 
information to our knowledge of PD initiation and progression to date. It has 
also been postulated that some genes change its expression in blood in the 
                                                          
4
 Biomarker or biological marker: a characteristic that is objectively measured and evaluated 
as an indicator of normal biological processes, pathogenic processes or pharmacological 
responses to a therapeutic intervention. 
Fig. 6. Progression of PD. 
Both representations show how Parkinson´s disease evolves according to Braak stages. 
dm, dorsal motor nucleus of the glossopharyngeal and vagal nerves; co, coeruleus–subcoeruleus 
complex; sn, substantia nigra; mc, anteromedial temporal mesocortex;  hc, high order sensory 
association areas and prefrontal fields;  fc, first order sensory association areas, premotor areas, as well 
as primary sensory and motor fields. 
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early phase or Parkinson´s disease [19]. However, there is still controversy 
about the number and identity of those genes. 
  
Once the clinical diagnosis has been done, there are some rating scales 
to evaluate the motor impairment and disability in PD patients: The Hoehn and 
Yahr scale, The Unified Parkinson´s Disease Rating Scale (UPDRS), The Short 
Parkinson Evaluation Scale (SPES) and the SCales for Outcomes in PArkinson´s 
disease (SCOPA).  
Most of these scales have not been fully evaluated for validity and 
reliability. However, the Hoehn and Yahr scale is one of the most widely used 
when rating the evolution of the disease. 
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I.5. Treatment. 
Parkinson´s disease is incurable and pharmacological and non-
pharmacological treatments only improve quality of life and functional 
capacity temporarily. Treatment is symptomatic, not neuroprotective, and 
does not modify the progression of the disease. For that reason, nowadays, it is 
necessary to find new and more effective treatments without disabling adverse 
effects.  
o I.5.a. Pharmacological therapy: it is the most common option. These 
agents only improve motor symptoms. Adverse effects may be due to 
presynaptic and postsynaptic adaptations in neurotransmitter and 
receptor interactions or in neurotransmitter release or in signaling 
cascades [20]. It is noteworthy that dopamine cannot be used as a 
therapeutic agent because it does not cross the blood-brain barrier 
(Figures 7 and 8). 
 
i. Precursor of dopamine: levodopa (L-dopa). More than 40 years after 
its discovery, it still is the best option for treating PD. After 5 years of 
treatment more than 50% of patients develop adverse effects: acute 
side effects (nausea, tachycardia) and chronic side effects (obsessive-
compulsive disorders -punding, gambling, compulsive shopping, 
hypersexuality, compulsive eating and compulsive medication use- 
and motor complications -dyskinesias and motor fluctuations: wearing 
off, on-off5-) [21]. 
                                                          
5
 Dyskinesia: involuntary, purposeless, irregular but sometimes repetitive movements. 
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ii. Dopamine agonists: bromocriptine, pergolide, pramipexole, ropinirole, 
apomorphine, cabergoline. They directly stimulate dopamine 
receptors by decreasing presynaptic dopamine synthesis. They may be 
used alone to delay the need for levodopa or may be used with 
levodopa to increase their effectiveness. Complications: 
hallucinations, confusion, drowsiness, psychosis. 
iii. Peripheral decarboxylase inhibitors: carbidopa, benserazide. Mainly 
used with levodopa to increase the percentage of L-dopa that enters 
to the brain (from 5% without them to 25% when using these 
inhibitors).  
Modified from [22] 
 
iv. Dopamine releasers: amantadine. Side effects: restlessness, 
depression, confusion and hallucinations. 
                                                                                                                                                         
   Wearing off: the benefits of a levodopa dose fade off gradually and do not last until the next 
dose. 
   On-off: sudden, sometimes unpredictable, changes in PD patient´s symptoms. 
Fig. 7. Metabolism of L-dopa.  
DDC: L-dopa decarboxylase;          
COMT: catechol-O-
methyltransferase;        
3-OMD: 3-O-methyldopa;                
MAO: monoamine oxidase;                  
3,4 DFA: 3,4-
dihydrophenylacetic acid; 3 
MT: 3-methoxytramine;                 
HVA: homovanillic acid;                      
BBB: blood-brain barrier. 
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v. Catechol-O-methyltransferase (COMT) inhibitors: tolcapone, 
entacapone. Mainly used in combination with L-dopa because they 
increase its half-life. Complications: sleep disturbances, insomnia, 
confusion and dyskinesia. 
vi. MAOB inhibitors: selegiline, rasagiline. Prevent in vivo metabolism of 
dopamine, i.e. they prolong the action of dopamine at the synapse. 
They are mainly used in combination with L-dopa to enhance its 
antiparkinsonian effect thus allowing a reduction in the dose of 
levodopa.  
vii. Anticholinergics: trihexyphenidyl, benztropine. They are especially 
effective against tremor. Side effects: confusion, agitation, 
hallucinations and drowsiness [23]. 
 
 
 
 
 
 
 
 
 
Taken from [23] Fig. 8. Sites of action of pharmacological therapies. 
Effect of pharmacological therapies on dopamine 
(DA) synthesis, release, reuptake and degradation.  
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There is some controversy between neurologists about which 
pharmacological agents should be prescribed and when and how much should 
be administered. The main question in the current treatment approaches is 
finding the appropriate time to include L-dopa in the therapy because, 
although levodopa is the most effective compound to treat Parkinson´s 
disease, there are some doubts about its toxicity and adverse effects. For that 
reason, the common option at the present time, especially if patient is younger 
than 65 years old, is to start the treatment with dopamine agonists till they 
cannot control motor symptoms. At that point, L-dopa is included in the 
therapy. 
There have been some studies in the last years to clarify the relation 
between L-dopa, toxicity and dyskinesia: 
 In in vitro studies, high concentrations of levodopa cause 
degeneration of cultured dopaminergic neurons; however, there 
are neither in vivo animal models nor PD patients studies that show 
harm in neurons after L-dopa treatment [24, 25].  
o Neuronal death in in vitro studies can be explained by the 
absence of glial cells and trophic factors (always present in 
in vivo systems) that could protect cells against harmful 
effects of reactive oxygen species, ROS, originated from the 
auto-oxidation of levodopa [24].  
o The ELLDOPA study [26], one of the most important trials 
carried out in the last years to explain the effect of levodopa 
in the progression of PD disease, concluded that there was a 
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significant positive effect in the evolution of patients who 
received levodopa but neuroimaging techniques showed 
opposite results. The authors of the study proposed that 
levodopa did not increase neuronal death, but it interfered 
in marker binding. 
 
 The cause of motor complications can be related to the abnormal 
pulsatile stimulation that the dopamine receptors receive during 
treatment. In the normal brain, the striatal dopamine levels and the 
activation of the dopamine receptors on striatal neurons remain 
approximately constant along the day, but this situation changes as 
the disease progresses because there is lack of striatal dopamine 
and the quantity of dopamine depends on external levodopa. As a 
consequence, dopamine receptors are exposed to alternating high 
and low dopamine concentrations (depending on L-dopa dose) and 
it is more and more complicated to buffer uptake and release of 
dopamine to maintain its concentration stable [25]. It is also 
thought that dyskinesia is an integral part of the antiparkinsonian 
response originated by L-dopa treatment and that this pulsatile 
stimulation could originate the beginning of the motor 
complications and the reduction of the positive effects of levodopa 
(Figure 9) [27]. A continuous infusion of L-dopa is the solution, but 
this is impractical. 
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Taken from [27] 
 
o I.5.b. Non-pharmacological therapy: it includes approaches that are 
less frequently used. 
 
i. Cell therapy: in the late 80s, human fetal mesencephalic tissue 
was used for grafting in PD patients to recover the striatum. 
Although these initial trials had promising results, some patients 
showed dyskinesia and long term studies about the benefits 
should have been done. Lately, cell replacement has almost 
been blocked due to ethical problems related to the use of 
Fig. 9. Diagram illustrating how dyskinesia emerges during long-term levodopa 
therapy.  
Panels illustrate early (a), mid (b), and late (c) stages of long-term levodopa therapy. The 
lines above the panels illustrate when the antiparkinsonian response (AntiPD) and 
dyskinesia (DYS) occur during the dose cycle. 
The magnitude of the dyskinesia response progressively increases from a subtle effect in 
early treatment to a more disabling form. The threshold for dyskinesia and the 
antiparkinsonian response are identical when dyskinesia first appears and both 
progressively decrease during long-duration levodopa therapy.  
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human fetuses, political problems such as changes in legislation 
about stem cells and funding [28], and technical problems as 
human fetuses are a limited cell source (it is necessary to use at 
least 6 for a single patient), there is poor rate of  transplanted 
cell survival -5 to 10%- and there is risk of uncontrolled cellular 
development -teratomas-, so dopaminergic cells must be 
completely differentiated in vitro before the transplant [29].  To 
avoid some of these problems, current research is focused on 
finding new sources of dopaminergic neurons: embryonic stem 
cells, adult neural stem cells, iPS6 cells in other tissues (blood, 
bone marrow, skin or umbilical cord blood), foreign cells which 
produce dopamine or GDNF… [30]. 
ii. Surgery: surgical procedures are only considered for people with 
intolerable adverse side effects from medication and without 
mental disorders. It means that only about 5 to 10% of PD 
patients are good candidates. Long term studies are necessary 
to establish the longevity of the benefits, that can range from 
almost imperceptible to nearly complete. In any case, after 
surgery it is necessary to adjust the medications. There are two 
types of procedures: lesioning (irreversible destruction of 
hyperactive neurons; -otomy) or stimulation (reversible stunning 
of hyperactive neurons; DBS or deep brain stimulation). The 
parts of the brain that are subject of surgery are the thalamus 
(ventral intermediate nucleus), the internal globus pallidus and 
                                                          
6
 iPS: Induced pluripotent stem. 
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the subthalamic nucleus. There can be side effects: infections, 
brain hemorrhage, seizures and even death (Table 2, Figure 10) 
[31]. 
 
 
Modified from [31] 
iii. Therapy with trophic factors7 [32]:  GDNF is one of the most 
powerful dopaminergic neurotrophic factors. It protects 
dopaminergic cells against toxins: in animal PD models it is 
neuroprotective and neuroregenerative against MPTP in mice 
and 6-OHDA in rats. The main problem in this approach is how to 
maintain and to transport GDNF to the appropriate cell type 
                                                          
7
 Trophic factors are important proteins for the survival and function of specific cellular 
subpopulatons.  
Fig. 10. Example of DBS: Thalamic 
deep brain stimulaton. 
Table 2. Surgery selection by primary problem. 
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[33]. Nevertheless, its therapeutic effect in humans is 
controversial because some recent studies have not observed 
significant improvement in PD patients after GDNF intra-
putamenal treatment [34].  
iv. Other options in development: PD vaccine (to stimulate immune 
system against the abnormal form of Syn), gene therapy, 
controlled doses of nicotine, caffeine, coenzyme Q10,… 
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I.6. Incidence and prevalence. 
The term incidence refers to the number of new cases of patients 
diagnosed on a given period of time, usually each year, whereas the term 
prevalence refers to the estimated population of individuals who are managing 
a disease at any given time [35]. 
Incidence rates are theoretically not affected by differences in survival 
of patients and therefore better measures of the risk of disease than 
prevalence estimates [36].   
In Parkinson´s disease, both parameters increase with age and are 
influenced by ethnicity (Asian population is less affected by PD) [35, 37]. 
Nevertheless, the effect of gender is controversial: although it seems that 
men are more affected than women, results are not always significant. The 
protective effect of estrogens is still on debate [36, 38]. 
The values of incidence in PD differ in various orders depending on the 
type of study: in cohort studies [38] (Figure 11), the evolution of the 
population is followed for a period of time during which all participants are 
interviewed, screened and diagnosed by specialists, but in studies based on 
medical records [37] (Figure 12) only patients which have visited the hospital, 
have a medical record and have been diagnosed are quantified. Consequently, 
cohort studies report higher incidence values. 
 Prevalence of Parkinson´s disease is ≈ 1% at the age of 65 and 
increases to 4-5% by the age of 85: PD is the second most common 
neurodegenerative disorder (Figure 13). 
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Taken from [38]                                                                  Taken from [37] 
 
 
 
 
 
 
 
 
                  
           Modified from [36] 
 
Fig. 11. Incidence rates per 1000 person-years 
of PD by age and gender: men (□) and women 
(∆). CI95% represented by vertical lines. 
Fig. 12. Incidence rates per 100000 
person-years of PD by age and gender. 
Fig. 13. Population-based prevalence studies of Parkinson´s disease. 
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I.7. Etiology.  
At the present time, the etiology of Parkinson´s disease remains 
unknown.  
The factor or combination of factors that trigger the neurodegenerative 
process need to be elucidated yet. Environment and/or genetics have been 
postulated as those factors. However, their role has been changing for the last 
30 years. 
The specific pathological pathway is also unknown: oxidative stress8, 
mitochondrial dysfunction, protein aggregation, inflammation, altered Ca2+ 
homeostasis… are some of the processes that seem to be altered in PD 
although their specific role (cause or consequence) is not clear.  
I.7.a. Environmental factors.  
In 1983, four addict people developed severe parkinsonism just one 
week after injecting intravenously the first dose of a new “synthetic heroine” in 
northern California. This drug contained MPTP9 plus variable amounts of 
MPPP10. These people showed the typical PD symptoms (flexed posture, 
immobility, reduced blinking, drooling, cogwheel rigidity in upper limbs…) and 
good response to L-dopa plus carbidopa with subsequent development of 
severe adverse effects [39]. 
                                                          
8
 Oxidative stress can be defined as an imbalance between the production of ROS and the 
antioxidant capacity of the cell. 
9
 MPTP is commercially  available as a chemical intermediate. 
10
 MPPP: 1-methyl-4-phenyl-4-propion-oxy-piperidine. 
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MPTP freely crosses the blood-brain barrier and, once in the brain, it is 
oxidized by MAOB to MPP+11 which is the active toxin (Figure 14) that selectively 
affects dopamine-containing neurons in the SN. MPP+ enters to the cell via the 
dopamine transporter and accumulates in the mitochondria where it binds to 
complex I (NADH-dehydrogenase), blocking mitochondrial respiration: this 
energy crisis leads to a massive cell death [6]. MPP+ also translocates into 
synaptic vesicles and stimulates the release of dopamine in the cytoplasm 
where it readily undergoes autoxidation, originating a burst of oxidative stress 
due to ROS [23]. 
 
 
Taken from [4] 
    
 
This chance fact, where an exogenous substance induced a phenotype 
extremely close to that observed in Parkinson´s disease patients, potentiated 
the research on environmental factors.  
Nowadays, there is no knowledge about any other compound with the 
same properties than MPTP. Neither the cellular specificity nor the similar 
phenotype and response to treatment have been found for any other 
substance. 
                                                          
11
 MPP+: 1-methyl-4-phenylpyridinium. 
Fig. 14. MPTP (left) and MPP+ (right) structures. 
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 Pesticides have been widely studied because their chemical structure is 
similar to MPTP and because it is known that acute exposures to them 
originate neurological dysfunction. However, the consequences of chronic and 
moderate exposures are less clear: changes in mood, sleeping, movement, 
cognition and other aspects have been investigated and the overall conclusion 
is that the earliest or most general response to pesticide neurotoxicity is a 
general malaise lacking in specificity and related to mild cognitive dysfunction 
[40]. With respect to PD, it is considered that pesticides increase risk of 
developing the disease, especially the herbicide paraquat and the insecticide 
rotenone12 [41]. Due to the important methodological differences between 
studies with respect to the size of the groups, the doses considered and the 
type of exposition, there are discrepancies about the size of this risk. 
Plenty of products (metals, medicines, food…) and habits (physical 
exercise, jobs, stress…), even other diseases (diabetes, anemia, depression…), 
have also been studied but the most consistent and significant results are for 
[42]: 
 Uric acid is a natural antioxidant that may reduce oxidative 
stress and, consequently, reduce the risk of developing PD and 
slow its progression. There are strong evidences that serum 
urate is a protective factor [43] [44]. 
 Coffee and tobacco can also be considered neuroprotective 
factors because caffeine is an antagonist of A2A receptors and 
                                                          
12
 Rotenone and paraquat, like MPTP, are inhibitors of complex I in mitochondria.  
Rotenone, MPTP and 6-OHDA are used to reproduce PD phenotype in animal models and 
cellular cultures. 
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nicotine inhibits the formation of Syn deposits, improves PD 
symptoms and stimulates dopamine-containing neurons. 
 
 
At present, although plenty of studies and effort have been done trying 
to find some environmental factor which could cause Parkinson´s disease, 
there is no definite candidate, just some potential neuroprotective or toxic 
compounds. That is why the contribution of environment to the development 
of the disease is still controversial [45]. 
 
I.7.b. Genetic factors. 
To address the heritability of the disease, epidemiological, case-control 
and twin studies have been conducted. These studies support that there is a 
genetic contribution to the development of PD, although the strength of 
familial aggregation remains uncertain because there is clear familial clustering 
only in a minority of cases. 
Monozygotic twins (MZ) have the same genome and, therefore, both 
will have the same phenotype in pure genetic diseases. Calculating the genetic 
contribution of a disease should be possible by comparing the concordance 
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rate13 in MZ versus the concordance rate in other siblings, usually dizygotic 
twins (DZ). 
  
For Parkinson´s disease, which is a multifactorial malady, results have 
been controversial: [46] showed that incidence rates of PD were not 
significantly different in MZ and DZ pairs, thus ruling out the genetic role in 
Parkinson´s disease. However, when considering age at onset, there was a 
significant result for those pairs with onset before 50 years that pointed out 
to a genetic effect. This study was based on clinical diagnosis. It was cross-
sectional, without follow-up and only considered white North-American men. 
Nevertheless, [47] analyzed the dopaminergic function of twin pairs that were 
clinically discordant for PD and observed that the concordance for striatal 
dysfunction was significantly higher in MZ pairs than in DZ pairs. Moreover, 
after a follow-up, this concordance was even higher pointing out to a role for 
inheritance in sporadic PD. Recently, another twin study [48], cross-sectional 
but also longitudinal, with Swedish men and women, found a modest but 
significant genetic effect for same-sex couples. 
The disparity in results observed could be due to the fact that in PD 
there is a long preclinical phase and that may distort the concordance rate 
observed in cross-sectional studies. 
                                                          
13
 The concordance rate is a quantitative statistical expression for the concordance of a given 
genetic trait, especially in pairs of twins in genetic studies. It is the proportion of pairs where 
both individuals share a certain characteristic. 
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In a meta-analysis of different studies about familial aggregation in PD, 
it was shown that there was an increased relative risk for first-degree relatives, 
ranging from 2.7 for child-parent pairs to 4.9 for sibling pairs [49]. Although it 
was complicated to compare the studies due to the different methodological 
methods used (different familial relationships, diagnostic procedures and 
follow-up), the tendency showed that heritability is present in PD. 
 
 
Nowadays, ≈10% of Parkinson´s disease is familial [50], i.e. monogenic 
forms of the disease. It is due to mutations in 5 genes: SNCA, PRKN, PINK1, DJ-1 
and LRRK2. Maybe, the traces of heritability found in the previously referred 
articles reflect the contribution of these or other genes to the malady.  
The remaining 90% of PD patients suffer from idiopathic or sporadic 
forms of PD14. Are those PD cases exposed to unknown environmental factors? 
Are there other genetic factors which have not been discovered yet? 
Nowadays, the majority opinion is that Parkinson´s disease will develop in 
those people because they have a specific genetic background which enhances 
their susceptibility to some environmental factors. When the external 
influences are present, the combination triggers the development of PD.  
                                                          
14
 Juvenile Parkinson´s disease (age at onset < 20 years) and early onset PD (20-50 years) are 
more common in familial forms of PD whereas idiopathic Parkinson´s disease usually develops 
lately (late onset > 50 years).  
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I.8. Familial PD. 
So far, five genes are responsible for the familial forms of PD: 
 
 I.8.a. SNCA (PARK1, PARK4): 4q22.1 
The SNCA gene has 6 exons and codifies for a protein, -synuclein 
orSyn, with 140 amino acids.   
 Protein structure: the N-terminal domain includes six 11-amino acid 
imperfect repeats with a highly conservative motif (KTKEGV); the 
middle region is hydrophobic and contains the non-amyloid 
component (NAC)15 which is supposed to give the protein its 
proneness to aggregate; and the C-terminal domain is acidic and 
includes residues that are post-translationally modified like 129S, 
whose phosphorylation increases propensity to fibrillize, and 125Y, 
whose phosphorylation prevents fibrillation (Figure 15) [51]. 
 
 
 
 
Modified from [51] 
The mutants are more prone to form aggregates, especially p.A53T 
which forms aggregates more readily than p.A30P [52]. Nevertheless, 
                                                          
15
 The reason why this name for the central domain is because Syn was first found in brain 
amyloid plaques, where it is the second major component, in AD patients. 
Fig. 15. SNCA structure.  
On the left, the three pathogenic missense mutations that have been described. 
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the protein, even when mutated, is natively unfolded, i.e. it has no 
secondary structure under physiological conditions. Despite this, and 
due to a reason that still remains unknown, Syn might change its 
unfolded structure and organize into more complex formations: in 
vitro it forms fibrils of highly organized secondary structure under 
low pH conditions or high temperature. In addition, environmental 
factors, metals and pesticides (like paraquat), can induce aggregation 
[53]. The proposed mechanism (Figure 16) supposes that different 
physiological factors, such as oxidative stress and exposition to 
pesticides, or non-physiological factors, such as low pH and high 
temperature, increase the proportion of a partially folded 
intermediate and, depending on how the conditions evolve, the 
intermediate unfolds or forms highly organized structures [54]. 
 
 
 
  
Taken 
 from 
 [54] 
 
 
 
 
 
                                             
 
Fig. 16. Model for -synuclein fibrillation.  
Oligomerization of the intermediate leads either to fibrils via a critical nucleus or to 
soluble oligomers, resulting in amorphous aggregates. Additional conformational 
changes occur between the aggregation-competent intermediate and the fibrils. 
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Moreover, in vitro, Syn can fold into other different complex 
structures (Figure 17). 
 
Taken from [53] 
 Tissue expression: -synuclein is expressed almost 
ubiquitously in human body, although its highest 
expression is in brain where it is present in 
presynaptic nerve terminals [55].  
Furthermore, Syn is the main component of 
Lewy bodies [56]: in PD, LB  are present in 
surviving neurons in SN but also in other affected 
brain regions. 
 Cellular localization: Syn is mainly cytosolic, 
although sometimes is bound to the membrane of 
synaptic vesicles.  
Syn seems to have a prion-like behavior. 
Monomeric and aggregated -synuclein are 
secreted and endocyted by neighboring cells. Once 
in the receptor cell, aggregates are transported 
through the endosomal pathway and finally 
degraded by lysosomes. However, if lysosomal 
capacity is compromised (aging, mutations,…) 
internalized Syn accumulate in the receptor cell forming Lewy-like 
inclusions. The mechanisms why donor and receptor cells transfer 
Syn are unknown [57, 58]. That explains why long-term transplanted 
Fig. 17.More 
Syn structures. 
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PD patients developed LB in their fetal grafted mesencephalic tissue 
[59, 60].                        
 Pathogenic gene variants: changes in Syn sequence or quantity 
cause PD with autosomal dominant inheritance; however, the only 
current explanation to that fact is that -synuclein has higher 
tendency to aggregate if it is mutated or if it is more abundant 
(duplications, triplications). Mutations in this gene are extremely rare 
and it seems that they do not change either protein structure or 
cellular localization or any other characteristic. 
o p.A53T (missense mutation): a highly penetrant mutation (85%) 
described by [61] in an Italian-American kindred (the Contursi 
family); other Greek families have also been described with this 
mutation. All carriers of the mutation but one had typical PD 
symptoms with early age at onset (30 to 50 years) and rapid 
progression.   
o p.A30P (missense mutation): described by [62] in a German family. 
Carriers presented typical PD symptoms. 
o p.E46K (missense mutation):  described by [63] in a Basque kindred. 
Patients showed typical PD features although cognitive decline 
(especially dementia and hallucinations) and early onset were more 
frequent. This characteristics plus the widespread presence of LB in 
the brain resembled dementia with Lewy bodies, a heterogeneous 
disorder that clinically and pathologically overlaps with PD, making 
DLB more probable than PD in those cases. 
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o Gene duplication and triplication: a linkage analysis conducted in a 
large kindred with typical PD features, rapid progression and early 
onset -although some members suffered from dementia and others 
postural tremor instead of parkinsonism- revealed that the 
responsible for the phenotype was the triplication of a region that 
included SNCA and 16 other genes [64, 65]. Syn levels were 
increased in these PD patients due to the increase in gene dosage: 
protein and mRNA levels doubled normal values in blood and 
brain as a consequence of the double number of SNCA alleles, 
which were all expressed. Moreover, the increased expression was 
correlated with a higher proneness to form aggregates in brain 
[66]. In a large Swedish kindred (Lister family complex) changes in 
gene dosage were also identified: in one branch, the Swedish-
American branch, the carriers of triplicated SNCA showed similar 
clinical features to these previously described, whereas at the 
Swedish branch, carriers of a duplication in a smaller region 
including SNCA and one more gene [67] developed parkinsonism 
but with a wider range of features when comparing with previous 
reported families which showed typical PD with late onset [68, 
69]. Gene dosage seems to be correlated with disease progression, 
age at onset and symptom severity. 
 Function: unknown. It has been suggested to act in multiple processes 
including synaptic vesicle biogenesis, brain lipid metabolism, 
cytoskeleton stability and lysosomal function. -synuclein aggregates 
are degraded by autophagy whereas monomers are degraded through 
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the proteasome [70].  -synuclein also participates in dopamine 
homeostasis in the presynaptic terminal (Figure 18). 
 
  
 
 
 
 
 
 
Modified from [51] 
 Polymorphisms: two are the most studied, although none of them is 
located inside the gene sequence. Both are considered possible 
susceptibility PD factors with influence in Syn expression. 
o Rep1 (D4S3481): is a polymorphic microsatellite repeat located 
≈10kb upstream of the translation start site. Its  sequence repeat is 
mixed, (TC)10-11(TT)(TC)8-11(TA)7-9(CA)10-13 [71], and different 
dinucleotide composition can originate the same microsatellite 
Fig. 18. Syn and dopamine homeostasis. 
1.-synuclein regulates dopamine synthesis by controlling the activity of tyrosine hydroxylase 
(TH) and L-dopa decarboxylase (DDC, also known as AADC: amino acid decarboxylase). 
2.-synuclein is involved in regulating synaptic vesicle function and dopamine release into the 
synaptic cleft. Vesicular monoamine transporter 2 (VMAT2) sequesters dopamine into vesicles. 
3.-synuclein is necessary for the trafficking of dopamine transporter (DAT) to the cell surface, 
which is necessary to reuptake dopamine and finish dopamine signaling. 
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length [72]. Although this could be considered as an additional 
complexity factor, [73] concluded that, in vitro, the overall 
sequence repeat length, and not the number of any specific 
dinucleotide, changes SNCA expression: taking allele 267 
expression as the reference, allele 271 increased 1.5 times the 
expression, allele 273 2.5 times and allele 269 3 times in SH-SY5Y 
cells (from human neuroblastoma) but not in 293T cells (from 
human kidney) [74]. However, [75] found a trend, not a significant 
result, that pointed out that allele 269 was related to lower mRNA 
levels in frontal cortex, temporal cortex and SN from control cases. 
Therefore, the real effect of Rep1 alleles in SNCA expression 
remains unclear.  
[76] were the first who described the microsatellite and its alleles 
and, lately, [77] concluded that allele 273 was more prevalent in 
PD cases than in controls in a German population. Other articles, 
[71] in an Italian population or [78] in a Singaporean population, 
did not obtain the same conclusion. The works by [79] in a Greek 
population, [80] a meta-analysis and [81, 82] in a population from 
USA determined that allele 271 was the real risk factor instead of 
273; moreover, [83] in Australians with European ancestries, [80] a 
meta-analysis and [81] in a population from USA16 observed that 
allele 267 could be neuroprotective. However, it is difficult to 
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 Depending on the article used as a reference, allele name may change: [76] described 
alleles 0 (267), 1 (269), 2 (271), 3 (273)… Nevertheless, alleles in [77] are 10 bp shorter than 
those. These are the most common nomenclatures, although some articles ([80] and [82] for 
example) mix both: their allele 263 is actually 271 in [76]. 
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explain how allele 271 can be a risk factor for PD when it is related 
to less Syn expression than allele 269, the most common. The 
frequency of the different alleles changes depending on ethnicity, 
being allele 273 more frequent in Asian population than in 
Caucasian, although allele 269 is always the most frequent [78]. 
Maybe, the actual risk factor is in linkage disequilibrium to Rep1 
but not itself. 
o rs356219 (A>G): is located 9kb downstream of the gene. Some 
articles, [84] in a Norwegian population, [85] in a Caucasian  
population from the USA (this same group also found that the G 
allele is associated with higher levels of plasmatic Syn in cases), 
[86] in an Italian population and [87] in Han Chinese,  concluded 
that the G variant is a PD risk factor, although there are opposite 
results, as in [88] in Swedish. In addition, in frontal cortex, C allele 
is related to higher mRNA quantities of SNCA112, an splicing 
variant without exon 5 which is considered to enhance Syn 
aggregation [89]. 
o Although there is no correlation between Rep1 alleles and 
rs356219 alleles or genotypes, their interaction with other 
supposed PD risk factors such as the H1/H2 haplotype in MAPT, has 
been studied: the majority of results conclude that there is no joint 
effect neither for Rep1-H1 [90, 91] nor for rs356219-H1 [92-94]. All 
these studies concluded that, separately, the G allele and the H1 
haplotype are PD risk factors but the risk does not increase with 
the presence of both, except for [95] who found that the 
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interaction between rs356219 and H1, i.e. the presence of the G 
allele plus the H1 haplotype, doubles the risk of developing PD.  
 Animal models: although any rodent model presents all the key 
features that are present in PD cases originated by SNCA [96],  they 
closely resemble the situation: 
o The knockout mice are viable and fertile and have normal brain 
structure (presynaptic terminals and dopamine neurons are 
normal). Therefore, -synuclein is not essential for neuronal 
development. However, there is a reduction in striatal dopamine 
[97]. 
o Overexpression of wild type Syn with heterologous promoter in 
mice recapitulates many features of PD: accumulation of insoluble 
-synuclein aggregates, loss of dopaminergic terminals and motor 
abnormalities (fine motor skills are altered) [98]. 
o Transgenic mice expressing mutated Syn show the common PD 
features, although p.A53T causes more toxic effects than p.A30P 
[99]. 
 
 
 I.8.b. PRKN (PARK2): 6q26 
PRKN gene has 12 exons and encodes for a protein, parkin, with 465 
amino acids. It is the second biggest gene in the human genome. 
 Protein structure: parkin has a N-terminal ubiquitin-like domain (Ubl), 
a linker region and a C-terminal RING (Really Interesting New Gene) 
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box that can be divided into three domains: RING1, RING2 and IBR (In-
Between-RING) (Figure 19) [100]. 
 
 
 
 
Taken from [100] 
 
 Tissue expression: ubiquitous.  
 Cellular localization: PRKN is mainly cytosolic but it is also present in 
nucleus and even in mitochondria because parkin can be recruited to 
the mitochondrial membrane when it loses membrane potential. 
 Function: parkin is an E3-ubiquitin ligase enzyme so it works in the 
unfolded protein response.  
Misfolded or short-lived proteins are targeted for degradation in the 
26S proteasome by covalent attachment of ubiquitin. Three enzymes 
participate successively in this process: 
 E1 (ubiquitin-activating enzyme) activates the ubiquitin in an ATP-
dependent manner. 
 E2 (ubiquitin-conjugating enzyme) binds ubiquitin. 
 E3 (ubiquitin-protein ligase) transfers ubiquitin from E2 to the target 
protein. 
Parkin interacts with E2 proteins (UbcH7, UbcH8) via its RING box and 
with its target proteins via its Ubl domain (Figure 20) [100]. 
It is known that PRKN labels some proteins for degradation (K-48 
linked poliubiquitination). However, to confirm which are its real 
Fig.19. Parkin structure. 
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targets in vivo is controversial (in vitro, tubulins, CDCrel-1, LRRK2 
aggregates [101] and more proteins are its targets [102]): 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Modified from [100] 
 
 Sp22, is a O-glycosylated human Syn form, only present in 
human brains (22KDa), that accumulates in LB in parkin-deficient 
cases. Only this form, and not the common Syn (16KDa), 
interacts with, and is ubiquitinated by, parkin [103].   
 in human brain, parkin, CHIP (E3 enzyme which, at least in vitro, 
could be another parkin substrate), and Hsp70 (molecular 
chaperone) work together to ubiquitinate and degrade Pael-R 
(parkin-associated endothelin receptor-like receptor; this protein 
has unknown function and encodes for a multipass endoplasmic 
Fig.20. Model of the parkin-directed 
ubiquitination pathway. 
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reticulum transmembrane protein) when there is some folding 
problem [104]. 
 synphilin-1 is an -synuclein-interacting protein without known 
function that interacts with parkin via the RING2 domain, not by 
the Ubl domain, and is ubiquitinated in rat brain [105]. 
In addition, Parkin catalyzes monoubiquitination and K-63 linked 
polyubiquitination, which are proteasome-independent mechanisms 
to regulate endocytosis, aggresome17 formation and NF-B signaling18, 
in conjunction with the heterodimeric E2 enzyme UbcH13/Uev1a. This 
process is mediated by PINK1 phosphorylation of parkin which 
increases its affinity to UbcH13/Uev1a [106]. Mutations in parkin or 
PINK1 block this process and that can be related to PD pathogenesis. 
 Pathogenic gene variants: parkin was first time associated with PD in 
Japanese population by [107]. They found that changes in this gene 
cause autosomal recessive Parkinson´s disease with slow progression, 
frequent dystonia, sleep benefit, good response to L-dopa, early 
onset (although there is a wide range of ages at onset, varying from 
early childhood to late adulthood) and without Lewy bodies presence 
in brain [108, 109]. This later aspect is on debate: not too many brains 
have been analyzed and, even when the majority of PRKN-related PD 
                                                          
17
 When there is an overload of damaged proteins in the cytosol and proteasome cannot 
degrade it, an aggresome (a proteinaceus inclusion body) is formed. This protective 
mechanism gives the cell more time to eliminate abnormal proteins. 
18
 This is a ubiquitously expressed transcription factor which mediates transcription of a 
number of pro-survival genes. 
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patients have no LB but neurofibrillary tangles19 [110], some of them 
do [111]; in addition, parkin has been identified in LB [112]. 
Changes in gene sequence affect PRKN function and, therefore, 
misfolded target proteins accumulate, but the molecular mechanisms 
that connect this protein aggregation and neuronal death remain 
unclear.  
The most frequent gene variants in PD cases are deletion of exon 4, 
deletion of exon 3 and deletion of exons 3 and 4 [113], although not 
only exonic deletions have been described: rearrangements, 
duplications, missense and nonsense mutations can be present too 
[114]. Homozygous and compound heterozygous for mutations in 
PRKN are affected by PD, but some carriers of just one mutation in 
parkin have also developed the malady and positron emission 
tomography studies suggest that parkin heterozygous, although 
usually asymptomatic, may exhibit nigrostriatal dysfunction [115]. 
The relation between haploinsufficiency or dominant-negative effect 
and pathogenicity has an unknown significance in those people, 
especially as [116, 117] have analyzed PRKN mutations in PD cases 
and control populations and have found that there is no evidence for 
association of heterozygous parkin sequence variants, mutations or 
polymorphisms, with risk or protection against AR-JP20. 
 Animal models: in mice, exon 3 knockout animals have normal brain 
morphology without reduction of nigrostriatal dopamine neurons. 
                                                          
19
 Tau-positive protein inclusions. 
20
 Autosomal recessive juvenil parkinsonim. 
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However, the absence of protein originates subtle motor, behavioral 
and cognitive deficits, increased dopamine level, reduced synaptic 
excitability and inhibition of glutamate neurotransmission [118]. In 
Drosophila, null mutants show reduced life span, locomotor defects, 
muscle fiber degeneration, sterility and mitochondrial pathology but 
no neuronal degeneration [119].  
Any of the models show a clear parkinsonism phenotype; that fact 
together with the wide range of phenotypes observed in PD cases 
seem to imply that parkin acts together with other factors to induce 
the disease. 
 
 
 I.8.c. PINK1 (PARK6): 1p36.12 
PINK1 gene has 8 exons and encodes for a protein (PTEN-induced 
putative kinase 1) with 581 amino acids. 
 Protein structure: two characteristics define the structure of the 
protein 
o the first 34 amino acids, i.e. the N-terminal end, target the protein 
to the mitochondria. 
o there is a highly conserved protein kinase domain (amino acids 156 
to 509) that shows a high degree of homology to the 
serine/threonine kinases of the Ca2+/calmodulin family [120]. 
 Tissue expression: ubiquitous.  
 Cellular localization: in mitochondria, where its localization is unclear: 
some studies show its kinase domain facing the cytosol whereas some 
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others place it on the inter-membrane space. PINK1 is also found in 
cytosol, where a fraction of it is exported after processing in the 
mitochondria [121]. 
 Pathogenic gene variants: [120] described for the first time that 
PINK1 causes recessively inherited forms of Parkinson´s disease. They 
showed it in Italian and Spanish families that presented typical PD 
with slow progression and good response to L-dopa but early onset. 
In PD patients, frameshifts, missense, nonsense, intronic and 
synonymous mutations have been described (Figure 21). However, 
deletions and multiplications are rare [122]. Individuals homozygous 
and compound heterozygous for mutations in PINK1 develop 
Parkinson´s disease, and some heterozygous too (familial or sporadic) 
although with delayed onset. Positron emission tomography studies 
support that fact: they have concluded that there is decreased 
dopaminergic function in asymptomatic heterozygous carriers of 
PINK1 suggesting that some mutations might predispose to PD [123]. 
Nevertheless, no study has found differences in the overall frequency 
of PINK1 mutations between PD cases and control population: maybe 
a specific mutation, possibly not described yet, is more prevalent in 
controls or in cases and can shed light to this confusing situation.  
Haploinsufficiency21, dominant-negative effect22  or dominant gain-of-
function mutations could not be enough to explain the different 
phenotypes observed in heterozygous. Those processes could be just 
                                                          
21
 There is a lack of active protein, the 50% is missing. 
22
 Mutated proteins block wild type proteins function. 
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PD risk factors and maybe it is a combination of PINK1 mutations plus 
environmental factors or mutations in PINK1 plus mutations that have 
not been yet described in other genes only in brain (somatic 
mosaicism) the real cause [124]. 
 
 
 
 
 
 
 
 
 
 
 
Taken from [124] 
 
 Function: it is a kinase. Further studies to establish the natural 
substrates of the protein are required although it is known that parkin 
and HtrA2 are some of them [125, 126]. Mutated proteins lose their 
activity (changes affect kinase activity or substrate recognition) but 
not their localization [121]: in vitro, p.G309D and p.L347P mutants 
showed reduced kinase activity (the effect was drastic in p.L347P 
whereas more modest in p.G309D). In both cases mutations affected 
neither mRNA levels nor cellular localization. Nevertheless, those 
mutated proteins can be less stable and more degraded. 
Fig. 21. PINK1 mutations reported in patients with parkinsonism.  
Missense and truncating mutations are depicted above and below 
the protein bar. Mutations found in homozygous or compound 
heterozygous state are in black. Mutations found in heterozygous 
state are in gray. 
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PINK1 also has an important role in mitochondrial protection: parkin 
interacts with PINK1 and both functionally cooperate to identify and 
label damaged mitochondria for selective degradation via autophagy 
(mitophagy) [127, 128]. The model (Figure 22) has some steps: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Modified from [127] 
 In normal conditions, the mature PINK1 is constantly cleaved by an 
unknown protease to its intermediate form that is degraded. PINK1 
cleavage is voltage-sensitive. 
 However, if the mitochondria are depolarized, there is a decrease in 
membrane potential, mature PINK1 is stabilized at the outer 
membrane and not cleaved. PINK1 recruits parkin from the 
cytoplasm in a membrane potential-dependent manner and 
activates it. Parkin ubiquitinates an unknown mitochondrial 
Fig. 22. Quality control model for depolarized mitochondria. 
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substrate(s) and, as a consequence, damaged mitochondria are 
degraded via mitophagy. 
 Mutations in both genes block the mechanism thus originating 
recessive familial PD.  
 Animal models: in mice, knockout PINK1-/- had no nigral degeneration 
but impaired mitochondrial respiration in striatum in early life (3-4 
months) and in cerebral cortex in late life (24 months). There was a 
selective increase in larger mitochondria although mitochondrial 
structure was not affected [129]. In Drosophila, PINK1 is 60% similar 
to the human gene including the mitochondrial targeting motif and 
the kinase domain. PINK1 mutants exhibited dopaminergic neuronal 
degeneration accompanied by locomotion defects but parkin rescued 
the phenotype demonstrating that parkin acts downstream of PINK1. 
There was mitochondrial dysfunction in these neurons and also, their 
size was increased. Mitochondrial integrity was damaged not only in 
dopaminergic neurons, also in sperm and flight muscle [130]. PINK1 
could be considered a critical factor required in dopaminergic 
neurons for maintaining mitochondrial integrity as well as neuronal 
function. [131] showed that, in Drosophila, PINK1 and parkin work in 
the same pathway regulating mitochondrial morphology (fission). The 
mechanism is unknown but fission regulation could provide the cell 
the way to segregate small damaged mitochondrial units that will be 
eliminated through autophagy thus eliminating oxidative stress (which 
is one of the prime suspects in PD). 
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Results in Drosophila resemble more those obtained in humans 
whereas in knockout mice the only similarities are that mitochondrial 
size and respiration are altered: the presence of nigral degeneration 
and the mechanism to regulate mitochondrial fission, which can be 
homolog to the quality control model for depolarized mitochondria 
described in humans, represent better the pathological phenotype 
observed in PD cases. 
 
 
 
 I.8.d. DJ-1 (PARK7): 1p36.23 
DJ-1 gene has 8 exons and encodes for a protein with 189 amino acids. 
 Protein structure: DJ-1 forms homodimers (Figure 23) [132]. 
It belongs to the ThiJ/PfpI superfamily. In this group, proteins with very 
different biochemical and cellular functions are included: intracellular 
proteases, amidotransferases, kinases…  
 
 
 
 
 
 
 
 
 
 
Modified from [133]  
Fig. 23. DJ-1 structure. 
a. Ribbon diagram of the DJ-1 monomer. The secondary structure elements are 
blue (-helices) and green (-strands). Positions of the N and C termini are 
indicated with arrows. 
b. Topology diagrams of DJ-1 (color-coded as in a). The -helices are represented 
by blue rectangles, and the -strands are represented by green arrows.  
c. Ribbon diagram of the DJ-1 dimer. Monomer A is blue and monomer B is green. 
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 Tissue expression: ubiquitous.  
 Cellular localization: the major part of the protein is cytosolic and 
nuclear although there is a pool in mitochondria (mitochondrial matrix 
and inter-membrane space) [134]. 
 Pathogenic gene variants: mutations in DJ-1 are uncommon. 
Nevertheless, [135] described families from Italy and the Netherlands 
who developed autosomal recessive PD with slow progression, good 
response to L-dopa (typical PD features) but early onset due to 
homozygous mutations in this gene. Phenotypically, DJ-1 patients are 
indistinguishable from parkin and PINK1-linked PD cases. 
Homozygous and compound heterozygous for DJ-1 mutations have 
been described, but there are not enough data to draw conclusions 
about the role of heterozygous mutations in this gene. Exonic 
deletions, frameshifts, nonsense and missense mutations have been 
reported. 
Mutations alter DJ-1 cellular distribution and cause loss of function 
and decreased protein stability. For example, the p.L166P change 
abrogates dimerization and, consequently, increases protein turnover 
through the ubiquitin-proteasome system (this mutant is present 
mainly in mitochondria and almost absent in cytosol and nucleus).  
Mutations in parkin account for the majority of changes in recessive 
Parkinson´s disease, whereas mutations in PINK1, and even more in 
DJ-1, are not so common. Moreover, it is unknown whether the 
absence of protein aggregates in brain is a common feature in 
recessive PD or not, as it is the case for parkin-caused PD, because few 
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anatomical studies have been conducted in brains of PD patients who 
carry mutations in DJ-1 or PINK1 genes to determine the presence of 
LB.   
 Function: DJ-1 has been involved in tumorigenesis, as a putative 
oncogene, and fertilization, but it also acts as a protective protein 
against oxidative stress.  In vitro, DJ-1 increases its expression to 
protect against oxidative stress-induced cell death caused by agents 
like H2O2, MPP
+
 or 6-OHDA. If mutated, this scavenger activity is 
reduced and cells are more susceptible to death [136]. This protective 
mechanism may involve Nrf2, an antioxidant transcriptional master 
regulator that triggers the protective cascade against oxidative 
conditions, because, in vitro, DJ-1 stabilizes it by preventing its 
association with KEAP1 (its inhibitor) and subsequent ubiquitination 
and proteasome-mediated degradation. It has not been determined 
how DJ-1 avoids the association of Nrf2 with Keap1 because physical 
interaction between DJ-1 and Nrf2 has not been reported [137]. 
Another explanation of this protective role of DJ-1 involves Cu/Zn-
Superoxide Dismutase 1 (SOD1) because, in vitro and in vivo, DJ-1 
participates in a pathway leading to the induction of SOD1 expression: 
under oxidative stress conditions, DJ-1 interacts with Erk1/2 (MAPK 
kinases) and translocates them to the nucleus to phosphorylate the 
transcriptional factor Elk1 which, on its turn, triggers SOD1 expression 
to counteract oxidative stimulation [138]. 
The redox sensitivity of DJ-1 also relates the protein to  mitochondrial 
maintenance (because it is recruited to the mitochondria when there 
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are oxidative conditions inside the cell [139]) and to clearance of 
Syn aggregates (because DJ-1 can act as a redox-dependent 
chaperone that eliminates Syn aggregates [140]). 
 
In addition, DJ-1 interacts in vitro with other proteins related to 
familial PD:  
 DJ-1 interacts with and stabilizes PINK1: one family was described 
whose members developed Parkinson´s disease due to digenic 
mutations, i.e. affected people carried one mutation in DJ-1 and 
other in PINK1. Heterozygous individuals for any of the mutations 
did not develop the disease. The relation between genotype and 
phenotype assumed that there was a functional interaction 
between both genes, interaction that was confirmed [141]. 
 Parkin, PINK1 and DJ-1 form the PPD complex in the cytosol: this is 
an E3 complex that promotes ubiquitination and degradation of 
aberrantly expressed and heat-shock induced parkin substrates. DJ-
1 stabilizes PINK1, although the presence of DJ-1 at the complex is 
not essential, and PINK1 potentiates parkin activity. This complex 
has also been described in vivo in human brain lysates [142]. 
 Finally DJ-1 also interacts in vitro with two nuclear proteins: p54nrb 
and pyrimidine tract-binding protein-associated splicing factor (PSF) 
which are multifunctional regulators of transcription.  PSF induces 
apoptosis by reducing the expression of neuroprotective proteins 
or anti-apoptotic genes. DJ-1 works with p54nrb to inhibit the 
repressing activity of PSF. However, mutated DJ-1 proteins are not 
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in the nucleus and, therefore, cannot protect the cell [143]. DJ-1 is a 
transcriptional co-activator that regulates transcription without 
directly binding any promoter. 
 Animal models: all knockout mice (DJ-1-/-) analyzed were viable and 
fertile and showed normal brain morphology. Their phenotypes 
supported conclusions obtained in previous studies  even when any of 
the rodent models developed all typical PD features [119]:  
o Some mice showed age-dependent and task-dependent motoric 
behavioral deficits, increased dopamine reuptake rates and 
elevated tissue dopamine content. 
o Others had reduced sensitivity of nigral neurons to dopamine, 
reduced dopamine overflow due to increased reuptake and 
decreased spontaneous locomotor activity (generalized 
hypokinesia). However, the number of dopamine-containing 
neurons in the SN at 3 and 12 months of age were normal. 
Nevertheless aged mice were not analyzed and cannot be 
discarded the fact that they could had neuronal degeneration. 
Taken together, these findings indicated that the nigrostriatal 
pathway was intact but dysfunctional [144]. 
o The influence of oxidative stress in DJ-1-/- mice was also studied and 
the in vivo results demonstrated previous in vitro conclusions. DJ-1 
is a protective protein against oxidative stress, its loss confers 
increased susceptibility to oxidative stress-induced neuronal death. 
Loss of DJ-1 exacerbated oxidative stress-induced neuronal death, 
by rotenone and MPTP, in primary cortical and dopaminergic 
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neurons. Neuronal death was only increased as a consequence of 
oxidative insults; non-oxidative insults had no influence on cell 
survival and restoration of DJ-1 mitigated the phenotypes. In this 
study, dopamine levels in the striatum were normal [145]. 
 
 
 I.8.e. LRRK2 (PARK8): 12q12 
LRRK2 (leucine-rich repeat kinase 2) gene has 51 exons and encodes for 
a protein, dardarin, with 2527 amino acids. 
 Protein structure: the protein contains several functional domains: 
ARM (armadillo), ANK (ankyrin repeat), LRR (leucine-rich repeat), ROC 
(Ras of complex proteins; with GTPase activity), COR (carboxy terminal 
of ROC), kinase and WD40 (rich in tryptophan and aspartate repeats). 
Four of these domains are related to protein-protein interactions: 
ARM, ANK, LRR and WD40 [146] (Figure 24). 
 
 
 
Taken from 
[147] 
Fig. 24. Domains and mutations in LRRK2. 
The LRRK2 protein is shown diagrammatically with amino acid numbers below each domain. 
Above the dimer are positions of known pathogenic mutations (in red) and some possible risk 
variants (in black). The dimer is present in a head-to-head orientation although it is not known. 
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 Tissue expression: dardarin is expressed in brain regions of direct 
relevance to the pathogenesis of PD like cerebral cortex, SNpc or 
striatum [148] and also in heart, kidney, lung, liver and peripheral 
leukocytes. 
 Cellular localization: in vitro studies suggest that LRRK2 is a cytosolic 
protein [101]. However, LRRK2 is also associated with a variety of 
membrane and vesicular structures (i.e. outer mitochondrial 
membrane) and the microtubule network [149, 150]. 
 Pathogenic gene variants: [151] described that there was a region 
associated with PD (12p11.2-q13.1) at the Sagamihara family from 
Japan. Affected cases presented typical idiopathic symptoms, good 
response to L-dopa, autosomal dominant inheritance and late onset. 
Nevertheless, there was incomplete penetrance: the “pathogenic” 
haplotype was shared by PD cases and healthy individuals within the 
family. Two years later, [152] and [153] found that it was due to 
mutations in LRRK2 gene. 
To date, more than 40 missense or nonsense mutations have been 
described. Only point mutations, no deletions nor duplications, have 
been found causing PD. Six of the described mutations are recognized 
as disease-causing variants and segregate with disease in large 
families: p.N1437H, p.R1441C, p.R1441G, p.Y1699C, p.G2019S, 
p.I2020T. Mutations in LRRK2 gene are the most common cause of 
Parkinson´s disease. They are present in up to 5-13% of familial cases 
and in 1-2% of sporadic PD patients. 
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p.N1437H mutation is located on the ROC domain. It has been found in 
a large Norwegian family segregating with autosomal dominant 
parkinsonism. However, more research is required to confirm that this 
family is suffering from PD [154]. 
Mutations p.R1441C and p.R1441G are located on the ROC domain 
and have been described in familial and sporadic cases. Both 
decrease GTPase activity [155, 156] due to the change they produce 
in the folding properties of the domain [157], but the localization, 
turnover and protein steady-state levels remain unaltered [158].  
p.R1441C is the second most recurrent PD mutation and is found in 
different ethnic races with high penetrance. Nevertheless, p.R1441G 
is most common in the Basque country and is rare outside Northern 
Spain [159]; its penetrance is high, increases with age and is 
independent of sex [160]. This position can be considered a hotspot 
because another mutation has been described (p.R1441H) in 
different populations (Greek, Italian, Taiwanese…) but it has never 
been found to co-segregate with PD in a large family. For this reason 
it is not considered a pathogenic variant [161].  
p.Y1699C mutation is located on the COR domain. It was found in the 
initial reports about LRRK2: [152, 153]. 
p.G2019S mutation is the most frequent cause of familial and 
sporadic PD. Its frequency is heterogeneous around the world with 
the highest values for Ashkenazi Jews and in North African Arab 
countries [162] (Figure 25). 
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Taken from [161] 
 
Its penetrance is incomplete and smaller than for p.R1441C and 
p.R1441G: it is estimated to be ≈75% at the age of 79 years, age-
dependent and sex-independent [163]. The mutation is located on 
the kinase domain and it increases the kinase activity by two to three 
folds [158]. This is the only effect it has; it does not modify the protein 
steady-state levels, its localization or its turnover.   
p.I2020T mutation is located on the kinase domain. Its influence on 
kinase activity remains controversial: some articles conclude that the 
activity is increased by the mutation [149] whereas others conclude 
the opposite, that it is decreased by the mutation [164, 165]. 
In general, PD cases that carry these mutations are clinically 
indistinguishable from idiopathic PD patients. 
 
Fig. 25. Worldwide distribution of p.G2019S mutation. 
The frequencies are for familial cases and, in brackets, for sporadic cases. 
I. INTRODUCTION.  I.8. Familial PD. 
60 
 
Furthermore, two polymorphic variants have been described as risk 
factors, only in Asian population, both increasing PD risk by 
approximately two-fold: 
p.G2385R is located on the WD40 domain. This mutation is absent in 
Caucasian subjects but it is considered a common risk factor for PD in 
Chinese population [166]. [167] observed that mutated protein does 
not change its cellular localization but it is considered to increase 
cellular susceptibility to oxidative stress.  
p.R1628P is located on the COR domain and it also increases the risk 
of Parkinson´s disease among Chinese [168]. 
 Function: LRRK2 is a kinase [158] and also a GTPase [169]. GTPase 
activity controls kinase activity (LRRK2 needs to bind GTP to act as a 
kinase) but GTPase activity is independent of kinase activity [155], i.e. 
kinase activity does not modulate GTP-binding affinity [165]. In 
conclusion, LRRK2 is a GTP/GDP-regulated protein kinase [170]. The 
various mutations present in the protein are scattered throughout 
the protein with some evidence of clustering into these two enzymatic 
domains. 
The function of dardarin is unknown to date: it is suggested to have a 
role as GTPase, as kinase involved in cellular signaling… amongst 
others. 
Dardarin can be involved in microtubules formation or stability 
because it is known that wild type and mutated p.R1441C LRRK2 
interact in vitro with α/β-tubulin heterodimers through the ROC 
domain, an interaction that is GTP- or GDP-independent. Although 
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these experiments were done in vitro, endogenous LRRK2 and α/β-
tubulin were found to co-localize in primary hippocampal neurons in 
vivo [171]. In addition, in bovine brains, as is also the case in mice 
brain, LRRK2 preferentially phosphorylates -tubulin and this 
phosphorylation is three times higher due to p.G2019S mutation. The 
increase in phosphorylation results in decreased microtubule 
dynamics and cumulative dysfunction/damage over time. 
Furthermore, LRRK2 enhances the polymerization of tubulin (isolated 
from bovine brain) in the presence of microtubule-associated 
proteins. Maintaining microtubule dynamics within a physiological 
range is essential for neuronal function and survival. This stability is 
necessary to avoid problems in axonal transport and synapse 
formation but mutations in LRRK2 could originate changes in the 
microtubules dynamics and cause neuronal dysfunction that could 
eventually lead to PD [172]. 
LRRK2 also regulates mitochondrial dynamics through its direct 
interaction with DLP1, a fission protein.  LRRK2 expression in vitro 
caused mitochondrial fragmentation, mitochondrial dysfunction and 
neuronal toxicity; LRRK2 mutants increased DLP1 expression and, 
therefore, increased fragmentation. LRRK2 kinase activity plays a 
critical role in this process [173].  
 
There is some controversy about if dardarin dimerizes or not. Some 
studies found that LRRK2 migrated in polyacrylamide gels at the 
double of its expected size (600KDa) and, consequently, they 
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concluded that LRRK2 was a dimer. It is supposed to be a homodimer 
although that is controversial too because there is the possibility that 
the dimer is formed by a truncated LRRK2 plus one complete protein. 
It is known that the WD40 domain is necessary for the formation of 
the dimer, and also for the kinase activity [174], and, that the 
interaction between both parts needs the LRR domain and the N-
terminal region too. Moreover, the dimer undergoes intra-molecular 
phosphorylation in its ROC domain that potentiates the kinase 
activity [175-177]. 
However, recent studies have characterized “the dimer” (called p600) 
and have concluded that LRRK2 seems to be predominantly 
monomeric within cells. The monomer possesses the kinase activity as 
well as the GTP binding activity and these activities do not change 
even when it dimerizes [178]. The homodimer could be just a minor 
subespecie in the cell [179] and the unexpected migration of the 
protein could be a characteristic of high molecular weight proteins as 
it has been reported in other proteins [180].   
To explain the relation between dimer and monomers some models 
have been proposed (Figures 26 and 27). Nevertheless, the effect of 
mutations on dimer formation remains unclear. 
 Animal models: knockout mice (LRRK2-/-) are viable and fertile, show 
normal development and brain morphology with a normal 
dopaminergic system. Knockout mice are not more sensitive to MPTP 
than wild type mice and have the same life span [181]. That is, they 
are indistinguishable from wild type mice. The only difference is on 
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their kidneys because aged mice have proteinaceous aggregates in 
their kidneys composed of Syn and ubiquitinated proteins. 
Moreover, they show a smaller size and weight and a granular aspect 
[182]. These results imply that LRRK2 is not important for survival or 
development of dopaminergic neurons. 
 
 
 
 
 
 
 
 
 
Taken from [179] 
 
However, mice expressing human wild type or mutant LRRK2 showed 
reduced extracellular dopamine levels in the striatum [183], and 
although over-expression of human LRRK2 protein did not cause 
degeneration, it promoted Syn aggregation in p.A53T mice. This 
effect was stronger when expressing the p.G2019S mutant [184]. 
Over-expression of human p.R1441G LRRK2 in mice caused age-
dependent and progressive motor-activity deficits and they were 
Fig. 26. Proposed model for LRRK2 dimer assembly. 
LRRK2 exists mostly as a monomer in the cytosol and can translocate to membrane 
where it dimerizes, becomes more active and subsequently phosphorylates its 
substrates. Membrane-associated LRRK2 possesses greater kinase activity, an 
increased propensity to bind GTP, and is relatively dephosphorylated, compared to 
cytosolic LRRK2. 
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responsive to L-dopa, features that resembled the human phenotype 
for PD [185]. They showed diminished dopamine release and there 
was more axonal fragmentation although the number of neurons in 
SNpc was normal and their anatomical organization too. These results 
stress how difficult is to obtain a good animal model for LRRK2.  
 
 
 
Modified from [186]
  
Fig. 27. Hypothetical model of 
kinase activation. 
A major fraction of LRRK2 
protein in cells may reside in 
large oligomers with low or no 
kinase activity. LRRK2 oligomers 
are dissociated through 
conformational changes 
induced by GTP binding within 
the ROC domain, which may 
lead to the formation of a dimer 
structure initially stabilized by a 
ROC-ROC interaction. LRRK2 
autophosphorylation may lead 
to the stabilization of the kinase-
active dimer, which can be 
destabilized by competing 
phosphatase activity, GTPase 
hydrolytic activity, or stochastic 
interactions with LRRK2 
oligomers.  
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I.9. Other PARK loci. 
There are more PARK loci, but their contribution to the monogenic 
forms of Parkinson´s disease is not as clear as it is for the 5 previous genes: 
 
 
 I.9.a. PARK3: 2p13 
[187] described a possible new PARK locus with autosomal dominant 
inheritance pattern. They found that different families with typical 
idiopathic PD symptoms (parkinsonism, response to L-dopa and LB 
presence) shared a haplotype in chromosome 2. However, it had 
reduced penetrance, i.e. unaffected people carried the “pathogenic” 
haplotype too, and the familial phenotype was wider than PD (some of 
the affected people also had dementia, cortical plaques and 
neurofibrillary tangles in their brains). This locus was lately associated 
to age at onset in Parkinson´s disease in the studies that [188, 189] 
conducted in families affected by PD. Their PARK3 regions partially 
overlapped with the original one and included the marker D2S1394 
which showed the highest association for age at onset in PD. 
In an attempt to refine the locus and find the concrete gene, [190] 
sequenced the coding region of the 14 genes located on PARK3 but 
could not find any pathogenic marker segregating with the disease. 
Other later studies have repeated the genotype for some of those 14 
genes without success. 
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 I.9.b. UCHL1 (PARK5): 4p14 
UCHL1 (ubiquitin carboxyl-terminal esterase L1 or ubiquitin C-terminal 
hydrolase) gene has 9 exons and encodes for a protein with 223 amino 
acids. 
UCHL1 is highly specific for neurons. It removes small amides and esters 
at the C-terminal extreme of ubiquitin and also hydrolyzes polymeric 
ubiquitin chains into monomers: it is involved in the ubiquitin 
proteasome system acting as a deubiquitinating enzyme [191]. It is also 
a dimerization-dependent ubiquityl ligase [192]. 
[193] found that members of one German family who were suffering 
from PD (tremor at rest, rigidity, bradykinesia, postural instability and 
good response to L-dopa) carried the mutation p.I93M, although 
penetrance was incomplete. This mutation implies partial loss of the 
hydrolase activity of the protein and, as a consequence, it could cause 
altered cleavage and turnover of the substrates, which remain 
unknown, leading to aggregation of proteins and cellular death; 
however, this decreased activity is not considered enough to cause PD 
and recent studies have concluded that, actually, its pathogenicity is 
due to a gain of function rather than to a loss of function: the mutation 
changes the structure of the protein and thus allows UCHL1 to be more 
prone to aggregation and to interact aberrantly with tubulin and with 
components of the chaperone-mediated autophagy inhibiting the 
process [194, 195]. The p.I93M mutation also increases the K-63 
ubiquitination of Syn, stabilizing it; both facts make that Syn 
aggregates can accumulate inside the cell causing neuronal death. 
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UCHL1 is considered a good candidate to explain autosomal dominant 
Parkinson´s disease in the family. Its functions, its presence in Lewy 
bodies and its high abundance in human brain support the hypothesis. 
However, just two siblings of the family were alive at that moment thus 
making the subsequent research impossible. In addition, other studies 
have tried to confirm the association between UCHL1 and PD but the 
p.I93M mutation, nor any different mutation at the same gene, have 
not been reported again either for familial or for sporadic PD cases: this 
mutation is either a rare cause of PD or it has no influence on the 
disease and its presence in the two siblings was coincidental [196, 197]. 
Other polymorphism in UCHL1, p.S18Y, was discovered due to all the 
analyses carried out to determine the influence of UCHL1 in PD [197]. 
This variant does not change the structure of the protein or its 
hydrolase activity but it reduces the dimerization-dependent ubiquityl 
ligase activity of UCHL1: p.S18Y in UCHL1 reduces the K-63 
ubiquitination in Syn and, therefore, Syn aggregates are not 
stabilized [192]. It is on debate whether or not the S>Y change is a 
protective factor against PD. The Y allele is considered a protective 
factor in some studies: [196] on German PD cases, familial and 
sporadic, and unrelated controls, [198] a meta-analysis of 11 previous 
studies with Asian and Caucasian populations analyzed together, or 
[199] the biggest meta-analysis to date with Asian and Caucasian 
populations analyzed separately (although results were significant only 
when using a recessive model for Asian population and a dominant 
model for Caucasian population; only a trend was found when using 
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other models). On the other hand, for other groups, the Y allele has no 
influence on PD risk: [200] in a French population, although they find 
association between Y and age at onset, [201] a case-control study 
plus meta-analysis of 8 previous studies (only Caucasian populations), 
[202] in Chinese sporadic PD cases and unrelated controls, or [203] in 
Japanese sporadic PD cases and unrelated controls. In the latter, there 
was a trend of association for those carrying the Y variant and a 
reduction of risk for early-onset disease. The opposite conclusions 
obtained could be explained by differences between studies in sample 
size and ethnicity as, for example, the Y variant is more common in 
Asians than in Caucasians. UCHL1 remains as a controversial PARK locus.  
 
 
 I.9.c. ATP13A2 (PARK9): 1p36 
After analyzing one Jordanian consanguineous family, [204] linked 
markers D1S436 and D1S2843 in region 1p36 with Kufor-Rakeb 
syndrome. Kufor-Rakeb syndrome is an autosomal recessive disorder 
characterized by juvenil onset, L-dopa responsive parkinsonism 
(rigidity, bradykinesia but not tremor at rest), rapid progression, 
dementia and pyramidal signs [205]. The causative gene was found in a 
non-consanguineous Chilean family who was also suffering this rare 
disease: ATP13A2 gene has 29 exons and encodes for an ATPase with 
1180 amino acids and 10 transmembrane domains. This ubiquitously 
expressed protein localizes in the lysosomal membrane. However, 
truncated proteins are retained in the endoplasmic reticulum (ER) and 
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are degraded by the proteasome [206]. Its function and substrates 
remain unknown although as a member of the P-type ATPase 
superfamily is supposed to use ATP to maintain an ion gradient and use 
the membrane potential to produce ATP. Deletions, duplications, 
insertions, splicing site mutations and nonsense mutations, that 
originate frameshifts and deleterious proteins, have been described in 
homozygosis or compound heterozygosis in Kufor-Rakeb cases.  
Even when the phenotype of Kufor-Rakeb disease partially overlaps 
with Parkinson´s disease, some studies have been conducted to analyze 
the possible relation between ATP13A2 mutations and juvenile or early 
onset PD. The influence seems to be minimal although there are 
discordant opinions: 
o No ATP13A2 mutation segregates with familial PD cases [207].  
o Missense mutations in ATP13A2 have been described in 
heterozygosity in idiopathic early onset PD cases but also in healthy 
controls [208]. 
o However, another study conducted in familial and idiopathic juvenile 
and early onset PD cases found one homozygous carrier for a 
missense mutation in ATP13A2 plus some heterozygous for other 
missense mutations. Their unaffected parents were heterozygous for 
these mutations. The authors considered the homozygous mutation 
as a proof of the role of ATP13A2 in PD pathogenesis [209].   
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 I.9.d. PARK10: 1p32 
The PARK10 locus was described by [210] after studying 51 Icelandic 
families (117 patients) with late onset Parkinson´s disease. Their 
genome-wide linkage analysis reported the highest value for marker 
D1S231 in 1p32 region. After that, some studies have been conducted 
to find the candidate gene related to late onset PD: [211] used 
iterative association mapping in singleton and multiplex families23 and 
concluded that some SNPs in HIVEP3 gene were related to risk for late 
onset PD whereas the EIF2B3 gene, and, to a lesser extent, USP24 
were associated with age at onset. [212] obtained significant results 
for CDCP2 gene in their whole genome association study (using 2 tiers, 
case-control and sibling pairs). [213] analyzed HIVEP3 and CDCP2 genes 
in multiplex and singleton families and confirmed that HIVEP3, that 
encodes for a protein that regulates transcription of viral genes and 
genes involved in immunity and inflammation which are processes 
affected in PD, was associated with PD. Nevertheless, their significant 
results were obtained for SNPs that were different from those 
associated with PD by [211] and did not found the association with 
CDCP2, confirming thus previous studies conducted with unrelated 
cases and controls. [214] did a 3 stage study with Norwegian, Irish and 
North-American unrelated cases and controls and concluded that 
USP24 gene was a PD risk factor.  
                                                          
23
 The definition of singleton and multiplex families is based on the total number of parent-
child triads and discordant sibpairs (DSP) in a family that can contribute to association tests. 
Singleton families contain only either a triad or a DSP. Multiplex families consist of at least two 
pairs of either triads or DSPs. 
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This locus could connect familial forms of the disease and late onset, 
which is characteristic of the idiopathic forms. However, this association 
still remains uncertain maybe due to the use of different methodologies 
and the diverse characteristics of the populations such as size and 
familial aggregation. 
 
 
 I.9.e. GIGYF2 (PARK11): 2q36-37 and PARK12: Xq21-25. 
[215] conducted a genome-wide linkage study in multiplex families 
that did not carry parkin mutations. Under two different models, 
stringent diagnosis of PD or broader criteria for inclusion, regions in 
chromosome 2 (2q36-37) and chromosome X (Xq21-25) were linked to 
PD. The study was later extended to include more multiplex families 
and the results were unchanged. However, in this case, the region in 
chromosome 2 was related to PD only when considering PD patients 
diagnosed with a restrictive criteria whereas the region in 
chromosome X was only related to PD when using a broader criteria 
for inclusion of PD patients [216]. In both studies, the major part of the 
association for the region in X chromosome was due to brother-brother 
pairs, with sister-sister pairs and mixed sex sibships having lower linkage 
values, thus introducing the possibility that sex has some influence on 
PD susceptibility. 
 
These two regions were named as PARK11 (2q36-37) and PARK12 (Xq21-
25). There has been no update on PARK12 and the gene responsible for 
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the PARK11-associated PD remains unclear: [217] tried to validate the 
previous results in Caucasian European multiplex families ([215, 216] 
used Caucasian and Hispanic North-American families). They analyzed 
the linkage in the putative causative region limited by markers D2S126 
and D2S125 but they could not replicate the values.  
There are tens of genes in the 2q36-37 region, but the highest linkage 
score was obtained for a microsatellite marker located in the GIGYF2 
gene. Therefore, the later studies have focused on it. The protein has an 
unknown function. It interacts with Grb10 which is a growth factor 
receptor-binding protein with potential role in insulin and insulin-like 
growth factor signaling. The sequencing of its 27 coding exons has 
shown that there are plenty of mutations and polymorphisms in the 
gene. However, the frequency of these variants has been reported as 
different or equal between familial cases and healthy controls 
depending on the articles, thus originating opposite conclusions: [218] 
concluded that GIGYF2 could be considered responsible for autosomal 
dominant familial forms of PD with incomplete penetrance in Italian 
and French populations, whereas [219] in a Spanish population, [220] 
in Portuguese and USA populations, including sporadic PD cases too, 
and [221] in a Japanese population, including sporadic PD cases too, 
found no evidence to consider GIGYF2 responsible for familial PD. 
Moreover, [222] found that the frequency for common variants and 
haplotypes was not different between Australian sporadic PD cases and 
controls. At the present time, this locus could be considered, at best, a 
rare PD cause. 
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 I.9.f. HtrA2 (PARK13): 2p13.1 
The mouse mutant mnd2 (motor neuron degeneration 2) was 
spontaneously generated in 1990. Its phenotype includes altered gait, 
muscle wasting, repetitive movements, akinesia, degeneration of 
striatal neurons followed by widespread neuronal death in the late 
stages, and death by the day 40 of age. The p.S276C mutation in the Omi 
gene is responsible for this phenotype.  
Omi, also known as HtrA2, is a nuclear-encoded mitochondrial serine 
protease that localizes to the mitochondrial intermembrane space. The 
p.S276C change is located on the protease domain of the protein and 
causes the loss of access to the active site pocket and the consequent 
decrease in the protease activity.  
It has been postulated that loss of the protease activity of HtrA2 
increases sensitivity to stress-induced cell death and is probable 
responsible for the massive loss of striatal neurons in the mice: HtrA2 
could be a sensor of unfolding stress in mitochondria and when it is 
mutated there would be accumulation of misfolded proteins leading to 
mitochondrial dysfunction and permeability. In this case HtrA2 would 
leave the mitochondria and would have an apoptotic role [223]. 
Due to the neurodegeneration and parkinsonism observed in this 
rodent model, some studies have been conducted to analyze the 
relation between HtrA2 and PD in humans. [224] found that HtrA2 
colocalized at Lewy bodies in brains of PD patients. They sequenced the 
coding regions of the gene plus the adjacent intronic sequences in 
German cases and controls and found that 4 sporadic PD cases with 
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typical PD features carried the p.G399S mutation in heterozygosis, 
whereas no control had it. This mutation decreases the protease 
activity of the protein because it is localized in its PDZ domain, which 
regulates this function. In addition, the p.A141S polymorphism was 
reported as a PD risk factor, only found in heterozygous state. The S 
variant also decreased the protease activity. Both variants are supposed 
to trigger the same pathological mechanism than the p.S276C mutation, 
although p.A141S could do it with a smaller effect. None of these three 
changes modifies the expression, stability or localization of the protein 
[224].  
These conclusions could not been replicated in a study with North-
American PD cases and controls where the p.G399S mutation was 
found in PD cases but also in healthy people and with the same 
frequency, there was no association between the p. A141S variant and 
PD, and, in addition, there was no association for any of the other 
polymorphisms they discovered by the sequencing of the complete 
gene [225]. There was no association even when stratifying the 
population in early or late onset. Recently, the analysis of the 5 most 
informative SNPs spanning the complete gene in a large number of 
cases and controls from populations collected worldwide showed 
again no association for this gene and PD [226].  
It is known that PINK1 phosphorylates HtrA2 in vitro, thus increasing its 
protease activity. In human brains, when PINK1 is mutated the levels of 
phosphorylation of HtrA2 are decreased [126]. Considering this 
interaction and modification and the hypothetical pathological 
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mechanism that involves HtrA2 in mnd2 neurodegeneration, it has 
been postulated that PINK1 and HtrA2 could work together in a 
mitochondrial pathway against stress. However, at least in Drosophila, 
HtrA2 is not essential in the pathway that involves parkin and PINK1 to 
control mitochondria integrity [227]. 
In conclusion, HtrA2 seems that does not have an essential role in PD 
pathogenesis. 
 
 
 I.9.g. PLA2G6 (PARK14): 22q13.1 
The function of the protein is essential for membrane homeostasis: it is 
a calcium-independent phospholipase A2 that catalyzes the hydrolysis 
of glycerophospholipids. 
Mutations in PLA2G6 were associated with homogeneous clinical 
presentations: NBIA (neurodegeneration associated with brain iron 
accumulation) INAD (infantile neuroaxonal dystrophy) and Karak 
syndrome. However, recently it has been associated with more 
heterogeneous phenotypes: in 5 families from India and Pakistan with 
young adult onset levodopa-responsive dystonia-parkinsonism cases, 
pyramidal signs and cognitive/psychiatric features but no iron 
accumulation, a genome-wide homozygosity study was conducted. 
Three of the families showed the highest values for homozygosity at 
chromosome 22 and a deeper analysis in the region found that three 
members of two different consanguineous families were homozygous 
for PLA2G6 mutations in the coding region [228]. 
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Other study analyzed the presence of mutations in PLA2G6 in patients 
that have early onset parkinsonism plus other features like dementia, 
dystonia, psychosis, i.e. a broad phenotype. Two compound 
heterozygous were described after sequencing the 17 coding exons plus 
the exon-intron boundaries in 29 affected Japanese people. Although 
few patients with a very severe and atypical phenotype were included, 
the high frequency of the mutations observed raised up the possibility 
that this gene was related to those complex phenotypes [229].  
Nevertheless, the situation is more complicated. At present time, there 
are confusing results about the relation between mutations in PLA2G6 
and autosomal recessive PD because the mutations have also been 
described in patients with typical forms of the disease (without severe 
and broad phenotypes). In addition there is controversy about the 
influence of heterozygosis and specific mutations in conserved coding 
regions. Furthermore, although all the studies have analyzed early 
onset PD patients, there are different results for sporadic and familial 
forms of the disease. 
All these facts are reflected in the latest studies conducted in Asian 
population: 
o One early onset Chinese PD patient (without atypical features) was 
homozygous for a mutation in the gene. However, neither his 
homozygous sister nor any of the heterozygous members of the 
family presented any PD feature [230]. 
o An heterozygous carrier for a mutation in PLA2G6 was reported after 
sequencing the 17 coding exons plus the exon-intron boundaries of 
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the gene in a Chinese population. This woman was suffering early 
onset sporadic PD without atypical features like dementia or 
dystonia [231].  
o A case-control study conducted in a Japanese population could not 
find any association between any of the three mutations analyzed 
and the risk of developing sporadic Parkinson´s disease [232]. 
 
 
 I.9.h. FBXO7 (PARK15): 22q12.3 
Parkinsonian-pyramidal syndrome is a rare disorder that exhibits both 
parkinsonian and pyramidal-associated symptoms. Symptoms start in 
young adulthood, progress relatively slow and may culminate in severe 
movement incapacity. The response to levodopa of the parkinsonism is 
variable. 
A genome-wide linkage study was conducted in an Iranian family with 
parkinsonian-pyramidal syndrome. The highest values were observed at 
chromosome 22 in a wide region that included 34 genes. Considering 
that the inheritance of the disease was autosomal recessive, the linked 
region was redefined and only 4 genes were included in the deeper 
analysis. After the sequencing of their coding regions, some variants 
were discovered in homozygosis. However, only one of them, p.R378G, 
located on FBXO7 gene, segregated with the disease [233].  
This gene encodes for a member of the F-box family of proteins. It 
includes an F-box motif, a 40 amino acids motif that interacts with Skp1 
and acts as the scaffold in the SCF ubiquitin ligase complex which plays 
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a role in the ubiquitin-mediated proteasomal degradation, an N-
terminal ubiquitin-like domain and a C-terminal proline rich region, both 
necessary to its target specificity. FBOX7 do not only works in SCF-
mediated functions, it also interacts with proteins like HURP (mitotic 
protein), cIAP1 (inhibitor of apoptosis protein 1) and PI31 (proteasome 
inhibitor protein). FBOX7 also enhances the interaction of CDK6 with its 
targets. Nevertheless, its pathological mechanism and the hypothetical 
proteins involved remain unknown. 
FBXO7 was confirmed as a pathological gene in other study with two 
European families whose members had early onset, pyramidal tract 
signs and progressive parkinsonism. Three novel mutations that 
segregated with the disease were reported in it: p.R498X in 
homozygosity in an Italian family and the compound heterozygous 
p.T22M with c.1144+1G/T in a Dutch family [234]. 
 
FBXO7 has two isoforms (Figure 28). 
It was observed in vitro that loss of isoform 1 is pathogenic because 
Dutch patients developed the disease even when they were expressing 
the isoform 2. The Italian and Iranian cases showed before, did not 
express any of the isoforms due to their homozygous mutation, i.e. the 
mutations decrease the stability of the protein. One possible 
explanation for that is that FBXO7 has lost its proper cellular 
localization: isoform 2 lacks the N-terminal part of the protein which is 
necessary for its nuclear localization [235]. 
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Taken from [235] 
 
 
 
 
Thousands of studies have been conducted to find more PARK loci or 
susceptibility genes. There have been regions associated in almost all the 
chromosomes and some genes have been postulated as risk factors, mainly 
those related to dopaminergic transmission (D2R, D3R, TH, MAOA, MAOB…) or 
xenobiotic metabolism (CYP2D6, cytochrome P4501A1…). However, it has been 
complicated to replicate the results except for SNCA, MAPT and GBA. Even the 
mitochondrial DNA (mtDNA) has been widely analyzed: complex I is impaired in 
PD patients and it is known that there is a close relation between some 
pathological genes and mitochondrial function or integrity. Moreover, some PD 
patients have mutations in their mtDNA.  
Two strategies have been employed: 
Fig. 28. Schematic representation of the FBXO7 protein isoforms. 
Here, it is represented the domain organization of both proteins. The previously 
described mutations are indicated. Ubl: ubiquitin-like domain; FP: FBXO7/PI31 domain; 
F-box: F-box motif; PRR: proline rich region. 
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 linkage disequilibrium studies: there are families were the disease is 
inherited due to the presence of a specific mutation. Genome-wide 
analyses and gene candidate approaches have been conducted to find 
regions where recombination in meiosis is lower than the expected. It is 
achieved by genotyping microsatellites which define the pathological 
region. However, due to the effect of penetrance, the reduced number 
of members in current families and the low percentage of cases caused 
by familial forms of Parkinson´s disease, nowadays this approach is less 
used.  
 association studies with PD cases and healthy controls to compare the 
frequency of specific variants looking for significant differences. Lots of 
studies with different sample sizes and populations from all over the 
world with familial and/or sporadic PD have been conducted. Nowadays 
this is the best technique to find candidates in multifactorial diseases, 
specially the genome-wide association studies (GWAS): in this approach, 
the entire genome is scanned using densely distributed genetic markers 
thus being a powerful approach to identify common genetic variants of 
weak effect that underlie the risk of a common disease like PD [51].  
 
The latest PARK loci have been found by GWAS:  
 
 I.9.i. PARK16: 1q32 
[236] concluded that there were 4 regions associated with PD in a 
Japanese population: two of them included already known PD loci 
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(SNCA and LRRK2) but there were two new associated regions: PARK16 
(1q32) and other including the gene BST1 (4q15).  
[237] replicated the association for PARK16 in a European population 
(and also for SNCA and LRRK2). Nevertheless, their fourth region 
included MAPT and no BST1, highlighting the possibility that these two 
genes could be related to ethnic-specific susceptibility. 
 
PARK16 includes 5 genes: SLC45A3, NUCKS1, RAB7L1, SLC41A1 and 
PM20D1. Some of them are functionally interesting candidate genes for 
PD etiology: SLC41A1 is a magnesium (Mg2+) transporter, RAB7L1 is a 
small GTP-binding protein that plays an important role in regulation of 
exo-and endocytotic pathways and NUCKS1 is a nuclear DNA-binding 
protein that contains several consensus phosphorylation sites for 
casein kinase II and cyclin-dependent kinases. 
Some case-control studies, mainly using sporadic PD cases, have been 
conducted to confirm the association and to refine the locus. The most 
studied polymorphisms have been those described in the GWAS that 
defined the locus: rs823128 and rs947211 are located on the putative 
promoter of RAB7L1 and in the intergenic region between SLC41A1 
and RAB7L1 respectively. Significant results have been obtained in 
Taiwanese [238], in Chilean [239], in Ashkenazi Jews [240] and in Han 
Chinese [241], but not in a Spanish population [242].  
In conclusion, more studies are required to clarify the concrete identity 
of PARK16 which could be influenced by ethnicity. 
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 I.9.j. PARK17 and PARK18 
PARK17 and PARK18 loci are still on debate: BST1, GAK, HLA, VPS35 and 
EIF4G1 are the candidates. 
 
The first GWAS in familial PD had no significant results, although the 
highest values were found for regions in 4q22 (SNCA), 17q21 (MAPT) 
and 4p (GAK/DGKQ) (rs1564282 and rs11248051 are located on GAK 
whereas rs11248060 is in DGKQ) [243]. 
Other GWAS done in European population concluded that SNCA, MAPT, 
BST1 (rs4698412) and a region in chromosome 12 (12q24) were 
associated with PD [244]. 
[245] concluded that there was a significant result for the SNP 
rs3129882 in intron 1 of HLA-DRA gene in their case-control study 
conducted in a Caucasian population from USA. 
And another GWAS in Dutch cases and controls found an initial 
association for SNCA and BST1 (rs12502586) and, after post-hoc 
analysis, also for MAPT, GAK/DGKQ (rs1564282 and rs2242235 and 
rs4690296 which are located far away from GAK and DGKQ, in gene 
PCGF3) and HLA (rs4248166)24 [246]. 
It is noteworthy that although the same regions have been reported as 
possible PD loci in different GWAS, the highest values are not always 
obtained for the same markers and those can be in different genes 
                                                          
24
 There were 36 SNPs with significant results, with the lowest value for rs4248166, spanning 
a region of 440.1 kb that included HLA-DRA. 
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separated for tens of kilobases. To confirm the results is necessary to do 
case-control studies: 
 BST1: [241] could not find any significant results for any of the 4 
SNPs described by [236] in a case-control study in Han Chinese 
(rs11931532, rs12645693, rs4698412, rs4538475). 
 GAK: it has been observed that there is association for rs1564282 
and PD in case-control studies in a Caucasian population from USA 
[247] and in Han Chinese [248]. However, [242] could not replicate 
the results for rs11248051 in a Spanish population. 
 HLA: [242] could not replicate the results for rs3129882 in a 
Spanish population.  
 
More GWAS in sporadic PD have found that markers in regions 
containing SNCA (4q22) and/or MAPT (17q21) loci are related to PD 
susceptibility: [249] in a Caucasian population and [250] in a British 
population. Both genes are considered associated with PD risk without 
any doubt although it remains unclear which is/are the precise 
susceptibility variant/s.  
[250] also found weak but consistent association for 4p15 (BST1) 
(rs4698412) and 4p16 (GAK) (rs1564282).  
 
At present, BST1 remains as a controversial PARK locus candidate 
because although some GWAS have found significant results in markers 
located on this gene, mainly for rs4698412,  further replication of those 
associations in case-control studies has not been obtained. 
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BST1 (4p15.32) encodes for a protein that catalyzes the formation of 
cyclic ADP-ribose (cADPR). cADPR mobilizes calcium from ryanodine-
sensitive intracellular Ca2+ stores in the endoplasmic reticulum. 
 
GAK (4p16.3) encodes for a kinase that regulates the cell cycle. The 
results observed in rs1564282 support the idea that this (and not DGKQ 
that encodes for a diacylglycerol kinase) could be PARK17 locus.  
However, VPS35 (16q11.2) has also been postulated as PARK17: VPS35 
is involved in the recycling of membrane proteins between endosomes 
and the trans-Golgi network, and it is evolutionarily highly conserved. 
An exome sequencing analysis was conducted in a Swiss family with 
autosomal dominant late onset PD. The p.N620N mutation in VSP35 
gene was described in heterozygosis in all the affected members of the 
family. It was also observed in three more families and in one patient 
with sporadic PD, but not in any of the controls analyzed [251]. The 
same results were obtained after the exome sequencing analysis of an 
Austrian family with the same phenotype than the Swiss family: tremor 
predominant dopa-responsive PD, similar to idiopathic Parkinson´s 
disease. The p.N620N mutation was present in all the affected family 
members and it was cosegregating with the disease in an autosomal 
dominant mode. It had high but incomplete age-dependent 
penetrance because unaffected carriers were reported too [252]. In 
addition, p.N620N was detected in 3 patients with autosomal 
dominant PD and also in 1 patient with sporadic PD but not in controls 
in a Japanese population [253].  
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The presence of the amino acid asparagine in position 620 is highly 
conserved among species. For all these reasons, the p.N620N change 
has been suggested as a pathogenic mutation. 
 
HLA-DRA (6p21.3) encodes for the major histocompatibility complex 
class II and it has been proposed as PARK18 locus. This could represent 
the link between inflammation and Parkinson´s disease which has been 
widely studied. 
Nevertheless, EIF4G1 (3q27.1) has also been named as PARK18: the 
genome-wide linkage analysis of a French family with autosomal 
dominant late onset Parkinson´s disease (phenotypically similar to 
idiopathic PD) revealed a significant linkage for the region 3q26-q28. 
The subsequent deeper analysis found that the p.R1205H mutation in 
EIF4G1 gene segregated with the disease in all the affected family 
members. The mutation was absent in unrelated control subjects but it 
was identified in heterozygosis in seven families from USA, Canada, 
Ireland, Italy and Tunisia. 
EIF4G1 is the core scaffold of the translation initiation complex (eIF4F) 
that regulates the translation initiation of mRNAs encoding 
mitochondrial, cell survival and growth genes in response to different 
stresses. The p.R1205H mutation impairs complex formation, consistent 
with a dominant-negative loss of function, and, therefore, it impairs the 
ability of cells to rapidly and dynamically respond to stress, presumably 
through changes in the translation of existing mRNAs essential to cell 
survival [254].  
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I.10. Genetic susceptibility factors. 
 
o I.10.a. MAPT: 17q21.31 
Microtubule-associated protein tau (MAPT) is a microtubule binding 
protein that is particularly abundant in axons. It interacts with tubulin and 
promotes its assembly into microtubules. Moreover, tau stabilizes the 
structure of microtubules and is also involved in axonal transport along this 
network through its interaction with the motor proteins dynein and kinesin.  
 There are six isoforms in adult human brain which can be 
differentiated by the number of N-terminal repeats (N repeats, each one with 
29 amino acids; there can be 0, 1 or 2) and C-terminal repeats (R repeats or 
microtubule-binding repeats, each one with 31 or 32 amino acids; there can 
be 3 or 4). Alternative splicing in exons 2 and 3 determines the number of N 
repeats whereas alternative splicing in exon 10 , which encodes for the 
second R repeat, determines the number of R repeats (4R bind more 
efficiently to microtubules than 3R) (Figure 29) [255]. In a normal brain, the 
levels of 4R and 3R forms are similar.  
All these functions are lost in tauopathies25 where the levels of 
phosphorylation of tau are higher than the normal and the ratio 4R/3R is 
altered. This originates deficits in microtubule stability and in microtubule-
dependent trafficking and subsequent neuronal death. In addition, tau 
                                                          
25
 Alzheimer´s disease (AD), progressive supranuclear palsy (PSP) or corticobasal degeneration 
(CBD) are some of these neurodegenerative disorders. 
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assembles into filaments through its N and R repeats. After cell death, the 
aggregates remain in the extracellular space. Those neurofibrillary tangles are 
the characteristic hallmark of tauopathies. 
Nevertheless, these deposits are abnormal in Parkinson´s disease which 
is a synucleinopathy (it is characterized by Syn deposits). 
 
 
 
 
 
Taken from [255] 
The relation between MAPT and Parkinson´s disease is nowadays 
genetic: 
There is a ≈2Mb region in 17q21.31, centered in MAPT, with high linkage 
disequilibrium that includes other genes like CRHR1, IMP5 and Saitohin [256]. 
Inside this region there is an inverted fragment of 900kb that defines two 
different haplotypes called H1 and H2. There has been no recombination 
between both haplotypes since they diverged over 3 million years ago. 
Fig. 29. Tau isoforms. 
Gray boxes represent the N repeats (coded by exons 2 and 3) or the R repeats (coded 
by exons 9, 10, 11 and 12). The second microtubule-binding repeat is highlighted in 
dark gray. 
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H1 haplotype (direct orientation) is distributed worldwide and shows a 
normal pattern of recombination and genetic variability, whereas H2 haplotype 
(inverted orientation) is almost exclusive of Caucasian population [257] and 
shows an extreme homogeneity, i.e. there are some H1 sub-haplotypes but no 
H2 sub-haplotypes. These two facts support the idea that the H2 haplotype 
suffered positive selection: its frequency increased rapidly starting just from 
few founder chromosomes [258]. 
The frequency of H1 haplotype has been analyzed in different 
neurodegenerative diseases: it is higher in PSP and CBD patients and also in PD 
cases. 
The major part of studies have used the 238bp intronic deletion present 
in MAPT to differentiate H1 and H2 [259], usually with the same conclusion: 
homozygous H1H1 carriers have increased risk to develop PD [260-263]. And 
that has been obtained for familial and sporadic PD cases, independently of 
sex, age at onset and even ethnicity, although some opposite results have 
been reported [264] (small sample size is the common given reason for those 
divergences).  
Some sub-haplotypes containing H1 plus other polymorphisms have 
been proposed to increase the probability to develop PD. However, the identity 
of those polymorphisms remains unclear. There is no validation for these 
results because there are different conclusions between studies (each study 
proposes a different SNP: rs242562, rs2435207, rs3785883…) and, moreover, 
GWAS have also pointed to other variants along MAPT gene or even further. 
Maybe, the high linkage disequilibrium (LD) along the chromosomal region 
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makes difficult to differentiate between the polymorphisms that are 
contributing to the disease from those that are merely in LD with the 
“functional” polymorphism. 
In conclusion, there is currently insufficient evidence to refine the 
disease association to a specific region within MAPT or neighboring genes. 
MAPT is the supposed candidate but it is possible that genes near it are also 
involved in PD. Furthermore, it is difficult to explain why the frequent H1 
haplotype is related to different pathologies (PD, PSP, CBD). 
There is also a proteic connection between tau and PD which includes 
-synuclein and can be related to the formation of aggregates:  
Syn and tau are abundant neuronal proteins. Normally both adopt an 
unfolded conformation but they can polymerize: Syn selfpolymerizes but tau 
requires cofactors and Syn can act as such. [265] observed that in vitro tau 
and Syn synergistically promote and propagate each other’s polymerization 
into fibrils. Syn initiates the process by the formation of amyloidogenic 
“seeds” which may be degraded after the initiation of tau polymerization. This 
induces a conformational change in tau and triggers the process.  Tau and 
Syn preferentially form homopolymers, although they can also associate in 
the same filament.  
Moreover, in vitro, Syn stimulates the phosphorylation of tau by 
GSK3, which is one of the over 20 kinases that have been found to 
phosphorylate it. Those three proteins form a heterotrimeric complex but heat 
I. INTRODUCTION.  I.10. Genetic susceptibility factors. 
90 
 
shock protein 70 (Hsp70) suppresses Syn-induced phosphorylation of tau by 
GSK3 through its direct binding to Syn [266]. 
 
o I.10.b. GBA: 1q22 
Gaucher disease (GD) is the most prevalent lysosomal storage disorder. 
It is an autosomal recessive maladie caused by homozygous or compound 
heterozygous mutations in the glucocerebrosidase (GBA) gene. 
Glucocerebrosidase (GCase) catalyzes the cleavage of the glycolipid 
glucocerebroside in glucose and ceramide. However, the mutated protein 
losses this ability thus leading to the accumulation of glucocerebroside mainly 
in macrophages: they increase their size and acquire a diagnostically 
characteristic appearance (they are called “Gaucher cells”). These macrophages 
accumulate in the spleen and liver, which causes organ enlargement and 
inflammation. 
Gaucher disease is clinically divided in 3 types:  
 Type 1 or nonneuronopathic is the most common. This is the mildest form of 
the disease with no primary central nervous system involvement. There is 
enough residual enzymatic activity to prevent glucocerebroside accumulation 
in other cells rather than macrophages. It is panethnic (although Ashkenazi 
Jews are the most affected population). 
 Type 2 or acute neuronopathic is the rarer and most severe type. It is 
associated with fatal progressive neurological manifestations that cause death 
usually in the first year of life. There is complete deficiency in GCase activity 
and glucocerebroside accumulates in neurons and other cell types. 
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 Type 3 or juvenile subacute neuronopathic has a slower progressive course 
with neurologic manifestations. People develop the disease in their 
adolescence and die when they are in their 30s. 
Some GD patients develop parkinsonism. They present LB with mutated 
GCase in their brains. Their phenotype is wide, ranging from idiopathic PD 
symptoms with good response to L-dopa to early onset PD with dementia. In 
addition, relatives of those patients (that usually are carriers of GBA mutations 
in heterozygosis) develop PD with higher frequency than general population. 
Furthermore, there is a higher frequency of GBA mutations in Parkinson´s 
disease patients and [267] has also reported that there is a significant 
deficiency of GCase activity in substantia nigra and cerebellum in PD cases 
without GBA mutations. 
Around 300 mutations have been described throughout the gene: 
missense mutations are the most frequent, although nonsense, intronic, 
splicing mutations, frameshifts, insertions, deletions and even recombinations 
have been described (there is a pseudogen only 16kb downstream the gene, 
just 2kb shorter and with 96% of homology26). 
Ashkenazi Jews are the most affected by Gaucher disease. The 70% of 
the GD cases carry the p.N370S mutation. However in other populations, were 
GD is less prevalent, p.L444P is more frequent than p.N370S. The frequency of 
mutations is supposed to be different between ethnic groups. 
                                                          
26
 It can influence the genotype and cause misleading results: for that reason genotyping 
should be done by sequencing all the exons with primers specific for the gene. 
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It is noteworthy that there is no correlation between clinical phenotype 
and genotype: vast phenotypic variations among patients with the same 
genotypes have been reported, even in sibling pairs and twins. Moreover, there 
are genotypic differences between patients with the same phenotype. There is 
also no correlation between phenotype and residual enzymatic activity.  
Most of the studies that have analyzed the frequency of GBA mutations 
in PD patients and in controls have concluded that GBA mutations can be 
considered as a PD risk factor (even for familial and early onset Parkinson´s 
disease): in Ashkenazi Jews [268], in Caucasians from Canada [269], in people 
from different ethnicities from USA [270], in Portuguese [271], in Italian [272], 
in Brazilian [273], in Chinese [274, 275] and in Korean [276]. Nevertheless, 
some studies (in Tunisian [277] and in Norwegian [278] for example) did not 
found significant association for GBA mutations and Parkinson´s disease. The 
large, collaborative, international multicenter study, with thousands of PD 
patients and controls, conducted by [279] shed light to this controversy. They 
observed that there is an increased probability to develop PD for carriers of 
GBA mutations, and that is not exclusive for a specific ethnicity or a specific 
mutation. Moreover they confirmed a previous conclusion obtained by [280]: 
the age at onset of Parkinson´s disease was significantly lower among patients 
with GBA mutations as compared with those without mutations. 
Nowadays, GBA is considered a PD risk factor, although there are 
important differences in methodology and in ethnicity between studies: for 
example, some studies sequenced the complete gene whereas others only 
analyzed concrete mutations, and the number of samples analyzed in some 
I. INTRODUCTION.  I.10. Genetic susceptibility factors. 
93 
 
cases was not enough to obtain true statistically significant results. Those 
divergences preclude the proper quantification of the risk and the frequency 
for specific mutations or in overall. 
Some models have been proposed to explain the possible connection 
between GBA mutations and PD: 
1. There could be a gain-of-novel-function in mutated GCase: the unstable or 
misfolded protein would contribute to enhance the aggregation of Syn by 
direct or indirect interaction. That would explain the presence of mutant 
GCase in LB although other explanation could be that Syn oligomers trap 
the misfolded GCase. 
2. Glucocerebrosidase is a membrane-associated lysosomal protein, but when 
mutated, it could alter the lysosomal or autophagic pathway thus leading 
to Syn accumulation and subsequent aggregation, or leading to 
dysfunctional mitophagy and, consequently, damaged mitochondria would 
accumulate thus causing cellular death. 
3. Mutant GCase, rather than the wild type protein, is a substrate for parkin-
mediated ERAD [281]27. As a consequence, GCase would block the 
interactions between parkin and its other substrates, leading to ER stress 
and cell death. 
                                                          
27
 Endoplasmic reticulum-associated degradation: misfolded proteins are detected by the ER 
quality control machinery and after several attempts to refold them by the ER chaperones, the 
misfolded proteins are retrotranslocated from the ER to the cytosol, ubiquitinated and 
eliminated by the ubiquitin–proteasome system. 
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4. The accumulation of glucocerebroside originates vesicles that are suitable 
for Syn aggregation because -synuclein changes its structure in a lipid 
environment and tends to aggregate on the surface of lipid vesicles. 
5. In a “Gaucher cell”, large amounts of exogenously ingested or endogenous 
Syn could aggregate and acquire the prion form. Therefore, it has been 
proposed that a second hit might occur in the GBA gene to produce a 
disease-causing somatic mutation in a subset of macrophages. In those 
patients that have the mutation, cellular death or enhanced transfer via 
exosomes28 could cause that these “Gaucher cells” unload the prion form of 
Syn into the extracellular environment near neurons (Figure 30) [282]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Modified from [283] 
                                                          
28
 Exosomes are small intraluminal membranous vesicles (50–100 nm) that are released into 
the extracellular environment. 
Fig. 30. A theoretical model 
for Syn as a prion in GBA-
associated parkinsonism. 
The asterisk denotes the less 
probable process. 
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Any of the models is definitive. Any can explain why only some GD 
patients develop parkinsonism and why only some PD patients are carriers of 
mutations in GBA gene. It is supposed that GBA just contributes to, but not 
initiates, the development of SNCA pathology: the mutations just exacerbate 
and accelerate the process. 
 
 
o I.10.c. NR4A2: 2q24.1 
 
NR4A2, also known as Nurr1, is essential for the development and 
survival of dopaminergic neurons. It is important not only during development 
but also in adulthood. 
Nurr1 does not work alone; it works with other transcriptional factors 
and neurotrophic growth factors in the different development and maturation 
stages of mesencephalic dopaminergic neurons. 
Nurr1 belongs to the nuclear receptor family of transcription factors, 
concretely to the subgroup of nuclear orphan receptors, because unlike the 
others, it functions independently of ligands: thus, the regulation of the activity 
of Nurr1 might be mediated by the control of its expression or by post 
translational modifications of the protein. 
Nurr1 acts as a monomer or as a dimer and, for example, activates the 
transcription of tyrosine hydroxylase and enhances the expression of 
dopamine transporter. It is highly expressed in the substantia nigra but also in 
other parts of the brain and the body. 
In addition, it is related to some PARK genes:  
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 Nurr1 transcriptionally regulates the expression of Syn: in vitro, in 
SH-SY5Y cells, there is an increased expression of -synuclein when 
the expression of Nurr1 is blocked. However, the expression of 
Syn is just slightly decreased when Nurr1 is overexpressed [284]. 
Moreover, the expression of Nurr1 is compromised in cells that 
contain Syn inclusions like dopamine-containing cells present in 
SN in brains from PD cases [285].  
 DJ-1 activates Nurr1 via the ERK1/2 pathway to upregulate the 
expression of tyrosine hydroxylase [286]. 
 
Nurr1 has also been associated with neuroprotection against stress 
(induced by CREB) [287] and with promotion of cell survival (it regulates the 
expression of Bax via an interaction-dependent repression of p53 [288]; and, 
once the NMDA receptor stimulation of neurons is triggered, CREB activates 
Nurr1 that increases the expression of BDNF to prevent apoptosis [289]). 
 
Some genetic studies have been conducted: 
[290] analyzed the exon sequence of the gene in German PD patients 
(familial and sporadic cases) and controls, and described two new mutations in 
heterozygosis in 10 familial cases. These patients had clinical features similar to 
those seen in idiopathic PD. These changes were in the noncoding exon 1            
(c.-291delT and c.-245T>G) and caused decreased expression of the gene, that is, 
lower levels of mRNA in vitro, in cell lines and in lymphocytes of affected 
individuals. They concluded that both mutations could be considered the cause 
of familial Parkinson´s disease with an autosomal dominant mode of 
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inheritance, because both mutations were described in heterozygosis. 
However, [291] and [292] tried to confirm this conclusions in 50 and 44 
familial PD cases with European origin by sequencing the exon 1 and neither 
of them found any mutation, even new mutations. [293] also sequenced the 
exon 1 in 108 PD cases with familial history and an apparent autosomal 
dominant PD, mainly French, and again did not find any mutation. 
 
The 7048G7049 variant in intron 6 (c.1361+16insG) was previously 
reported in a study about mental and neurologic disease. [294] analyzed it by 
sequencing and restriction enzyme analysis in familial and sporadic PD cases 
and in controls from USA. They found that this mutation in homozygosis could 
be considered a risk factor for PD (familial and sporadic cases). The carriers 
did not differ in their clinical features from those of typical PD. Nevertheless, 
[295] obtained a different conclusion: in white controls and PD cases found 
that heterozygous carriers of the mutation had an increased risk to develop 
PD. And [296], also in a population from USA, found no significant differences 
for this intronic variant neither in homozygosis nor in heterozygosis between 
healthy controls and familial Parkinson´s disease patients. In addition, they 
could not find any of the two previously described mutations in exon 1 in this 
group. [297] obtained the same results than [296] for intron 6 and exon 1 in a 
group composed of controls and sporadic PD cases mainly from Germany, 
although they described two new mutations in exon 1: c.-253C>T and c.-223C>T. 
 
At the present time, genetic alterations at the NR4A2 locus are neither a 
major cause of familial PD in Europe nor a significant PD risk factor.  
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I.11. Dementia. 
Dementia is a syndrome characterized by progressive deterioration of 
intellectual functions (cognition and behavior). 
Some risk factors have been described [298]: 
 Age: there are early cases of dementia but the majority of people 
develop it after the age of 65; the prevalence for people older than 
65 years is around 6%. 
 Sex: there are controversial results; the majority of studies have not 
found any relation but some of them have concluded that women 
are more affected, particularly at older ages [299]. 
 High education level and physical activity, as it implicates reduced 
vascular risk and obesity and enhanced fitness, are considered 
protective factors, whereas controversial conclusions have been 
reported for body mass index, alcohol consumption and smoking. 
 
Dementia is one of the non-motor symptoms that a PD patient can 
develop. Its risk increases with longer evolution periods: 20 years after the 
diagnosis, almost 80% of PD patients will show dementia [300].  
Clinicopathological studies have shown that dementia is more common 
in PD patients whose main feature is akinesia or rigidity than in those with 
tremor dominant phenotypes [301]. Early indicators associated with cognitive 
decline include increasing apathy, impaired attention and concentration, 
forgetfulness and excessive daytime sleepiness. However, the diagnosis of 
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Parkinson´s disease with dementia (PDD) is challenging because the presence 
of dementia and parkinsonism describes also other disease: dementia with 
Lewy bodies (DLB).  
 
PDD and DLB could be considered part of a continuous spectrum of 
syndromes mainly characterized by parkinsonism and dementia, but they are 
considered two different clinicopathological syndromes.  
It is considered that a person is affected by DLB if there are 24 or less 
months of difference between the beginning of motor symptoms and the 
beginning of cognitive decline. If dementia occurs later in the disease it is 
considered PDD. This definition is arbitrary because it is known that the onset 
of dementia is earlier in DLB than in PDD and that the progression is faster and 
shorter, but this earlier onset is not always before the 24th month after the 
beginning of motor symptoms. Other features that differentiate PDD and DLB 
are that the frequency of visual hallucinations is greater in DLB than in PDD 
and that PDD patients possess LB deposits in their brains but DLB cases 
possess LB deposits in a more widespread pattern plus cortical A plaques, in 
a situation that is reminiscent of AD patients that present A aggregates but 
also neurofibrillary tangles [302]. 
Not all PD patients will develop dementia. Nevertheless, mild cognitive 
impairment (M.C.I.) is present since the earliest stages. M.C.I. can be defined as 
a cognitive decline from previous performance baseline, that is considered 
abnormal for the patient´s age, but with retention of normal daily functioning 
I. INTRODUCTION.  I.11. Dementia. 
100 
 
[301]. This cognitive impairment can stabilize, evolve to dementia or recover to 
normal cognition. The fact that people showing M.C.I. recover their normal 
cognition argues against the supposed consecutive steps in cognitive decline: 
normal cognition → M.C.I. → dementia. 
The most widely test used to determine the cognitive state of PD 
patients is the Mini-Mental State Examination (MMSE) [303]: this test lasts ≈10 
minutes and measures multiple cognitive domains like orientation, 
registration, attention and calculation, recall, language and visuospatial 
function. However, the Montreal Cognitive Assessment (MoCA) test [304] is 
more sensitive to identify mild cognitive impairment [305, 306], also in PD 
[307], and for that reason it is nowadays more recommended than MMSE 
especially in patients with cognitive complaints and functional impairment 
whose MMSE score is ≥2629. Nevertheless, MMSE is adequate to measure 
progression once patients develop dementia.  
MoCA is very similar to MMSE in duration (≈10 minutes), maximum 
score (30 points) and cognitive domains measured (orientation, recall, 
visuospatial function, attention, language but also executive functions).  
 
Dementia with Lewy bodies (DLB), Parkinson´s disease (PD) and other 
maladies like frontotemporal dementia (FTD), Huntington´s disease (HD), 
Creutzfeldt-Jakob disease (CJD)… only represent ≈30% of dementia cases. 
                                                          
29
 It is considered that there is normal cognition function if MMSE score is ≥26. Sometimes the 
cutoff is 24 instead of 26. 
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Dementia is mainly caused by  Alzheimer´s disease (AD), ≈50% of cases, and 
vascular dementia (VaD)30, ≈20% of cases [308]. 
It is essential to select a well-characterized affected population and do 
longitudinal studies (better than cross-sectional ones) to avoid inaccurate 
results due to the heterogeneous etiology of dementia. 
 
 
I.11.a. Alzheimer´s disease (AD): 
Alzheimer´s disease is a progressive neurodegenerative disorder that 
begins as mild short term memory deficits and culminates in total loss of 
cognition and executive functions. It is characterized by neuronal loss, mainly in 
hippocampus and cerebral cortex associated with two hallmark pathological 
lesions: extracellular deposition of amyloid plaques (mainly formed by A) and 
intracellular deposition of neurofibrillary tangles (mainly formed by paired 
helical filaments of hyperphosphorylated tau) [309]. 
The majority of AD patients present the late onset form of the disease 
and have no familial history; the etiology is unknown although some genetic 
and/or environmental factors have been postulated as pathogenic.  
The APOE gene (AD2) is nowadays the strongest and most highly 
replicated genetic risk factor for non-familial AD, concretely the 4 allele. In 
humans, there are mainly three isoforms (Figure 31) [310]: 
                                                          
30
 It may be caused by various types of vascular pathology in the brain, such as infarctions. 
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Modified from [310] 
APOE (apolipoprotein E) regulates the metabolism of lipids by directing 
their transport, delivery and distribution from one tissue or cell type to 
another: for this purpose, APOE binds to lipids and forms lipoprotein particles 
that bind to specific cell surface receptors [311]. It is expressed by several cell 
types, but with highest expression in the liver and in the central nervous 
system. APOE also works in synaptic function, immune regulation and 
intracellular signaling. 
The pathogenic mechanism of APOE in AD is not clear: there are 
controversial results about the influence of APOE in A aggregation, 
accumulation and clearance. Those processes could be different between the 
three isoforms. 
The influence of APOE in Parkinson´s disease has also been studied but 
there are opposite and not definitive conclusions: 4 allele has been mostly 
associated with higher PD risk ([312] in familial PD, [313] in Mexican), but also 
Fig. 31. ApoE isoform-specific differences. 
Amino acids in positions 130 and 176, which are traditionally named as 112 and 158, 
respectively, determine the charge and structural properties of the protein, which 
may ultimately influence the functional properties of the isoform: 2 and 3 bind 
preferentially to HDLs (high-density lipoproteins) whereas 4 to VLDLs (very-low-
density lipoproteins).  
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with lower PD risk ([314] in Caucasians non-Hispanics), decreased age at onset 
([315] in Caucasian, [312, 316] in familial PD, [317] in Australian) and risk of 
dementia in PD ([318] sporadic and familial PD, [316] in familial PD). However, 
2 allele has also been considered a PD risk factor ([319] a meta-analysis, 
[320] in Thai) and some studies have concluded that any APOE allele is related 
to Parkinson´s disease ([321] in Irish, [322], [323] in Norwegian, [324] in a 
large case-control study with thousands of people). 
Factors like the ethnicity, the sample size and the objective of the study 
might have originated those divergences. Future studies should be longitudinal 
and conducted in large populations. 
 
Around 1% of the cases is clustered in families with mutations in the 
genes APP, PSEN1 or PSEN2 and develop the early onset autosomal dominant 
form of the disease. Familial and sporadic cases have the same clinical features 
and there is no cure for them. 
APP (AD1) is ubiquitously expressed. Its physiological function is 
unknown [325]. APP encodes for a single-pass transmembrane protein with a 
large extracellular domain that resembles a signal-transduction receptor 
[326]. It is cleaved by the -secretase complex, a proteolytic complex formed 
by PSEN1 or PSEN2, Aph1, PEN2 and Nicastrin; the last 3 proteins are 
necessary for the assembly of the complex [327] (Figure 32).  
Presenilins (PSEN1 -AD3- and PSEN2 -AD4-) are ubiquitous. These 
intramembrane cleaving proteases are the catalytic members of the -
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secretase complex. They also work in other processes like protein degradation 
or calcium homeostasis regulation: they are passive ER Ca2+ leak channels but 
when mutated they lead to supranormal Ca2+ release from the ER [328]. 
 
 
 
 
Modified from [329] 
The main supposed pathological process that originates AD is related to 
APP processing (Figure 33). The 90% of mutations described in AD familial 
cases are in presenilins. They cause a change in the cleavage point in the 
amyloidogenic pathway: in normal conditions, A40 is the majority fragment 
whereas when PSEN1 or PSEN2 are mutated, A42 is the most common 
fragment. A42 is more amyloidogenic and more prone to aggregate than 
A40. APP duplications are also pathogenic [330, 331]. 
Amyloid is transported and released to the surface. In AD patients, A 
monomers aggregate into fibrils and form extracellular plaques. Amyloid can 
be removed by autophagy but during the onset of AD, although autophagy is 
increased, the transfer of autophagic vesicles to the lysosomes is impeded and 
Fig. 32. The -secretase complex. 
The gap in presenilin reperesents the endoproteolytical cleavage necessary to activate it.  
The circle represents an early onset Alzheimer´s disease mutation. 
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this may contribute to the accumulation of A. The subtle effects of the 
oligomers on synapses progressively cause neural injury, neuritic dysfunction 
and finally death. 
 
 
 
 
 
 
 
Modified from [332] 
Mutations in any of those 3 genes may act by increasing the steady 
state level of A, altering the A42/40 ratio or altering the amyloidogenic 
potential of A. More A monomers and less clearance can trigger their 
aggregation and initiate the pathogenic cascade. That would explain the 
pathological process in less than 1% of the affected people so there have to be 
Fig. 33. Cleavage of the amyloid precursor protein (APP). 
It is sequential and occurs by two pathways.  The nonamyloidogenic processing of APP 
involves -secretase and -secretase and generates the A40 fragment whereas the 
amyloidogenic processing involves the -secretase and the -secretase and can generate 
the A40 or the A42 fragments. Both processes also generate soluble ectodomains 
(sAPP and sAPP) and identical intracellular C-terminal fragments (AICD). AICD act as 
transcription factors in the nucleus.  
The dark gray fragment in APP is the A peptide.  
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other undescribed mechanisms involved in the pathogenesis because A 
deposits are present in all AD cases. 
 
At the present time, the calcium hypothesis is being explored. A 
oligomers can insert into the plasma membrane and form Ca2+-permeable 
pores. Calcium signaling is utilized by neurons to control a variety of functions, 
including membrane excitability, neurotransmitter release, gene expression, 
cellular growth, differentiation, free radical species formation and cell death. 
The hypothesis supposes that there could be a remodeling in calcium signaling 
that would result in the learning and memory deficits that occur early during 
the onset of Alzheimer´s disease.  
[333] described for the first time the gene CALHM1 (calcium 
homeostasis modulator 1) that encodes for a multipass transmembrane 
glycoprotein. CALHM1 is a cell surface protein of neuronal origin, although it is 
also present in ER membrane, that shares sequence similarities with NMDAR. 
It homomultimerizes and generates a calcium-selective cation current at the 
plasma membrane. CALHM1 controls cytosolic calcium concentrations, a 
mechanism that may lead to ERK1/2 activation [334]. Cytosolic Ca2+ is critical 
for the regulation of APP processing, and the p.P86L change decreases the 
concentration of calcium and that originates an increase in A levels as there 
is an inhibition of the control of APP processing by CALHM1 (Figure 34).  
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Taken from [334] 
CALHM1 also increases Ca2+ leak from the ER and, more importantly, 
reduces ER Ca2+ uptake. As a result, the calcium content of the endoplasmic 
reticulum is drastically decreased and that triggers the ER stress which can 
evolve to cell damage [335]. 
[333] conducted a case-control study that showed that the p.P86L 
mutation was associated with Alzheimer´s disease. However, other case-
control studies have not found that association for p.P86L and AD either in 
Caucasians or in Asians ([336], [337] in Japanese, [338] in Chinese Han). It is 
noteworthy that the L allele is less frequent in non-Caucasian populations than 
in Caucasian.  
Moreover, there are studies that have analyzed the influence of this 
mutation in the A levels in cerebrospinal fluid: [339] found that this relation 
exists in healthy people, whereas [340] found that there is no relation 
between p.P86L and A42 levels in AD patients. 
Fig. 34. Influence of the p.86L mutation in the role of CALHM1 in calcium signaling: 
relevance for APP metabolism and Alzheimer´s disease pathogenesis. 
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I.11.b. Frontotemporal dementia (FTD):  
Frontotemporal dementia (FTD) is the second most common cause of 
dementia in people younger than 65 years. Men and women are equally 
affected. There is focal atrophy of the frontal and temporal lobes that leads to 
progressive behavioral changes, cognitive decline and language difficulties and, 
finally, to severe dementia.  
There are three clinical subtypes (one behavioral and two language 
variants): 
o bvFTD (behavioral variant of FTD) is characterized by loss of empathy, 
apathy, selfishness, neglect of personal hygiene,  disinhibition, 
irritability, gluttony… 
o in SD (semantic dementia) there is anomia31 and impaired 
comprehension of words, objects or faces, although there is a relative 
preservation of grammar and pronunciation and the speech is fluent. 
Patients use generic terms like “thing” and are unable to understand 
less frequent words. 
o in PNFA (progressive non-fluent aphasia32), patients have problems with 
pronunciation; their speech is non-fluent, agrammatical, and poorly 
articulated with phonological errors. However, word comprehension 
and object recognition are well preserved [341, 342]. 
 
                                                          
31
 Anomia: language disorder that prevents call things by their name. 
32
 Aphasia: loss of the ability to produce or understand the language. 
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FTD forms part of a neuropathologically heterogeneous disorder called 
frontotemporal lobar degeneration (FTLD). FTLD also includes amyotrophic 
lateral sclerosis (ALS), progressive supranuclear palsy (PSP) and corticobasal 
degeneration (CBD). There is no cure for FTLD patients although there are some 
symptomatic treatments. 
 PSP is characterized by postural instability and falls within the first year of 
disease, supranuclear gaze palsy and symmetric parkinsonism minimally or 
unresponsive to levodopa (there is brainstem-predominant atrophy). 
 CBD is characterized by markedly asymmetric parkinsonism with dystonic 
posture, myoclonus33, apraxia34, alien limb syndrome and sensory or visual 
neglect (there is cortical-predominant atrophy) [343]. 
 ALS is a progressive neurodegenerative disease that affects motor neurons: 
the death of upper and lower motor neurons in the brainstem, motor cortex 
and spinal cord leads to progressive muscle weakening, paralysis and 
eventually death due to respiratory failure. Around 90% of cases are sporadic 
whereas the remaining 10% are familial caused by mutations in some genes: 
SOD1, TARDBP, FUS, VCP and CHMP2B amongst others [344]. 
 
FTLD can be histologically divided into two major subtypes: FTLD with 
tau-positive inclusions (FTLD-tau) and FTLD with ubiquitin-positive and TDP-43-
positive but tau-negative inclusions (FTLD-TDP) (Figure 35) [345].  
                                                          
33
 Myoclonus: brief, shock-like, involuntary muscle jerks. 
34
 Apraxia: the patient wants to do a movement, and there is no physical constraint, but it is 
not possible. 
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Taken from [345] 
Tau inclusions accumulate in neurons and are formed by 
hyperphosphorylated and aggregated tau proteins. Although they are present 
in PSP and CBD patients only some FTD cases carry mutations in MAPT gene: 
missense mutations, that modify tau interaction with microtubules and that 
can change its potential to aggregate into filaments, and splicing mutations, 
that affect the splicing of exon 10 and thus alter the ratio 4R/3R. Those proteins 
are more easily abnormally hyperphosphorylated and self-aggregate into 
filaments more readily [255]. 
MAPT mutations are mainly present in families with dominant forms of 
FTD. Nevertheless, other families with similar clinical features that show 
linkage to the same chromosomal region (17q21) have been described. They 
Fig. 35. Clinical, genetic and pathological spectrum of frontotemporal lobar 
degeneration. 
FTD overlaps with motor neuron disease (FTD-MND or FTD-ALS) as well as with the 
parkinsonian syndromes PSP and CBD. MND comprises a group of conditions with 
progressive motor neuronal loss where ALS is the most frequent presentation (>75%). 
It can be viewed as a motor-dementia-parkinsonism continuum: premortem diagnosis is 
often a challenge due to the overlapping clinical features. 
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carry mutations in a different gene: PGRN. Those patients have FTLD-TDP 
inclusions. 
PGRN encodes for a 593 amino acid extracellular glycoprotein widely 
expressed. It is composed of seven and a half granulin peptides (6kDa 
molecules rich in cysteine) separated by interlinked spacer regions that are 
cleaved by some proteases (elastase, proteinase 3…) into individual granulins 
(Figure 36). The levels of PGRN and granulins are controlled by some proteins, 
like SLPI, and both act as multifunctional secreted growth factors playing key 
roles in cell division, survival, migration, embryogenesis, transcriptional 
repression, inflammation and others [346, 347]. 
 
 
Modified from [347] 
PGRN mutations lead to a reduction in protein activity or level: they are 
mostly nonsense mutations or frameshifts that originate defective mRNAs that 
are degraded by the nonsense-mediated RNA decay pathway (NMD). However 
complete or near-complete deletions of the gene, splicing mutations, signal 
peptide mutations and coding variants that might cause loss of function by 
structural changes or by reduced protein production or secretion have also 
Fig. 36. Progranulin structure. 
The progranulin protein (top) and the consensus sequence of the processed granulin 
peptides (grn) (bottom). 
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been described. Consequently, [348, 349] concluded that haploinsufficiency is 
pathogenic and leads to neurodegeneration. 
 
It is necessary to elucidate the connection between PGRN mutations, 
the affected function and TDP-43 accumulation. 
 
 TAR DNA binding protein-43 (TDP-43) is encoded by TARDBP gene. It is a 
nuclear DNA/RNA binding protein of 414 amino acids, highly conserved and 
ubiquitously expressed that acts as a shuttle between the nucleus and the 
cytoplasm (Figure 37). TDP-43 regulates transcription, pre-mRNA splicing (by 
recruiting splicing factors) and microRNA processing [350]. TDP inclusions are 
composed of ubiquitinated and hyperphosphorylated C-terminal fragments of 
TDP-43 and accumulate in neuronal cytoplasm. TARDBP is mutated in familial 
and sporadic ALS but not frequently in FTD although FTD patients also have 
TDP-43 inclusions. It is unclear whether those aggregates are a cause or a 
consequence of the disease pathogenesis. 
Recently a new subgroup has been described: a small number of FTLD 
cases with ubiquitin-positive TDP-43-negative inclusions have shown FUS-
positive inclusions but no abnormal posttranslational modifications in this 
protein have yet been identified. FUS gene is not usually mutated; mutations 
have only been described in some familial ALS patients.  
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FUS is a ubiquitously expressed nuclear DNA/RNA binding protein of 
526 amino acids that regulates transcription, pre-mRNA splicing and mRNA 
transport. It can act as a shuttle between the nucleus and the cytoplasm (Figure 
37). Its functions and its structure are very similar to those described for TDP-43 
[350]. 
Taken from [350] 
 
 FTLD is a genetically complex disorder, with multiple genetic factors 
contributing to the disease. The majority of FTLD cases are sporadic (60-90%). 
Fig. 37. TDP-43 and FUS structure.  
TDP-43 contains two RNA binding domains, a glycine-rich C-terminal domain involved in protein-
protein interactions, a nuclear localization signal (NLS) and a nuclear export signal (NES). The 
majority of mutations described are located on the Gly-rich region and that could mean that the 
ability to interact with other proteins is essential for TDP-43. 
FUS contains a glycine-rich region, an RNA binding domain, a NLS, a NES, and other regions to 
interact with proteins like a Zinc finger. Most of the mutations described in familial ALS are located 
on the NLS. Therefore, its accumulation in the cytoplasm seems to be pathogenic. 
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Mutations in MAPT and PGRN account for the 20% of the familial cases, 
whereas mutations in TARDBP, FUS, VCP and CHMP2B are rare. Patients with 
VCP mutations present FTLD-TDP inclusions whereas those with CHMP2B 
present ubiquitin-positive TDP-43-negative inclusions.  
Some important genetic, functional and structural aspects of FTLD 
pathogenesis remain unknown: the influence of other genes that have not 
been described yet, the relation between protein inclusions and gene 
mutations, especially in those cases where the mutated protein and the 
aggregated protein are different, the initial cause that triggers the pathogenic 
mechanism or the cellular processes that are affected initially or subsequently. 
 
 
I.11.c. Huntington´s disease (HD): 
Huntington´s disease is an autosomal dominant neurodegenerative 
disorder characterized by chorea35, cognitive decline, intellectual impairment 
and emotional disturbances. With the progression of the disease, motor rigidity 
and dementia predominate. There is massive GABAergic striatal neuronal 
death and also atrophy of the cerebral cortex, thalamus and other brain 
regions though with a less severe extent [351]. 
It is progressive, fatal (with death in the 15-20 years after diagnosis) and 
caused by an abnormal CAG repeat expansion in exon 1 of the HTT gene that 
                                                          
35
 Chorea: sudden jerking movements which are entirely random in their timing and in their 
distribution about the body. 
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originates a protein (htt or huntingtin) with abnormally long polyglutamine 
(polyQ) fragments in their N-terminal extreme. As with most of the diseases 
caused by expansion of triplet repeats, there are three main groups of 
expansions: the normal range, that comprises expansions with less than 27 
repeats, the preclinical range, that includes expansions between 27 and 35 
repeats, and the pathogenic range, with those expansions of 36 or more 
repeats [352].  
HD is monogenic, fully penetrant and marked by the anticipation effect, 
i.e. the onset is earlier and the progression of the disease faster in successive 
generations of an affected family. The 90% of HD cases are familial although 
there are “de novo” patients too: cases that originate from asymptomatic 
parents with normal repeat lengths that have expanded to the symptomatic 
range. 
Htt is ubiquitously expressed in the central nervous system and is 
mainly a cytosolic protein although it has also been identified in nucleus, 
plasma membrane, mitochondria, lysosomes and endoplasmic reticulum. It can 
act as a shuttle between the cytoplasm and the nucleus but the expanded 
polyQ disrupts the balance of htt distribution and leads to its accumulation in 
the nucleus. Those large intranuclear toxic inclusion bodies formed by mutant 
htt are the pathological hallmark of HD. 
The precise function of huntingtin remains elusive; although it is 
required for normal development, deletion in mice is letal. It interacts, mainly 
by its N-terminus, with many proteins with very different functions: 
endocytosis and vesicle transport, cell signaling, apoptosis or transcriptional 
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regulation amongst others. However, that changes due to the polyQ repeat 
because the structure of the protein is altered, it undergoes extensive 
posttranslational modifications such as cleavage, that forms toxic N-terminal 
fragments, and due to the polyQ fragment, the protein is more prone to 
aggregate [353]. 
The mutant htt has some conformational states: a soluble (nontoxic) 
conformer in equilibrium with a soluble toxic conformer. The ubiquitin-
proteasome system can clear them. Nevertheless, this mechanism is impaired 
in HD patients and, therefore, the protein changes its structure to the 
misfolded conformer that cannot be degraded and forms the insoluble 
aggregates. 
All these structural changes are supposed to trigger the pathogenic 
cascade that affects some cellular processes in HD patients. There is 
transcriptional dysregulation (the aggregates bind and sequester proteins, 
including factors that regulate transcription; in addition, the soluble mutated 
htt has different affinity to its usual interactors; as a consequence, some genes 
have different expression, for example, BDNF expression is decreased) [354], 
caspase activation, NMDAR activation, calcium dyshomeostasis, defective 
axonal trafficking (mutant proteins interact with proteins localized in axons 
and block the transport of organelles along them) and abnormal 
mitochondrial dynamics (fission is increased and fusion is decreased and that 
originates an increased mitochondrial fragmentation; there is also abnormal 
mitochondrial bioenergetics) (Figure 38) [355]. 
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Taken from [356] 
 
I.11.d. Creutzfeldt-Jakob disease (CJD) 
Although some recent studies, that need further validation, have 
concluded that other genes are associated, at present, all prion diseases are 
caused by, and only, the prion protein.  
The human prion protein (PrP) is encoded by the PRNP gene. This 
protein is N-glycosylated and mainly attached to the plasma membrane by a C-
Fig. 38. Intracellular pathogenesis in Huntington´s disease.  
Mutant htt (blue helical structure) with an expanded polyglutamine repeat (in red) undergoes a 
conformational change and interferes with cellular trafficking, especially of BDNF. Mutant htt is 
cleaved at several points to generate toxic fragments with abnormal compact β conformation. A 
major action of mutant htt is interference with gene transcription, in part via PGC1α, leading to 
decreased transcription of BDNF and nuclear-encoded mitochondrial proteins. Mutant htt can 
also lead to increased transglutaminase activity thus producing an abnormal covalent link 
between proteins. 
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terminally linked glycosyl phosphatidylinositol anchor. PrP is highly expressed 
in brain, hearth, lungs… and has an unknown function.  
The pathogenic mechanism that causes prion diseases starts when PrP 
changes from its normal conformation (PrPc, or cellular PrP) to the pathogenic 
conformer (PrPSc, or scrapie PrP). PrPc changes its structure by the direct 
interaction with the scrapie form: this is the only requisite. The spontaneous 
conversion of PrPc to PrPSc is very slow but this conversion is accelerated when 
there are PrPSc “seeds”. This is just a conformational change, neither splicing 
nor postranslational modifications are involved. PrPc has a majority of -helix 
in its structure, whereas PrPSc is mostly folded in -sheets, is more prone to 
aggregate and also protease-resistant. PrPSc polymerizes into amyloid 
aggregates and spreads between cells and even between organisms (Figure 
39). 
 
 
Modified from [357] 
The human prion36 diseases (also called transmissible spongiform 
encephalopathies or TSE) can be (Table 3):  
 Inherited: familial Creutzfeldt-Jakob disease, or CJD, is characterized by 
dementia with fast evolution; Gerstmann-Sträussler-Scheinker disease, 
                                                          
36
 Prion means “protein infectious agent” and they represent a new type of infectious agent 
that do not have nucleic acids. 
Fig. 39. The conformational change in PrP triggers the pathogenic pathway.  
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or GSS, is characterized by ataxia37 and unpredictable clinical course; 
and fatal familial insomnia, or FFI, is characterized by insomnia and 
autonomic nervous system dysfunction that progresses to dementia. 
They are caused by mutations in the PRNP gene. Mutations are 
sufficient to cause the conformational conversion and, therefore, the 
disease. Only about the 10% of cases are familial. They have an 
autosomal dominant mode of inheritance and are nearly 100% 
penetrant. 
 Acquired: iatrogenic CJD and kuru, that is mainly due to cannibalism and 
generally presented as an ataxic disorder although in the terminal 
phases of the disease dementia is frequent. The transmission of prions 
from one specie to another with non-identical sequences is possible. 
Animals like sheep or cattle are also affected. Depending on the host, 
the type of inoculum and the route of inoculation, the incubation time 
lasts for weeks, months or years. 
 Sporadic: sCJD; although recently sFFI has also been described. The 
majority of prion disease cases are sporadic. Their ethiology is 
unknown. There are no mutations in the PRNP gene but it has been 
postulated that horizontal transmission, somatic mutations that affect 
the exonic region in the PRNP gene or spontaneous events that trigger 
the conformational change in PrP can be involved. 
 
 
 
                                                          
37
 Ataxia: decreased ability to coordinate movements. 
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Taken from [358] 
 
The neurophatological features that describe human prion diseases are 
spongiform degeneration, gliosis and neuronal loss in the absence of an 
inflammatory reaction. The damage is mainly located on cerebral cortex,  basal 
ganglia, thalamus and cerebellum. There is no cure and men and women are 
equally affected [359, 360]. 
Although most of the mutations described in PRNP gene cause one 
concrete prion disease, in some cases, the same mutation generates different 
phenotypes. That is the case for the p.D178N mutation that has been described 
in FFI and familial CJD cases. [361] observed that the disease was determined 
by the co-segregation of this mutation and the polymorphism located on 
position 129 (p.M129V): FFI for 129M carriers or CJD for 129V carriers. 
The p.M129V polymorphism also increases the risk for sCJD: 
homozygous individuals (MM or VV) have more risk to develop sCJD than 
heterozygous (MV). And homozygosity for either allele is also related with 
faster progression in all familial and sporadic prion diseases.  
Table 3. Human prion diseases. 
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This polymorphism has been widely studied in other neurodegenerative 
diseases (FTLD, ALS or AD). However, no definite conclusion has been 
obtained. For example, in Alzheimer´s disease, [362] found that homozygous 
carriers (129VV) were significantly more frequent in early onset Dutch AD 
cases; nevertheless, [363] found that in early onset German AD cases 129MM 
genotype was the most frequent whereas [364-366] could not associate any of 
the genotypes of this polymorphism with sporadic Alzheimer´s disease 
(independently of the onset) in any of the populations studied (Spanish, Italian 
and Japanese, respectively). 
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I.12. Others. 
There are other proteins considered potential candidates to explain PD 
pathogenesis: 
 
 I.12.a. NFE2L2 and KEAP1 (or Nrf2 and INrf2): 
Cells have mechanisms to control the levels of ROS and electrophiles to 
avoid the damage that oxidative stress can have on their survival, 
development and evolution. One of them involves NFE2L2 and KEAP1. 
Although some aspects are still on debate, at the present time, it is 
thought that, in basal conditions, NFE2L2 forms a complex with KEAP1 and 
other proteins (Figure 40) and is constantly ubiquitinated and degraded via 
the proteasome. 
 
 
 
 
 
Modified from [367] 
Fig. 40. Structure of the complex.  
A KEAP1 homodimer acts as the substrate adaptor and binds, NFE2L2 via its C-terminal 
domain, and Cul3, via its N-terminal domain. Cul3 serves as the scaffold protein that forms 
the E3 ligase complex with Rbx1 which recruits the E2 enzyme.  
Cul3 is neddylated (small circle). Neddylation, is the process by which Nedd8, a small 
ubiquitin-like protein (there are structural and sequence similarities between both 
proteins), is conjugated onto a conserved lysine residue. Neddylation occurs by a similar 
process as ubiquitination (E1, E2 and E3) and is reversible. Nedd8 stimulates the transfer of 
ubiquitin from E2 onto the substrate (NFE2L2 in this case) and also facilitates the 
elongation of the polyubiquitin chain. 
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However, when there is oxidative stress, the sensor cysteines of KEAP1 
are oxidized and NFE2L2 is released from the complex and translocates to 
the nucleus where it heterodimerizes with other proteins, such as small Maf 
and Jun, and triggers the transcription of genes involved in the protective 
cascade against oxidative conditions such as enzymes involved in drug 
metabolism -NQO1- and glutathione homeostasis -GST-, chaperones, 
proteasome subunits, neurotrophic factors -BDNF- or transporters -Mrp1- 
amongst others which have antioxidant or electrophile responsive 
elements (ARE/EpRE) on their promoters [368, 369]. In addition, NFE2L2 
regulates the expression of KEAP1, Cul3 and Rbx1, what can be considered a 
feedback auto-regulatory loop. 
 
  
 I.12.b. LAMP-2A and hsc70: 
There are two main cellular mechanisms involved in protein 
degradation: the ubiquitin-proteasome system and autophagy.  
There are three types of autophagic processes: 
 Macroautophagy and microautophagy are not selective processes. Both 
degrade cytosolic regions that contain proteins or even organelles 
present in a wide range of eukaryotes, mammals included. In 
macroautophagy, a de novo formed isolation membrane sequesters a 
cytosolic region and then, this membrane seals into a double membrane 
vesicle (autophagosome) that fusions with lysosomes to acquire the 
necessary enzymes to degrade its inner content (autophagolysosome). 
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However, in microautophagy, the lysosomal membrane directly engulfes 
the cytosolic region that will be degraded [370].  
 Chaperone-mediated autophagy (CMA) only occurs in mammals and 
consists in the degradation of individual cytosolic proteins. The target 
proteins have a motif, KFERQ, which is recognized by the hsc70 
chaperone. Hsc70 plus cochaperones, that regulate its activity or act as 
cochaperones themselves (hop, hip, bag-1, hsp40 and hsp90), and the 
target protein bind to the CMA receptor, LAMP-2A, at the lysosomal 
membrane. After unfolding the protein, it crosses the lysosomal 
membrane, supposedly through a pore formed by oligomerized LAMP-
2A, assisted by a lysosomal form of hsc70 (lys-hsc70) present in the 
lumen. There, the protein is rapidly degraded and the hsc70 chaperone 
complex is released from the lysosomal membrane and can bind to other 
proteins to start the process again [371]. 
 
The gene LAMP-2 codifies for three different isoforms (LAMP-2A, LAMP-
2B and LAMP-2C) that have the same heavily glycosylated luminal domain 
but differ in their short cytoplasmic tail and the single transmembrane 
domain (those domains are partially codified by exon 9 which is alternatively 
spliced). Only LAMP-2A is involved in CMA.  
The HSP70 multigene family of chaperones is composed of 
constitutively expressed members such as hsc70 and stress-inducible 
members such as hsp70. Hsc70, also called HSPA8, works in the proper 
folding of newly synthesized proteins and those subject to stress-induced 
denaturation, in the refolding of misfolded or aggregated proteins, 
I. INTRODUCTION.  I.12. Others. 
125 
 
preventing protein aggregation, promoting ubiquitination and degradation 
of misfolded proteins, in the translocation of proteins into cellular 
compartments such as mitochondria and chloroplasts and also in CMA. 
 
CMA is maximally activated during stresses that damage proteins such 
as starvation or oxidative stress. Its activity is decreased in aging, because 
the levels of LAMP-2A at the lysosomal membrane decrease with age, and 
in familial PD, although wild type Syn is degraded by CMA, the mutants 
p.A53T and p.A30P bind strongly to the CMA-receptor at the lysosomal 
membrane but do not translocate into the lysosomal lumen and even block 
the process38 [372]. As a consequence, long-lived damaged cytoplasmic 
proteins are less efficiently degraded and the accumulation of damaged 
proteins increases cellular susceptibility to stressors. Although 
macroautophagy, that occurs constitutively in cells, is activated to 
compensate this deficiency, that could not be enough. 
In addition, [373] found that the expression of LAMP-2A and hsc70 was 
significantly reduced in substantia nigra and amygdala of PD brains when 
comparing to healthy controls, and that autophagy-related proteins seemed 
to accumulate in Lewy bodies.  
 
Therefore, dysfunctional autophagy is considered one of the possible 
causes of Parkinson´s disease. 
 
 
                                                          
38
 Some frequent covalent modifications of Syn such as oxidation, nitration, formation of 
dopamine adducts… also have the same effect on CMA activity. 
I. INTRODUCTION.  I.12. Others. 
126 
 
 I.12.c. Neurotrophic factors (CDNF, MANF, BDNF): 
Neurotrophic factors are small secreted proteins that regulate the 
number, development, maturation and survival of neurons by binding to 
their receptors [374]. 
 
 CDNF (cerebral dopamine neurotrophic factor) and MANF 
(mesencephalic astrocyte-derived neurotrophic factor) belong to the fourth 
and most recently discovered family of neurotrophic factors. Their 
expression in the human body is widespread and, if they follow the same 
expression pattern observed in other animals, both are expressed at all 
developmental stages and in adults.  
CDNF and MANF are highly homologous and evolutionary conserved in 
vertebrates; in invertebrates, however, there is just one similar 
neurotrophic factor that resembles more to MANF than to CDNF: 
 in Drosophila, it is required for the maturation of the embryonic 
nervous system and the maintenance of neuronal connectivity. When it 
is abolished, there is high dopaminergic cellular death, embryonic 
lethality and a rough decrease of dopamine levels [374]. 
 in zebrafish, there is no apparent abnormal phenotype when MANF is 
abolished but there is a reduction of dopamine-containing neurons 
during embryogenesis and a lower dopamine level. The phenotype is 
not as lethal as in fly but the different outcomes may be due to 
significant differences in the organization of neurotransmitter systems 
between invertebrates and vertebrates [375]. 
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In any case they/it are/is necessary for the proper neuronal 
development and survival. 
 
Nowadays, due to the fact that the current PD treatments are just 
symptomatic and cannot stop the degenerative process, CDNF and MANF 
are considered promising therapeutic agents in PD, even more than GDNF, 
for their effectiveness, neuroprotective and neurorestorative role observed 
in animal models:  
o [376] observed that, in rats, CDNF treatment, before or after the striatal 
injection of 6-OHDA39, had a protective or reparative effect, 
respectively, on dopamine-containing neurons in the SN.  In mice, CDNF 
also protected the nigrostriatal system and promoted its recovery after 
MPTP treatment [377].  
o MANF selectively promoted in vitro, in embryonic rat neurons, the 
survival of dopaminergic nigral neurons. This effect was not observed in 
either GABAergic or serotonergic cells. Moreover, its effect was more 
powerful than that observed for GDNF and BDNF [378]. 
 
Nevertheless, the receptors and signaling pathways where they are 
involved remain unclear. There is just some more information about MANF 
obtained from in in vitro studies that have reported that  
                                                          
39
 6-OHDA does not cross the blood-brain barrier. When it is injected in the striatum to 
reproduce the PD phenotype in an animal, it produces lesions on nerve endings and progresses 
retrogradely towards the substantia nigra to damage the cell bodies. When it is injected in the 
SN, the neurons lose their phenotype within 24h and the striatal dopamine depletion starts 2 to 
3 days later. Its damaging mechanism is unknown but it is supposed to involve ROS generation 
(although inhibition of mitochondrial complex I or induction of ER stress have been proposed 
too). 
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 it is upregulated in non-neuronal cultures when there is an excess of 
unfold proteins and the unfold protein response (UPR) is induced to 
restore homeostasis. It also inhibits ER stress-induced cell death [379], 
 it protects against apoptosis in neuronal cultures; it is supposed that 
MANF mimics Ku70 mechanism, i.e. the inhibition of the proapoptotic 
Bax and the prevention of mitochondrial cell death signaling, because 
both share high structural homology at their C-terminal domains [380].  
 
 
BDNF is highly and widely expressed in the central nervous system and 
supports the differentiation, maturation and survival of dopaminergic 
neurons, at least in vitro: it is supposed that inhibits apoptosis and 
stimulates sprouting and neuronal reorganization [381].  
BDNF is translated as a preprotein. There are many different functional 
promoters that are tissue and brain-region specific and generate many 
isoforms with the same 3´ end but with different 5´ extremes resulting in 
signal peptides with different lengths that are cleaved to obtain the mature 
protein [382]. The precursor protein and the mature protein are both 
active via two different receptor systems.  
 
The most studied polymorphism, p.V66M, is localized in the signal 
peptide and, consequently, is cleaved during the maturation of BDNF. Its 
relevance is due to the study conducted by [383]. They concluded that the 
M allele was associated with poorer verbal episodic memory and 
hippocampal function in vivo. In vitro assays demonstrated that this allele 
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impaired intracellular trafficking and secretion of BDNF and also changed 
the cellular localization: the V allele was mainly localized in dendrites 
whereas the M allele was mainly localized in cell bodies.  
The M allele is not observed in lower primates so, if it is conserved, it 
may confer to humans some compensatory advantage in other biological 
processes.  
 
BDNF has been associated with varied neurological (AD, PD, HD, 
multiple sclerosis…) and psychiatric disorders (schizophrenia, depression, 
bipolar disorder, eating disorders…) with controversial results. 
  
With regard to Parkinson´s disease: 
♦ In the rat PD model, BDNF is neuroprotective against MPTP and 6-OHDA 
treatment. It is effective when administered before those toxic agents 
but not after, that is, it is not neurorestorative. 
♦ BDNF concentration was significantly lower, i.e. decreased expression, 
in the brain of PD patients when comparing to healthy controls, 
especially in the nigrostriatal dopaminergic regions [384]. This could 
explain the massive neuronal death observed in PD cases.  
♦ Some association studies have been conducted to analyze the influence 
of the p.V66M change in PD pathogenesis. 
o The majority of them have concluded that there is no significant 
difference in the allelic or genotypic frequency between PD cases and 
controls:  
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 in sporadic PD in Chinese populations [385] and [386]. [386] also 
analyzed the effect of p.G2385R in LRRK2 and observed that when 
both polymorphisms were present in the same person, the PD risk 
was increased, particularly in patients with an onset age older than 
60. 
 in a population from USA [387], in a Greek population [388] and in a 
Caucasian population, where, moreover, the polymorphism does 
not seem to modify clinical features in PD cases [389],  
 in familial PD in a worldwide population [390],  
 and also in a meta-analysis based on 6 studies in sporadic PD, 4 in 
Asians, Chinese and Japanese, and 2 in Caucasians, from UK and 
Sweden [391]. 
  
o However, [392] observed that in an Italian population, the allelic and 
genotypic frequencies for this variant were different between 
sporadic PD cases and controls. The M allele was more frequent in 
aged PD patients with cognitive impairment and more severe disease 
progression. 
 
 
In conclusion, the p.V66M polymorphism does not seem to play a major 
role in the pathogenesis of PD. 
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 I.12.d. ARMCX family: 
After the completion of the Human Genome Project there are plenty of 
new genes with unknown features. The components of the ARMCX cluster 
are some of them.  
These 6 short genes, ≈4.5 to 8kb, are localized in the X chromosome 
(Xq22.1) and are exclusive to Eutherian mammals. In humans, they evolved 
from a single ancestor gene, ARMC10, in chromosome 7. 
All the members of the family share some characteristics that were 
predicted in silico:   
o their entire coding region is in a single exon. The absence of 
alternative splicing might point out the importance of their correct 
expression; 
o have six armadillo or armadillo-like repeats in tandem and a DUF634 
mammal domain with unknown function. The arm repeat is a 
degenerate protein sequence motif of about 42 amino acids that 
forms a conserved three-dimensional structure composed of 3 -
helices that allows proteins to have many functions and to interact 
with many proteins [393]; 
o have a signal peptide and a mitochondrial targeting signal. Four of the 
members of this gene family also have a nuclear localization signal. 
 
At the present time just some information has been obtained by in vitro 
studies:  
All the murine members of the cluster (ARMCX1-6) are expressed in the 
nervous system. In addition, murine ARMCX3, which is an outer 
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mitochondrial membrane protein, interacts with Sox10, that is a 
transcription factor involved in a wide variety of developmental processes, 
including sex determination and neurogenesis. This interaction might reveal 
that there is a signal transduction cascade that connects the nucleus and the 
mitochondria [394]. 
 
In humans, ARMCX1 is transcriptionally regulated by CREB and Wnt/-
catenin signaling [395]. Moreover, ARMCX1 and ARMCX2 expression, which 
is widespread in the human body, is lost in cell lines established from 
different human carcinomas [396]. For those reasons, it has been related 
to tumorigenesis. 
Human ARMCX1, 2, 3 and 6 are mitochondrial proteins. And, at least 
ARMCX3, is a member of the KIF5/Miro/Trak240 protein complex responsible 
for the mitochondrial transport along exons. ARMCX3 interaction is Ca2+-
dependent and is not related with the regulation of the motor activity of 
the kinesin [397]. 
 
Nowadays, just some details are known and not for the six ARMCX. 
Therefore, plenty of work is still needed to clarify the essential features of all 
the members of the cluster.  
However, they are good candidates to explain PD pathogenesis due to 
their localization in chromosome X, in the hypothetical PARK12 locus, and 
                                                          
40
 Mitochondrial trafficking in neurons is mediated by kinesin motors (KIF5). Rho GTPases 
(Miro1 and Miro2) and kinesin adaptors (Trak2) are also necessary to link the mitochondria to 
the kinesin motors. 
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their possible connection with the mitochondria. In silico predictions and 
biochemical assays seem to confirm their cellular localization; in addition, 
ARMCX members possibly regulate mitochondrial dynamics and trafficking, 
which are essential to supply appropriate energy to distal neuronal 
branches, and thus for correct neurotransmission and neuronal viability. 
 
 
 
 I.12.e. TOR1A: 
Dystonia is a movement disorder characterized by repetitive or 
sustained involuntary muscle contractions, writhing and torsion are 
conspicuous, that affect one or more body parts. Patients present abnormal 
interneuronal signaling but not neurodegeneration. 
Dystonia can be primary, when is the only or major symptom, or 
secondary, when is just one of several symptoms within another, frequently 
neurological, oncological or metabolic disorder, after intoxication or after 
trauma.  
Although some primary dystonias have an unknown cause, they are 
frequently inherited as Mendelian traits. Due to their wide phenotypical 
spectrum, their classification followed a clinical criterion for long time. 
Nevertheless, recently it has been replaced by a genetic criterion (Table 4) 
[398].  
DYT1 is the most common and severe form of hereditary primary 
dystonia. The disease typically begins in childhood (age at onset ≈12), in an 
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extremity, and frequently generalizes. It is due to mutations in the TOR1A 
gene. 
Taken from [398] 
 
TOR1A, or torsinA, is widely distributed across the body and the central 
nervous system [399]. Nevertheless, DYT1 manifests as a tissue-specific 
(neuronal) disorder despite affecting a widely expressed protein. It is 
noteworthy that its highest expression is in dopaminergic neurons. That 
Table 4. The genetic dystonias. 
PDC: paroxysmal dystonic choreoathetosis; AD: autosomal dominant; AR: autosomal recessive. 
Dystonia plus syndromes are monogenic dystonias without detectable neuroanatomical 
abnormalities but with additional neurological manifestations such as myoclonus and 
parkinsonism. Paroxysmal dystonias or dyskinesias include episodes of dystonic involvement and 
no gross neuropathological anomalies. 
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observation raised questions about a potential function of TOR1A in 
dopaminergic cells and/or a role for a dopamine-related defect in DYT1. 
Subsequent neurochemical analyses of postmortem brain tissue did not 
clearly resolve these questions.  In addition, no pathological lesions have 
been detected neither in SNpc neurons nor in any other central nervous 
system region from DYT1 patients [400]. 
At the present time, the only confirmed connection between dopamine 
and dystonia is that dystonia affects patients with mutations in PARK2 or 
PARK14 and is also a common secondary motor symptom in PD. Moreover, 
[401] reported that TOR1A accumulated in Lewy bodies in brains from 
sporadic Parkinson´s disease cases. The pattern of staining was different in 
SNpc, where TOR1A was preferentially distributed around the halo rather 
than the central core, than in cortex, where it was uniformly distributed 
throughout the Lewy body. 
 
TOR1A is a lumenal glycoprotein, without transmembrane domain, 
localized inside the ER and the nuclear envelope (NE) [402] that belongs to 
the AAA family of ATPases [403, 404]. Due to its activity and cellular 
localization, it has been postulated to work as a molecular chaperone 
assisting in the proper folding of secreted and/or membrane proteins.  
TOR1A interacts with LULL1, an ER transmembrane protein, LAP1, an 
integral protein of the NE inner membrane, and also with SUN1, another NE 
protein component of the LINC complex that couples the nuclear interior to 
cytoskeletal networks [405]. For that reason it has also been proposed to 
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have a role in the structure and/or function of the endoplasmic reticulum 
and the nuclear envelope.  
There are some other proposals about its function:  
 It may play a role in the secretory pathway because the overexpression 
of TOR1A suppresses the delivery to the plasma membrane of 
membrane proteins such as the dopamine transporter; or it may 
regulate the synaptic vesicle recycling; 
 It can play a role in the cytoskeletal network because it interacts with 
vimentin in the cytoplasm, which is important for cellular motility and 
adhesion; and also binds tau and kinesin light chain in the cytoplasm so 
it may affect microtubule stabilization, neurite outgrowth and polarity. 
In any case, its real function is unknown. 
 
A 3 bp deletion in TOR1A gene causes the majority of cases (≈80%) 
although this mutation has low penetrance (30-40%). The in frame deletion 
results in the loss of a glutamic acid residue at position 302 or 303 in the 
carboxy terminal region of the protein.  
The nuclear envelope is the primary site of dysfunction in DYT1: 
mutated proteins accumulate in perinuclear inclusions. Moreover, the 
mutated proteins alter their normal cellular distribution and are more 
present in the NE than in the ER. They also sequester wild type TOR1A in NE 
[406].  
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The deletion does not alter the solubility of TOR1A neither its ability to 
multimerize nor its ATPase activity. However, its stability is altered: the 
mutated protein is degraded via macroautophagy, like other short-lived 
proteins, whereas the wild type protein is degraded by the proteasome, as 
the long-lived proteins. Its influence in TOR1A function is unclear: [407, 408] 
postulated that mutations in TOR1A could cause changes in the interaction 
of cytoskeletal components with the nuclear envelope; due to the mutation, 
this interaction could be prolonged changing from transient to permanent. 
 
The p.D216H polymorphism has been proposed to modify the 
penetrance of dystonia in p.delE302/303 carriers: the H allele was less 
frequent in patients that carried the deletion compared to nonmanifesting 
carriers of the deletion [409]. Moreover, [410] observed that the frequency 
of the H allele in trans (i.e., on the non-GAG deleted chromosome) was 
significantly increased in nonmanifesting GAG-deletion carriers without 
dystonia compared to those with dystonia. They concluded that the H 
allele is protective in trans and that the D allele in cis is required for the 
disease to be penetrant. However, the H allele is rare (frequency ≈12%) so 
this modifying effect only affects a small subset of deletion carriers. 
Nevertheless, how this could happen remains unknown: in cell cultures, 
the H allele caused protein inclusions similar to those observed in GAG-
TOR1A. Furthermore, the presence of both alleles in cis cancelled the effect: 
when both were present, the protein had a reduced tendency to form 
inclusions [411].  
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 I.12.f. GSK3: 
GSK3 is a serine-threonine kinase expressed in the brain and some 
other tissues, that works in multiple signaling pathways.  
Among other functions, it is a potential negative regulator of BDNF and 
is, in turn, regulated by BDNF-mediated signaling: to induce microtubule 
assembly and axonal outgrowth, DOCK3 promotes GSK3 recruitment to 
the membrane, where it is phosphorylated and thus inactivated. GSK3 is a 
master regulator of microtubule dynamics in growth cones 
It is associated with neurodegenerative diseases, mainly with 
tauopathies, where tau is hyperphosphorylated and assembles into 
neurofibrillary tangles, because GSK3 is one of the 20 kinases that can 
phosphorylate tau. However, its exact implication is not clear. Moreover, 
there are some evidences that point out to an involvement of GSK3 in PD 
pathogenesis, although Parkinson´s disease is a synucleinopathy:  
 Syn stimulates the GSK3 kinase activity on tau. The increased 
phosphorylation of tau results in destabilization of the microtubule 
associated network, cytoskeletal dysfunction and modification of 
synaptic plasticity [412]. 
 [413] observed that, in vitro, two SNPs altered the transcription and 
the splicing of the gene: 
o the T allele of rs334558, located in the promoter, had  greater 
transcriptional activity (1.4-fold increase) than the C allele;  
o the intronic polymorphism rs6438552 had an effect on splicing: 
there was a difference between both alleles on the use of splice 
acceptor sites in downstream introns resulting thus in different 
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proportion of protein isoforms depending on the allele although 
the mechanism for this splicing modulation is unknown. The T allele 
originated more splicing variants with higher kinase activity on tau. 
They also conducted a genetic study in Australian and Chinese PD 
patients and controls that highlighted that there was no significant 
difference neither in the allelic nor in the genotypic frequency 
between both groups for any of the two polymorphisms. 
Nevertheless, they observed that in H1H1 haplotype carriers (MAPT 
gene) there was an underrepresentation of the TT genotype for any 
of the SNPs, suggesting that the T allele, in rs334558 or in 
rs6438552, was protective. That was just a trend, not a significant 
result.  
 
Subsequent genetic analyses in PD patients, [95] in a British 
population, [93] in a Caucasian population and [412] in an Indian 
population, have also reported that there is no significant difference 
neither in the allelic nor in the genotypic frequency between both 
groups for any of the two polymorphisms (rs334558, rs6438552). 
Despite all this, there are other additional controversial conclusions:  
 [95] observed that there was no interaction between any of the 2 
SNPs in GSK3 and MAPT H1/H2 haplotype.  
 [93] concluded that there was no pairwise interaction between any 
of them and H1/H2 haplotype or rs356219 (SNCA gene). 
 [412] reported that there was no significant difference even 
considering haplotypes. However, when considering age at onset, 
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the CC haplotype (rs334558-6438552) was moderately associated 
with increased risk of late onset PD (LOPD; defined by an onset after 
40) whereas the TC haplotype showed a protective effect against 
LOPD. 
 
Nevertheless, other studies did find significant differences: 
 [414] observed that the CC genotype in rs334558 was protective 
against PD in a Greek population. They also observed that the 
frequency of this genotype was decreased in PD cases carrying the 
H1H1 haplotype. There was no significant result for rs6438552. In 
addition, the TT haplotype (rs334558-6438552) was 
overrepresented in PD cases compared to controls, independently 
of the MAPT haplotype, so it could be considered a risk factor. 
 [415] only analyzed rs334558 in Han Chinese sporadic PD patients 
and controls and found that the T allele was a protective PD factor.  
Therefore, the influence of both SNPs on PD pathogenesis is confusing. 
 
 
 I.12.g. Homocysteine (MTHFR, MTR and CBS): 
Homocysteine (Hcy) is a non-protein amino acid that arises during 
methionine metabolism (Figure 41).  
 
When there is a metabolic problem, homocysteine accumulates inside 
the cells. This excess of Hcy is toxic for them and, consequently, it is 
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exported into the circulation even when that exposes all tissues to the 
potential toxicity of hyperhomocysteinemia (HHcy)41. 
 
Taken from [416] 
 
 
HHcy occurs when there is a 
deficiency in vitamins, that are 
essential cofactors for MTR -
vitamin B12-, CBS and CGL -vitamin 
B6- (moreover THF derives from 
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 HHcy: abnormally high level of homocysteine in blood. 
Fig. 41. Methionine metabolism.  
Methionine (MET) is activated to S-
adenosylmethionine (SAM) by the 
methionine adenosyltransferase (MAT). SAM 
is the major methyl group donor in the cell (it 
is used by methyltransferases -MT- such as 
the catechol-O-methyltransferase, COMT, 
that catalyzes the conversion of L-dopa -X- 
into 3-OMD -X-CH3-). The resultant product is 
SAH (S-adenosylhomocysteine) which is 
subsequently hydrolyzed to homocysteine 
(HCY) and adenosine. These reactions form 
the transmethylation pathway.  
Homocysteine is removed either by its 
irreversible conversion to cysteine 
(cystathionine -synthase, CBS, and 
cystathionine -lyase, CGL, are involved in the 
transulfuration pathway which has a limited 
distribution: it is only found in the liver, 
kidney, small intestine and pancreas) or by 
remethylation to methionine (by the 
betaine:homocysteine methyltransferase  -
BHMT- or by the methionine synthase -MS or 
MTR-; BHMT has a limited tissue distribution 
and is mainly present in the liver whereas MS 
is widely distributed). 
SER; serine;     
MTHFR:methylenetetrahydrofolate 
reductase;  
5-CH3-THF:  5-methyltetrahydrofolate;  
5,10-CH2-THF:  
5,10-methylenetetrahydrofolate;  
THF: tetrahydrofolate;  
DMG: dimethyl glycine. 
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folic acid -vitamin B9-), or due to genetic mutations in MTHFR, MTR or CBS, 
that are rare disorders.  
However, some polymorphisms have also been associated with altered 
Hcy levels in plasma [417]. Hyperhomocysteinemia is more pronounced and 
has more toxic and serious effects in those individuals who carry mutations. 
They represent a minority of severe cases. 
 
 MTHFR: due to mutations that abrogate the enzyme activity, patients in 
infancy or adolescence present developmental delay, motor and gait 
dysfunction, seizures and other neurological abnormalities. There are two 
frequent polymorphisms: 
o In the heterozygous or homozygous state, c.C677T, which is located in the 
predicted catalytic domain of the protein, correlates with reduced 
enzymatic activity and increased thermolability of the protein [417]. The 
majority of studies that have analyzed this polymorphism conclude that 
homozygous TT carriers have significantly elevated plasma Hcy levels. 
However, [418] observed that, in North-Irish men, the insertion c.844ins68 
in CBS seems to “normalize” homocysteine levels in c.677TT individuals. 
o c.A1298C, located in the predicted regulatory domain, decreases MTHFR 
activity although to a lesser extent. Only compound heterozygous carriers, 
that is c.A1298C and c.C677T, show elevated Hcy levels [419].  
 CBS: missense mutations in this gene also cause homocystinuria42. The major 
clinical manifestations involve the eyes, and the central nervous, skeletal and 
vascular systems. 
o c.T833C is a frequent polymorphism. [420], working in fibroblasts, 
observed that some of the carriers also have an insertion of 68bp in cis with 
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 Homocystinuria: increased excretion of homocysteine in the urine. 
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it. This insertion, c.844ins68, is an almost exact duplication of the previous 
68bp and includes intronic and exonic sequence as well as the wild-type T 
allele at position 833. The insertion creates a new acceptor splicing site that 
allows the skipping of the C allele: splicing using this new splicing acceptor 
site generates mRNAs with the normal size and without the C whereas 
splicing using the canonical acceptor site generates aberrant mRNAs that 
include the insertion with its 2 nonsense codons and that are degraded in 
the nucleus. [421] found mRNAs with the C allele in liver and proposed 
that there could be a third putative noncanonical splicing site that 
originates mRNAs with the normal size but including the C variant. The 
insertion is only present in individuals who carry the c.T833C 
polymorphism. [422] reported that the insertion is not pathogenic and 
does not alter either the enzymatic activity or the level of plasma 
homocysteine. 
 
In the major part of individuals with HHcy, the concentration of 
homocysteine reached in plasma is not high enough to cause direct toxic 
effects, i.e. Hcy does not act as a direct toxin, but there is an increase in the 
susceptibility to those effects. High homocysteine levels accelerate cell 
ageing and promote DNA damage; in addition, there are some evidences 
that point out that homocysteine facilitates the aggregation of Aand the 
phosphorylation of tau [423, 424]. 
Hyperhomocysteinemia is a confirmed risk factor for the development 
of vascular disease [425, 426]. In addition, it seems that there is a link 
between HHcy and risk of developing dementia but the influence of vitamin 
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levels and genetic factors and the identification of which is the cause and 
which the consequence are controversial: 
♦ [427] conducted a follow-up study in mostly Caucasian people from 
the Framingham (USA) cohort and observed that there was a strong 
association between plasma homocysteine levels and the risk of 
developing dementia and Alzheimer’s disease. That conclusion was 
independent of age, sex, APOE genotype, plasma vitamin levels, and 
other putative risk factors for dementia and Alzheimer’s disease.  
♦ Other cross-sectional studies also reported the same conclusion, i.e. 
elevated plasma homocysteine levels were associated with poor 
cognition and dementia [428-430]. 
♦ In two studies conducted only in Australian men43, one cross-sectional 
[431] and one longitudinal [424], increased levels of plasma 
homocysteine were related to higher risk of cognitive impairment or 
dementia, respectively. In both analyses, for the c.C677T 
polymorphism, the T allele carriers, that have higher Hcy levels, had 
higher risk than the C allele carriers. However, [432], in a longitudinal 
study conducted in a British population, observed that the 
polymorphisms c.C677T and c.A1298C (MTHFR) were not associated 
with changes in cognitive performance (verbal fluency, verbal memory 
and abstract reasoning). The influence of vitamin levels was not 
analyzed in any of those three studies. 
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 There is no suggestion to date that Hcy may have a gender-specific effect with regards to 
cognition. 
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In Parkinson´s disease patients, hyperhomocysteinemia has been 
repeatedly reported. However, there are experimental evidences that point 
out that L-dopa treatment increases the concentration of plasma 
homocysteine rather than vitamin deficiency (normal vitamin levels were 
described in PD cases with HHcy; moreover, higher intake of folate or 
vitamins B6 and B12 did not lower the risk of developing PD) or the disease 
per se [433]: 
♦ In a Polish population, [434] observed that levodopa-treated PD 
patients, PD-L, had Hcy levels higher than controls. That conclusion was 
independent of c.C677T genotype and L-dopa doses.  
♦ [435] reported that homocysteine plasma levels were significantly 
increased in a Taiwanese population when comparing PD-L with non-
treated PD cases or controls. Only in PD-L, Hcy levels were related to 
c.C677T genotype being the TT genotype the most frequent and 
associated with the highest Hcy concentration, as previously reported. 
Homocysteine levels were not correlated with folate and vitamin B12 
concentrations, disease duration or L-dopa dose. There were no 
significant results for c.A1298C. 
♦ Hcy levels analyzed in Spanish controls and PD cases, classified as 
cognitively normal, with mild cognitive impairment or demented, were 
only correlated with age and inversely associated with vitamin B12, B6 
and folic acid. PD patients (all had received levodopa therapy) 
presented homocysteine levels higher than controls although the level 
did not predict the cognitive status of the cases. Homocysteine levels 
were independent of sex, disease duration, L-dopa doses and genetic 
I. INTRODUCTION.  I.12. Others. 
146 
 
variants in MTHFR (c.C677T, c.A1298C), MTR (c.A2756G) or CBS 
(c.844ins68). Moreover, any of those variants was associated neither 
with PD risk nor with cognitive status [436]. Nonetheless, a previous 
study concluded that PD patients with HHcy had worse mood and 
cognitive function [437]. 
 
More studies are required to obtain definite conclusions and to 
elucidate the pathogenic mechanisms, if any. Moreover, all those 
neurological disorders are more frequent in elder people, where vitamin 
deficiencies, which can develop because of low dietary intake, disturbed 
absorption in the gastrointestinal tract or by interaction with some 
medications, are the most common cause for HHcy and it is not clear 
whether dietary vitamin supplies, which decrease homocysteine plasma 
levels, can be considered protective factors against those disorders being 
that elevated Hcy levels have been described even in people without 
vitamin deficiency and homocysteine lowering treatments for older people 
without dementia have not been able to demonstrate an improvement in 
cognitive performance. 
 
 I.12.h. TOMM40: 
The most repeated statistically significant results obtained when 
analyzing the genetic influences in late onset Alzheimer´s disease (LOAD) are 
located in the APOE region (APOE, TOMM40 and APOC1 genes). It is 
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currently accepted that the 4 allele (APOE) is a risk factor for LOAD and 
that it is also associated with lower age at onset. However, genetic markers 
in the three genes have shown association and, although that has been 
considered the effect of the high linkage disequilibrium in the region, where 
the accurate risk marker is located remains unknown. 
 
To solve this question, [438] decided to deeply analyze the region by 
phylogenetic studies in Caucasian AD patients and healthy controls. They 
obtained very interesting results for a poly-T polymorphism located in 
TOMM40 gene, rs10524523. The length of the homopolymer was 
correlated with the genotype in APOE: for 4 alleles, the poly-T was 
relatively long -21 to 30T- with a unimodal distribution of lengths, whereas 
for 3 alleles, a bimodal distribution of lengths was evident -12 to 16T and 
28 to 37T-; 2 alleles had a similar distribution than 3.  
 
[439] analyzed the length of the homopolymer in different populations 
residing in USA and compared their results with previously published 
studies conducted in other ethnicities. Whites and Hispanics shared a 
similar allelic distribution, and the same was reported for Asian (Japanese, 
Han Chinese and Korean) and for African Americans and Ghanaians.  Long 
alleles (l; 20≤T≤29) were the minority in all the populations and had similar 
values; the differences were observed in the percentage of short (s; T≤19) 
and very long (vl; T≥30) alleles: African Americans and Ghanaians had a 
higher frequency of short alleles than the others and carried very very long 
alleles, even 54T, whereas Asian had a higher frequency of very long alleles. 
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Surprisingly, in Japanese, and especially in Ghanaians and African 
Americans, there were s and vl alleles associated with the 4 allele. 
 
[438] also observed that alleles ≥27T were associated with earlier age 
at onset in LOAD. 
This finding could explain the current heterogeneity observed in the 
age at onset of Alzheimer´s disease patients that carry the 3 allele, which 
was supposed to be a neutral factor for AD (Figure 42). 
 
Taken from [440] 
However, other studies that analyzed more LOAD cases than [438] 
obtained opposite conclusions: [441], only in LOAD cases, and [442] in 
Fig. 42.  Left: Alzheimer´s disease age at onset curves by APOE genotype. 
Right: Hypothetical Alzheimer´s disease age at onset curves by TOMM40-APOE 
haplotype.  
rs10524523 marker, when modeled together with APOE subtype and age will 
translate into a more precise prediction of risk at a particular age than 
predictions based on APOE subtype alone.  
3: short, Sh, (T≤19) and very long, VL, poly-T (T≥30); 4: long, L, (20≤T≤29). 
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LOAD cases and controls, both in Caucasian population, did not find any 
correlation between the length of the poly-T and the age at onset.  
Surprisingly, [442] also observed that there was a trend for very long 
alleles and older age at onset. Moreover, they found no association 
between the homopolymer length and the mRNA expression of APOE or 
TOMM40 in the parietal cortex and also no different expression of those 
genes in LOAD cases when comparing to controls. 
Nevertheless, [443] observed that the expression level of TOMM40 
was decreased in blood in patients when comparing to age, sex and 
ethnicity matched Asian controls. They did not analyze the length of the 
polymorphism and its relation with gene expression. 
TOMM40 is the channel-forming subunit of the translocase located in 
the mitochondrial outer membrane. It forms a complex with other proteins 
that is essential for protein import into the mitochondria. Almost all the 
mitochondrial proteins employ the TOM machinery for their import 
because the majority of them are encoded by nuclear genes [444]. 
For its function, it has been postulated that it could influence APOE 
transcription depending on the poly-T length or that it could alter the 
interaction between APOE and the mitochondria.  
Although TOMM40 has not been studied in PD cases, its probable 
relation with other neurodegenerative disorder such as AD, and even with 
the age at onset, plus its function in mitochondria, make this gene a good 
candidate for further analysis.   
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I.13. Epigenetics in PD. 
Epigenetics is the study of mitotically and/or meiotically heritable 
changes that cannot be explained by changes in DNA sequence. The term 
epigenetics literally means ‘‘above genetics’’ and describes mechanisms 
layered on top of the DNA sequence information that are perpetuated. Some 
broader definitions do not consider the requisite of heritability, thus defining 
epigenetics as the information not encoded in the DNA sequence, i.e. stable 
and long-term alterations not present in the DNA sequence. 
Although all somatic cells in a given individual are genetically identical, 
with the exception of T- and B- cells, there are different cell types that form 
highly distinct anatomic structures with disparate physiologic functions. This is 
due to the epigenetic control of gene expression that plays a critical role in 
cellular differentiation [445]. 
Therefore, one person carries one genome but hundreds or even 
thousands of epigenomes: even each cell can have its own epigenome and 
change it depending on time and environmental factors (the environment 
especially influences epigenome during developmental periods) (Figure 43) 
[446]. 
For example: 
[447] conducted an epigenetic study in Spanish monozygotic twin pairs 
and concluded that some epigenetic marks such as DNA methylation and H3 
and H4 acetylation, and, consequently, gene expression profiles, were more 
different between the components of monozygotic twin pairs as they aged, and 
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the difference was more pronounced in those that had spent less time 
together and/or had different lifestyles, pointing out the influence of 
environmental factors. These differential marks were distributed throughout 
their genomes, affecting repeat DNA sequences and single-copy genes. 
 
 
 
 
 
Modified from [446] 
[448] postulated that differences in the DNA methylation patterns 
observed between some parts of the brain (cerebral cortex, cerebellum and 
pons) could explain their different expression patterns. They also concluded 
that the DNA methylation pattern correlated much more strongly within a 
brain region across individuals than within an individual across brain regions. 
Fig. 43.  Intra- and interindividual variation in epigenetics. 
Epigenetics is dynamic and there are evidences for variation in it between tissues and 
individuals although the influence of environment needs further investigation.  
For the same genotype, different epigenotypes could explain different phenotypes. 
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Histone modifications, DNA methylation and some RNA-mediated 
processes44 are part of epigenetics. 
 
 
A. Histone modifications: 
Chromatin is mainly composed of DNA, histones and non-histone 
chromatin proteins that facilitate the packing of the DNA into higher order 
structures thus allowing its storage in the nucleus. 
The basic structural unit of the chromatin is the nucleosome, which 
consists of 147bp of DNA wrapped around a histone octamer made of two 
copies each of the core histones H2A, H2B, H3 and H4 (Figure 44).  
 
 
Modified from [449] 
                                                          
44
 RNA-mediated processes involve non-coding RNAs: small (shorter than 200 nucleotides; 
miRNAs -microRNAs-, siRNAs -short interfering RNAs-, piRNAs -PIWI-interacting RNAs-, rasiRNAs 
-repeat-associated RNAs- and others less well characterized) and long (lncRNA: longer than 200 
nucleotides). They can epigenetically transmit regulatory information thus controlling gene 
expression. Although some examples of those processes have been described, more extensive 
research is necessary to clarify and define all their characteristics. 
Fig. 44.  Chromatin structure. 
Schematic representation of three nucleosomes and three histone modifications (small 
circles). 
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Core histones are evolutionarily highly conserved basic proteins that 
tightly bind with the negatively charged DNA. Each histone, which is 
predominantly globular, contains a flexible domain called the histone tail, 
which remains outside of the nucleosome and that is the target for reversible 
post-translational modifications [450]. 
The histone modifications45 that have been described in humans are: 
 methylation (R-me1, R-me2a, R-me2s or K-me1, K-me2, K-me3) is carried 
out by lysine methyltransferases and arginine methyltransferases, 
whereas demethylation by lysine demethylases; 
 acetylation (K-ac):  acetyltransferases (HATs) and deacetylases (HDACs) 
are responsible for this modification; 
 phosphorylation (S-ph or T-ph) is due to serine/threonine kinases; 
 ubiquitination (K-ub) is carried out by ubiquitilases; 
 sumoylation (K-su): sumoylases are responsible for this modification; 
 ADP ribosylation (E-ar) is due to ADP ribosyltransferases; 
 deamination (R>citrulline) is carried out by deaminases; 
 and proline isomerization (P-cis>P-trans): proline isomerases are 
responsible for this modification. 
All the modifications are dynamic except methylation of arginines [451]. 
Histone modifications can alter chromatin structure, and therefore 
gene expression, by recruiting non-histone proteins or by changing the 
                                                          
45
 R, K, S, T, E and P refer to the corresponding amino acids; 1: mono; 2: di; 3: tri; a: 
asymmetric; S: symmetric. 
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interaction between histones and DNA (changes in internucleosomes 
interactions). Nevertheless, many questions remain unclear: its individual 
contribution to this regulation, the possible combined effect when some are 
present in the same or different histone tail or its time-dependent variation 
amongst others, making the histone code an extremely complex and unknown 
mechanism. 
 
B. DNA methylation: 
Mammalian DNA methylation has been implicated in a diverse range of 
cellular functions and pathologies, including tissue-specific gene expression, 
development, cell differentiation, silencing of mobile elements, genomic 
imprinting, X chromosome inactivation, regulation of chromatin structure, 
carcinogenesis and aging [449]. 
DNA methylation is generally associated with a repressed chromatin 
state and inhibition of promoter activity, i.e. transcriptional repression. Two 
models of repression have been proposed (Figure 45): 
 
 
Modified from [452] 
Fig. 45. Mechanisms of DNA-methylation-mediated repression. 
a. DNA methylation in the binding sequences of some transcription factors can prevent their 
binding thus inhibiting transcriptional activation. 
b. Methyl-CpG-binding proteins (MBPs) recognize and bind to methylated DNA and recruit 
chromatin modifiers to establish a repressive chromatin environment. 
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DNA methylation is a covalent modification of DNA catalyzed by DNA 
methyltransferases (DNMTs).  
There are different DNMTs: 
o DNMT1 is the maintenance methylase. It works on hemimethylated 
DNA to methylate cytosines and thus restore the symmetrical DNA 
methylation pattern on daughter DNA strands generated during 
replication. 
o DNMT3A and DNMT3B are the de novo methyltransferases that 
methylate previous unmethylated DNA. 
o DNMT2 has a very weak methylating activity. Its structure suggests 
that this enzyme is actually involved in the recognition of DNA 
damage, DNA recombination and mutation repair. 
o DNMT3L does not contain intrinsic DNA methyltransferase activity but 
physically associates with DNMT3A and DNMT3B and modulates their 
catalytic activity. 
DNMT1, DNMT3A, DNMT3B and DNMT3L interact with HDAC and other 
proteins and participate in the regulation of gene transcription [453, 454]. 
Some of those other proteins include the two families of MBPs that 
exist in mammals (•) and proteins involved in chromatin remodeling 
complexes, that use the energy associated with ATP hydrolysis to effect 
changes in nucleosome arrangement or composition (): 
 MBDs: MeCP2, MBD1, MBD2, MBD3 and MBD4 share a MBD (methyl-
CpG-binding domain) domain to bind to methylated DNA. However, 
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MBD3 harbors a critical mutation in its MBD domain that abrogates 
its binding to methylated DNA. MBD1 can also bind unmethylated 
DNA via its CxxC zinc-finger motif.  
All MBDs, except MBD4, repress gene transcription by interacting 
with histone deacetylases, other histone-modifying enzymes and 
chromatin remodeling complexes. In contrast, MBD4 is a thymine 
glycosylase which acts as a DNA repair protein and targets sites of 
cytosine deamination: it is likely to have a role in limiting the 
mutagenicity of 5-methylcytosine (5mC) which converts to thymine 
(T). This enzyme is also able to repair and excise non-methylated CpG 
when mutates to UpG. 
 Kaiso-like: Kaiso, ZBTB4 and ZBTB38 share a triple zinc-finger domain, 
to bind methylated DNA, and a BTB/POZ domain, involved in protein-
protein interactions to repress transcription. Kaiso and ZBTB4 can 
also bind to unmethylated DNA [455]. 
 
 The SNF2H or ISWI family, that act by mobilizing nucleosomes along 
the DNA. 
 The Brahma or SWI/SNF family, that transiently alter the structure of 
the nucleosomes, thus exposing the DNA-histone contacts. Some of 
the remodelling complexes that belong to this family also promote 
the replacement of conventional core histones with variant forms 
thus acting as “exchanger complexes” [456]. 
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Gene expression and chromatin structure are tightly correlated and 
dependent on the interaction of numerous proteins: DNMTs, MBPs, chromatin 
remodeling complexes, histone-modifiers, transcription factors or polymerases 
amongst others.  
This is reflected in the two types of chromatin that can be distinguished 
(Figure 46):  
 
 
 
 
 
 
 
 
Taken from [457] 
Fig. 46. Schematic representation of silent heterochromatin and active euchromatin. 
On the top, open chromatin or euchromatin, where transcriptional machinery easily works: 
acetylation of the histones causes an open chromatin configuration that is associated with 
transcriptional activity.  
On the bottom, closed chromatin or heterochromatin where there is gene silencing: methylated 
cytosines are recognized by MBPs, which in turn recruit histone deacetylases to the site of 
methylation, converting the chromatin into a closed structure that can no longer be accessed by 
the transcription machinery. 
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 Euchromatin is more loosely packed, which allows the access of 
transcription factors and other components to promoter regions, 
thereby enabling genes to be transcribed. There are low levels of DNA 
methylation and high levels of histone acetylation and trimethylation 
at H3K4, H3K36 and H3K79. 
 Conversely, heterochromatin is more compactly arranged, leading to 
transcriptional inhibition due to the inaccessibility of promoter 
elements. It is associated with low levels of acetylation, high levels of 
methylation at H3K9, H3K27 and H4K20 and high DNA methylation 
[451]. 
 
 
In addition to the previously described interactions associated with 
DNA methylation, this modification has some specific characteristics: 
In eukaryotes, methylation occurs almost exclusively in cytosines and, in 
mammals, more concretely in CpG46 dinucleotides (Figure 47).  
  
Modified 
from [456] 
 
                                                          
46
 The “p” represents the phosphodiester bond that links both nucleotides. 
Fig. 47. Conversion of cytosine to 5-methylcytosine by a DNA 
methyltransferase (DNMT). DNMT catalyzes the transfer of a methyl 
group from SAM to the C5 position of the cytosine. 
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It is noteworthy that the frequency of CpG dinucleotides in the human 
genome is lower than the expected due to cytosine deamination47. 
Nevertheless, there are some genomic regions where the observed frequency 
is closer to the expected. Those intergenic and intragenic regions across the 
genome are called CpG islands.  CpGs abound in CpG islands but they are 
generally not methylated or have relatively low levels of methylation. 
Paradoxically, mostly of CpG dinucleotides are scattered across the genome, 
not located in the CpG islands, and methylated.  
In overall, the 80% of cytosines located in CpG dinucleotides are 
methylated [446]. 
CpG islands are defined by three characteristics: G+C content of 0.5 or 
greater; observed/expected CpG dinucleotide ratio of 0.6 or greater; and all 
these characteristics occurring within a sequence longer than 200 nucleotides 
[458]. 
Depending on their presence, genes are classified as: 
I. CG rich: the 60%; all the housekeeping genes and one half of the 
tissue-specific. There is a CpG island in their promoter but with low 
methylation level. 
                                                          
47
 Unmethylated cytosine deaminates and converts to uracil (U). Nevertheless, when it occurs,  
the mutation is rapidly corrected and almost never fixes in the genome. However, the 
deamination of 5-methylcytosine (it converts to T) is slowly corrected and, as a consequence, it 
is more often fixed in the genome. 
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II. CG poor: the remaining 40%; the other half of tissue-specific genes. 
There is no CpG island in their promoter but the CpG dinucleotides 
are highly methylated [459, 460].  
The promoters in housekeeping genes are poorly methylated and gene 
transcription is not repressed thus allowing their expression in all the cells. But 
the differences observed in the promoters of the tissue-specific genes generate 
rather than explain questions about the regulation of genic expression: how 
are the promoters of the CG rich genes organized in expressing and non-
expressing tissues, considering that CpG islands remain unmethylated in both 
situations?  
 
Although DNA methylation has been viewed as a stable epigenetic 
mark, studies in the past decade have revealed that this modification is not 
static. DNA demethylation has been observed in specific contexts and can 
occur through active or passive mechanisms: 
 Passive demethylation occurs when there is no maintenance of the 
methylation pattern after DNA replication. If DNMT1 is inhibited or 
absent, the newly synthesized DNA will not be methylated and 
successive rounds of cell division will result in passive demethylation. 
 Active demethylation: a large variety of mechanisms have been 
proposed to explain how 5mC is replaced by C, but still need to be 
verified experimentally in vivo. There could be different pathways of 
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demethylation depending on the cell type, the moment and the 
genomic target (Figure 48). 
Modified from [461] 
Fig. 48. Putative pathways for cytosine demethylation. 
1. Deamination of 5mC into T by cytosine deaminases such as AID or APOBEC, followed by 
excision of the T (generation of an abasic site) by the DNA glycosylases TDG or MBD4 and 
repair by the base excision repair (BER) pathway, which removes the rest of the nucleotide and 
filles the gap by DNA polymerases and ligases.  
2. Oxidative demethylation of 5mC which is hydroxylated into 5-hydroxymethylcytosine (5hmC) 
by TET enzymes. It can be further oxidized into 5-formylcytosine (5fC), and finally into 5-
carboxylcytosine (5caC) or deaminated into 5-hydroxymethyluracil (5hmU). All these modified 
bases could lead to replication-dependent passive demethylation or to active demethylation 
via excision by DNA glycosylases (TDG, SMUG1) followed by BER. In addition, a putative 
decarboxylase could lead to decarboxylation of 5caC directly back to cytosine. 
I. INTRODUCTION.  I.13. Epigenetics in PD. 
162 
 
5hmC is the only modified base that has been detected but [462] could 
not correlate the levels of 5hmC and 5mC as one could expect considering that 
5hmC is exclusively generated from 5mC. 
The presence of 5mC in genomic DNA is constant (≈4-5%). However, 
the levels of 5hmC are strongly tissue-specific [463] with the highest levels in 
the central nervous system, where it is present in all the brain regions, and 
the lower levels in liver, muscle, heart... The amount of 5hmC increases with 
age until it reaches a final stable plateau but, in any case, it represents less 
than the 1% [464].  
These details point out the possibility that active demethylation via 
5hmC is an inaccurate mechanism. Although there are other possibilities to 
explain these controversial data such as short lives of 5fC, 5caC and 5hmU or 
inefficient detection limits in current analytical methods or even that 5hmC is 
more than an intermediate of oxidative demethylation and have a specific 
function in development or regulation acting as a new epigenetic mark. 
Moreover, previous methylation datasets need careful reevaluation 
because the standard methods to detect 5mC do not differentiate it from 
5hmC or do not recognize this new base:  
 methylation-sensitive restriction enzymes do not distinguish 5mC and 
5hmC [465]; 
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 the anti-5mC antibody has a high selective affinity to 5mC but not to 
5hmC (anti-5hmC are in development) [466]; 
 known 5mC binding proteins such as MBD1, MBD2 and MBD4, do not 
to recognize 5hmC; 
 bisulfite treatment, which is the gold standard, converts unmethylated 
cytosines into uracils whereas 5mCs remain unaltered and 5hmCs 
form an adduct (cytosine-5-methylenesulfonate or CMS). CMS and 
5mC are resistant to deamination and therefore both are read as C 
whereas Us are replaced by Ts in the subsequent PCR amplification 
[467]. Nevertheless, it has been postulated that 5hmC and 5mC could 
be differentiated by the efficiency of the PCR process, because the 
formation of the CMS adduct could inhibit the amplification; different 
studies, however, obtained opposite conclusions about that [466, 
467]. 
Nowadays some techniques have been developed to overpass this 
limitation. Most of the methods use glucosyltransferases to transfer a glucose 
group, that can be modified, onto 5hmC followed by mass spectroscopy, 
enzyme digestion, affinity purification [468] or even by radioactivity [469].  
However, these assays determine the genomic position of specific 
cytosines or quantify their level of hydroxymethylation. But do not combine 
both possibilities. 
That has recently changed, because [470] developed the first method 
for quantitative mapping of 5hmC in genomic DNA at single-nucleotide 
resolution called oxidative bisulfite sequencing (oxBS-Seq) which compares two 
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sequences obtained from the same sample that has been treated with bisulfite 
(unmethylated Cs convert into Us) or chemically oxidized (5hmC converts into 
5fC which is bisulfite treated and converted into U). Nevertheless, more 
methods need to be developed to determine 5hmC in a cheap, easy, sensitive, 
efficient, reproducible and precise way as it is for 5mC. 
 
Could epigenetic processes lead to Parkinson´s disease? 
Only few studies have focused on this new hypothesis. Some of them 
have analyzed the levels of 5-methylcytosine in genes related to PD 
pathogenesis (Table 5).  
 
Work [471] [472] [473] [474] 
Region 
analyzed 
293bp in 
TNFpromoter 
469bp in UCHL1 
promoter and 
exon 1; 
346bp in MAPT 
promoter; 
464 bp and  
292bp in APP 
promoter; 
329bp in PSEN1 
promoter and 
exon1 
443bp in SNCA 
intron1 
153bp in SNCA 
intron1 
Brain 
regions 
SNpc and cortex Cortex SNpc, cortex and 
putamen 
SNpc, cortex 
and putamen 
Healthy 
controls/PD 
patients 
8/7 26/8 6/6 7 people 
affected by 
other non-
neurodegenera
tive diseases 
Table 5. Comparison of the studies that have carried out DNA methylation anaylisis in PD. 
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where used as 
controls 
/12PD+DLB 
Method of 
analysis 
Bisulfite 
treatment, PCR 
amplification, 
cloning and 
sequencing 
Bisulfite 
treatment, PCR 
amplification 
and mass 
spectroscopy 
Bisulfite 
treatment, PCR 
amplification, 
cloning and 
sequencing 
Bisulfite 
treatment, PCR 
amplification, 
cloning and 
sequencing 
Conclusions DNA 
methylation 
levels were not 
different when 
comparing cases 
and controls: in 
both groups, 
SNpc was less 
methylated than 
cortex 
No differences 
in DNA 
methylation 
levels were 
detected in any 
of the regions 
analyzed when 
comparing 
controls and 
cases  
Hypomethylatio
n was observed 
across the three 
regions in PD 
cases. 
In addition, the 
differentially 
methylated CpG 
sites were 
associated with 
predicted 
transcription 
factor binding 
sites, suggesting 
that reduced 
methylation 
could promote 
Syn expression 
in PD brain 
There were no 
differences in 
cortex and 
putamen. 
However, PD 
cases presented 
lower DNA 
methylation 
levels than the 
controls in SNpc 
 
The conclusions are promising: although there were not significant 
differences in all the studies, these were observed in SNCA, one of the five 
genes responsible for familial PD. 
Low DNA methylation levels in its intron 1 could lead to increased gene 
expression and thus be a pathogenic risk factor. 
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These results highlight the possible influence that epigenetic marks 
could have on PD pathogenesis. Although more studies are needed to confirm 
this hypothesis, these reports point out that not only genetic marks should be 
considered in the future to analyze susceptibility factors in Parkinson´s disease. 
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Genetics in Parkinson´s disease: 
1. Analysis of genetic susceptibility factors in Spanish population. 
 
2. Analysis of genetic determinants in cognitive status in Parkinson´s 
disease. 
 
3. Analysis of genetic variability in the ARMCX gene family in PD. 
 
Epigenetics in Parkinson´s disease: 
4. Quantitation of DNA methylation levels in promoters of genes 
responsible for familial Parkinson´s disease. Pilot analysis. 
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Subjects: 
For all the individuals, their personal data were obtained from clinical 
histories. In addition, all provided an informed written consent48. 
PD cases were diagnosed by neurologists that evaluated the motor 
impairment and disability following the UPDRS scale. Healthy controls were not 
related to PD cases and belonged to DNA/brain banks present in the respective 
institutions. 
 
Individuals from different Spanish regions were analyzed in our genetic 
studies:  
A. Basque country: Hospital Universitario Donostia, San Sebastián. 
 
 Healthy controls (n = 96) PD cases (n = 170) 
Sex  women: 57 (59.38%) women: 76 (44.71%) 
Age (years)* mean: 73.41 (11.45)** mean: 63.83 (10.15)** 
Evolution (years) - mean: 6.18 (4.64)** 
Familial history - yes: 72 (42.35%) 
n = number of individuals. 
* For PD cases, that is age at onset. 
**In parenthesis, the standard deviation. 
                                                          
48
 For patients with dementia from Navarra, this was obtained from a relative. 
Table 6. Demographic characteristics of the entire Basque population. 
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The sex distribution between PD cases and healthy controls was 
statistically different (Pearson´s X2 = 5.281; p<0.05, p=0.022). Furthermore, their 
mean age was statistically different too (Mann-Whitney U test; p<0.05, 
p=0.000).  
 
Therefore, we eliminated individuals with extreme values for age. The 
groups that we finally analyzed were (Table 7): 
 
 Healthy controls (n = 86) PD cases (n = 151) 
Sex  women: 50 (58.14%) women: 68 (45.03%) 
Age (years)* mean: 66.91 (8.28)** mean: 65.98 (7.67)** 
Evolution (years) - mean: 6.40 (4.77)** 
Familial history - yes: 64 (42.38%) 
n = number of individuals used in the calculation. 
* For PD cases, that is age at onset. 
**In parenthesis, the standard deviation. 
 
There was no statistically significant difference in sex distribution 
between healthy controls and PD cases (Pearson´s X2 = 3.765; p>0.05, p=0.052). 
Their mean age was not statistically different either (Mann-Whitney U test; 
p>0.05, p=0.308). 
 
Table 7. Demographic characteristics of the Basque population analyzed. 
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B. Andalusia: Hospital Virgen del Rocío, Sevilla. 
Catalonia: Hospital de la Santa Creu i Sant Pau, Barcelona. 
Region of Valencia: Hospital Universitari i Politècnic la Fe, València; 
Hospital Clínic Universitari, València; Hospital Universitari Doctor Peset, 
València; Hospital Universitari Arnau de Vilanova, València; Hospital 
Universitari General, València; Hospital Universitari de la Ribera, Alzira 
and Hospital de Sagunt, Sagunt. 
 
 Healthy controls (n = 311) PD cases (n = 419) 
Sex  women: 119 (38.26%) women: 181 (43.20%) 
Age (years)* mean: 61.83 (12.25)** mean: 56.43 (11.47)** 
Evolution (years) - mean: 10.92 (6.64)** 
Familial history - yes: 78 (28.57%)*** 
n = number of individuals. All the healthy controls were from Sevilla whereas PD cases 
were from Valencia (113), Sevilla (180) and Barcelona (126).  
* For PD cases, that is age at onset. 
**In parenthesis, the standard deviation. 
***There was no information about familial history for all the individuals from Valencia 
and for 33 from Sevilla. Therefore, familial history was calculated considering 273 people. 
 
The sex distribution between PD cases and healthy controls was not 
statistically different (Pearson´s X2 = 1.795; p>0.05, p=0.180). Nevertheless, their 
mean age was statistically different (Mann-Whitney U test; p<0.05, p=0.000).  
 
Table 8. Demographic characteristics of the entire non-Basque population. 
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Therefore, we eliminated the individuals with extreme values for age. 
The groups that we finally analyzed were (Table 9): 
  
 
 
 
 
 
n = number of individuals. There were 100 PD patients from Valencia, 163 from Sevilla and 86 
from Barcelona. All the healthy controls were from Sevilla. 
* For PD cases, that is age at onset. 
**In parenthesis, the standard deviation. 
***There was no information about familial history for all the individuals from Valencia and for 
29 from Sevilla. Therefore, the calculation was done considering 220 people. 
 
The sex distribution between PD cases and healthy controls was not 
statistically different (Pearson´s X2 = 0.757; p>0.05, p=0.384). Their mean age 
was not statistically different either (Mann-Whitney U test; p>0.05, p=0.081).  
 
 
o To carry out our third objective, we selected some individuals from the 
non-Basque population previously described in Tables 8 and 9. More 
concretely (Table 10): 
 Healthy controls (n = 304) PD cases (n = 349) 
Sex  women: 117 (38.49%) women: 146 (41.83%) 
Age (years)* mean: 60.48 (10.84)** mean: 59.35 (9.47)** 
Evolution (years) - mean: 9.62 (5.37)** 
Familial history - yes: 59 (26.82%)*** 
Table 9. Demographic characteristics of the non-Basque population analyzed. 
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 Healthy controls (n = 160) PD cases (n = 113) 
Sex  Women: 57 (35.63%) Women: 44 (38.94%) 
Age (years)* mean: 61.81 (12.40)** mean: 57.55 (9.12)** 
Evolution (years) - mean: 11.08 (5.89)** 
n = number of individuals used in the calculation. Healthy controls were from Sevilla; PD cases 
were from Valencia. 
* For PD cases, that is age at onset. 
**In parenthesis, the standard deviation. 
The distribution of sex between PD cases and healthy controls was not 
statistically different (Pearson´s X2; p>0.05, p=0.577). However, their mean age 
was statistically different (t-student test; p<0.05, p=0.01).  
Therefore, we had to conduct a paired case-control study. PD cases and 
healthy controls with the same sex and age (even with one year of difference) 
were matched. For those new groups (Table 11): 
 
   Healthy controls (n =  95) PD cases (n = 95) 
Sex  Women: 38 (40%) Women: 38 (40%) 
Age (years)* mean:  58.96 (8.63)** mean: 58.92 (8.61)** 
Evolution (years) - mean: 10.45 (5.32)** 
n = number of individuals used in the calculation. 
* For PD cases, that is age at onset. 
**In parenthesis, the standard deviation. 
 
Table 10. Demographic characteristics of the individuals selected from the non-Basque population. 
Table 11. Demographic characteristics of the individuals included in the paired case-control study. 
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C. Navarre: Clínica Universitaria de Navarra, Pamplona. 
 
As previously said, our second objective was the analysis of genetic 
determinants in cognitive status in Parkinson´s disease. However, as we had 
the possibility to analyze healthy controls from Navarra, and not only PD cases, 
we decided to also search for genetic susceptibility factors on PD pathogenesis 
on Navarrese individuals (Table 12): 
 
 Healthy controls (n = 59) PD cases (n = 119) 
Sex  women: 32 (54.24%) women: 45 (37.82%) 
Age (years)* mean: 68.53 (6.40)** mean: 59.61 (9.05)** 
Evolution (years) - mean: 14.35 (4.67)** 
n = number of individuals.  
* For PD cases, that is age at onset. 
**In parenthesis, the standard deviation. 
 
The sex distribution between PD cases and healthy controls was 
statistically different (Pearson´s X2 = 4.334; p<0.05, p=0.037). Furthermore, their 
mean age was statistically different too (Mann-Whitney U test; p<0.05, 
p=0.000).  
Due to the differences observed in the demographic characteristics 
between both groups, the relevance of the results obtained could be 
compromised. 
Table 12. Demographic characteristics of the entire Navarrese population. 
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PD patients were classified into three categories depending on their 
results after the cognitive assessment (Table 13): 
 
 
 Normal cognition  
(n = 50) 
Mild cognitive 
impairment (n = 36) 
Dementia (PDD) 
(n = 25) 
Sex  women: 16  
(32%) 
women: 13  
(36.11%) 
women: 12 (48%) 
Age (years)* mean: 57.24  
(7.34)** 
mean: 62.51  
(8.66)** 
mean: 62.96 
(9.59)** 
Evolution 
(years) 
mean: 14.55  
(3.81)** 
mean: 13.83  
(4.76)** 
mean: 14.61 
(4.87)** 
n = number of individuals.  
* As they are PD cases, that is age at onset. 
**In parenthesis, the standard deviation. 
Sex distribution between them was not statistically different (Pearson´s 
X2 = 1.847 (2df); p>0.05, p=0.397). Their period of evolution was not statistically 
different either (Kruskal-Wallis test; p=0.794). Nevertheless, their mean age was 
statistically different (ANOVA test; p<0.05, p=0.003): the group with normal 
cognition had a younger onset than the others. 
As the individuals with cognitive impairment (mild or severe) had similar 
mean age at onset, period of evolution and proportion of males/females (and 
small genetic differences -see Results IV.2-) these individuals were included in a 
unique group named cognitive impairment (C.I.; 61 PD cases, i.e. 36 with M.C.I. 
Table 13. Demographic characteristics of PD patients. 
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and 25 with dementia) that was compared against the individuals with normal 
cognition but Parkinson´s disease (N.C.; 50 PD cases) to find genetic 
susceptibility factors on cognitive impairment.  
It is noteworthy that both groups, N.C. and C.I., were statistically 
different for mean age at onset and that could influence the results obtained. 
 
 
With regard to the epigenetic study, the analyses were conducted in 
two different Spanish groups: 
 In blood from 5 randomly selected male-female pairs of Parkinson´s 
disease patients, age and period of evolution-matched, from the Region 
of Valencia. 
o Mean age at onset, years: 58.40 (standard deviation: 10.54). 
o Mean evolution, years: 12.10 (standard deviation: 8.32). 
 
 In substantia nigra, parietal cortex and occipital cortex from 5 PD cases 
and 5 controls from the Biobanc HCB-IDIBAPS, Barcelona, Catalonia 
(Table 14). Their clinical status was confirmed by post-mortem brain 
analysis. Controls, unlike PD patients, did not present Lewy bodies. 
However, 4 had other neurological injuries such as vascular 
encephalopathy and/or AD related pathology and, therefore, 3 of them 
had suffered vascular dementia. 
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 Healthy controls (n = 5) PD cases (n = 5) 
Sex  3 men and 2 women 3 men and 2 women 
Age (years)* mean: 77.80 (6.80)** mean: 81.00 (3.81)** 
n = number of individuals. 
* That is age at the moment of death. 
**In parenthesis, the standard deviation. 
For one of the controls, we could not obtain DNA from SN, so for this brain region our 
results are based on the values of only 4 individuals. 
  
 
 
 
 
  
Table 14. Demographic characteristics of the brain donors. 
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Cognitive evaluation: 
The cognitive state was determined for all the subjects from Navarra 
with the Mini Mental State Examination (MMSE) and the Blessed Dementia 
Scale (BDS). In addition, to precisely define the rate of cognitive impairment, 
the different cognitive domains were evaluated by the following tests: verbal 
episodic memory using the Free and Cue Selective Reminding test of Buschke 
and Cerad word list; visual episodic memory by copy and delayed recall of two 
simple figures [Massachusetts General Hospital Boston]; the Boston naming 
test to check language; attention and executive functions with the Raven 
Progressive matrices, semantic (animals), and phonetic (words starting with 
‘‘p’’) verbal fluency, Trail Making Test parts A and B, the Stroop test, and digit 
span forward and backwards. Furthermore, activities of daily living were 
evaluated with the Interview for Deterioration in Daily Living in Dementia scale 
(IDDD) and depression was rated using the Yesavage Geriatric Depression 
Rating Scale (GDS). All these tests were blindly applied by the same person 
[436]. 
 
 
 
 
 
The methodological process was different between genetic and 
epigenetic studies and, therefore, it will be explained separately. 
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III.1. Genetics in PD. 
DNA extraction: 
The DNA we used was extracted and quantified in the respective 
hospitals from whole blood using standardized protocols. 
Primers design: 
Primers, except for the pyrosequencing assays, were designed using 
Gene Runner (Michael Spruyt and Frank Buquicchio, version 3.01, 1994, 
Hastings Software Inc.; http://www.generunner.net/) based on genomic DNA 
sequences obtained from the UCSC genome browser 
(http://genome.ucsc.edu/) [475].  
To enhance their ability to amplify the target DNA during PCR, we 
designed them, whenever possible, with the following characteristics:  length 
between 18 and 25 nucleotides, absence of secondary structures (neither 
intramolecular nor intermolecular, including with the other member of the 
pair), melting temperature lower than 65⁰C, melting temperature difference 
between the members of the pair lower than 2⁰C and cytosine or guanine as 
the last nucleotides at the 3´ end. 
Genotyping: 
All the genotyping methods carried out were based on PCR 
amplification: PCR, allele-specific PCR (AS-PCR), restriction fragment length 
polymorphism (RFLP), pyrosequencing and fragment analysis. As a 
consequence, each time, an aliquot of the PCR was loaded in an agarose gel 
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(1.5%) to confirm the presence of a band of the correct size, and thus the 
success of the reaction, by electrophoresis. 
1. PCR: to determine the presence of the insertion in CBS and the deletion in 
MAPT, the previously described steps were sufficient (PCR reaction 
followed by electrophoresis in a 1.5% agarose gel). 
PCR mix per one reaction (1X) for a final volume of 15µL: 10.8µL Milli-Q water + 
1.5µL 10X buffer + 0.5µL dNTPs 5mM each + 0.5µL primers 10µM (F+R) + 0.7µL TAQ 
DNA polymerase 1U/µL (Biotools) + 1µL DNA 50ng/µL. 
 
2. AS-PCR: two primers, that only differed in their last 3´nucleotide, which 
corresponded to the two alleles of the SNP to analyze, plus a common 
primer at the opposite strand were necessary; two PCRs were conducted 
per individual, each one with a different primer combination. The band 
pattern observed after the 1.5% agarose electrophoresis was enough to 
determine the genotype.  
PCR mix per one reaction (1X) for a final volume of 20µL: 15µL Milli-Q water + 2µL 
10X buffer + 0.5µL dNTPs 5mM each + 0.5µL primerF 10 µM + 0.5µL primerR 10 µM 
+ 0.5µL TAQ DNA polymerase 1U/µL (Biotools) + 1µL DNA 50ng/µL. 
Exception: in UCHL1 assays, 1µL of DMSO was also added adjusting the final 
volume with 14µL of Milli-Q water.  
 
3. RFLP: these assays are based in that differences in the nucleotide sequence 
at the position analyzed create or destroy restriction endonuclease 
recognition sequences.  
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Once the region of interest had been amplified, a restriction reaction was 
carried out and the genotype determined by the restriction fragments 
pattern obtained visualized in an electrophoresis.  
PCR mix per one reaction (1X) for a final volume of 25µL: 20µL Milli-Q water + 
2.5µL 10X buffer + 0.5µL dNTPs 5mM each + 0.5µL primers (F+R) 10 µM + 0.5µL TAQ 
DNA polymerase 1U/µL (Biotools) + 1µL DNA 50ng/µL. 
For APOE the PCR mix per one 50µL reaction (1X) was:  36.5µL Milli-Q water + 5µL 
10X buffer + 1.1µL dNTPs 5mM each + 1.1µL primer (F+R) 10 µM + 2.5µL DMSO + 
0.8µL TAQ DNA polymerase (Biotools) + 3µL DNA 50ng/µL. 
Exception: when additives were needed to improve specificity, the final volume 
was kept constant by adjusting the amount of water in the mix. The SNPs 
requiring additives were 1.25µL of DMSO for rs6684770 in ATP13A2 and 
rs2298969 in HTT.  
 
Restriction mix per one 15µL reaction (1X): 1.5µL 10X buffer + 0.2µL restriction 
enzyme 5-10U/µL (Fermentas or NEB) + 13.3µL PCR. 
Manufacturer´s instructions were followed to obtain successful reactions: mostly 
of them were incubated overnight at 37⁰C but some required specific conditions 
such as different incubation temperature, addition of BSA and/or SAM49. 
 
In these reactions, the presence of a second recognition site for the same 
restriction enzyme, not affected by the DNA change analyzed, which was 
thus always used by the enzyme, served as an internal control, in addition 
of the use of positive controls with known genotype. This was a useful 
strategy to ensure that there had not been partial restrictions.  
                                                          
49
 BSA: bovine serum albumin. SAM: S-adenosyl methionine. 
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For the design of these assays, the NEBcutter V2.0 tool 
(http://tools.neb.com/NEBcutter2/) from NEB was used. 
 
4. Pyrosequencing: it is a sequencing-by-synthesis method. The first step of 
the process involves a PCR amplification with one of the primers biotin-
labeled at its 5´-terminus. Once it has finished, the incorporated 
biotinylated primer is immobilized on streptavidin-coated beads and, thus, 
a single-stranded PCR product is purified. Then, the pyrosequencing 
primer, which has been designed in the opposite strand to the biotin-
labeled primer, and, moreover, with its 3´ end around 1bp before the 
variable nucleotide to interrogate, is hybridized and the sequencing 
reaction starts.  
Only if the added nucleotide is complementary to the template DNA it is 
incorporated by a DNA polymerase. The release of pyrophosphate 
molecules, PPi, during the iterative incorporation of nucleotides, can be 
monitored in real time because they are quantitatively converted into a 
proportional light signal by the consecutive activity of three enzymes 
(Figure 49) [476]. 
The pyrosequencing assays, i.e. the primer design, the dispensation order 
and other features necessary for the proper development of the reaction, 
were designed using the PyroMark Assay Design Software 2.0 from Qiagen.  
The reaction was carried out in a PyroMark MD sequencer using NDTS 
(nucleotide dispensing tips). Results were analyzed by the program 
PyroMark MD 1.0. These and all the other necessary products for the 
pyrosequencing were from Qiagen. 
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 Modified from [476] 
 
 
PCR mix per one reaction (1X) for a final volume of 25µL: 19.4µL Milli-Q water + 
2.5µL 10X buffer + 0.5µL dNTPs 5mM each + 0.5µL primerF 10 µM + 0.5µL 
primerR 10 µM + 0.6µL TAQ DNA polymerase 1U/µL (Biotools) + 1µL DNA 50ng/µL. 
 
5. Fragment analysis: one of the primers used in the PCR amplification had to 
be labeled with a fluorescent tag. In our case, 6FAM.  
PCR mix per one reaction (1X) for a final volume of 10µL: 7.2µL Milli-Q water + 1µL 
10X buffer + 0.25µL dNTPs 5mM each + 0.25µL primers (F+R) 10 µM + 0.5µL TAQ 
DNA polymerase 1U/µL (Biotools) + 0.8µL DNA 50ng/µL. 
Fig. 49. Enzymatic cascade of the pyrosequencing reaction. 
S-dATP is added as nucleotide for extension. The 
incorporation of the complementary S-dATP by the Klenow 
fragment of DNA polymerase I at the 3´ end of the 
pyrosequencing primer results in the release of PPi, which is 
in turn used to convert adenosine phosphosulfate (APS) into 
ATP. The ATP provides the energy to form an unstable 
luciferase–luciferin–AMP complex, which in the presence of 
oxygen results in the release of light in a proportional amount 
to the available ATP and thus PPi. Unincorporated S-dATP as 
well as to a small extent ATP is degraded to the 
mononucleotides by apyrase before adding the next 
nucleotide. Carefully balanced proportions of the respective 
enzymes ensure the preferential incorporation of the 
nucleotide instead of degradation.   
When a non-complementary nucleotide is added, it is 
degraded by apyrase, there is no generation of ATP and, 
therefore, no release of light.  
This modified nucleotide, S-dATP, is used instead of dATP, 
which would act as a direct substrate of the luciferase and 
thereby uncouple the generation of a bioluminometric signal 
from the release of PPi. In all the other cases, unmodified 
nucleotides are used: dCTP, dTTP and dGTP.  
 To prohibit primer degradation and thus out-of-phase 
signals, an exonuclease-deficient DNA polymerase is used for 
nucleotide incorporation. 
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1µL of PCR was diluted with Milli-Q water to a final volume of 20µL and then 
processed following the appropriate protocol. 
 
These assays analyzed the length of the fragment, rather than its 
sequence. For that purpose, amplicons were subjected to capillary 
electrophoresis using an automated DNA sequencer ABI Prism 3130XL (Life 
Technologies) with the GeneScan-500Liz Size Standard as the size marker. 
Fragment sizes were obtained by analyzing the data with the program 
Gene Mapper. These and all the other necessary products were from Life 
Technologies. 
 
There is a frequent problem when using PCR to analyze homopolymers 
such as those found in TOMM40: there is a significant amount of ‘slippage’ 
during each DNA amplification cycle, causing the newly polymerized strand 
to have either fewer or more nucleotides than the original template 
strand. After several cycles of PCR, the amplification product contains a 
complex mixture of PCR amplicons that vary in length at the poly-T locus, 
some of them with the true poly-T length. As a consequence, it is difficult 
to analyze the electropherograms produced by capillary electrophoresis of 
the PCR products in order to determine precisely the original template 
length. However, the lengths of the PCR amplicons are normally 
distributed, i.e. each electropherogram shows a cluster of peaks with a 
normal distribution of peak heights (Figure 50).  
We assumed that the true amplicon length had the highest frequency in 
the mixture of PCR-product lengths, reflected by the highest intensity peak 
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within the cluster: the fragment length of the highest peak, or the Mode 
value, indicated the original (pre-PCR) fragment length [439]. 
 
 
 
 
 
[Obtained from our own experiments] 
 
 
 
 
 
Genotyping controls. 
To control the quality and reproducibility of the genotyping results, we 
included, in each reaction, individuals with known genotypes obtained by 
Sanger sequencing50. Moreover, 20% of the assays were independently 
repeated in order to check for consistency. 
                                                          
50
 We used the same primers, PCR mix and PCR conditions for the sequencing than for the  
genotyping except in the AS-PCR assays where it was necessary to design the second common 
primer (forward or reverse depending on the case) and thus different PCR conditions were 
followed. PCR mix in those cases was the same than for RFLP assays. 
Fig. 50. Example of an electropherogram showing the slippage and the “stutter” peaks. 
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All the sequencing reactions to obtain the positive controls as well as 
those to genotype PD cases and healthy controls by fragment analysis and 
pyrosequencing assays were carried out at the DNA Analysis Facility of the 
Instituto de Biomedicina de Valencia by Beatriz Águeda Gómez and Silvia 
Aparicio Domingo. 
 
We would like to thank to Dr. Elvira V. De Marco (Institute of 
Neurological Sciences, National Research Council, Mangone, Cosenza, Italy) for 
sending us DNA from two heterozygous individuals for GBA mutations (one for 
p.N370S and other for p.L444P) that we used as positive controls. 
 
 
 
All the primers used in this section are shown, alphabetically ordered, in 
Annex I, where the mutations and polymorphisms studied are described as well 
as the criteria to select them, the primer sequences, the size of the fragment 
amplified, the PCR conditions and the method of DNA analysis. For those which 
are RFLP, there are two more features, the restriction enzymes used and the 
percentage of agarose necessary to differentiate the restriction fragments by 
electrophoresis. 
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III.2. Epigenetics in PD. 
DNA extraction: 
The DNA we used from the Valencian patients was extracted and 
quantified in the respective hospitals from whole blood using standardized 
protocols. 
 We followed the Maxwell 16 Mouse Tail DNA Purification Kit 
instructions to extract DNA from each individual´s brain region: around 30mg of 
tissue were dissected and afterwards introduced in the Maxwell 16 Instrument 
(Promega). Finally, it was quantified by using the Qubit dsDNA BR Assay kit and 
the Qubit Fluorometer (Life Technologies). 
 
Bisulfite treatment: 
Although there are other options, bisulfite treatment is the gold 
standard technique to analyze 5-methylcytosine (5mC). In this process, 
unmethylated C converts into U whereas 5mC remains unaltered. Although 
5mC can also react with bisulfite, the reaction is extremely slow and the 
equilibrium favors 5mC rather than the deaminated product T. 
[477] were the first who used sodium bisulfite to differentiate C and 
5mC, and later, [478] optimized the technique (Figure 51). 
At the present time, commercial kits are available for this purpose. The 
original procedure has been replaced by easy, short, effective, exhaustively 
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tested and optimized alternative protocols which minimize DNA degradation 
and conversion failure, i.e. Cs that do not change to Us or 5mCs that change to 
Ts.  
We opted for the EZ DNA Methylation-Gold kit (Zymo Research) and 
treated 1g of DNA per individual and region. Finally, it was quantified by using 
NanoDrop 2000 (Thermo Scientific) as if it was RNA, because bisulfite treated 
DNA has an absorption coefficient at 260nm that resembles that of RNA. 
Modified from [479] 
CpG island prediction: 
The 5 genes responsible for the familial 
forms of Parkinson´s disease were analyzed: DJ-1, 
LRRK2, PINK1, PRKN and SNCA.  
Fig. 51. Chemical conversion of cytosine into uracil.  
The reaction is highly single-strand specific and cannot 
be performed on double-stranded DNA. 
The first step, the formation of the sulfonated cytosine 
derivative (cytosine-SO3) is reversible. The extent of 
adduct formation is controlled by pH, bisulfite 
concentration and temperature. The forward reaction 
is favoured by low pH and the reverse reaction by high 
pH. 
In the second step of the reaction, cytosine-SO3 
undergoes hydrolytic deamination to give uracil-SO3. 
This step is catalyzed by basic substances, such as 
sulfite, bisulfite and acetate anions. Since sulfonation is 
favoured by acidic pH, the reversible sulfonation 
reaction and the subsequent irreversible deamination 
step are both carried out at pH below 7. 
The third step involves alkali treatment to remove the 
bisulfite adduct. 
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For each one, we considered ≈3000bp upstream the transcription 
starting site (TSS) and ≈3500bp downstream it to include the promoter and the 
first exons, where CpG islands are frequently present.  
It was sufficient to observe the distribution of CG dinucleotides in those 
sequences to confirm that there was an accumulation of CG dinucleotides 
around the TSS. Nevertheless, to precisely delimit the CpG island, we uploaded 
the regions to 5 prediction programs:  
o Softberry: 
http://linux1.softberry.com/berry.phtml?topic=cpgfinder&group=prog
rams&subgroup=promoter 
o CpG cluster: http://bioinfo2.ugr.es/CpGcluster/ [480] 
o Zeus2: http://zeus2.itb.cnr.it/cgi-bin/wwwcpg.pl 
o Bioinformatics: http://www.bioinformatics.org/sms2/cpg_islands.html 
o Emboss: http://www.ebi.ac.uk/Tools/seqstats/emboss_cpgplot/ 
 
All the programs except CpG cluster define CpG islands as [458] did and 
therefore calculate G+C content and CpG fraction using a 200bp window 
moving across the sequence at 1bp intervals. However, CpG cluster considers 
that there is no objective standard for defining CpG islands and thus do not 
calculate any of those three parameters: it is based on the physical distance 
between neighboring CGs and can find shorter CpG islands. Furthermore it 
points out that the algorithms that use the moving-window approach cannot 
accurately define the island boundaries to single-pair resolution. 
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Furthermore, we annotated the CpG island that UCSC genome browser 
considered. 
 
Below are the results we obtained for the CpG island prediction. In each 
case, the table indicates the different predicted sizes whereas the image shows 
their localization in the converted sequence and, in addition, the position of the 
designed primers (arrows; the white circle indicates which is biotin-labeled). 
Bold thymines correspond to unmethylated cytosines. The numbers on the 
sides of the sequence indicate the assays designed to analyze the CpG island. 
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1. DJ-1: NM_007262 (it has a longer exon 1 than NM_01123377). 
 
 
 
 
Non-coding exon 1 is colored red. 
 
[UCSC] [Softberry] [CpG 
cluster] 
[Zeus 2] [Bioinfor
matics] 
[Emboss] 
925 925 840 1079 1075 335+507 
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2. LRRK2: NM_198578. 
 
 
 
 
Exon 1 is colored in red (non-coding) and in blue (coding). 
 
[UCSC] [Softberry] [CpG 
cluster] 
[Zeus 2] [Bioinfor
matics] 
[Emboss] 
558 282 649 895 899 403+235 
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3. PINK1: NM_032409. 
 
 
 
 
Exon 1 is colored in red (non-coding) and in blue (coding). 
 
[UCSC] [Softberry] [CpG 
cluster] 
[Zeus 2] [Bioinfor
matics] 
[Emboss] 
506 435 779 965 969 749 
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4. PRKN: NM_013988 (although the three isoforms share the same exon 1). 
 
 
 
Exon 1 is colored in red (non-coding) and in blue (coding). 
 
[UCSC] [Softberry] [CpG 
cluster] 
[Zeus 2] [Bioinfor
matics] 
[Emboss] 
641 522 778 1027 1027 772 
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5. SNCA: exon 1 is non-coding in all four isoforms. 
 
Exon 1 in NM_001146055 is colored in pink. Exon 1 in NM_000345 is 
colored in green. Exon 1 in NM_007308 and NM_001146054 is underlined.  
X and Z delimit the regions analyzed by [473] and [474], respectively. 
[UCSC] [Softberry] [CpG 
cluster] 
[Zeus 2] [Bioinfor
matics] 
[Emboss] 
862 364 282+579+ 
149+306 
200+1762 1761 591 
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 It is noteworthy that the limits of the CpG islands were mostly different 
between programs even when they were based on the same principles. At 
least, in all the 5 cases, there was a “core” island shared by all of them. 
 
Primers design: 
The methylation analysis was carried out by pyrosequencing. Therefore, 
three primers were necessary: two for the PCR reaction (forward plus reverse; 
one of them biotin-labeled) and one more, the pyrosequencing primer, in the 
opposite strand to the biotin-labeled primer for the sequencing reaction. 
The pyrosequencing assays, i.e. the primer design, the dispensation 
order and other features necessary for the proper development of the 
reaction, were designed using the PyroMark Assay Design Software 2.0 from 
Qiagen based on genomic DNA sequences obtained from UCSC genome 
browser (http://genome.ucsc.edu/) [475]. 
Prior to performing the experiment, we analyzed the presence of other 
frequent SNPs in the sequences to be analyzed by using the Single Nucleotide 
Polymorphism database, dbSNP (http://www.ncbi.nlm.nih.gov/projects/SNP/) 
because their presence could alter the assay. Only for DJ-1 3 we found that 
there was a polymorphism (rs35675666) that was taken into account in the 
design and thus in the dispensation order to overpass failures. 
Primers satisfied some specific features to enhance the success of the 
amplification reaction:  
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 length between 18 and 30 nucleotides; 
 absence of secondary structures or primer dimer formation;  
 melting temperature difference between the members of the pair 
lower than 2⁰C; 
 amplicon length between 100 and 500 nucleotides (optimal size 
around 300); 
 inclusion of a limited number of CG dinucleotides in the primer 
sequence, no more than 2, which should be located as far as possible 
from the 3´ end. Otherwise the primers would have been entirely 
selective for methylated templates and thus will only amplify 
methylated sequences; 
 inclusion of some Ts originated from non-CpG Cs at, or near, the 3´ end 
of the primer to ensure amplification of only bisulfite modified DNA 
[481]. 
 
It should be noted that, after the bisulfite reaction, the two DNA strands 
are no longer complementary and therefore can be independently amplified 
(Figure 52). 
 
Our first intention was to analyze the whole predicted CpG islands. 
Nevertheless, pyrosequencing has its own limitations and reactions longer than 
50 nucleotides and/or sequences that include homopolymers longer than 4 
nucleotides do not work properly. Moreover, the distribution of CG 
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dinucleotides in the target sequence determined where primers could be 
designed following the previously explained necessary characteristics.  
Therefore, we designed 
some assays for each gene but 
only covered specific regions 
(specific CpG sites). We tried to, 
at least, study areas before, in 
and after the TSS, included in 
the “core” CpG island.  
In addition we made a 
trial prediction about the 
position of the promoter in 
those genes with FirstEF 
(http://rulai.cshl.edu/tools/Firs
tEF/) and WWW Promoter Scan 
(http://www-
bimas.cit.nih.gov/molbio/pros
can/) to check that, anyhow, 
analyzed regions partially 
overlapped with it (see Annex 
II).    
              Modified from [478] 
 
 
Fig. 52. Bisulfite genomic sequencing procedure. 
The two complementary strands in the original DNA 
are labeled a and b. Cytosine residues and their 
corresponding uracil and thymine conversion 
products are shown in bold type. a and b are no longer 
complementary after the bisulfite treatment. 
III. MATERIAL AND METHODS.                                            III.2. Epigenetics in PD. 
203 
 
Pyrosequencing: 
Previously to pyrosequencing, we confirmed by sequencing51 that all the 
PCR amplifications corresponded to our target sequences. In addition, all the 
primer sets were tested with non-bisulfite treated DNA as a template to 
eliminate the possibility that they amplified PCR products from unconverted 
DNA. 
Furthermore, other important detail was checked: PCR bias. It is a 
sequence-dependent and often strand-specific bias that originates because the 
primers might not proportionally amplify methylated and unmethylated 
sequences, which are different after bisulfite conversion, thus leading to an 
inaccurate estimation of methylation [482]. For this purpose, PCRs were 
carried out with DNA with known methylation percentages (0, 50 and 100) and 
then DNA methylation levels were analyzed by pyrosequencing to confirm that 
the observed and the expected methylation levels matched and, thus, there 
was no bias. We used the EpiTect PCR Control DNA Set from Qiagen which 
includes methylated and unmethylated bisulfite treated human DNA. 
Each time, an aliquot of the PCR was loaded in an agarose gel (1.5%) to 
confirm the presence of a band, and thus the success of the reaction, by 
electrophoresis52. Then, they were pyrosequenced or, when appropriate, 
Sanger sequenced.  
                                                          
51
 We used the same PCR mix and PCR conditions in sequencing than in pyrosequencing. 
52
 Except when using non-bisulfite treated DNA where the success was the absence of 
amplification. 
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For each condition tested, individual and region or tissue analyzed, we 
obtained three independent replicates. 
 
The reactions were carried out in a PyroMark MD sequencer using NDTS 
(nucleotide dispensing tips). Results were analyzed by the program PyroMark 
Q-CpG 1.0.9. These and all the other necessary products for the 
pyrosequencing were from Qiagen. [For more details about pyrosequencing, 
see section III.1. Genetics in PD, Genotyping, Pyrosequencing]. 
All pyrosequencing (and sequencing) reactions were carried out at the 
DNA Analysis Facility of the Instituto de Biomedicina de Valencia by Beatriz 
Águeda Gómez and Silvia Aparicio Domingo. 
 
 
 
In Annex II, and alphabetically ordered, all the pyrosequencing assays 
conducted are described as well as the primer sequences, the size of the 
fragment amplified and the PCR conditions. 
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Statistics: 
The X2 test was used to compare the proportion of males/females 
between groups. The t-student test (ANOVA test) or the Mann-Whitney test 
(Kruskal-Wallis test), depending on the number of groups to compare and their 
distribution, were used to compare the mean age and the period of evolution.  
The asymptotic Pearson’s chi-square goodness-of-fit test was used to 
check that the distribution of the polymorphisms at control groups followed 
the HWE. There were only three deviations, i.e. p-values lower than 0.05, that 
are indicated when corresponds at the discussion section. 
Most of genotype and allele frequencies between the PD cases and 
controls were compared by using the X2 test. Nevertheless, Fisher´s exact test 
was used for mutations at GBA, NR4A2 and APP, which are less frequent. 
To estimate the effects of genotypes and demographic factors on the 
probability to develop PD, a binary logistic regression model was calculated 
when appropriate, thus obtaining sex- and age-correlated OR. 
Haploview [483] was used to determine haplotypes when necessary. 
Those with frequency lower than 1% were not considered. The colors and 
values indicated at the linkage disequilibrium maps have been calculated using 
the parameter D´. 
 
Regarding to the epigenetic study, due to the low number of data, a 
non-parametric test (the Mann-Whitney test) was used to compare means. 
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To estimate the statistical power of our studies we used the tool in 
http://statpages.org/proppowr.html. Results are described at the following 
table and below there is an explanation:  
 
Population 
Difference in 
proportions (X) 
1- (Y) → Z 
Basque53  0.19 80 0.05 → 5% 
non-Basque  0.11 80 0.05 → 5% 
non-Basque paired case-control  0.20 80 0.05 → 5% 
 Navarrese cases vs controls 0.20 80 0.10 → 10% 
Navarrese 2 groups cases 0.23 80 0.10 → 10% 
 
“Taking into account the number of individuals included, if, between 
the two groups, there is a true difference in proportions of X or more, it could 
be detected in the Y% (power, i.e. 1-) of cases with an error of Z% ()54.” 
 
                                                          
53
 Basque: Table 7; Results IV.1. non-Basque: Table 9; Results IV.1. non-Basque paired case-
control: Table 11; Results IV.3. Navarrese cases vs controls: Table 12; Results IV.2. Navarrese 2 
groups cases, i.e. considering N.C. and C.I.: Table 13; Results IV.2. 
54
 Type I error or error is related to the rate of false positives. In our case that is the error of 
accepting that there is a difference in proportions between the two groups when there is not 
such difference. Frequently used values for  are 0.05 and 0.1.  
Type II error or  error is related to the rate of false negatives. In our case, the error of 
accepting that there is no difference in proportions when there is a difference. 1-, the 
power, is the capacity of detecting a true difference; a value of 80% is the most frequently 
used. 
Table 15. Results for the calculation of the proportion difference power. 
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The statistical analysis was conducted by using IBM SPSS Statistics, 
version 20. 
Vicent Giner Bosch, assistant professor at the Department of applied 
statistics and operational research and quality at the Universitat Politècnica de 
València, guided us and solved our statistical doubts during the analysis of the 
results. 
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Genetics in Parkinson´s disease: 
IV.1. Analysis of genetic susceptibility factors in Spanish 
population. 
 
To determine possible genetic susceptibility factors in Parkinson´s 
disease in Spanish population, Basque and non-Basque, the genes and 
mutations/polymorphisms analyzed were55: 
 the three genes that have been considered genetic susceptibility 
factors in PD: 
o MAPT: H1/H2 haplotype;  
o GBA: p.N370S and p.L444P;  
o NR4A2: c.864+246C>T; 
 a controversial PARK locus: UCHL1, rs5030732 (p.S18Y);  
 TOR1A, which is related to dystonia, a secondary motor symptom in PD: 
rs1801968 (p.D216H) and p.delE302/30356; 
 the gene that is considered a genetic susceptibility factor in AD: APOE, 
genotype;  
 a new one that could replace it: TOMM40, rs10524523 (poly-T 
homopolymer). 
 
                                                          
55
 The criteria to select those mutations and polymorphisms is explained in Annex I. 
56
 There was no individual, neither PD case nor healthy control, that presented the 
p.delE302/303. Therefore, we did not include it in the analysis. 
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We studied two different Spanish populations: one from the Basque 
country and another one of non-Basque origin (Sevilla, Barcelona and 
Valencia). Although both are Spanish, we analyzed them by separate because 
individuals from the Basque country may be genetically different to the rest of 
Spanish people due to their higher rate of endogamy. 
 
1. Basque population: 
The individuals analyzed were described in Table 7 (see section III. 
Material and methods, Subjects). 
 
First, we analyzed the presence of mutations in GBA (p.N370S and 
p.L444P) (Table 16):  
 
GBA p.N370S p.L444P p.N370S + p.L444P 
Healthy controls 0 heterozygous 0 heterozygous 0 heterozygous 
PD cases 1 heterozygous 0 heterozygous 1 heterozygous 
Fisher´s exact test p=1 p= -  p=1 
  
Although there was no statistically significant difference, the individual 
that presented the mutation was eliminated from the study on genetic 
susceptibility factors in PD because mutations in GBA are considered some of 
those factors. 
Table 16. Frequency of mutations p.N370S and p.L444P (GBA). 
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The relevant results, that is, those that reached statistical significance 
(p<0.05) or a strong tendency towards this (p<0.1) are listed below. The 
results obtained for the rest of polymorphisms (p-value higher than 0.1) are 
detailed in Annex III.  
Frequencies are indicated in parenthesis. p-values lower than 0.05, i.e. 
statistically significant results, are in bold and shadowed. p-values lower than 
0.1 are highlighted in bold. We calculated odds ratio for the distribution of 
alleles in such polymorphisms to know their effect on PD risk or protection.  
 
 (1): MAPT. 
 
 
 
 
 
 
 
The distribution of alleles between healthy controls and PD cases was 
almost statistically different (p=0.080), being the H1 haplotype the potential 
susceptibility factor (Table 17). Nevertheless, there was no relevant result 
when considering genotypes (Table D, Annex III). Only when grouping them in 
H1H1 and H1H2+H2H2, the H1H1 genotype showed a trend towards 
increasing the risk of developing PD (p=0.073). 
Gene and polymorphism Alleles 
MAPT, H1/H2 haplotype H1 H2 
Controls 113 (65.70) 59 (34.30) 
PD cases 220 (73.33) 80 (26.67) 
 X
2
 = 3.068; 1df; p=0.080 
OR:1.44,  CI95%=[0.96-2.16] 
Table 17. Allelic frequency of H1/H2 haplotype (MAPT). 
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(2): APOE.  
 
 
 
 
 
 
 
 
The only statistically significant result was obtained when individuals 
were classified according to the number of 4 alleles that they carried (Table 
18; see also Tables F and G, Annex III). The proportion of 4 +/- individuals was 
higher for PD cases than for healthy controls. Moreover, bearing a copy of the 
4 allele doubles the risk for PD (OR:2.09).  
We could not, however, analyze the effect of carrying two 4 alleles as 
no homozygous,4 +/+,  were found in our populations. 
 
 
2. Non-Basque population. 
The individuals analyzed were described in Table 9 (see section III. 
Material and methods, Subjects). 
Gene and 
polymorphism 
Genotypes
APOE, genotype 4 +/+ 4 +/- 4 -/- 
Controls 0 (0) 12 (13.95) 74 (86.05) 
PD cases 0 (0) 38 (25.33) 112 (74.67) 
 X
2
 = 4.239; 1df; p=0.039 
OR: 2.09,  CI95%=[1.03-4.26] 
Table 18. Frequency of APOE genotype when considering the number of 4 alleles. 
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First, we analyzed the presence of mutations in GBA (p.N370S and 
p.L444P) (Table 19): 
 
GBA p.N370S p.L444P p.N370S + p.L444P 
Healthy controls 1 heterozygous 2 heterozygous 3 heterozygous 
PD cases 7 heterozygous 10 heterozygous 17 heterozygous 
Fisher´s exact test p=0.074 p=0.042 p=0.005 
   
We observed that the presence of mutations in GBA was a genetic 
susceptibility factor that increased the risk to develop PD. 
The individuals that presented the mutations were, consequently, 
eliminated from the study on genetic susceptibility factors in PD because they 
were already carrying those factors; even healthy controls were eliminated 
because they might develop PD in the future due to the presence of this risk 
factor. 
 
The relevant results, that is, those that reached statistical significance 
(p<0.05) or a strong tendency towards this (p<0.1) are listed below. The 
results obtained for the rest of polymorphisms (p-value higher than 0.1) are 
detailed in Annex III.  
Frequencies are indicated in parenthesis. p-values lower than 0.05, i.e. 
statistically significant results, are in bold and shadowed. p-values lower than 
Table 19. Frequency of mutations p.N370S and p.L444P (GBA). 
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0.1 are highlighted in bold. We calculated odds ratio for the distribution of 
alleles in such polymorphisms to know their effect on PD risk or protection. 
In addition, we also include the sex and age-correlated odds ratios 
calculated by using a binary logistic regression model that estimated the effect 
of their genotypes and demographic factors on the probability to develop PD. 
 
(1): MAPT. 
 
Gene and polymorphism Genotypes Alleles 
MAPT, H1/H2 haplotype H1H1 H1H2 H2H2 H1 H2 
Controls 138 
(45.85) 
124 
(41.20) 
39 
(12.96) 
400 (66.45) 202 (33.55) 
PD cases 199 
(59.94) 
105 
(31.63) 
28 
(8.43) 
503 (75.75) 161 (24.25) 
 X
2
 = 12.937; 2df; p=0.002 X2 = 13.375; 1df; p=0.000 
OR:1.58 , CI95%=[1.24-2.02] 
 
 
 
 
 
The H2H2 genotype was taken as a reference, i.e. OR:1. 
 
 df p-value OR CI95% 
Lower Upper 
H1H1 vs H2H2 1 0.007 2.133 1.230 3.699 
H1H2 vs H2H2 1 0.497 1.219 0.689 2.156 
Table 20. Genotypic and allelic frequency of H1/H2 haplotype (MAPT). 
Table 21. Results of the binary logistic regression model for the H1/H2 haplotype. 
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The distribution of genotypes and alleles between healthy controls and 
PD cases was strongly statistically different (p=0.002 and p=0.000, respectively; 
Table 20), being the H1 haplotype an important risk factor that increases the 
risk to develop Parkinson´s disease in 1.58 times (CI95%=[1.24-2.02]). Under the 
binary logistic regression model, H1H1 carriers presented a significant 
increased risk to develop PD, with an age and sex-correlated odds ratio of 2.133 
(CI95%=[1.230-3.699]). Although H1H2 carriers seemed to have more risk than 
H2H2, there was no statistically significant difference (p=0.497) (Table 21).  
 
 
(2): TOR1A.  
 
Gene and polymorphism Genotypes 
TOR1A, rs1801968 (p.D216H) GG GC CC 
Controls 249 (82.72) 52 (17.28) 0 (0) 
PD cases 269 (81.02) 57 (17.17) 6 (1.81) 
 X
2
 = 5.497; 2df; p=0.064 
 
There was a trend towards significance when considering genotypes in 
p.D216H (p=0.064). We consider that this result is due to the absence of 
homozygous CC controls, as this genotype has a very low frequency. Due to 
that fact, we could not calculate its effect on PD pathogenesis under the binary 
logistic regression model (Table 22). 
 
Table 22. Genotypic frequency of p.D216H (TOR1A). 
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(3): APOE.  
The distribution of genotypes between healthy controls and PD cases 
was statistically different (p=0.040) as well as the distribution of alleles 
(p=0.010) (Table 23). 2 allele was the main responsible (p=0.005/0.001) 
(Table 24). 
 
 
 
 
In our Spanish non-Basque population, carrying the 2 allele increased 
the risk of developing PD in almost two times (OR:1.87), but most of this 
 Genotypes Alleles 
APOE,  
genotype 
22 23 33 34 44 24 2 3 4 
Controls 9 
(2.99) 
28 
(9.30) 
189 
(62.79) 
60 
(19.93) 
2 
(0.66) 
13 
(4.32) 
59 
(9.80) 
466 
(77.41) 
77 
(12.79) 
PD cases 12 
(3.61) 
52 
(15.66) 
185 
(55.72) 
53 
(15.96) 
4 
(1.20) 
26 
(7.83) 
102 
(15.36) 
475 
(71.54) 
87 
(13.10) 
 X
2
 = 11.615; 5df; p=0.040 X2 = 9.166; 2df; p=0.010 
 2 +/+ 2 +/- 2 -/- 2 + 2 - 
Controls 9 (2.99) 41 (13.62) 251 (83.39) 50 (16.61) 251 (83.39) 
PD cases 12 (3.61) 78 (23.49) 242 (72.89) 90 (27.11) 242 (72.89) 
 X
2
 = 10.604; 2df; p=0.005 X2 = 10.099; 1df; p=0.001  
OR: 1.87,  CI95%=[1.27-2.76] 
Table 23. Genotypic and allelic frequency of APOE genotype. 
Table 24. Frequency of APOE genotype when considering the number of 2 alleles. 
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effect was due to 2 +/- carriers, i.e. the main risk factor is the presence of 
only one 2 allele, as it was observed for the results obtained under the binary 
logistic regression models (Tables 25 and 26):  only 23 and 24 genotypes 
reached statistical significance (p=0.011 and 0.043, respectively) and were 
related to an increased risk to develop PD (OR:1.928 and 2.055, respectively). 
When considering the number of 2 alleles, the age- and sex-correlated odds 
ratio again reached statistical significance (p=0.001) for those bearing one 
allele (OR:2.005; CI95%=[1.319-3.048]).  
All the values for OR are similar and indicate that the probability of 
developing PD doubles for 2 +/- carriers. 
 
 df p-value OR CI95% 
Lower Upper 
22 vs 33 1 0.471 1.387 0.570 3.376 
23 vs 33 1 0.011 1.928 1.165 3.191 
24 vs 33 1 0.043 2.055 1.024 4.125 
4 vs 33 1 0.423 2.014 0.364 11.141 
34 vs 33 1 0.588 0.890 0.583 1.358 
The 33 genotype was taken as a reference, i.e. OR:1. 
 
 
 
 
Absence of 2 alleles was taken as a reference, i.e. OR:1. 
 df p-value OR CI95% 
Lower Upper 
2 +/+ vs 2 -/- 1 0.444 1.413 0.584 3.420 
2 +/- vs 2 -/- 1 0.001 2.005 1.319 3.048 
Table 25. Results of the binary logistic regression model for APOE genotypes. 
Table 26. Results of the binary logistic regression model considering the number of 2 alleles. 
IV. RESULTS.                                              IV.1. Spanish: Basque and non-Basque. 
220 
 
As we observed that H1H1 carriers (MAPT) and 2 +/- carriers (APOE) 
have an increased risk to develop PD, we calculated if there was a combined 
effect of both factors in non-Basque individuals (Tables 27 and 28): 
 
 
 
 
 
 
 
 df p-value OR CI95% 
Lower Upper 
H1H1 and  2 +/- vs  
no H1H1 and no 2 allele 
1 0.000 3.229 1.790 5.824 
H1H1 and no 2 allele vs 
no H1H1 and no 2 allele 
1 0.000 1.886 1.326 2.681 
no H1H1 and  2 +/- vs  
no H1H1 and no 2 allele
1 0.006 2.336 1.279 4.266 
Individuals that do not carry any 2 allele and are not H1H1 were taken as a 
reference, i.e. OR:1. 
There was statistical significance in all three comparisons (p<0.05):  
 H1H1 carriers without any 2 allele showed an increased risk of 
developing PD (almost two times; OR:1.886) when compared to 
those that were 2 -/-  and H1H2 or H2H2 (effect of H1/H2 
haplotype).  
H1H1 2 +/- Healthy controls  PD cases 
+ + 20 (6.64) 44 (13.25) 
+ - 118 (39.20) 155 (46.69) 
- + 21 (6.98) 34 (10.24) 
- - 142 (47.18) 99 (29.82) 
Table 28. Results of the binary logistic regression model for the combined effect. 
Table 27. Distribution of non-Basque cases and controls depending on their 
genotype for MAPT and APOE. 
+: carrier of H1H1 genotype or one 2 allele in APOE; -: absence. 
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 The risk was higher, OR: 2.336, for those that were H1H2 or H2H2 but 
differed in the number of 2 alleles that carried (effect of 2 allele). 
[In both cases, OR values are around 2 as previously obtained: Tables 21, 25 
and 26.] 
 However, for those individuals that differed in both factors, there 
was a difference in the risk of developing PD of more than three 
times: OR:3.229 (CI95%=[1.790-5.824]). Therefore, the presence of 
both factors is even riskier. 
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IV.2. Analysis of genetic determinants in cognitive status in 
Parkinson´s disease. 
Some PD patients develop cognitive impairment (from mild to severe, 
that is, dementia) during the evolution of the disease. This study pretended to 
find the genetic susceptibility factors that could explain the appearance of this 
non-motor symptom. 
To that purpose we analyzed the frequency of 
mutations/polymorphisms located in  
 genes related to other diseases where dementia is consubstantial 
such as  
o AD: APP (rs463946), PSEN1 (rs165932), PSEN2 (rs6426554) and 
CALHM1 (rs2986017 -p.P86L-); 
o HD: HTT (rs10015979, rs363066, rs363096, rs2298969 and 
rs110501); 
o CJD: PRNP (rs4815729 and rs1799990 -p.M129V-); 
o FTD: GRN (rs11547442 -p.L46P-, rs34975779 -p.V452V- and 
rs1141754 -p.Q479K-) and TARDBP (rs11547736 -p.S92X-);  
o Kufor-Rakeb syndrome, that is also characterized by 
parkinsonism: ATP13A2 (rs2871776, rs6684770 and rs4920608); 
 genes that encode neurotrophic factors such as CDNF (rs7094179 and 
rs7099185), MANF (rs11538558 and DOCK3 -rs4441646-) and BDNF 
(rs6265 -p.V66M-); 
 genes involved in processes proposed to be related to PD: 
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o homocysteine metabolism, CBS (c.844ins68), MTR (rs1805087 -
c.A2756G-) and MTHFR (rs1801133 -c.C677T- and rs1801131 -
c.A1298C-);  
o protection against oxidative stress, NFE2L2 (rs1806649 and 
rs10183914) and KEAP1 (rs8113472);  
o chaperone-mediated autophagy, HSPA8 (rs1461496 and 
rs4936770) and LAMP-2A (rs7057652, rs42897, rs42895 and 
rs42890);  
o and, due to its relation with tau homeostasis, GSK3 (rs334558 
and rs6438552).  
 
In addition, some possible genetic susceptibility factors to PD 
pathogenesis were studied: p.N370S and p.L444P mutations (GBA), Rep1 
microsatellite and rs356219 polymorphism (SNCA), H1/H2 haplotype (MAPT), 
as well as three pathogenic mutations: rs33939927 -p.R1441G and p.R1441C- 
and rs34637584 -p.G2019S- (LRRK2). Furthermore, a genetic susceptibility 
factor in AD (APOE genotype) and a new one related to it (poly-T 
homopolymer length, rs10524523, TOMM40) were considered57. 
 
                                                          
57
 The criteria to select those mutations and polymorphisms is explained in Annex I. 
The following mutations were not present in any of the individuals. Therefore, they were not 
included at the subsequent analysis: 
 GRN: rs11547442 (p.L46P), rs34975779 (p.V452V) and rs1141754 (p.Q479K); 
 TARDBP: rs11547736 (p.S92X);  
 MANF: rs11538558; 
 LRRK2: rs33939927 (p.R1441C). 
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 The analysis was divided in two phases:  
1. initially, all these mutations/polymorphisms were studied in the 
individuals described in Table 12 (see section III. Material and 
methods, Subjects), i.e. healthy controls and PD cases, to 
determine if any of them could be considered a genetic 
susceptibility factor on PD risk in Navarrese population.  
 
First, we analyzed the presence of mutations in  
 LRRK2: 2 PD cases (1.68%) carried the p.R1441G mutation (both were 
cognitively normal) and 3 (2.52%) carried the p.G2019S (two presented 
mild cognitive impairment and the third was cognitively normal). 
Obviously, no control carried them. 
 GBA: two patients presented the p.L444P mutation (both were 
cognitively normal), whereas the PD case that carried the p.N370S 
variant had mild cognitive impairment. One of the control individuals 
also carried this mutation. There was no statistically significant 
difference when comparing the frequency of those mutations between 
controls and cases (Fisher´s exact test, p=1). 
 
It is noteworthy that the individuals that presented mutations in GBA or 
LRRK2 were excluded from the subsequent analysis because those factors 
could involve specific pathological pathways not shared by the other non-
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carriers: they were already carrying pathogenic mutations (LRRK2) or high risk 
susceptibility factors (GBA). 
 
The relevant results, that is, those that reached statistical significance 
(p<0.05) or a strong tendency towards this (p<0.1) are listed below. 
Frequencies are indicated in parenthesis. p-values lower than 0.05, i.e. 
statistically significant results, are in bold and shadowed. p-values lower than 
0.1 are highlighted in bold. We calculated odds ratio for the distribution of 
alleles in such polymorphisms to know their effect on PD risk or protection. 
 
When it was possible, we estimated haplotypes that could modify the 
risk to develop PD. We did not calculate sex and age-correlated odds ratios for 
the genotypes by using a binary logistic regression model as controls and 
cases had statistically significant different mean age and sex distribution and, 
moreover, both groups were composed by a significant different number of 
individuals. Therefore, caution should be taken when interpreting these 
results. 
 
The results obtained for the rest of polymorphisms, i.e. those without 
statistical significance (p-value higher than 0.1), are detailed in Annex IVa. 
 
 
IV. RESULTS.                                                                   IV.2. Cognitive status in PD. 
226 
 
(1): SNCA.  
 
 
 
The distribution of genotypes and alleles between healthy controls and PD 
cases was statistically different (p=0.049 and p=0.018, respectively). The A 
allele was protective against PD (OR: 0.56; CI95%=[0.34-0.92]), especially in AA 
genotypes, which were more frequent amongst controls (51.72%) than cases 
(34.23%) (Table 29). When classifying the individuals as AA vs AG+GG, there 
was a statistically significant difference (p=0.028): AA carriers had a decreased 
risk to develop PD (OR:0.49; CI95%=[0.26-0.94]). 
 
 
 
 
 
 
Gene and 
polymorphism 
Genotypes Alleles 
SNCA, rs356219 AA AG GG A G 
Controls 30 
(51.72) 
25 
(43.10) 
3 
(5.17) 
85 
(73.28) 
31 
(26.72) 
PD cases 38 
(34.23) 
58 
(52.25) 
15 
(13.51) 
134 
(60.36) 
88 
(39.64) 
 X2 = 6.034; 2df; p=0.049 X2 = 5.571; 1df; p=0.018 
OR: 0.56,  CI95%=[0.34-0.92] 
Table 29. Genotypic and allelic frequency of rs356219 (SNCA). 
IV. RESULTS.                                                                   IV.2. Cognitive status in PD. 
227 
 
(2): MAPT. 
 
 
The distribution of genotypes and alleles between healthy controls and PD 
cases was strongly statistically different (p=0.001 and p=0.000, respectively), 
being the H1 haplotype an important risk factor that increased the risk to 
develop Parkinson´s disease in 2.55 times (CI95%=[1.59-4.09]); H1H1 carriers 
were overrepresented amongst PD patients (62.16% vs 31.03% in controls) 
and had an increased risk to develop the disease (Table 30). When classifying 
the individuals as H1H1 vs H1H2+H2H2, there was a statistical significance 
(p=0.0001): H1H1 carriers had an increased risk to develop PD (OR:3.65; 
CI95%=[1.86-7.17]). 
 
 
 
 
Gene and 
polymorphism 
Genotypes Alleles 
MAPT,  
H1/H2 haplotype 
H1H1 H1H2 H2H2 H1 H2 
Controls 18 
(31.03) 
25 
(43.10) 
15 
(25.86) 
61 
(52.59) 
55 
(47.41) 
PD cases 69 
(62.16) 
26 
(23.42) 
16 
(14.41) 
164 
(73.87) 
58 
(26.13) 
 X2 = 14.781; 2df; p=0.001 X2 = 15.514; 1df; p=0.000 
OR: 2.55, CI95%=[1.59-4.09] 
Table 30. Genotypic and allelic frequency of H1/H2 haplotype (MAPT). 
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(3): HTT. 
 
Gene and 
polymorphism 
Genotypes Alleles 
  HTT, rs363096 TT TC CC T C 
Controls 5 
(8.62) 
30 
(51.72) 
23 
(39.66) 
40 
(34.48) 
76 
(65.52) 
PD cases 22 
(19.82) 
54 
(48.65) 
35 
(31.53) 
98 
(44.14) 
124 
(55.86) 
 X2 = 3.796; 2df; p=0.150 X2 = 2.944; 1df; p=0.086 
OR: 1.50, CI95%=[0.94-2.39] 
 
Only the polymorphism rs363096 in the gene HTT showed an almost 
statistically significant result (p=0.086): the T allele tended to increase the risk 
to develop PD (OR: 1.50; CI95%=[0.94-2.39]) (Table 31). When classifying the 
individuals as TT vs TC+CC, the same tendency was observed (p=0.059).  
This effect was also observed when considering the haplotypes formed by the 
5 markers analyzed along the gene, which were in high linkage disequilibrium 
as observed at Figure 53: the haplotypes ATCAT and ATTAT, that only 
differentiate in the third position, i.e. the correspondent to rs363096, were 
protective against PD (p=0.002) and almost risky (p=0.087), respectively (Table 
32).  
 
Table 31. Genotypic and allelic frequency of rs363096 (HTT). 
IV. RESULTS.                                                                   IV.2. Cognitive status in PD. 
229 
 
 
The order of the markers at the haplotype is: rs10015979 – rs363066 – rs363096 – rs2298969 
– rs110501. Missing ORs correspond to those haplotypes absent in one of the populations. 
 
 
 
 
 
 
 
 
 
 
Haplotype Overall 
frequency 
Frequencies: 
Case, Control  
Chi square 
(X2) 
p-value OR [CI95%] 
GTTAT 0.328 0.346, 0.293 0.983 0.321 1.28 [0.71-2.32] 
ATCAT 0.266 0.211, 0.371 9.995 0.002 0.45 [0.24-0.84] 
AGCGC 0.151 0.163, 0.129 0.681 0.409 1.31 [0.59-2.89] 
ATCGC 0.147 0.156, 0.129 0.437 0.508 1.25 [0.56-2.77] 
ATTGT 0.033 0.037, 0.026 0.300 0.584 1.44 [0.29-7.21] 
ATTAT 0.017 0.025, 0.000 2.930 0.087 - 
GTTAC 0.012 0.009, 0.017 0.433 0.510 0.53 [0.04-6.93] 
GTTGT 0.011 0.017, 0.000 2.007 0.157 - 
Fig. 53. Linkage disequilibrium map in HTT. 
Table 32. Haplotypes in HTT. 
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(4): ATP13A2 (Kufor-Rakeb syndrome; dementia and parkinsonism). 
 
Only the polymorphism rs6684770 gave relevant results: the distribution of 
genotypes and alleles between healthy controls and PD cases was statistically 
different (p=0.044 and p=0.016, respectively), being the T allele the 
responsible for the 1.89 times (CI95%=[1.12-3.19]) increased risk to develop 
Parkinson´s disease (Table 33). When classifying the individuals as TT+TC vs 
CC, a statistical significance was observed (p=0.020). TT and TC carriers were 
affected by an increased risk (OR:2.15; CI95%=[1.13-4.11]). 
 
  
 
Gene and 
polymorphism 
Genotypes Alleles 
ATP13A2, rs6684770 TT TC CC T C 
Controls 2 
(3.45) 
21 
(36.21) 
35 
(60.34) 
25 
(21.55) 
91 
(78.45) 
PD cases 11 
(9.91) 
54 
(48.65) 
46 
(41.44) 
76 
(34.23) 
146 
(65.77) 
 X2 = 6.237; 2df; p=0.044 X2 = 5.849; 1df; p=0.016 
OR: 1.89,  CI95%=[1.12-3.19] 
Table 33. Genotypic and allelic frequency of rs6684770 (ATP13A2). 
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Furthermore, we studied the effect of the haplotypes formed by this and the 
other two polymorphisms analyzed in ATP13A2, rs4920608 and rs2871776, on 
PD pathogenesis: 
 
The order of the markers at the haplotype is: rs4920608 – rs6684770 – rs2871776. 
 
One of them, ATG, was statistically risky (p<0.05) and 
two more, GCG and ATA, were almost protective and 
risky, respectively (p<0.1) (Table 34). Nevertheless, 
other factors, besides the allele present in rs6684770, 
determine the protective or risky effect of the 
haplotypes, maybe due to the low linkage 
disequilibrium observed along the region (Figure 54). 
 
 
Haplotype Overall 
frequency 
Frequencies: 
Case, Control  
Chi square 
(X2) 
p-value OR [CI95%] 
ACA 0.314 0.307, 0.327 0.149 0.700 0.91 [0.50-1.65] 
GCG 0.206 0.179, 0.258 2.927 0.087 0.63 [0.32-1.24] 
ATG 0.148 0.179, 0.089 4.890 0.027 2.23 [0.95-5.26] 
ACG 0.147 0.130, 0.180 1.552 0.213 0.68 [0.31-1.48] 
GTG 0.114 0.111, 0.119 0.044 0.834 0.92 [0.39-2.19] 
GCA 0.034 0.042, 0.018 1.290 0.256 2.39 [0.41-14.01] 
ATA 0.027 0.037, 0.007 2.746 0.098 5.45 [0.42-71.21] 
GTA 0.010 0.015, 0.001 1.434 0.231 - 
Fig. 54. Linkage 
disequilibrium 
map in ATP13A2. 
Table 34. Haplotypes in ATP13A2. 
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(5): CDNF (neurotrophic factor).  
 
The distribution of genotypes between cases and controls was statistically 
different (p=0.017), mainly due to the absence of homozygous CC patients 
and the higher frequency of TT carriers in PD cases (65.77% vs 56.90% in 
controls). The same tendency was observed when analyzing the alleles: the T 
allele showed a trend towards increasing the risk to develop PD (OR: 1.61; 
CI95%=[0.93-2.78]) (Table 35). 
The combined effect of this polymorphism and rs7094179, also located at the 
CDNF gene, revealed two trends in accordance with the previous observation: 
carriers of the haplotype TT presented a higher risk to develop PD (p=0.055), 
whereas those carrying the GC were more protected against Parkinson´s 
disease (p=0.077) (Table 36). 
Gene and 
polymorphism 
Genotypes Alleles 
CDNF, rs7099185 TT TC CC T C 
Controls 33 
(56.90) 
21 
(36.21) 
4 
(6.90) 
87 
(75.00) 
29 
(25.00) 
PD cases 73 
(65.77) 
38 
(34.23) 
0 
(0) 
184 
(82.88) 
38 
(17.12) 
 X2 = 8.175; 2df; p=0.017 X2 = 2.979; 1df; p=0.084 
OR: 1.61,  CI95%=[0.93-2.78] 
Table 35. Genotypic and allelic frequency of rs7099185 (CDNF). 
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The order of the markers at the haplotype is: rs7094179 – rs7099185. 
 
(6): DOCK3 (“neurotrophic factor”).  
 
The distribution of genotypes between cases and controls was statistically 
different (p=0.035), mainly due to the absence of homozygous CC controls.  
Nevertheless, the proportion of alleles A and C was almost the same when 
comparing healthy controls and PD cases (p=0.633) (Table 37). 
 
 
Haplotype Overall 
frequency 
Frequencies:
Case, Control  
Chi square 
(X2) 
p-value OR [CI95%] 
GT 0.572 0.567, 0.581 0.060 0.807 0.94 [0.54-1.65] 
TT 0.230 0.262, 0.169 3.692 0.055 1.75 [0.88-3.48] 
GC 0.103 0.082, 0.143 3.137 0.077 0.54 [0.22-1.34] 
TC 0.095 0.089, 0.107 0.261 0.610 0.82 [0.32-2.09] 
Gene and polymorphism Genotypes Alleles 
DOCK3, rs4441646 AA AC CC A C 
Controls 37 
(63.79) 
21 
(36.21) 
0 
(0) 
95 
(81.90) 
21 
(18.10) 
PD cases 75 
(67.57) 
27 
(24.32) 
9 
(8.11) 
177 
(79.73) 
45 
(20.27) 
 X2 = 6.678; 2df; p=0.035 X2 = 0.228; 1df; p=0.633 
Table 36. Haplotypes in CDNF. 
Table 37. Genotypic and allelic frequency of rs4441646 (DOCK3). 
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(7): MTHFR (homocysteine metabolism). 
 
 
The C allele in rs1801133 (c.C677T) showed a trend (p=0.066) towards 
increasing the risk to develop PD. However, there were no relevant results 
when considering genotypes: only when grouping the individuals in CC+CT 
and TT carriers, the same trend was observed (p=0.062). 
Gene and 
polymorphism 
Genotypes Alleles 
MTHFR, rs1801133 
(c.C677T) 
CC CT TT C T 
Controls 18 
(31.03) 
29 
(50.00) 
11 
(18.97) 
65 
(56.03) 
51 
(43.97) 
PD cases 46 
(41.44) 
55 
(49.55) 
10 
(9.01) 
147 
(66.22) 
75 
(33.78) 
 X2 = 4.130; 2df; p=0.127 X2 = 3.378; 1df; p=0.066 
OR: 1.54,  CI95%=[0.97-2.44] 
MTHFR, rs1801131 
(c.A1298C) 
AA AC CC A C 
Controls 38 
(65.52) 
18 
(31.03) 
2 
(3.45) 
94 
(81.03) 
22 
(18.97) 
PD cases 53 
(47.75) 
46 
(41.44) 
12 
(10.81) 
152 
(68.47) 
70 
(31.53) 
 X2 = 5.816; 2df; p=0.055 X2 = 6.073; 1df; p=0.014 
OR: 0.51,  CI95%=[0.30-0.88] 
Table 38. Genotypic and allelic frequencies of rs1801133 and rs1801131 (MTHFR). 
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Nevertheless, in rs1801131 (c.A1298C), the distribution of alleles between 
healthy controls and PD cases was statistically different (p=0.014), being the A 
allele protective against PD (OR: 0.51; CI95%=[0.30-0.88]): it was more frequent 
in controls (81.03%) than in cases (68.47%). This effect was only observed 
when this allele was found in homozygosity: AA carriers represented the 
65.52% of controls whereas the 47.75% of cases (Table 38). When classifying 
the individuals as AA vs AC+CC, there was a statistically significant difference 
(p=0.028): AA carriers had a decreased risk to develop PD (OR:0.48; 
CI95%=[0.25-0.93]). 
 
As both are in the same gene, we analyzed the possible effect that a 
haplotype could have on PD risk: 
The order of the markers at the haplotype is: rs1801133 (c.C677T) – rs1801131 (c.A1298C). 
The results were the expected for the possible combinations of the almost 
risky C allele (rs1801133) and the protective A allele (rs1801131): they 
compensated the effect of the other when together (CA; p=0.730), and gave 
an almost protective haplotype when the almost risky C was absent (TA; 
0.054) and a risky haplotype when the protective A was absent (CC; p=0.017) 
(Table 39). 
Haplotype Overall 
frequency 
Frequencies:  
Case, Control 
Chi square 
(X2) 
p-value OR [CI95%] 
TA 0.368 0.332, 0.438 3.728 0.054 0.64 [0.36-1.14] 
CA 0.360 0.353, 0.372 0.119 0.730 0.92 [0.52-1.64] 
CC 0.268 0.309, 0.188 5.673 0.017 1.93 [1.00-3.72] 
Table 39. Haplotypes in MTHFR. 
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(8): HSPA8 (chaperone-mediated autophagy).  
 
 
The distribution of alleles between healthy controls and PD patients was 
almost statistically different (p=0.071) and the T allele tended to be protective 
(OR: 0.65; CI95%=[0.41-1.04]). The frequency of homozygous TT was almost the 
same in cases and controls, whereas TC carriers were more frequent in 
controls (44.83%) than in cases (27.03%) (Table 40). When classifying the 
individuals as TT+TC vs CC, a statistical significance was observed (p=0.021): 
carrying at least one T allele was protective against PD (OR:0.47; CI95%=[0.24-
0.90]). 
When combining these results and the obtained for the other polymorphism 
analyzed in HSPA8, rs4936770, it was observed that the presence of the T 
allele was always protective although it only reached an almost statistically 
significant effect at the haplotype TG (Table 41). 
Gene and 
polymorphism 
Genotypes Alleles 
HSPA8, rs1461496 TT TC CC T C 
Controls 11 
(18.97) 
26 
(44.83) 
21 
(36.21) 
48 
(41.38) 
68 
(58.62) 
PD cases 20 
(18.02) 
30 
(27.03) 
61 
(54.95) 
70 
(31.53) 
152 
(68.47) 
  X2 = 6.421; 2df; p=0.040 X2 = 3.252; 1df; p=0.071 
OR: 0.65,  CI95%=[0.41-1.04] 
Table 40. Genotypic and allelic frequency of rs1461496 (HSPA8). 
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The order of the markers at the haplotype is: rs1461496 – rs4936770. 
 
(9): LAMP-2A (chaperone-mediated autophagy). 
rs7057652: There was a statistically significant difference between both 
groups for the distribution of genotypes and alleles. The T allele increased the 
risk to develop PD in 2.40 times (CI95%=[1.38-4.17]), especially in homozygosis: 
there were more patients (43.24%) that carried the TT genotype than controls 
(20.69%). The effect was the same independently of sex, although in males it 
did not reach statistically significant difference (Table 42).  
rs42890: There was a statistically significant difference between both groups 
for the distribution of alleles, and almost for genotypes. The G allele increased 
the risk to develop PD in 1.94 times (CI95%=[1.14-3.29]), especially in 
homozygosis: there were more patients (54.95%) that carried the GG 
genotype than controls (36.21%). When analyzing the results by sex, the G 
allele was more frequent in PD cases than in controls; however, in men the 
difference did not reach statistically significant difference. Moreover, the 
distribution of genotypes in women was different than in the overall group, 
although the GG genotype was the most frequent (Table 43). 
Haplotype Overall 
frequency 
Frequencies:
Case, Control  
Chi square 
(X2) 
p-value OR [CI95%] 
CG 0491 0.517, 0.443 1.673 0.196 1.35 [0.77-2.35] 
TG 0.293 0.262, 0.350 2.844 0.092 0.66 [0.36-1.21] 
CA 0.160 0.168, 0.143 0.338 0.561 1.21 [0.56-2.61] 
TA 0.056 0.053, 0.063 0.160 0.689 0.83 [0.25-2.73] 
Table 41. Haplotypes in HSPA8. 
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Gene and 
polymorphism 
Genotypes Alleles 
LAMP-2A, rs7057652 TT TG GG T G 
Controls, overall 12 
(20.69) 
12 
(20.69) 
34 
(58.62) 
27 
(30.00) 
63 
(70.00) 
PD cases, overall 48 
(43.24) 
17 
(15.32) 
46 
(41.44) 
77 
(50.66) 
75 
(49.34) 
 X2 = 8.474; 2df; p=0.014 
ZmfG
2 = 7.431; 1df; p=0.006 
ZC
2 = 8.230; 2df; p=0.016 
X2 = ZA
2 = 9.844; 1df; p=0.002 
ZmfA
2 = 8.999; 1df; p=0.003 
OR: 2.40,  CI95%=[1.38-4.17] 
Controls, women 3 
(9.38) 
12 
(37.50) 
17 
(53.13) 
18 
(28.13) 
46 
(71.88) 
PD cases, women 12 
(29.27) 
17 
(41.46) 
12 
(29.27) 
41 
(50.00) 
41 
(50.00) 
 X2 = 6.107; 2df; p=0.047 
ZfG
2 = 6.078; 1df; p=0.014 
X2 = ZfA
2 = 7.143; 1df; p=0.008 
OR: 2.56,  CI95%=[1.28-5.13] 
Controls, men - - - 9  
(34.62) 
17  
(65.38) 
PD cases, men - - - 36  
(51.43) 
34  
(48.57) 
 - X2 = Zm
2 = 2.152; 1df; p=0.142 
Table 42. Genotypic and allelic frequency of rs7057652 (LAMP-2A). 
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Gene and 
polymorphism 
Genotypes Alleles 
LAMP-2A, rs42890 GG GT TT G T 
Controls, overall 21 
(36.21) 
13 
(22.41) 
24 
(41.38) 
41 
(45.56) 
49 
(54.44) 
PD cases, overall 61 
(54.95) 
16 
(14.41) 
34 
(30.63) 
94 
(61.84) 
58 
(38.16) 
 X2 = 5.463; 2df; p=0.065 
ZmfG
2 = 3.828; 1df; p=0.051 
ZC
2 = 4.875; 2df; p=0.087 
X2 = ZA
2 = 6.079; 1df; p=0.014 
ZmfA
2 = 5.098; 1df; p=0.024 
OR: 1.94,  CI95%=[1.14-3.29] 
Controls, women 7 
(21.88) 
13 
(40.63) 
12 
(37.50) 
27 
(42.19) 
37 
(57.81) 
PD cases, women 17 
(41.46) 
16 
(39.02) 
8 
(19.51) 
50 
(60.98) 
32 
(39.02) 
 X2 = 4.232; 2df; p=0.121 
ZfG
2 = 4.231; 1df; p=0.040 
X2 = ZfA
2 = 5.091; 1df; p=0.024 
OR: 2.14,  CI95%=[1.10-4.16] 
Controls, men - - - 14  
(53.85) 
12  
(46.15) 
PD cases, men - - - 44  
(62.86) 
26  
(37.14) 
 - X2 = Zm
2 = 0.644; 1df; p=0.422 
Table 43. Genotypic and allelic frequency of rs42890 (LAMP-2A). 
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It is noteworthy that the gene LAMP-2A is located at chromosome X and, 
therefore, males present only one allele whereas females present two. 
Pearson´s X2 may not be appropriate to test for association of X chromosome 
markers but there are not standardized association tests. We decided to 
calculate the statistical tests proposed by [484]58. 
 
 
The high linkage disequilibrium pattern 
observed along this gene (Figure 55) revealed 
that there were two haplotypes with 
relevance on PD pathogenesis: GAAT was 
more frequent in PD cases than in controls 
whereas TAAG was more frequent in controls 
than in patients. Both differentiate in their 
first and fourth position, i.e. rs42890 and 
rs7057652, respectively: when the G allele 
(rs42890) and the T allele (rs7057652) are 
present, haplotype GAAT, as both increase 
the risk to develop PD, carriers have an 
increased risk too, whereas their absence, haplotype TAAG, protects against 
PD (Table 44). 
 
                                                          
58
 ZmfA
2
 and ZmfG
2
 are the weighted sum of Zm
2
 plus ZfA
2
 or ZfG
2
, respectively. Both are modified 
tests to allow the differential allele effects in males and females. ZC
2
 is a genotype-based test 
where allele frequencies are estimated separately for males and females. 
Fig. 55. Linkage disequilibrium 
map in LAMP-2A. 
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The order of the markers at the haplotype is rs42890 – rs42895 – rs42897 – rs7057652. 
 
 Modelling genetic risk against PD. 
We have tried to find a mathematical model to quantify the 
contribution of the variants on the risk to develop Parkinson´s disease59. To 
simplify the process, we considered the genotypes, neither the alleles nor the 
haplotypes, that reported relevant results, i.e. p-value < 0.05 (X2 test)60: 
 
1. Risk of developing Parkinson´s disease (58 controls and 111 PD 
patients)61: 
I. rs356219 (SNCA): AA vs AG+GG, p=0.028. 
II. haplotype (MAPT): H1H2+H2H2 vs H1H1, p=0.0001. 
III. rs6684770 (ATP13A2): CC vs TT+CT, p=0.020. 
IV. rs7099185 (CDNF): CC vs TT+TC, p=0.005. 
                                                          
59
 Due to the number of individuals analyzed and their demographic and cognitive 
characteristics, the relevance of this model is compromised. 
60
 Again, individuals carrying mutations in GBA or LRRK2 were not considered.  
61
 The risk variants are underlined. 
Haplotype Overall 
frequency 
Frequencies: 
Case, Control 
Chi square 
(X2) 
p-value OR [CI95%] 
GAAT 0.388 0.461, 0.265 9.191 0.002 2.37 [1.31-4.29] 
TCAG 0.349 0.347, 0.354 0.012 0.913 0.97 [0.54-1.73] 
GAGG 0.091 0.085, 0.100 0.145 0.703 0.84 [0.32-2.19] 
TAAG 0.080 0.021, 0.179 19.059 0.00001 0.10 [0.02-0.43] 
GAAG 0.045 0.031, 0.067 1.682 0.195 0.45 [0.11-1.78] 
GCAT 0.029 0.032, 0.024 0.142 0.707 1.34 [0.25-7.31] 
Table 44. Haplotypes in LAMP-2A. 
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V. rs4441646 (DOCK3): AA+AC vs CC, p=0.026. 
VI. rs1801131 (c.A1298C, MTHFR): AA vs AC+CC, p=0.028. 
VII. rs1461496 (HSPA8): TT+CT vs CC, p=0.021. 
VIII. rs7057652 (LAMP-2A): TG+GG vs TT, p=0.004. 
IX. rs42890 (LAMP-2A): GT+TT vs GG, p=0.021. 
 
We employed a binary logistic regression model to quantify the 
relevance of these nine variables on PD risk. 
The following equation explains what a binary logistic regression is: 
 
   
                          
                                
In our case,  
 P is the probability that an individual presents PD (to be a case), 
whereas 1 – P is the probability that an individual is healthy (to be a 
control).  
 The term P / (1-P) is the odds ratio, i.e. the increase or decrease in the 
risk to develop Parkinson´s disease. 
 Each Xi represents a variable (genotype) that influences on the risk 
(value 1 for the underlined risk variants and 0 for the others) and a, b1, 
b2… are numerical coefficients. 
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Table 45 shows how many cases and controls were correctly assigned 
by the model. 
 
 
 
 
 
The results we obtained were63 (Table 46): 
Although we introduced nine variables, I, VI and IX were not included in the model
64
. 
The model fitted best including variables IV and V, despite that they did not show statistical 
significance in the model (p-value ≈1)
65
. 
                                                          
62
 Sensitivity can be defined as the proportion of PD cases that are correctly assigned by the 
model, that is, capacity to identify positives. Specificity is defined as the proportion of 
controls that are correctly assigned by the model, i.e. capacity to identify negatives. 
63
 Due to the differences between controls and cases regarding age at onset/age at collection 
and sex distribution, these variables were not considered. 
Observed 
Predicted 
health Percentage Correct 
Control PD case 
health 
Control 32 26 55.2 (specificity)62 
PD case 18 93 83.8 (sensitivity) 
Overall Percentage   74.0 
 b df p-
value 
OR (eb) CI95% 
Lower Upper 
haplotype (MAPT) X1 1.402 b1 1 0.000 4.062 e
b1 1.886 8.750 
rs6684770 (ATP13A2) X2 1.034 b2 1 0.009 2.812 e
b2 1.295 6.106 
rs7099185 (CDNF) X3 21.878 b3 1 0.999 3.17*10
9 eb3 0.000  
rs4441646 (DOCK3) X4 20.090 b4 1 0.999 5.31*10
8 eb4 0.000  
rs1461496 (HSPA8) X5 0.988 b5 1 0.011 2.685 e
b5 1.259 5.724 
rs7057652 (LAMP-2A) X6 0.954 b6 1 0.023 2.595 e
b6 1.138 5.918 
constant -23.131 a 1 0.999 0.000   
Table 46. Results of the binary logistic regression model to determine PD risk. 
Table 45. Classification of the individuals analyzed under the binary logistic regression model. 
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In all cases, individual OR>1. Nevertheless, these values were different 
to the previously reported as they were obtained under other mathematical 
assumptions. For example, an individual that carried the H1H1 genotype in 
MAPT presented 4.062 times (CI95%=[1.886-8.750]), instead of 3.65 
(CI95%=[1.86-7.17]), more risk to develop PD than other person that carried the 
H1H2 or the H2H2. 
What would happen if a person presents the risk variants in variables II 
(X1), III (X2), IV (X3), VII (X5) and VIII (X6)? 
                                             
                                                            =        = 
22.76 
 
   
                  
This person would have 22.76 times more possibilities to develop the 
disease or would develop PD with a probability of 95.79%. 
 
Finally, we analyzed the distribution of the nine variables in cases and 
controls (Figure 56 and Table 47): 
                                                                                                                                                         
64
 These three variables were not included because they did not present statistical 
significance and, furthermore, did not help to differentiate controls and cases. As they were 
redundant and not useful, were excluded. 
65
 In addition, for their particular distribution, as the CC genotype in rs4441646 (DOCK3) is 
only present in PD cases and only a few controls carry the genotype CC in rs7099185 (CDNF), 
b3 and b4 show an extreme value and a as well to compensate it. 
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The mean of PD risk variants carried by healthy controls was 3.39, 
whereas for PD patients was 5. Medians were 4 and 5, respectively. 
 
Number of risk 
variants carried 
0 1 2 3 4 5 6 7 8 9 
Healthy controls 
1.72 
(1) 
10.34 
(6) 
17.24 
(10) 
18.97 
(11) 
27.59 
(16) 
20.69 
(12) 
1.72 
(1) 
0 
(0) 
1.72 
(1) 
0 
(0) 
PD patients 
0 
(0) 
0 
(0) 
3.60 
(4) 
14.41 
(16) 
21.62 
(24) 
25.23 
(28) 
15.32 
(17) 
13.51 
(15) 
6.31 
(7) 
0 
(0) 
Table 47. Percentage of controls and cases that carry each number of risk variants. 
Number of individuals are in parenthesis. 
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Fig. 56. Distribution of the number of risk variants carried by healthy controls and PD patients. 
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We also tried to determine if there was some correlation between 
them as this could shed some light on the biological pathogenic mechanisms. 
Only rs7057652 and rs42890, both in LAMP-2A, showed some (intermediate 
for controls and high for cases) as expected due to the high linkage 
disequilibrium observed along the region. 
 
 
2. subsequently, the frequency of these mutations/polymorphisms 
was analyzed only in PD patients to determine if any of them could 
be considered a genetic determinant of cognitive status in 
Parkinson´s disease. Although cases had been classified into three 
categories depending on their results after the cognitive 
assessment (Table 13; see section III. Material and methods, 
Subjects), considering the demographic similarities and that there 
were almost no differences in genotype nor in allele distributions 
(-see “Below…” at the final part of this section IV.2.-) between PD 
patients with cognitive impairment (mild or severe)66, we grouped 
them into a unique group named cognitive impairment (C.I.; 61 PD 
cases, i.e. 36 with M.C.I. and 25 with dementia) that was compared 
against the individuals with normal cognition but Parkinson´s 
disease (N.C.; 50 PD cases). Thereby, we increased the power of our 
analysis.  
 
 
                                                          
66
 M.C.I. and dementia do not represent the same process but are somehow connected. 
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The relevant results, that is, those that reached statistical significance 
(p<0.05) or a strong tendency towards this (p<0.1) are listed below. The 
results obtained for the rest of polymorphisms (p-value higher than 0.1) are 
detailed in Annex IVb. 
Frequencies are indicated in parenthesis. p-values lower than 0.05, i.e. 
statistically significant results, are in bold and shadowed. p-values lower than 
0.1 are highlighted in bold. We calculated odds ratio for the distribution of 
alleles in such polymorphisms to know their effect on PD risk or protection. 
When it was possible, we calculated haplotypes that could 
increase/decrease the risk to develop cognitive impairment during PD. When 
appropriate, we calculated sex, but not age-correlated odds ratios for the 
genotypes by using a binary logistic regression model because the cases from 
the groups N.C. and C.I. had similar distribution of sex but statistically 
different mean age at onset. 
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(1): APOE.  
 
 
 
There were not statistically or almost statistically significant results when 
considering genotypes or alleles (Table AH) or even the number of 4 alleles 
(Table AI). Nevertheless, when individuals where classified depending on the 
number of 2 alleles they carry, we observed that the 2 allele was more 
frequent in C.I. (19.67%) than in N.C. (8.00%) and that there was a trend 
(p<0.1) that pointed out to the involvement of this allele in the increased risk 
to develop cognitive impairment during the evolution of PD (OR: 2.82; 
CI95%=[0.85-9.37]). This effect was mainly observed for 2+/- carriers (2+/+ 
individuals were almost non-existent) (Table 48). 
 
 
 
 
 
 
 2 +/+ 2 +/- 2 -/- 2 + 2 - 
N.C. 1 
(2.00) 
3 
(6.00) 
46 
(92.00) 
4 
(8.00) 
46 
(92.00) 
C.I. 0 
(0) 
12 
(19.67) 
49 
(80.33) 
12 
(19.67) 
49 
(80.33) 
 X2 = 5.458; 2df;  p=0.065 X2 = 3.034; 1df;  p=0.082 
OR: 2.82,  CI95%=[0.85-9.37] 
Table 48. Frequency of APOE genotype when considering the number of 2 alleles. 
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(2): CDNF (neurotrophic factor).  
 
There was only a trend: the G allele in rs7094179 showed a tendency to 
protect against cognitive impairment in PD patients (p=0.083; OR: 0.61; 
CI95%=[0.35-1.07]). It was more frequent at the N.C. group (71.00%) than at 
the C.I. (59.84%). However, there was no effect when considering genotypes 
(Table 49). When classifying the individuals as GG vs GT+TT, GG carriers 
showed a tendency to protect against cognitive impairment in PD (p=0.097). 
 
When this polymorphism and rs7099185, also located at the CDNF gene, were 
analyzed together, the haplotype GT (that included the G allele from 
rs7094179) also showed a tendency to protect against cognitive impairment 
(p=0.092). It was more frequent at the N.C. group (0.630) than at the C.I. 
(0.517) (Table 50). 
 
Gene and 
polymorphism 
Genotypes Alleles 
CDNF, rs7094179 GG GT TT G T 
N.C. 25 
(50.00) 
21 
(42.00) 
4 
(8.00) 
71 
(71.00) 
29 
(29.00) 
C.I. 21 
(34.43) 
31 
(50.82) 
9 
(14.75) 
73 
(59.84) 
49 
(40.16) 
 X2 = 3.135; 2df; p=0.209 X2 = 3.005; 1df; p=0.083 
OR: 0.61,  CI95%=[0.35-1.07] 
Table 49. Genotypic and allelic frequency of rs7094179 (CDNF). 
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The order of the markers at the haplotype is: rs7094179 – rs7099185. 
 
(3): CBS (homocysteine metabolism).  
 
The insertion c.844ins68 was more frequent in C.I. (11.48%) than in N.C. 
(5.00%). However, that was just a trend (p=0.086). The supposed increased 
risk to develop cognitive impairment for carriers of the insertion (OR: 2.46; 
CI95%=[0.85-7.08]) was not observed in genotypes (p=0.233) even though 
ins/ins and ins/- were more frequent in C.I. than in N.C. (Table 51). 
Haplotype Overall 
frequency 
Frequencies:  
C.I., N.C. 
Chi square 
(X2) 
p-value OR [CI95%] 
GT 0.568 0.517, 0.630 2.835 0.092 0.63 [0.36-1.11] 
TT 0.261 0.294, 0.220 1.559 0.212 1.48 [0.78-2.81] 
TC 0.090 0.107, 0.070 0.949 0.330 1.59 [0.59-4.31] 
GC 0.081 0.081, 0.080 0.001 0.981 1.01 [0.36-2.80] 
Gene and 
polymorphism 
Genotypes Alleles 
CBS, c.844ins68 ins/ins ins/- -/- ins - 
N.C. 0 
(0) 
5 
(10.00) 
45 
(90.00) 
5 
(5.00) 
95 
(95.00) 
C.I. 1 
(1.64) 
12 
(19.67) 
48 
(78.69) 
14 
(11.48) 
108 
(88.52) 
 X2 = 2.918; 2df; p=0.233 X2 = 2.944; 1df; p=0.086 
OR: 2.46,  CI95%=[0.85-7.08] 
Table 51. Genotypic and allelic frequency of c.844ins68 (CBS). 
Table 50. Haplotypes in CDNF. 
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(4): MTR (homocysteine metabolism).  
 
The A allele increased the risk to develop cognitive impairment during PD in 
3.36 times (CI95%=[1.56-7.24]). It had a statistically significant effect especially 
for AA carriers (81.97% C.I. vs 58.00% N.C.) (Table 52). 
 
(5): NFE2L2 (protection against oxidative stress). 
There were not statistically or almost statistically significant results either for 
genotypes or for alleles (Table AU). Nevertheless, there was a haplotype more 
frequent in PD patients with cognitive impairment (0.617) than in those with 
normal cognition (0.502): GG. That was just a trend (p=0.086) (Table 53). 
 
 
 
Gene and polymorphism Genotypes Alleles 
MTR, rs1805087 
(c.A2756G) 
AA AG GG A G 
N.C. 29 
(58.00) 
17 
(34.00) 
4 
(8.00) 
75 
(75.00) 
25 
(25.00) 
C.I. 50 
(81.97) 
11 
(18.03) 
0 
(0) 
111 
(90.98) 
11 
(9.02) 
 X2 = 9.875; 2df; p=0.007 X2 = 10.333; 1df; p=0.001 
OR: 3.36,  CI95%=[1.56-7.24] 
Table 52. Genotypic and allelic frequency of rs1805087 (MTR). 
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The order of the markers at the haplotype is: rs1806649 – rs10183914. 
 
 
(6): KEAP1 (protection against oxidative stress).  
 
 
The distribution of alleles between C.I. and N.C. was almost statistically 
different (p=0.094) and the G allele tended to be protective against mental 
deterioration (OR: 0.38; CI95%=[0.12-1.22]). Its effect reached statistical 
significance in genotypes (p=0.028), concretely for the homozygous GG cases, 
Haplotype Overall 
frequency 
Frequencies: 
C.I., N.C. 
Chi square 
(X2) 
p-value OR [CI95%] 
GG 0.565 0.617, 0.502 2.942 0.086 1.60 [0.91-2.81] 
AA 0.250 0.215, 0.292 1.735 0.188 0.66 [0.35-1.26] 
GA 0.142 0.129, 0.158 0.374 0.541 0.79 [0.36-1.75] 
AG 0.043 0.039, 0.048 0.108 0.743 0.80 [0.20-3.14] 
Gene and polymorphism Genotypes Alleles 
KEAP1, rs8113472 GG GT TT G T 
N.C. 47 
(94.00) 
2 
(4.00) 
1 
(2.00) 
96 
(96.00) 
4 
(4.00) 
C.I. 49 
(80.33) 
12 
(19.67) 
0 
(0) 
110 
(90.16) 
12 
(9.84) 
 X2 = 7.165; 2df; p=0.028 X2 = 2.799; 1df; p=0.094 
OR: 0.38,  CI95%=[0.12-1.22] 
Table 53. Haplotypes in NFE2L2. 
Table 54. Genotypic and allelic frequency of rs8113472 (KEAP1). 
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which were more frequent at the N.C. group (94.00%) than at the C.I. 
(80.33%) (Table 54).  
 
(7): HSPA8 (chaperone-mediated autophagy).  
 
 
The distribution of alleles between C.I. and N.C. was statistically different, 
being the A allele protective against cognitive impairment in PD (OR: 0.43; 
CI95%=[0.22-0.82]). The distribution of genotypes between both groups was 
statistically different too (p=0.045) and the protective effect of the A variant 
was important in homozygous AA carriers (p=0.094) but more in heterozygous 
AG (p=0.036; OR: 0.407; CI95%=[0.175-0.943]), as results from the binary 
logistic regression model conclude (Table 56).  
 
Gene and 
polymorphism 
Genotypes Alleles 
HSPA8, rs4936770 AA AG GG A G 
N.C. 5 
(10.00) 
20 
(40.00) 
25 
(50.00) 
30 
(30.00) 
70 
(70.00) 
C.I. 2 
(3.28) 
15 
(24.59) 
44 
(72.13) 
19 
(15.57) 
103 
(84.43) 
 X2 = 6.203; 2df; p=0.045 X2 = 6.649; 1df; p=0.010 
OR: 0.43,  CI95%=[0.22-0.82] 
Table 55. Genotypic and allelic frequency of rs4936770 (HSPA8). 
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The GG genotype was taken as a reference, i.e. OR:1. 
 
When combining these results and the obtained for the other polymorphism 
analyzed in HSPA8, rs1461496, it was observed that the presence or absence 
of the A allele, only in the presence of the C allele at rs1461496, determined 
the protective or risky effect of two haplotypes: CA and CG, respectively 
(Table 57). 
 
The order of the markers at the haplotype is: rs1461496 – rs4936770. 
 
 
 
 df p-value OR CI95% 
Lower Upper 
AA vs GG 1 0.094 0.230 0.041 1.285 
AG vs GG 1 0.036 0.407 0.175 0.943 
Haplotype Overall 
frequency 
Frequencies: 
C.I., N.C. 
Chi square 
(X2) 
p-value OR [CI95%] 
CG 0.517 0.588, 0.431 5.448 0.020 1.88 [1.07-3.30] 
TG 0.262 0.256, 0.269 0.049 0.826 0.94 [0.50-1.77] 
CA 0.167 0.117, 0.229 4.987 0.026 0.45 [0.21-0.97] 
TA 0.053 0.039, 0.071 1.101 0.294 0.53 [0.15-1.88] 
Table 56. Results of the binary logistic regression model for rs4936770 (HSPA8) genotypes. 
Table 57. Haplotypes in HSPA8. 
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(8): LAMP-2A (chaperone-mediated autophagy). 
There were only statistically and almost statistically significant results at the 
polymorphism rs42897. However, the effect of alleles and genotypes on 
cognitive impairment was opposite depending on the sex of the cases: in 
women, the A allele increased the risk to develop cognitive impairment 
whereas in men it was protective against the development of cognitive 
impairment on PD (Table 59). 
 
The study of the haplotypes composed by the four markers analyzed along the 
gene revealed that one, GAAG, was statistically more frequent in patients with 
normal cognition (0.064) than in those with cognitive impairment (none of 
them carried it): p=0.018. In this case, the A allele in rs42897 showed a 
protective effect against cognitive impairment (Table 58). There was an 
irregular linkage disequilibrium pattern along the region although it was 
mainly high (Figure 57). 
 
The order of the markers at the haplotype is rs42890 – rs42895 – rs42897 – rs7057652. 
Missing ORs correspond to those haplotypes absent in one of the populations. 
Haplotype Frequency Frequencies: 
C.I., N.C. 
Chi square 
(X2) 
p-value OR [CI95%] 
GAAT 0.465 0.476, 0.451 0.098 0.755 1.11 [0.64-1.94] 
TCAG 0.348 0.360, 0.333 0.123 0.726 1.13 [0.63-2.02] 
GAGG 0.085 0.081, 0.091 0.041 0.839 0.88 [0.33-2.37] 
GAAG 0.028 0.000, 0.064 5.559 0.018 - 
GCAT 0.028 0.035, 0.019 0.348 0.555 1.87 [0.31-11.18] 
TAAG 0.020 0.035, 0.000 2.248 0.134 - 
TAAT 0.013 0.000, 0.030 2.507 0.113 - 
Table 58. Haplotypes in LAMP-2A. 
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Gene and 
polymorphism 
Genotypes Alleles 
LAMP-2A, rs42897 AA AG GG A G 
N.C., overall 44 
(88.00) 
5 
(10.00) 
1 
(2.00) 
60 
(90.91) 
6 
(9.09) 
C.I., overall 53 
(86.89) 
2 
(3.28) 
6 
(9.84) 
78 
(90.70) 
8 
(9.30) 
 X2 = 4.648; 2df; p=0.098 
ZmfG
2 = 7.248; 1df; p=0.007 
ZC
2 = 7.385; 2df; p=0.025 
X2 = ZA
2 = 0.002; 1df; p=0.964 
ZmfA
2 = 7.012; 1df; p=0.008 
OR: 0.98,  CI95%=[0.32-2.98] 
N.C., women 11 
(68.75) 
5 
(31.25) 
0 
(0) 
27 
(84.38) 
5 
(15.63) 
C.I., women 23 
(92.00) 
2 
(8.00) 
0 
(0) 
48 
(96.00) 
2 
(4.00) 
 X2 = 3.725; 1df; p=0.054 
ZfG
2 = 3.725; 1df; p=0.054 
X2 = ZfA
2 = 3.377; 1df; p=0.066 
OR: 4.44,  CI95%=[0.81-24.46] 
N.C., men - - - 33 (97.06) 1 (2.94) 
C.I., men - - - 30 (83.33) 6 (16.67) 
 - X2 = Zm
2 = 3.660; 1df; p=0.056 
OR: 0.15,  CI95%=[0.02-1.32] 
Table 59. Genotypic and allelic frequency of rs42897 (LAMP-2A). 
IV. RESULTS.                                                                   IV.2. Cognitive status in PD. 
257 
 
It is noteworthy that LAMP-2A is located at chromosome X and, therefore, 
males present only one allele whereas females present two. Pearson´s X2 may 
not be appropriate to test for association of X chromosome markers but there 
are not standardized association tests. We decided to calculate the statistical 
tests proposed by [484]67. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                          
67
 ZmfA
2
 and ZmfG
2
 are the weighted sum of Zm
2
 plus ZfA
2
 or ZfG
2
, respectively. Both are modified 
tests to allow the differential allele effects in males and females. ZC
2
 is a genotype-based test 
where allele frequencies are estimated separately for males and females. 
Fig. 57. Linkage disequilibrium map in LAMP-2A. 
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 Modelling the genetic risk for cognitive decline in PD. 
We have tried to find a mathematical model to quantify the 
contribution of the variants on the risk to develop cognitive impairment 
during the disease68. 
To simplify the process, we considered the genotypes, neither the 
alleles nor the haplotypes, that reported significant results, i.e. p-value < 0.05 
(X2 test): 
 
 
2. Risk of developing cognitive impairment during PD (111 PD patients: 
50 normal cognition (N.C.) and 61 cognitive impairment (C.I.))69: 
X. rs1805087 (c.A2756G, MTR): AG+GG vs AA, p=0.006. 
XI. rs8113472 (KEAP1): GG vs GT+TT, p=0.036. 
XII. rs4936770 (HSPA8): AA+AG vs GG, p=0.017. 
 
Again, we employed a binary logistic regression model to quantify the 
influence of these three variables on the risk to develop cognitive impairment 
during PD. 
The following equation explains what a binary logistic regression is: 
                                                          
68
 Due to the number of individuals analyzed and their demographic and cognitive 
characteristics, the relevance of this model is compromised. 
69
 The risk variants are underlined. 
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In our case,  
 P is the probability that an individual presents cognitive impairment (to 
belong to the C.I. group), whereas 1-P is the probability that an 
individual is cognitively normal (to be part of the N.C. group).  
 The term P / (1-P) is the odds ratio, i.e. the increase or decrease in the 
risk to develop cognitive impairment during PD. 
 Each Xi represents a variable (genotype) that influences on the risk 
(value 1 for the underlined risk variants and 0 for the others) and a, b1, 
b2… are numerical coefficients. 
 
Table 60 shows how many subjects were correctly assigned by the model. 
 
 
 
 
                                                          
70
 Sensitivity can be defined as the proportion of C.I. that are correctly assigned by the model, 
that is, capacity to identify positives. Specificity is defined as the proportion of N.C. that are 
correctly assigned by the model, i.e. capacity to identify negatives. 
Observed 
Predicted 
cognitive status Percentage Correct 
N.C. C.I. 
cognitive 
status 
N.C. 35 15 70.0 (specificity)70 
C.I. 18 43 70.5 (sensitivity) 
Overall Percentage   70.3 
Table 60. Classification of the subjects analyzed under the binary logistic regression model. 
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The results we obtained were71 (Table 61): 
 
 
 In all cases, individual OR > 1. That means that all the variables 
increased the risk to develop cognitive impairment during Parkinson´s disease, 
although only for variables X and XII it reached statistical significance. For 
example, an individual that carried the AA genotype in MTR presented 3.131 
times (CI95%=[1.271-7.715]) more risk to show an altered cognitive status than 
other person that carried the AG or the GG genotypes. 
 
What would happen if a person carries the risk variants in variables X 
(X1), XI (X2) and XII (X3)? 
                                                          
71
 The mean age at onset when comparing N.C. and C.I. was statistically different. Therefore, 
it was not considered. The percentage of males and females was similar between groups and 
it was considered in the model but the model did not included it because sex did not reach 
statistical significance. 
It is noteworthy that the number of individuals in both groups was small and that could be 
considered a limitation for the calculations. 
 b df p-
value 
OR (eb) CI95% 
Lower Upper 
rs1805087 (c.A2756G, MTR) X1 1.141 b1 1 0.013 3.131 e
b1 1.271 7.715 
rs8113472 (KEAP1) X2 1.382 b2 1 0.051 3.985 e
b2 0.996 15.942 
rs4936770 ( HSPA8) X3 0.989 b3 1 0.021 2.689 e
b3 1.163 6.220 
constant -1.384 a 1 0.004 0.250   
Table 61. Results of the binary logistic regression model to determine the risk of developing 
cognitive impairment. 
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                                                               = 
       = 8.40 
 
   
                 
This person would have 8.40 times more possibilities to develop 
cognitive impairment during PD or would develop it with a probability of 
89.36%. 
Finally, we analyzed the distribution of the three variables in patients 
with normal cognition (N.C.) and with cognitive impairment (C.I.)72 (Figure 58 
and Table 62): 
 
 
 
 
 
 
                                                          
72
 We also tried to determine if there was some correlation between them, but we observed 
that there was not any. There was not correlation between these three and the previous nine 
either. 
Fig. 58. Distribution of the number of risk variants carried by N.C. and C.I. groups. 
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Furthermore, we studied how many variants affecting PD presented 
individuals of both groups (Table 63 and Figure 59). 
 
Number of cognitive 
impairment risk variants carried 
0 1 2 3 
N.C. 20.00 (10) 50.00 (25) 26.00 (13) 4.00 (2) 
C.I. 4.92 (3) 24.59 (15) 62.30 (38) 8.20 (5) 
Number of PD risk 
variants carried 
0 1 2 3 4 5 6 7 8 9 
N.C. 
0 
(0) 
0 
(0) 
2.00 
(1) 
20.00 
(10) 
26.00 
(13) 
14.00 
(7) 
16.00 
(8) 
16.00 
(8) 
6.00 
 (3) 
0 
(0) 
C.I. 
0 
(0) 
0 
(0) 
4.92 
(3) 
9.84 
(6) 
18.03 
(11) 
34.43 
(21) 
14.75 
(9) 
11.48 
(7) 
6.56 
(4) 
0 
(0) 
Table 63. Percentage of N.C. and C.I. cases that carry each number of PD risk variants. 
Number of individuals are in parenthesis. 
Table 62. Percentage of N.C. and C.I. subjects that carry each number of risk variants. 
Number of individuals are in parenthesis. 
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The mean of cognitive impairment risk variants carried by the cases 
with normal cognition was 1.14, whereas for those with cognitive impairment 
was 1.74. Medians were 1 and 2, respectively.  
The mean of PD risk variants carried by the subjects from the N.C. 
group was 4.94, whereas for C.I. was 5.28. Medians were 5 and 5, 
respectively. 
 
  
Fig. 59. Distribution of the number of PD risk variants carried by N.C. and C.I. groups. 
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Below are the relevant results (p<0.1) we obtained when comparing PD 
patients with mild cognitive impairment to those that had developed 
dementia (PDD). Frequencies are in parenthesis73. 
 
(1): The A allele at rs6426554 in PSEN2 was more frequently found in 
individuals with M.C.I. than in PD cases suffering from dementia although 
without reaching statistical significance (p=0.075) pointing out to a protective 
tendency against dementia (Table 64). This trend reached statistical 
significance (p=0.039) when classifying the cases in AA and AG+GG, being the 
AA genotype protective against dementia (OR:0.33; CI95%=[0.11-0.95]). 
 
 
Gene and polymorphism Genotypes Alleles 
PSEN2, rs6426554 AA AG GG A G 
M.C.I. 24 
(66.67) 
11 
(30.56) 
1 
(2.78) 
59 
(81.94) 
13 
(18.06) 
Dementia 10 
(40.00) 
14 
(56.00) 
1 
(4.00) 
34 
(68.00) 
16 
(32.00) 
 X
2
 = 4.280; 2df; p=0.118 X2 = 3.167; 1df; p=0.075 
OR: 0.47, CI95%=[0.20-1.09] 
 
 
                                                          
73
 A binary logistic regression model and some descriptive graphics and tables comparing the 
groups M.C.I. and PDD are detailed in Annex IVc. 
Table 64. Genotypic and allelic frequency of rs6426554 (PSEN2). 
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(2): The T allele in rs2986017, CALHM1, increased the risk to develop dementia 
in PD in 2.81 times (CI95%=[1.07-7.41]). Although there was no statistically 
significant difference in the frequency of genotypes (p=0.124) (Table 65). 
When they were grouped depending on the presence of the T allele, i.e. 
TT+TC vs CC, there was a statistical significance (p=0.042) pointing out that 
the T allele increased the risk to develop dementia (OR:3.33; CI95%=[1.02-
10.91]). 
 
Gene and polymorphism Genotypes Alleles 
CALHM1, rs2986017 (p.P86L) TT TC CC T C 
M.C.I. 2 
(5.56) 
4 
(11.11) 
30 
(83.33) 
8 
(11.11) 
64 
(88.89) 
Dementia 3 
(12.00) 
7 
(28.00) 
15 
(60.00) 
13 
(26.00) 
37 
(74.00) 
 X
2 = 4.170; 2df; p=0.124 X2 = 4.590; 1df; p=0.032 
OR: 2.81, CI95%=[1.07-7.41] 
 
 
 
(3): In the gene HTT, the ATCAT haplotype was protective against dementia in 
PD: it was significantly more present in cases with M.C.I. than in those with 
dementia (Table 66, Figure 60).  
 
Table 65. Genotypic and allelic frequency of rs2986017 (CALHM1). 
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The order of the markers at the haplotype is: rs10015979 – rs363066 – rs363096 – rs2298969 – 
rs110501.  
 
 
 
 
 
 
 
 
 
 
 
Haplotype Overall 
frequency 
Frequencies: 
Dementia, M.C.I.  
Chi square 
(X2) 
p-value OR [CI95%] 
GTTAT 0.376 0.439, 0.331 1.470 0.225 1.58 [0.89-2.81] 
ATCAT 0.193 0.092, 0.263 5.502 0.019 0.28 [0.12-0.63] 
ATCGC 0.189 0.200, 0.181 0.073 0.787 1.13 [0.56-2.29] 
AGCGC 0.141 0.144, 0.138 0.007 0.932 1.05 [0.47-2.33] 
ATTGT 0.026 0.003, 0.042 1.777 0.183 0.07 [0.00-2.87] 
ATTAT 0.017 0.040, 0.001 2.654 0.103 - 
GTTGT 0.015 0.017, 0.014 0.020 0.889 1.22 [0.13-11.62] 
GGCGC 0.015 0.016, 0.014 0.006 0.938 1.15 [0.12-11.30] 
GTCAT 0.012 0.028, 0.002 1.608 0.205 - 
Fig. 60. Linkage disequilibrium map in HTT.  
Table 33. Haplotypes in HTT. 
Table 66. Haplotypes in HTT. 
IV. RESULTS.                                                                   IV.2. Cognitive status in PD. 
267 
 
(4): The distribution of alleles in SNP rs2871776 in ATP13A2, was very similar 
between cases with M.C.I. and those with dementia. However, the difference in 
genotypes was almost statistically significant (p=0.053) with a higher 
frequency of heterozygous individuals in M.C.I. cases when compared to those 
with dementia (Table 67).  
 
 
(5): In NFE2L2, there was a protective haplotype, GA, that was significantly 
more present in cases with M.C.I. than in those with dementia (Table 68). 
 
The order of the markers at the haplotype is: rs1806649 – rs10183914. 
 
Gene and polymorphism Genotypes Alleles 
ATP13A2, rs2871776  AA AG GG A G 
M.C.I. 7 
(19.44) 
12 
(33.33) 
17 
(47.22) 
26 
(36.11) 
46 
(63.89) 
Dementia 9 
(36.00) 
2 
(8.00) 
14 
(56.00) 
20 
(40.00) 
30 
(60.00) 
 X
2
 = 5.891; 2df; p=0.053 X2 = 0.190; 1df; p=0.663 
Haplotype Overall 
frequency 
Frequencies: 
Dementia, M.C.I. 
Chi square 
(X2) 
p-value OR [CI95%] 
GG 0.618 0.673, 0.579 1.093 0.296 1.50 [0.84-2.67] 
AA 0.216 0.233, 0.204 0.142 0.706 1.19 [0.61-2.33] 
GA 0.128 0.047, 0.184 4.989 0.026 0.22 [0.08-0.63] 
AG 0.038 0.047, 0.031 0.190 0.663 1.54 [0.36-6.64] 
Table 67. Genotypic and allelic frequency of rs2871776 (ATP13A2) 
Table 68. Haplotypes in NFE2L2. 
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IV.3. Analysis of genetic variability in the ARMCX gene family in 
PD. 
The ARMCX gene family is comprised by 6 genes. We analyzed 
polymorphisms located along them: 
 ARMCX1: rs6616255 and rs1044275;  
 ARMCX2: rs5951282;  
 ARMCX3: rs6995;  
 ARMCX4: rs2179670 and rs6523506;  
 ARMCX5: rs2235827;  
 ARMCX6: rs285816274.  
 
The individuals analyzed were described in Table 11 (see section III. 
Material and methods, Subjects).  
As these individuals were selected from those used for the analysis of 
genetic susceptibility factors in Spanish populations (see Results IV.1), we also 
had, for them, genetic information about the APOE genotype, the poly-T 
homopolymer length (rs10524523, TOMM40), the H1/H2 haplotype (MAPT), 
mutations p.N370S and p.L444P (GBA), mutation c.864+246C>T (NR4A2), 
polymorphism p.S18Y (rs5030732, UCHL1), and rs1801968 (p.D216H) and 
p.delE302/303 (TOR1A). 
 
                                                          
74
 The criteria to select those polymorphisms is explained in Annex I. 
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First, we determined the presence of mutations in GBA in healthy 
controls and PD cases and found two heterozygous carriers of the p.N370S 
and one heterozygous carrier of the p.L444P mutation in the PD group (no 
control carried the mutations).  There were not significant differences 
between groups75.  
The individuals that presented the mutations were eliminated from 
the study on genetic susceptibility factors in PD as their disease was most 
likely caused by those same mutations. 
 
The relevant results, that is, those that reached statistical significance 
(p<0.05) or a strong tendency towards this (p<0.1) are listed below. The 
results obtained for the rest of polymorphisms (p-value higher than 0.1) are 
detailed in Annex V. 
Frequencies are indicated in parenthesis. p-values lower than 0.05, i.e. 
statistically significant results, are in bold and shadowed. p-values lower than 
0.1 are highlighted in bold. We calculated odds ratio for the distribution of 
alleles in such polymorphisms to know their effect on PD risk or protection.  
In addition, we show the sex and age-correlated odds ratios calculated 
by using a binary logistic regression model that estimated the effect of their 
genotypes and demographic factors on the probability to develop PD. 
 
                                                          
75
 Fisher´s exact test: p=0.497 (p.N370S); p=1 (p.L444P); p=0.246 (p.N370S+p.L444P). 
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It is noteworthy that the ARMCX genes are located at chromosome X 
and, therefore, males present only one allele whereas females present two. 
Pearson´s X2 may not be appropriate to test for association of X chromosome 
markers but there are not standardized association tests. We decided to 
calculate the statistical tests proposed by [484]76. 
 
(1): APOE. 
 
 
The distribution of alleles between healthy controls and PD cases was 
statistically different (p=0.048). However, that was not the case for genotypes 
(p=0.093) (Table 69). When considering the number of 4 alleles, it was 
observed that 4 +/- carriers (there were not 44 carriers) were almost 
                                                          
76
 ZmfA
2
 and ZmfG
2
 are the weighted sum of Zm
2
 plus ZfA
2
 or ZfG
2
, respectively. Both are modified 
tests to allow the differential allele effects in males and females. ZC
2
 is a genotype-based test 
where allele frequencies are estimated separately for males and females. 
 Genotypes Alleles 
APOE,  
genotype 
22 23 33 34 44 24 2 3 4 
Controls 0 
(0) 
7  
(7.37) 
65 
(68.42) 
22 
(23.16) 
0  
(0) 
1 
(1.05) 
8 
(4.21) 
159 
(83.68) 
23 
(12.11) 
PD cases 3 
(3.26) 
8  
(8.70) 
69  
(75.00) 
10 
(10.87) 
0  
(0) 
2 
(2.17) 
16 
(8.70) 
156 
(84.78) 
12 
(6.52) 
 X2 = 7.973; 4df; p=0.093 X2 = 6.058; 2df; p=0.048 
Table 69. Genotypic and allelic frequency of APOE genotype. 
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protected against PD (p=0.050; OR: 0.47; CI95%=[0.22-1.01]) (Table 70). Under 
the binary logistic regression model, the protective effect reached statistical 
significance (p=0.044; OR:0.428; CI95%=[0.188-0.976]) only for 34 carriers 
(Table 71). 
 
 
 
 
 
 
 
 
 df p-value OR CI95% 
Lower Upper 
23 vs 33 1 0.891 1.078 0.369 3.150 
24 vs 33 1 0.606 1.893 0.167 21.480 
34 vs 33 1 0.044 0.428 0.188 0.976 
The 33 genotype was taken as a reference, i.e. OR:1. As there were not individuals in both 
groups carrying genotypes22 and 44, these calculations could not been conducted for 
them. 
  
(2): MAPT.  
The distribution of alleles between healthy controls and PD cases was 
strongly statistically different (p=0.005), being H1 haplotype an important risk 
factor to develop Parkinson´s disease (OR: 1.99; CI95%=[1.23-3.22]). 
Furthermore, this effect was also observed when considering genotypes: 
 4 +/+ 4 +/- 4 -/- 
Controls 0 (0) 23 (24.21) 72 (75.79) 
PD cases 0 (0) 12 (13.04) 80 (86.96) 
 X2 = 3.831; 1df; p=0.050 
OR: 0.47,  CI95%=[0.22-1.01] 
Table 70. Frequency of APOE genotype when considering the number of 4 alleles. 
Table 71. Results of the binary logistic regression model for APOE genotypes. 
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there was a statistically significant difference between both groups (p=0.029) 
(Table 72) and carriers of the H1H1 genotype had around 4 times more risk to 
develop PD than those that carried the H2H2 genotype. On its turn, 
heterozygous carriers seemed to have higher risk than the H2 homoygous 
individuals, but the result did not reach statistical significance (Table 73). 
 
 
 
 
                 The H2H2 genotype was taken as a reference, i.e. OR:1. 
 
 
(3): ARMCX6.  
The only ARMCX gene that showed some relevant result was ARMCX6 
where the distribution of alleles and genotypes between healthy controls and 
Gene and polymorphism Genotypes Alleles 
MAPT, H1/H2 haplotype H1H1 H1H2 H2H2 H1 H2 
Controls 48 
(50.53) 
35 
(36.84) 
12 
(12.63) 
131 
(68.95) 
59 
(31.05) 
PD cases 62 
(67.39) 
26 
(28.26) 
4 
(4.35) 
150 
(81.52) 
34 
(18.48) 
 X
2
 = 7.063; 2df; p=0.029 X2 = 7.991; 1df; p=0.005 
OR: 1.99,  CI95%=[1.23-3.22] 
 df p-value OR CI95% 
Lower Upper 
H1H1 vs H2H2 1 0.025 3.922 1.184 12.991 
H1H2 vs H2H2 1 0.200 2.260 0.650 7.859 
Table 72. Genotypic and allelic frequency of H1/H2 haplotype (MAPT). 
Table 73. Results of the binary logistic regression model for the H1/H2 haplotype. 
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PD cases were close to be statistically different (p≈0.070) (Table 74). However, 
there was no significant result under the binary logistic regression model, i.e. 
there was no specific risk or protective genotype (Table 75). Moreover, sex 
seemed to have no influence. 
 
 
Gene and 
polymorphism 
Genotypes Alleles 
ARMCX6, rs2858162 CC CT TT C T 
Controls, overall 10 
(10.53) 
12 
(12.63) 
73 
(76.84) 
23 
(17.29) 
110 
(82.71) 
PD cases, overall 16 
(17.39) 
16 
(17.39) 
60 
(65.22) 
34 
(26.56) 
94 
(73.44) 
 X
2
 = 3.179; 2df; p=0.204 
ZmfG
2
 = 3.338; 1df; p=0.068 
ZC
2
 = 3.443; 2df; p=0.179 
X2 = ZA
2
 = 3.283; 1df; p=0.070 
ZmfA
2
 = 3.307; 1df; p=0.069 
OR: 1.73,  CI95%=[0.95-3.14] 
Controls, women 1 
(2.63) 
12 
(31.58) 
25 
(65.79) 
14 
(18.42) 
62 
(81.58) 
PD cases, women 2 
(5.56) 
16 
(44.44) 
18 
(50) 
20 
(27.78) 
52 
(72.22) 
 X
2
 = 1.992; 2df; p=0.369 
ZfG
2
 = 1.965; 1df; p=0.161 
X2 = ZfA
2
 = 1.829; 1df; p=0.176 
Controls, men - - - 9 (15.79) 48 (84.21) 
PD cases, men - - - 14 (25.00) 42 (75.00) 
 - X
2
 = Zm
2
 = 1.478; 1df; p=0.224 
Table 74. Genotypic and allelic frequency of rs2858162 (ARMCX6). 
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The TT genotype was taken as a reference, i.e. OR:1. 
 
As members of the ARMCX gene family are relatively close at the X 
chromosome, we decided to analyze the relevance of haplotypes on PD 
pathogenesis (Figure 61). 
 
 
 
 
 
 
 
 
ARMCX6 df p-value OR CI95% 
Lower Upper 
rs2858162 CC vs TT 1 0.325 1.597 0.629 4.058 
rs2858162 CT vs TT 1 0.309 1.690 0.615 4.646 
Fig. 61. Linkage disequilibrium map. 
The polymorphisms analyzed in ARMCX gene family are ordered by their location 
at chromosome X. rs2235827 (ARMCX5) is located ≈943kb downstream rs5951282 
and shows no LD with any of the other polymorphisms. Therefore, it is not present.  
The intensity of the red color is directly correlated to the strength of the linkage 
disequilibrium between the markers. 
Table 75. Results of the binary logistic regression model for rs2858162 (ARMCX6). 
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Based on the pattern observed, we considered that linkage 
disequilibrium was strong in one block that included six polymorphisms 
(showed in bold at Figure 61) and, thus, we analyzed whether its frequency was 
different between controls and cases and could be considered a PD risk or 
protective factor (Table 76):  
The order of the markers at the haplotype is: rs6523506(ARMCX4) - rs6616255(ARMCX1) -
rs1044275(ARMCX1) - rs2858162(ARMCX6) - rs6995(ARMCX3) - rs5951282(ARMCX2).  
Missing ORs correspond to those haplotypes absent in one of the populations. 
 
The TACCAC haplotype appeared more frequently in PD cases (21.8%) 
than in healthy controls (13.5%) although without reaching statistical 
significance, so it could not be considered a risk haplotype. However, the 
TACTAC haplotype only appeared in healthy controls (3.5%) and the statistical 
analysis pointed out to a protective effect against PD pathogenesis. Both just 
differ in the fourth position, that corresponds to rs2858162 (ARMCX6).
  
Haplotype Overall 
frequency 
Frequencies: 
Case,Control 
Chi square 
(X2) 
p-value OR [CI95%] 
GACTAC 0.260 0.248, 0.271 0.171 0.679 0.89 [0.47-1.68] 
GACTAT 0.178 0.150, 0.205 1.371 0.247 0.68 [0.33-1.42] 
TACCAC 0.176 0.218, 0.135 3.120 0.077 1.79 [0.85-3.77] 
GGCTAT 0.134 0.123, 0.145 0.269 0.604 0.83 [0.37-1.88] 
GATTGC 0.092 0.094, 0.090 0.010 0.922 1.05 [0.40-2.74] 
GACTGC 0.080 0.094, 0.068 0.600 0.439 1.42 [0.51-3.97] 
GACCAC 0.027 0.032, 0.023 0.190 0.663 1.40 [0.25-7.80] 
TACTAC 0.018 0.000, 0.035 4.490 0.034 - 
GGCTAC 0.013 0.017, 0.010 0.254 0.614 1.71 [0.14-20.54] 
Table 76. Haplotypes in ARMCX gene family. 
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Epigenetics in Parkinson´s disease: 
IV.4. Quantitation of DNA methylation levels in promoters of 
genes responsible for familial Parkinson´s disease. Pilot analysis. 
There are 5 genes responsible for the familial forms of PD: SNCA, PRKN, 
PINK1, DJ-1 and LRRK2. We wanted to study if their influence on pathogenesis 
was not only genetic. For that purpose, we analyzed the levels of DNA 
methylation around their transcription start site where variations in this 
epigenetic mark could influence their expression. 
 
Initially, we conducted a pilot trial in blood, frontal cortex, occipital 
cortex, hippocampus and substantia nigra from one individual from Hospital 
12 de Octubre, Madrid, to test the methodological process (as described in 
section III.2. Epigenetics in PD), to better know the range of values we would 
obtain lately and to explore the concordance in methylation levels between 
different areas of the same tissue as well as with other tissues.  
As expected for housekeeping genes, the promoters77 of DJ-1, LRRK2, 
PINK1, PRKN and SNCA were poorly methylated in all the tissues to allow their 
ubiquitous expression. 
 
                                                          
77
 There was only one CpG island in each gene, located around the TSS, as expected for CG 
rich genes. 
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Then, we carried out a second trial with blood from 5 randomly 
selected male-female pairs of Parkinson´s disease patients, age and period of 
evolution-matched, from the Region of Valencia (they were described in 
section III.Material and methods, Subjects). 
As previously observed for the individual from the initial trial, there 
were low methylation levels in blood78. 
 
 
Finally, we conducted our study in substantia nigra, parietal cortex and 
occipital cortex from the individuals described in Table 14 (see section 
III.Material and methods, Subjects). 
We compared the levels of DNA methylation in substantia nigra, 
parietal cortex and occipital cortex between healthy controls and PD cases, 
with special interest for the results in SN because, unlike parietal cortex and 
occipital cortex, that have not been described as affected by PD pathogenesis 
and could be considered “control brain regions”, it is extensevely affected in 
PD [17]. 
Furthermore, we did not compare the values between brain regions 
because, as [448] concluded, the DNA methylation pattern correlates much 
more strongly within a brain region across individuals than within an 
individual across brain regions. 
 
                                                          
78
 The results are shown in Annex VI. 
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The results are shown in Annex VI. Per each assay and brain region, 
there is a table and a graphic with the mean methylation percentages for each 
group, healthy controls and PD cases, per position and overall. The number in 
parenthesis at the tables, as well as the error bars at the graphics, represent 
the standard deviation. 
Statistically significant results, i.e. p-values lower than 0.05, are 
highlighted in bold and shadowed at the tables and indicated with an  at the 
graphics. In addition, p-values lower than 0.1 are highlighted in bold and 
marked with a ○. 
 
Due to the characteristics of our study, i.e. low number of individuals 
analyzed, low levels of DNA methylation observed, small differences and high 
standard deviation values, our results could be considered as trends that 
should be replicated in a larger study.  
In addition, as observed in the two previous trials, the promoters of DJ-
1, LRRK2, PINK1, PRKN and SNCA were poorly methylated in all brain regions to 
allow their ubiquitous expression and there was not an overall tendency in 
differences of DNA methylation levels between controls and cases.  
Thus, we will focus on the most relevant results (Tables 77 and 78): 
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 “Promoter” indicates that our trial predictions located it in this area. However, in some 
assays, the predicted promoter overlapped with exons or introns (marked with a  •). 
80
 In isoform NM_000345. 
81
 In isoform NM_000345. 
Assay Target79 Brain 
region 
Position p-
value 
Methylation 
percentage 
DJ-1 2 Exon 1 • Occipital 
cortex 
2 0.095 Healthy controls > 
PD cases 
DJ-1 2 
(1) 
Exon 1 • Substantia 
nigra 
3 0.063 Healthy controls > 
PD cases 
LRRK2 2 Exon 1 Parietal 
cortex 
9 0.095 Healthy controls < 
PD cases 
PRKN 2 
(3b) 
Intron 1  
(• partially overlaps) 
Occipital 
cortex 
6 0.056 Healthy controls > 
PD cases 
PRKN 2 
(3b) 
Intron 1  
(• partially overlaps) 
Substantia 
nigra 
2 0.063 Healthy controls > 
PD cases 
PRKN 2 
(3b) 
Intron 1  
(• partially overlaps) 
Substantia 
nigra 
3 0.063 Healthy controls > 
PD cases 
PRKN 2 
 
Intron 1  
(• partially overlaps) 
Substantia 
nigra 
Overall 0.063 Healthy controls > 
PD cases 
SNCA 1 
 
“Promoter” Parietal 
cortex 
Overall 0.095 Healthy controls < 
PD cases 
SNCA 2 Exon 180   
(• partially overlaps) 
Occipital 
cortex 
3 0.095 Healthy controls > 
PD cases 
SNCA 2 Exon 181   Occipital Overall 0.095 Healthy controls > 
Table 77. Results with 0.05<p<0.1. 
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 In isoforms NM_007308 and NM_001146054. 
83
 “Promoter” indicates that our trial predictions located it in this area. However, in some 
assays, the predicted promoter overlapped with exons or introns (marked with a  •). 
(• partially overlaps) cortex PD cases 
SNCA 3 Exon 182 Occipital 
cortex 
1 0.095 Healthy controls < 
PD cases 
Assay Target83 Brain 
region 
Position p-
value 
Methylation 
percentage 
PINK1 2 
(2) 
Exon 1 • Substantia 
nigra 
2 0.016 Healthy controls > 
PD cases 
PRKN 1 
(3a) 
“Promoter” Substantia 
nigra 
3 0.016 Healthy controls > 
PD cases 
PRKN 2 
(3b) 
Intron 1  
(• partially overlaps) 
Parietal 
cortex 
6 0.032 Healthy controls > 
PD cases 
PRKN 2 
(3b) 
Intron 1  
(• partially overlaps) 
Occipital 
cortex 
2 0.032 Healthy controls > 
PD cases 
SNCA 1 
(4a) 
“Promoter” Parietal 
cortex 
3 0.008 Healthy controls < 
PD cases 
SNCA 1 
(4a) 
“Promoter” Parietal 
cortex 
6 0.016 Healthy controls < 
PD cases 
SNCA 1 
(4a) 
“Promoter” Substantia 
nigra 
6 0.016 Healthy controls > 
PD cases 
Table 78. Results with p<0.05. 
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We predicted, in silico, for the positions with statistically significant 
differences between PD cases and healthy controls and, moreover, for the 
almost statistically significant positions related to them or located in substantia 
nigra, that where all located at the “promoter”, if they where transcription 
factor binding sites. This could correlate the differences in DNA methylation 
with possible pathogenic differences in transcription and, thus, in protein 
expression. 
We uploaded fragments of ≈100 nucleotides centered in our target 
position in each case to the following prediction programs, selecting 
vertebrates and/or human when it was possible: 
o TFSEARCH: http://www.cbrc.jp/research/db/TFSEARCH.html [485] 
o  JASPAR CORE: http://jaspar.genereg.net/ [486] 
o AliBaBa 2.1 and PATCH:  
http://www.gene-regulation.com/pub/programs.html 
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 In isoform NM_000345. 
85
 In isoform NM_000345. 
86
 In isoform NM_000345. 
SNCA 2 
(4b) 
Exon 184   
(• partially overlaps) 
Occipital 
cortex 
2 0.032 Healthy controls > 
PD cases 
SNCA 2 
(4b) 
Exon 185   
(• partially overlaps) 
Occipital 
cortex 
7 0.008 Healthy controls > 
PD cases 
SNCA 2 
(4b) 
Exon 186   
(• partially overlaps) 
Substantia 
nigra 
8 0.016 Healthy controls > 
PD cases 
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Per each transcription factor, we obtained information from UniProt 
(http://www.uniprot.org/): the [X] represents its UniProt ID. They are more 
deeply analyzed in the Discussion.  
Below are the results we obtained87. 
 
(1) DJ-1 (NM_007262); assay 2. 
 
Sp1 [P08047] binds to GGACGGCGCG whereas NRF-1 [Q16656] binds to 
CGCGCGTGCG.88 
 
                                                          
87
 In all figures, lollipops represent cytosines in CpG dinucleotides.  
For the numeration, the +1 was assigned to the A from the first codon translated, i.e. ATG. 
Therefore, negative positions are located upstream to it, whereas positive positions are 
downstream. 
These representations are derived from those present in section III.2. Epigenetics in PD, CpG 
island prediction. 
88
 C corresponds to the black lollipop. 
Fig. 62. Schematic representation of the DNA region from -1126 to -1048 in DJ-1 
(NM_007262). 
The DNA sequence is striped red because it was located in the non-coding exon 1 and, 
moreover, the predicted promoter overlapped with it. There was an almost statistical 
difference (p=0.063) for DNA methylation levels between healthy controls and PD cases in 
position 3 (black lollipop, -1094) in substantia nigra.  
The * at the reverse primer indicates that it was biotinylated in 5´. 
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(2) PINK1 (NM_032409); assay 2. 
 
Sp1 [P08047] binds to CGGCGGGCGGTC whereas AP-2-alpha [P05549] binds to 
CCGGCGGGC or CGGCGGGCGG, depending on the prediction program. 
 
(3) PRKN (NM_013988);  
(3a) assay 1. 
 
FOXC1 [Q12948] binds to AACGCGTA (- strand). 
Fig. 63. Schematic representation of the DNA region from +310  to +398 in PINK1 (NM_032409). 
The DNA sequence is striped because the predicted promoter overlapped with it. In addition, it is 
coloured blue when represents the coding part of exon 1 and black for intron 1. There was a 
statistical difference (p=0.016) for DNA methylation levels between healthy controls and PD cases 
in position 2 (black lollipop, +355) in substantia nigra.  
The * at the reverse primer indicates that it was biotinylated in 5´. 
Fig. 64. Schematic representation of the DNA region from -230 to -142 in PRKN (NM_013988). 
The DNA sequence is striped black because it was located 5´ upstream the transcription start site 
and, moreover, the predicted promoter overlapped with it. There was statistical difference 
(p=0.016) for DNA methylation levels between healthy controls and PD cases in position 3 (black 
lollipop, -187) in substantia nigra. 
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(3b) assay 2.  
 
 position 2: Sp1 [P08047] and WT1 [P19544] bind to GCGCCGCCCC.  
 position 3: Sp1 [P08047] binds to CGCCCCGGT and CCCACGCCCCG; AP-
2-alpha [P05549] binds to CCCACGCCC; HIF1 [Q16665] binds to 
GGGCGTGG (- strand). 
 position 6: Sp1 [P08047] binds to CGCCCCGCC and GGCGCCACGC; AP-2-
alpha [P05549] binds to GCCACGCCC; HIF1 [Q16665]  binds to 
GGGCGTGG (- strand).  
 
 
 
 
 
Fig. 65. Schematic representation of the DNA region from +3 to +91 in PRKN (NM_013988). 
The DNA sequence is striped where the promoter was predicted to be located. In addition, it is 
blue for the coding part of exon 1 and black (or white) for intron 1. When comparing DNA 
methylation levels between healthy controls and PD cases, there were relevant results for 
positions 2 (in SN and occipital cortex), 3 (in SN) and 6 (in occipital and parietal cortex) (black 
lollipops, +44, +51 and +69, respectively). 
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(4) SNCA; 
 
(4a) assay 1.  
 
 position 3: ELK1 [P19419] binds to GCGCCGGGAG; AP-2-alpha [P05549] 
binds to GCCGGGAGA; ETS1 [P14921] binds to CTCCCG (- strand). 
 position 6: GATA-1 [P15976] binds to ATCAGCGGTG;  Sp1 [P08047] 
binds to CCCCACCGCT (- strand); HOXA5 [P20719] binds to CGCTGATT   
(- strand). 
 
 
 
 
 
 
Fig. 66. Schematic representation of the DNA region from -1620 to -1532 in SNCA. 
The DNA sequence is striped black because it was located 5´ upstream to the transcription start 
site, or in intron 1, depending on the isoform considered, and, moreover, the predicted promoter 
overlapped with it. When comparing DNA methylation levels between healthy controls and PD 
cases, there were relevant results for positions 3 (in parietal cortex) and 6 (in parietal cortex and 
SN) (black lollipops, -1586 and -1551, respectively). 
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(4b) assay 2. 
 
 position 2: there was no transcription factor binding site predicted for 
it. 
 position 7: ELK1 [P19419] binds to CGACGCGGAAGTGA; Sp1 [P08047] 
binds to CGCCGCGACG; AP-2-alpha [P05549] binds to GCCGCGACG; SPIB 
[Q01892] binds to CGCGGAA. 
 position 8: Sp1 [P08047] binds to CGGAAGTGAG; ELK1 [P19419] binds 
to CGACGCGGAAGTGA; ICSBP [Q02556] binds to GCGGAAGTGA; SPIB 
[Q01892] binds to CGCGGAA; FEV [Q99581] binds to GCGGAAGT. 
 
 
  
Fig. 67. Schematic representation of the DNA region from -1479 to -1390 in SNCA. 
The DNA sequence is striped green because it was located in exon 1 (isoform NM_000345) 
and, moreover, the predicted promoter overlapped with it. When comparing DNA 
methylation levels between healthy controls and PD cases, there were relevant results for 
positions 2 (in occipital cortex), 7 (in occipital cortex) and 8 (in SN) (black lollipops, -1458,   
-1442 and -1440, respectively). 
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 Our first objective was to determine the effect of known or suspected 
genetic susceptibility factors in two Spanish populations, one of Basque 
descent and a second of non-Basques. The candidates were: three genes that 
have been considered genetic risk factors in PD (MAPT, GBA and NR4A2), a 
controversial PARK locus (UCHL1), TOR1A, which is related to dystonia, the 
gene that is considered a genetic susceptibility factor in AD (APOE) and a new 
one related to it (TOMM40). 
 
UCHL1 (PARK5) encodes for a protein involved in the ubiquitin 
proteasome system that is highly specific for neurons [191]. Both 
characteristics could be relevant in PD pathogenesis. It was considered a 
cause of familial forms of Parkinson´s disease when [193] found that members 
of one German family carried the p.I93M mutation, although penetrance was 
incomplete. However, it could not be replicated in subsequent studies [196, 
197] and at present, this mutation is considered either a rare cause of PD or 
with no influence on the disease (its presence in the two German siblings 
could be coincidental).  
Despite this result, the intensive analysis of the gene reported other 
possible candidate to explain PD pathogenesis: the p.S18Y polymorphism 
[197]. The Y allele has been considered a protective factor in some studies 
[196, 198, 199], whereas for other groups it has no influence on PD risk [200-
203]. 
The Y allele is more frequent in Asians than in Caucasians. Its 
protective effect has been more frequently observed in Asians, but also in 
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Caucasians. However, in overall, the studies point out that this allele has no 
influence on PD risk. [199], based on a meta-analysis of thousands of 
individuals, only observed some effect depending on the model employed, 
whereas [201], in a larger population, concluded that there was no effect. 
In our case, our statistical power to detect some significance was the 
same (in Basque population) or higher (in non-Basque population) than the 
described in most of the previous studies and we observed that the Y allele in 
p.S18Y showed neither a tendency for protection nor for risk in any of the two 
Spanish populations (Annex III, Tables E and I). Therefore, we do not consider 
it a genetic susceptibility factor in our population.  
It could be possible that this allele was related to protection against PD 
pathogenesis at early age [198, 200, 203], but we did not analyze this 
possibility due to the average age of our populations. 
 
 
Although dystonia is secondary in Parkinson´s disease, we studied the 
influence of mutations in TOR1A, which is responsible for the most common 
and severe form of hereditary primary dystonia -DYT1-, on PD pathogenesis. 
More concretely, the presence of p.delE302/303, that causes the majority of 
DYT1 cases (≈80%).  
This protein has its highest expression in dopaminergic neurons and it 
accumulates in Lewy bodies in brains from sporadic PD cases [401]. 
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Nevertheless, no pathological lesions have been detected neither in SNpc 
neurons nor in any other central nervous system region from DYT1 patients 
[400]. Despite that, we thought that the presence of TOR1A mutations in PD 
patients could follow a similar pattern to the observed for GBA. However, 
none of the individuals analyzed carried the deletion. This stresses the 
difference that exists between dystonia and GD in their relation with PD. 
Moreover, we studied the p.D216H polymorphism, that has been 
proposed to modify the penetrance of dystonia in p.delE302/303 carriers 
[409, 410]. As there were no p.delE302/303 carriers, it was, therefore, not 
possible to analyze the relation between both variants. We did not find any 
relevant result (Annex III, Tables E and J): only for non-Basques the 
distribution of genotypes for this polymorphism showed an almost statistically 
significant result but it was due to the absence of healthy CC carriers (Table 
22). As a consequence, our results do not point out that TOR1A has an 
influence on PD pathogenesis. At most, it could be a rare PD risk factor. 
 
 
NR4A2, also known as Nurr1, is essential for the development and 
survival of dopaminergic neurons. It is important not only during development 
but also in adulthood. It is highly expressed in the substantia nigra but also in 
other parts of the brain and the body. For all these reasons, some genetic 
studies have been conducted to determine if it is involved in PD but with 
controversial results: 
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 two mutations were described in heterozygosis in the noncoding 
exon 1 (c.-291delT and c.-245T>G) by [290] when analyzed German 
PD patients (familial and sporadic cases) and controls. Nevertheless, 
[291-293] could not replicate this conclusion in other European 
populations; 
 [294] concluded that the 7048G7049 variant in intron 6 
(c.1361+16insG) was a PD risk factor in homozygosis, but [295] 
observed that only heterozygous carriers had an increased risk to 
develop PD and [296, 297] found that it was not a genetic 
susceptibility factor 
 
Therefore, we opted for analyzing a different mutation that we found 
after sequencing intron 3, which is highly conserved in mammals. The 
c.864+246C>T variant was not present in the Basque population and its 
frequency in non-Basque population was not statistically different between 
healthy controls and PD cases (Annex III).  
As the previously described mutations, it is not a genetic susceptibility 
factor on PD pathogenesis in our populations. 
 
 
GBA is a genetic susceptibility factor on PD: some GD patients develop 
parkinsonism and present LB with mutated glucocerebrosidase in their brains. 
Moreover, relatives of those patients (usually carriers of GBA mutations in 
heterozygosis) develop PD with higher frequency than general population. 
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Furthermore, there is a higher frequency of GBA mutations in Parkinson´s 
disease patients when compared to healthy population and [267] has also 
reported that there is a significant deficiency of glucocerebrosidase activity in 
substantia nigra and cerebellum in PD cases without GBA mutations. 
Some models have been proposed to explain the possible connection 
between GBA mutations and PD. None can explain why only some GD patients 
develop parkinsonism and why only some PD patients are carriers of 
mutations in GBA gene. It is supposed that GBA just contributes to, but not 
initiates, the development of SNCA pathology: the mutations just exacerbate 
and accelerate the process. 
Most of the studies that have analyzed the frequency of GBA 
mutations in PD patients and in controls have concluded that GBA mutations 
can be considered as a PD risk factor (even for familial and early onset 
Parkinson´s disease): in Ashkenazi Jews [268], in Caucasians from Canada 
[269], in people from different ethnicities from USA [270], in Portuguese 
[271], in Italian [272], in Brazilian [273], in Chinese [274, 275] and in Korean 
[276].  
Although some studies (in Tunisian [277] and in Norwegian [278] for 
example) did not found significant association for GBA mutations and 
Parkinson´s disease, the large, collaborative, international multicenter study, 
with thousands of PD patients and controls, conducted by [279] observed that 
there is an increased probability to develop PD for carriers of GBA mutations, 
and that is not exclusive for a specific ethnicity or a specific mutation.  
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Even though we only analyzed the two most frequent mutations 
(p.N370S, p.L444P) from the almost 300 that have been described in the gene, 
we observed that they represent a genetic susceptibility factor that increases 
the risk to develop PD, at least on non-Basque population (Table 19). It is 
noteworthy that in Basque population, despite the reduced size of the groups, 
which affects the power to detect statistical significance, the relative 
frequency of mutations was significantly smaller than in non-Basque 
individuals: only one patient presented a mutation (p.N370S) (Table 16). 
 
 
PD is a synucleinopathy, i.e. it is characterized by Syn deposits. 
Nevertheless, MAPT is an important genetic susceptibility factor. There is a 
≈2Mb region in 17q21.31, centered in MAPT, with strong linkage 
disequilibrium that includes other genes like CRHR1, IMP5 and Saitohin [256]. 
Inside this region there is an inverted fragment of 900kb that defines two 
different haplotypes called H1 (direct orientation) and H2 (inverted 
orientation; almost exclusive of Caucasian population [257]). Homozygous 
H1H1 carriers have an increased risk to develop PD [260-263] in both, familial 
and sporadic PD cases, independently of sex, age at onset and even ethnicity. 
In our non-Basque population, we confirmed the effect of the H1H1 
haplotype: the distribution of genotypes and alleles between healthy controls 
and PD cases was strongly statistically different (p=0.002 and p=0.000, 
respectively), being the H1 haplotype an important risk factor that increased 
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the risk to develop Parkinson´s disease in 1.58 times (CI95%=[1.24-2.02]; Table 
20). Under a binary logistic regression model, H1H1 carriers presented a 
significant increased risk, with an age and sex-correlated odds ratio of 2.133 
(CI95%=[1.23-3.699]; Table 21). However, in the Basques, no significant results 
for this locus were observed (Table 17).  
 
 
APOE, and concretely the 4 allele, is nowadays the strongest and 
most highly replicated genetic risk factor for non-familial AD. Actually, most of 
the statistically significant results obtained when analyzing the genetic 
influences in late onset AD are located in a region that comprises this gene 
but also TOMM40 and APOC1.  
The precise risk marker could remain unknown. To further study this, 
some groups analyzed TOMM40 and [438] observed that the length of a poly-
T homopolymer present in its intron 6 was correlated to the genotype in APOE 
in the majority of individuals: 3 carriers presented short (T≤19) and very long 
(T≥30) alleles whereas 4 carriers presented long (20≤T≤29) alleles with 2 
carriers having a similar distribution than 3 carriers. 
We studied the effect of APOE genotype and TOMM40 poly-T length 
on PD pathogenesis. 
Despite that AD and PD are very different in, for example, symptoms, 
brain regions affected or proteic accumulations, the effect of APOE on PD has 
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been deeply analyzed. Nonetheless, results are controversial. We hypothesize 
that, as there are frequent but opposed statistically significant results when 
analyzing the APOE genotype [312-324], this is not the factor directly involved 
on PD pathogenesis but, in turn, is closely related to the real pathogenic 
factor by either location or function. 
In our Basque population, we found that carrying at least one copy of 
the 4 allele increased the risk for PD (p=0.039; Table 18). This result is in 
agreement with those of [312], in familial PD, and [313], in Mexican. 
Nevertheless, a different result was obtained in the non-Basques: the 
distribution of alleles between healthy controls and PD cases was statistically 
different (p=0.010) as well as the distribution of genotypes (p=0.040) (Table 
23). 2 allele was the main responsible for this differences (Table 24) and 
more concretely, the presence of only one 2 allele: only 23 and 24 
genotypes reached statistical significance under the binary logistic regression 
models (Tables 25 and 26) and were related to an increased risk to develop PD 
(OR:1.928 and 2.055, respectively). This result is similar to the obtained by 
[319], a meta-analysis, and [320], in Thai (with lower statistical power than 
us).  
Furthermore, for non-Basque population we observed that there was a 
combined effect of H1H1 genotype (MAPT) and the presence of one 2 allele 
in APOE: carriers of both presented three times more tendency to develop PD 
than those that did not present any of these variants (OR:3.229; CI95%=[1.790-
5.824]; Tables 27 and 28). 
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Our results do not shed light into the controversy on APOE alleles and 
their relation with PD pathogenesis: each Spanish population points out in a 
different direction and, moreover, this direction is different to the observed 
by other studies conducted in sporadic Caucasian cases (with similar statistical 
power) that mostly concluded that any of the alleles influenced PD 
pathogenesis [321-323].  
 
With regard to the poly-T homopolymer in TOMM40, mostly of the 
healthy controls and PD patients presented the previously described pattern 
for APOE genotype – TOMM40 length, being the long allele the less frequent 
in both groups, as expected. We observed no influence of the poly-T length on 
PD pathogenesis neither in Basque nor in non-Basque population (Annex III, 
Tables H and L). The same result was observed by [487], that analyzed, in 
Polish controls and PD cases, the APOE genotype and the poly-T length and 
concluded that there was no significant association at the single allele, 
genotype or haplotype (TOMM40-APOE) level for any of the genes89. Only 
those two studies have studied the influence of the homopolymer on PD 
pathogenesis but both point out in the same direction: this polymorphism on 
TOMM40 is not a genetic susceptibility factor, at least in our populations. 
Furthermore, there is an important detail to point out about these 
results in APOE and TOMM40: 
                                                          
89
 There is a difference between their study and ours because they divided the long alleles in  
two types: La (T: 20-22) and Lb (T: 26-30). 
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the Hardy–Weinberg principle states that, in the absence of natural 
selection, mutation, migration, non-random mating, random genetic drift90, 
gene flow, and meiotic drive, the genotypic frequencies and the allele 
frequencies of a population remain constant from one generation to the next 
[488, 489]91.  
When conducting a genetic association study, the control group is 
analyzed to determine if there are deviations from the Hardy-Weinberg 
equilibrium (HWE), that is, if any of those processes is acting on it and, 
therefore, if it is appropriate to be compared with the case group92. 
For the assessment of deviations from the Hardy–Weinberg 
equilibrium in the data, the most popular approaches include the asymptotic 
Pearson’s chi-square goodness-of-fit test, which is simple and straightforward 
although very sensitive to small sample size or rare allele  frequency, and the 
exact test, which is valid for any sample size and minor allele frequency. The 
exact test can be performed through complete enumeration of heterozygote 
genotypes or on the basis of the Markov chain Monte Carlo procedure [489]. 
In our genetic association study, both control groups (Basque and non-
Basque) presented a deviation from the HWE for the polymorphism in 
TOMM40 and also for the genotype in APOE in the non-Basque controls.  
                                                          
90
 When a population is small, the allele frequencies can drift from generation to generation. 
This process is known as genetic drift. 
91
 This is an ideal situation because a population will never be exactly in HWE. 
92
 Cases do not need to be in HWE. In fact, screening with HWE of data sets of affected 
individuals has been proposed as a relatively efficient method for detecting gene–disease 
associations. 
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As this result was obtained by using the Pearson’s X2 goodness-of-fit 
test, we decided to use the exact test (GENEPOP program on the web: 
http://genepop.curtin.edu.au/genepop_op1.html [490]). The program 
calculated the exact test for HWE by the two previously described methods 
and confirmed the previously obtained result: there was a deviation from the 
HWE in all three cases. 
Although traditionally it has been considered that deviations from the 
HWE can also be due to genotyping errors and thus could highlight 
methodological errors, see [491] for example, [492] demonstrated that testing 
for HWE should not be used as a criterion for identifying SNPs with 
genotyping errors at unmatched case-control association studies and that this 
practice was unjustified. Furthermore, [493] remarked that only gross 
genotyping errors could cause deviations from the HWE as could happen in 
GWAS where the number of markers genotyped can be greater than tens of 
thousands, and genotypes are assigned through automated procedures which 
analyze hybridization intensities. 
Moreover, in our case, the methodological process we followed to 
determine the genotypes in APOE and TOMM40 was robust: standardized 
protocols that had been widely checked were used and, in addition, the 
results passed the respective quality controls. As a consequence, genotyping 
errors do not represent a feasible reason to explain the deviation. 
A priori, those control populations were not affected by any of the 
selective processes that explain deviations from HWE and the influence of 
both polymorphisms on population selection is not strong enough to explain 
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that fact. Even population stratification seems unlikely because populations 
from Sevilla or Donosti are mostly Caucasian, i.e. they are not compossed by 
different ethnical groups. Therefore, there is no obvious apparent reason to 
explain the deviation beyond that it is occurring by chance. 
Anyway, as a consequence of this deviations from HWE for Basque and 
non-Basque control groups, we have to reformulate two of our explanations: 
 it is possible that, actually, the polymorphism in TOMM40 has an 
effect on PD pathogenesis that we have not detected either in 
Basque or in non-Basque population. 
 the effect of the 2 allele in APOE on PD pathogenesis in non-Basques 
might be an artifact due to the HWE deviation observed that distorts 
the real genetic effect. 
 
In summary, in Basques and non-Basques, relevant results have been 
obtained for the same mutations/polymorphisms, i.e. GBA, MAPT and APOE. 
Nevertheless, the differences we have observed, especially in MAPT and GBA, 
which are clear genetic susceptibility factors in PD (but even in APOE) may 
involve that despite Basque and non-Basque populations are Spanish, due to 
the historical isolation that Basques have maintained and thus their higher 
rate of endogamy, the genetic susceptibility factors that affect them in 
respect to PD pathogenesis are slightly different than those that affect other 
Spanish populations. Therefore, our results should be maintained as for 
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Basque and non-Basque population and not be extrapolated to the overall 
Spanish population. 
  
 
Parkinson´s disease is a complex maladie with unknown etiology. 
Nowadays, there still are plenty of unanswered questions about it: could 
there be more than one pathological mechanism but only one disease? What 
explains the different symptoms that PD patients present? Why are there 
differences in how cases respond to treatment?... 
There are five genes responsible for familial PD, a minority of cases 
(≈10%) [50]. However, even in those familiar cases there are remaining 
questions to solve such as, for example, the mechanisms that explain how 
they act in a pathological way. Why they affect dopamine-containing neurons 
in SNpc if their expression is widespread? In addition, not all those cells and 
not only those cells are affected, and the spatial and temporal pattern of cell 
death is not always the same… 
We decided to focus on the sporadic forms of the disease, that is, on 
the majority of patients (≈90%), the individuals where there is not a known 
cause that explains why they are affected.  
The common disease-common variant hypothesis [494] postulates 
that these patients could carry genetic susceptibility factors that trigger the 
onset of the disease even in combination with a relatively common genetic 
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background. These genetic factors are ancient variants, i.e. they are frequent 
at the population, but have an inherent pathogenic capacity that can be 
enhanced when combined with some environmental factors.  
Nevertheless, how could those pathogenic variants not be eliminated 
by the natural selection over the years if they have a pathogenic and active 
potential? Maybe it could be explained by the fact that PD is mostly a late 
onset disease, and therefore relatively immune from natural selection, whose 
prevalence has recently increased as the human life expectancy has done it. 
These variants could confer some competitive advantage in 
young/reproductive age even at the price of increasing the chances of an 
unhealthy ageing. Moreover, in overall population the pathogenic effect 
seems to be weak. 
 
 Based on the common disease-common variant hypothesis, we propose 
an additive model to explain Parkinson´s disease pathogenesis: 
Let´s assume that there are  
o genetic variants frequent in the population that are 
susceptibility factors in PD, for example, the H1 haplotype93. 
We could also include here even the APOE allele, although this 
is more controversial. Those genetic susceptibility factors 
                                                          
93
 H1 haplotype could be considered not risky per se although less optimum than the H2 
haplotype, which has suffered positive selection. For H1/H2 haplotype (MAPT) and APOE 
genotype, as it could be for other variants, it remains unclear if they are the risk factors or are 
closely related to the real pathogenic factors by either location or function. 
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originate elements, i.e. proteins/RNAs, with standard or low 
quality. 
o other minority factors, such as GBA mutations, which are less 
frequent but have higher pathogenic potential: they originate 
defective proteins or RNAs (extremely low quality elements).94  
Each person carries a unique combination of these factors95 that has a 
specific pathogenic potential.  
Each cell works employing the elements it has: therefore, in individuals 
that carry a high-risk load, cells work at suboptimal conditions due to the low 
quality of their components and are, as a consequence, more prone to suffer 
stress. Some people carry a very high-pathogenic combination and cross the 
threshold: there will be a period of time while their cells can return to the 
homeostatic situation, but in a specific moment (due to some environmental 
factor or to the ageing process…) they are overpassed, and thus, there is 
cellular dysfunction that finally leads to cellular death and PD pathogenesis. 
It is noteworthy that, for example, glucocerebrosidase, tau and APOE, 
which are the proteins that could be affected for those variants, do not work 
in processes exclusive for dopamine-containing neurons. In addition, their 
                                                          
94
 There could be even more types of variants with different degrees of pathogenicity and 
inversely related frequencies.  
The variants could affect expression, function, interactions… of proteins/RNAs and thus 
decrease their quality. This aspect is the most difficult to determine: even for the already 
accepted genetic susceptibility factors in PD, almost all those questions remain unclear. 
95
 People from the same population share more similarity: that would explain the genetic 
differences observed for Basques and non-Basques. Moreover, each combination of factors 
could originate different pathological mechanisms and thus, different evolutions and 
symptoms. 
V. DISCUSSION. 
304 
 
expression is widespread96. Therefore, to explain why only some tissues are 
affected in PD, there should be some kind of tissue specificity, i.e. in these 
brain regions, the affected elements (for example, glucocerebrosidase, tau 
and APOE) would participate in critical pathways or would work in 
combination with tissue-specific proteins/RNAs... 
 
 Our second objective was to study possible genetic risk factors for the 
development of cognitive impairment during the evolution of Parkinson´s 
disease. 
 
To that purpose, using a case-control approach in PD patients with 
different cognitive status (N.C. and C.I.), we compared the frequency of 
mutations or polymorphisms located in:  
 genes related to other diseases where dementia is consubstantial 
such as AD (APP, PSEN1, PSEN2 and CALHM1), HD (HTT), CJD 
(PRNP), FTD (GRN and TARDBP) and Kufor-Rakeb syndrome, also 
characterized by parkinsonism (ATP13A2);  
 genes that encode neurotrophic factors such as CDNF, MANF (and 
DOCK3) and BDNF; 
 and genes involved in homocysteine metabolism, CBS, MTR and 
MTHFR, protection against oxidative stress, NFE2L2 and KEAP1, 
chaperone-mediated autophagy, HSPA8 and LAMP-2A, and GSK3, 
                                                          
96
 Furthermore, their pathogenic mechanism remains unknown, although all have been 
related to Syn, and more concretely, to changes in its proneness to aggregate. 
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due to its relation with tau homeostasis, that is, processes and 
proteins proposed to be related to PD. 
 
Furthermore, as healthy controls were also included in the study, some 
possible genetic susceptibility factors to PD pathogenesis were studied in GBA, 
SNCA and MAPT. Furthermore, a genetic susceptibility factor in AD (APOE 
genotype) and a new one related to it (poly-T homopolymer length, TOMM40) 
were considered. 
 
 
We observed that there was no influence of poly-T length (TOMM40) 
(Annex IVa, Table P) on PD pathogenesis as previously determined in Basque 
and non-Basque population. As some studies previously concluded, [321] in 
Irish, [322], [323] in Norwegian and [324] in a large case-control study with 
thousands of people, we observed no risk for PD associated to APOE (Annex 
IVa, Tables N and O). We did not obtain this conclusion either in Basque or in 
non-Basque population: again, our results about APOE genotype and PD were 
controversial. At least we observed that the long allele in TOMM40 was the 
most frequent, as expected, and that mostly of the individuals presented the 
previously described pattern for APOE genotype – TOMM40 length. 
 
Although there were more PD cases carrying mutations in GBA than 
controls, the difference had no statistical significance. The frequency was 
higher than the observed in Basque population but not as high as the 
observed in non-Basque population. It is possible that, in this case, as 
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happened in other studies, the analysis of only the two most frequent 
mutations (p.N370S, p.L444P), instead of all the existing variants that have 
been described in the gene, and the size of the sample analyzed precluded the 
proper quantification of the risk. 
 
For the Rep1 microsatellite (SNCA), some alleles have been considered 
as risk factors: 273 by [77] in a German population although other articles, 
[71] in a Italian population or [78] in a Singaporean population, did not obtain 
the same conclusion (we do not even observed this allele); 271 by [79] in a 
Greek population, [80] a meta-analysis and [81, 82] in a population from USA; 
moreover, [83] in Australians with European ancestries, [80] a meta-analysis 
and [81] in a population from USA97 observed that allele 267 could be 
neuroprotective. However, we did not obtain any relevant result (Annex IVa, 
Table M): the allele 269 was the most frequent, as expected, but the 
distribution of the alleles and genotypes was not different between groups. 
The length of this polymorphism has been related to PD susceptibility by its 
influence in Syn expression, although this is still controversial [74, 75].  
 
It is noteworthy that the demographic characteristics of controls and 
cases, that is, the percentage of males and females and their mean age, were 
statistically different. Therefore, the relevance of our results is compromised. 
 
                                                          
97
 Depending on the article used as a reference, allele name may change: [76] described 
alleles 0 (267), 1 (269), 2 (271), 3 (273)… Nevertheless, alleles in [77] are 10 bp shorter than 
those. These are the most common nomenclatures, although some articles ([80] and [82] for 
example) mix both: their allele 263 is actually 271 in [76]. 
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Nevertheless, and despite that, there were two statistically significant 
results that confirmed that two polymorphisms were important genetic 
susceptibility factors in PD, as other groups have previously concluded: 
o rs356219 (SNCA) (Table 29); the distribution of genotypes and alleles 
between healthy controls and PD cases was statistically different 
(p=0.049 and p=0.018, respectively). The A allele was protective 
against PD (OR: 0.56; CI95%=[0.34-0.92]), especially in AA genotypes, 
(OR:0.49; CI95%=[0.26-0.94]). [84] in a Norwegian population, [85] in a 
Caucasian  population from the USA, [86] in an Italian population and 
[87] in Han Chinese,  also concluded that the G variant was a PD risk 
factor, that is, that the A variant was protective. Nevertheless, [88] in 
Swedish observed the opposite. 
o H1/H2 haplotype (MAPT) (Table 30); the distribution of genotypes 
and alleles between healthy controls and PD cases was strongly 
statistically different (p=0.001 and p=0.000, respectively), being the 
H1 haplotype an important risk factor that increased the risk to 
develop Parkinson´s disease in 2.55 times (CI95%=[1.59-4.09]). The 
same effect was observed for the H1H1 carriers. We, in non-Basque 
population (the result in Basque population was slightly different) as 
well as [260-263], obtained the same conclusion. 
 
These variants have been mainly studied for their relation with PD 
pathogenesis.  
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Any of them, except the APOE genotype, showed any statistically or 
almost statistically significant result when comparing the PD patients 
depending on their cognitive status. 
For APOE, there were not statistically or almost statistically significant 
results when considering genotypes or alleles or even the number of 4 alleles 
(Annex IVb, Tables AH and AI). Nevertheless, when individuals where 
classified depending on the number of 2 alleles they carry, we observed that 
the 2 allele was more frequent in C.I. (19.67%) than in N.C. (8.00%) and that 
there was a trend (p<0.1) that pointed out to the involvement of this allele in 
the increased risk to develop cognitive impairment during the evolution of PD 
(OR: 2.82; CI95%=[0.85-9.37]). This effect was mainly observed for 2+/- 
carriers (Table 48). 
Previous studies reported that the 4 allele, not the 2, could be 
associated with risk of dementia in PD ([318] sporadic and familial PD, [316] in 
familial PD). In addition, [495] concluded that carrying at least one 4 allele 
was associated with more rapid cognitive decline in British PD patients. The 
same study observed that H1 haplotype was correlated with lower 
performance in memory tasks but not with the rate of general cognitive 
decline but [496] obtained that the H1 haplotype was a genetic risk factor for 
PD and also was associated with an increased risk to develop dementia in 
Spanish PD patients.  
 
We did not obtain any similar result for APOE, MAPT or even GBA: 
[497], in white Europeans, concluded that mutations in GBA, not only p.N370S 
and p.L444P, were not only more frequent in PD patients than in controls, but 
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also more frequent in PD patients with dementia. The presence of those 
mutations had no influence on age at onset or motor symptoms. 
 
It is noteworthy that we studied cognitive impairment98 and not only 
dementia as the other studies did, but, M.C.I. and dementia groups were not 
different for the distribution of APOE, MAPT or GBA. It is possible that the 
characteristics of the two groups that were compared, controls and cases, 
have influenced this result. 
 
 
For the other polymorphisms and mutations analyzed (see the first 
lines of this second objective), the major part of differences were observed 
when we compared PD patients and healthy controls, which was not our main 
objective, especially because, as previously said, the relevance of our results 
was compromised due to the differences present between both groups in 
their demographic characteristics and number of individuals. Nevertheless, as 
observed with rs356219 (SNCA) and H1/H2 haplotype (MAPT), those 
inconvenients might not be enough to cover their real risk or protection 
potential:  
                                                          
98
 Mild cognitive impairment is present since the earliest stages of PD, but not all PD patients 
will develop dementia because M.C.I. can stabilize, evolve to dementia or recover to normal 
cognition. Despite that M.C.I. and dementia do not represent the same process as are 
somehow connected, the size of M.C.I. and dementia groups was small, and both did not 
present statistically different percentage of males and females, mean age at onset and period 
of evolution, and were genetically similar (see Results IV.2.), we opted for considering 
individuals with dementia and mild cognitive impairment together, i.e. C.I. group, to increase 
the statistical power of our analysis. 
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 HTT (Huntington´s disease): the T allele in rs363096, tended to 
increase the risk to develop PD (p=0.086; OR: 1.50; CI95%=[0.94-2.39]) 
(Table 31). This effect was also observed for the haplotypes ATCAT, 
protective against PD (p=0.002), and ATTAT, almost risky (p=0.087) 
(Table 32). 
 ATP13A2 (Kufor-Rakeb syndrome; dementia and parkinsonism): for 
rs6684770, the distribution of genotypes and alleles was statistically 
different (p=0.044 and p=0.016, respectively), being the T allele the 
responsible for the 1.89 times (CI95%=[1.12-3.19]) increased risk to 
develop Parkinson´s disease (Table 33). Moreover, the haplotype ATG 
was significantly risky (p<0.05) and two more, GCG and ATA, were 
almost protective and risky, respectively (p<0.1) (Table 34). 
Previous studies have analyzed mutations, not polymorphisms, in ATP13A2, 
and have concluded that its connection with PD is minimal [207, 208]. 
Nevertheless, there were discordant opinions [209]. 
 CDNF (neurotrophic factor): the distribution of genotypes in rs7099185 
was statistically different (p=0.017) and the T allele showed a trend 
towards increasing the risk to develop PD (p=0.084; OR: 1.61; 
CI95%=[0.93-2.78]) (Table 35). There were trends for two haplotypes 
(rs7094179-rs7099185): TT was almost risky (p=0.055), whereas GC 
was almost protective (p=0.077) (Table 36). 
 DOCK3 (“neurotrophic factor”): the distribution of genotypes in 
rs4441646 between cases and controls was statistically different 
(p=0.035) (Table 37). 
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 MTHFR (homocysteine metabolism): the C allele in rs1801133 
(c.C677T) seemed to increase the risk to develop PD in 1.54 times 
(p=0.066). Moreover, in rs1801131 (c.A1298C), the distribution of 
alleles was statistically different (p=0.014), being the A allele 
protective against PD (OR: 0.51; CI95%=[0.30-0.88]). Its effect almost 
reached statistically significant results when considering genotypes 
(p=0.055) (Table 38). There were also relevant results when 
considering haplotypes (Table 39). 
 HSPA8 (chaperone-mediated autophagy): in rs1461496, the 
distribution of alleles was almost statistically different and the T allele 
tended to be protective (p=0.071; OR: 0.65; CI95%=[0.41-1.04]). The 
difference in genotypes reached statistical significance (p=0.040) 
(Table 40). The TG haplotype was almost protective against PD 
pathogenesis (p=0.092) (Table 41). 
 LAMP-2A (chaperone-mediated autophagy): there was a statistically 
significant difference between both groups for the distribution of 
genotypes and alleles in rs7057652. The T allele increased the risk to 
develop PD in 2.40 times (CI95%=[1.38-4.17]). The effect was the same 
independently of sex, although in males it did not reach statistically 
significant difference (Table 42). In rs42890, there was a statistically 
significant difference for the distribution of alleles. The G allele 
increased the risk to develop PD in 1.94 times (CI95%=[1.14-3.29]), 
especially in homozygosis (Table 43). In addition, there were two 
haplotypes with relevance on PD pathogenesis: GAAT (p=0.002) and 
TAAG (p=0.00001) (Table 44). 
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However, the differences observed between the groups N.C. and C.I., 
which only differed in their mean age at onset, were slightly more numerous 
than the observed between the individuals with M.C.I. and dementia: 
 CDNF (neurotrophic factor): the G allele in rs7094179 showed a 
tendency to protect against cognitive impairment in PD patients 
(p=0.083; OR: 0.61; CI95%=[0.35-1.07]) (Table 49). The haplotype GT 
(rs7094179-rs7099185) also showed the same tendency (p=0.092) 
(Table 50). 
[498] observed that the G allele, rs7094179, showed a trend towards 
increased risk to develop PD in a Korean population, although the genotypes 
did not affected mRNA expression levels in peripheral lymphoblasts. However, 
as previously described (Tables 35 and 36), we only found some relevant 
results, when comparing PD cases and healthy controls, for rs7099185 and for 
some haplotypes where this G allele was not risky. 
 CBS (homocysteine metabolism): the difference in alleles was almost 
statistically significant (p=0.086) being the insertion c.844ins68 the risk 
factor (Table 51). 
 MTR (homocysteine metabolism): the A allele increased the risk to 
develop cognitive impairment during PD in 3.36 times (p=0.001; 
CI95%=[1.56-7.24]). The difference was statistically significant even in 
genotypes (p=0.007) (Table 52). 
 NFE2L2 (protection against oxidative stress): the haplotype GG 
(rs1806649-rs10183914) was more frequent in PD patients with 
cognitive impairment (p=0.086) (Table 53). This was the only relevant 
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result we observed. Nevertheles, [499] observed that in rs10183914, 
frequencies were not different when comparing either Polish or 
Swedish PD patients and healthy controls, whereas the distribution of 
genotypes in rs1806649 was statistically different, being the GG 
genotype more frequent in Polish PD cases than in controls (in Swedish 
population there was no difference). In addition, some of the 
haplotypes formed by these two plus other polymorphisms influenced 
the risk to develop PD and/or the age at onset in both populations. 
 KEAP1 (protection against oxidative stress): the distribution of alleles 
was almost statistically different (p=0.094) and the G allele tended to 
be protective against mental deterioration (OR: 0.38; CI95%=[0.12-
1.22]). Its effect reached statistical significance in genotypes (p=0.028), 
concretely for the homozygous GG cases (Table 54).  
 HSPA8 (chaperone-mediated autophagy): in rs4936770, the 
distribution of alleles was statistically different, being the A allele 
protective against cognitive impairment in PD (p=0.010; OR: 0.43; 
CI95%=[0.22-0.82]). The distribution of genotypes between both groups 
was statistically different too (p=0.045) (Table 55). Relevant results 
were also observed for some haplotypes (Table 57). 
 LAMP-2A (chaperone-mediated autophagy): there were only 
statistically and almost statistically significant results at the 
polymorphism rs42897. However, the effect of alleles and genotypes 
on cognitive impairment was confusing and opposite depending on the 
sex of the cases (Table 59). One haplotype, GAAG, was statistically 
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more frequent in patients with normal cognition than in those with 
cognitive impairment (p=0.018) (Table 58). 
 
We did not observe relevant results either for BDNF (neurotrophic 
factor) or for GSK3 in any of the comparisons we carried out. These 
conclusions have also been obtained by other groups: 
 p.V66M (BDNF): the majority of the studies except one, [392] in an 
Italian population, have concluded that there is no significant 
difference in the allelic or genotypic frequency between PD cases and 
controls: [385] and [386] in sporadic PD in Chinese populations, [387] 
in a population from USA, [388] in a Greek population, [389] in a 
Caucasian population, [390] in familial PD in a worldwide population 
and also [391] in a meta-analysis based on 6 studies in sporadic PD, 4 
in Asians, Chinese and Japanese, and 2 in Caucasians, from UK and 
Sweden. It does not seem to play a major role in the pathogenesis of 
PD. 
 rs334558 and rs6438552 (GSK3): [413] conducted a genetic study in 
Australian and Chinese PD patients and controls that highlighted that 
there was not significant difference either in the allelic or in the 
genotypic frequency between both groups for any of the two 
polymorphisms. Subsequent genetic analyses in PD patients, [95] in a 
British population, [93] in a Caucasian population, [412] in an Indian 
population and [500] a meta-analysis, have also reported the same 
conclusion. Nevertheless, other studies did find significant differences: 
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[414] observed that the CC genotype in rs334558 was protective 
against PD in a Greek population whereas [415] only analyzed 
rs334558 in Han Chinese sporadic PD patients and controls and found 
that the T allele was a protective PD factor. Its role in PD pathogenesis 
seems to be minor. 
 
In our study, none of the individuals carried the mutations we analyzed 
in TARDBP or GRN (frontotemporal dementia) pointing out that they had no 
influence on PD pathogenesis. Other groups have studied which is the 
influence of carrying mutations on these genes on PD pathogenesis:  
 [501] sequenced the entire GRN gene in a Belgian population and 
concluded that mutations on it had no role in the genetic etiology of 
PD. 
 Mutations in TARDBP do not appear to contribute to the pathogenesis 
of PD either: [502] in a population from USA, [503] in a French-
Canadian population and [504] in Dutch patients and controls obtained 
this conclusion after sequencing the entire coding region or only the 
exon 6, where almost all the mutations that have been described at 
the present time are located. 
A priori, the genetic determinants selected and analyzed could be 
divided in two groups99: 
                                                          
99
 Nevertheless, the results we obtained pointed out that both categories, i.e. PD risk and 
cognitive impairment, could be related. 
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 For those that have been related to PD risk, we replicated some 
previously described results (also observed in our Spanish population –
see Results IV.1-): the H1 haplotype (MAPT) and the G allele in 
rs356219 (SNCA) were PD risk factors whereas the poly-T length in 
TOMM40 had no influence and the effect of the APOE genotype on PD 
risk was again controversial. Nevertheless, mutations in GBA were not 
genetic susceptibility factors on PD pathogenesis.  
With regard to the effect of those variants on the development of 
dementia in Parkinson´s disease, we only observed that the 2 allele in 
APOE showed some tendency to increase the risk to develop cognitive 
impairment. However, neither this result nor the others for MAPT and 
GBA agreed with the few previous conclusions reported by others. 
 For those that we considered that could determine the appearance of 
dementia in PD: 
o For some of these variants, TARDBP, GRN, BDNF and GSK3, studies 
have already been conducted, mainly to determine their effect on 
PD risk, and most of the results are negative, as was our case. 
Therefore, they do not seem to have an important role either on PD 
risk or in the development of cognitive impairment. 
o For others, we observed differences not only for their influence on 
cognitive status, but also when analyzing the PD risk. 
Polymorphisms present in the same gene (ATP13A2, HTT, CDNF, 
HSPA8, LAMP-2A, NFE2L2) as well as genes that work in the same 
pathway (homocysteine metabolism, chaperone-mediated 
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autophagy) pointed out in different directions. Those, as well as 
KEAP1, DOCK3 and the genes related to AD, which mainly gave 
differences when comparing cases with M.C.I. and dementia, should 
be more deeply analyzed. 
 
In any case, it is hasty to postulate which could be their influence on 
Parkinson´s disease. We selected them for their hypothetical relation to PD or 
dementia but there are no pathogenic mechanisms described that connect 
any of them with the beginning of the disease or its evolution. To that 
purpose, the influence of the variants on protein function, expression, 
interactions… should be studied as well as the combined effect that some of 
them could have, as our additive model proposes. 
 
Our mathematical models have served as drafts of the results we could 
obtain once the study has been replicated with larger and more 
homogeneous groups. Their values of specificity and sensitivity were low, i.e. 
an important percentage of influence on the fact of developing PD/cognitive 
impairment was not explained by the variables analyzed. 
We also analyzed the distribution of the  
 nine PD risk variants in cases and controls (Figure 56 and Table 47) and 
observed that the 90% of healthy controls carried 1 to 5 whereas 90% 
of patients carried 3 to 7, pointing out that these were genetic 
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susceptibility factors, not pathogenic factors, as they were observed in 
both groups, although, on average, cases carried more risk variants 
than controls (5 vs 3.39, respectively).  
 three cognitive impairment risk variants in cases with different 
cognitive status (N.C. and C.I.) (Figure 58 and Table 62) and observed 
that the mean of cognitive impairment risk variants carried by the 
cases with normal cognition was 1.14, whereas for those with 
cognitive impairment was 1.74. As previously said, they could be 
genetic susceptibility factors, not pathogenic factors.  
We could suppose that the variants have an additive effect (additive 
model; common disease - common variant hypothesis) and act in 
conjunction but also with other genetic and even environmental factors, as 
the sensitivity and specificity values indicate, to influence on the cause or 
evolution of Parkinson´s disease, respectively.  
Nevertheless, there was no correlation between the variables (9 and 3, 
respectively and separately) that could have shed some light on the affected 
biological mechanisms that contribute to the development of Parkinson´s 
disease or cognitive dysfunction. 
Moreover, our results did not indicate that both processes were 
genetically related as relevant variants were different in both processes, the 
distribution of the nine PD risk variants on cases was not different when 
comparing N.C. and C.I. (Table 63 and Figure 59) and there was no correlation 
between these 9 and the other 3. 
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It is noteworthy that in our analysis, there were demographic 
differences between groups, the statistical power was low and, furthermore, 
we grouped cases with mild cognitive impairment and dementia together.  
However, despite that, we replicated some previously reported results, 
i.e. MAPT and SNCA, and obtained some relevant results for the variants that 
we considered that could determine the appearance of dementia in PD. We 
should replicate our study with larger and more homogeneous groups but, at 
least, these results represent some trends to be considered in the future. 
 
 
 Our third objective was to determine the relation between genetic 
variability in the ARMCX gene family and PD pathogenesis in Spanish 
population. 
To that purpose, we used a non-Basque subpopulation of healthy 
controls and PD patients that had been previously analyzed for possible 
genetic susceptibility factors in Parkinson´s disease (see Results IV.1. and 
Discussion, first objective): therefore, as observed for the overall non-Basque 
population there was no influence of p.S18Y (UCHL1), p.delE302/303 and 
p.D216H (TOR1A), c.864+246C>T (NR4A2) and poly-T length (TOMM40) on PD 
pathogenesis (Annex V) and H1H1 carriers (MAPT) had an increased risk to 
develop the disease (p=0.025; OR: 3.922; CI95%=[1.184-12.991]). (Tables 72 
and 73). 
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However, there were two differences: 
 although p.N370S and p.L444P mutations (GBA) were more frequent in 
PD patients than in healthy controls there was not statistical 
significance. In this, like in other studies that have analyzed GBA gene, 
methodology, i.e. we only considered two mutations from the almost 
300 that have been described, and sample size, that is, the number of 
individuals analyzed in this case was ≈3-4 smaller than before (Results 
IV.1.), might be the reason why there were not relevant results when 
considering the presence of mutations in GBA as a risk factor. 
 furthermore, the results for APOE genotype revealed that the 4 allele 
was protective against the disease as [314], in Caucasians non-
Hispanics, concluded. More concretely, the protective effect reached 
statistical significance (p=0.044; OR:0.428; CI95%=[0.188-0.976]) only 
for 34 carriers (Table 71). In this subpopulation, APOE genotypes 
were in HWE. One more time, the results for APOE were controversial 
and it remains unclear if it is a risk factor or if it is closely related to the 
real pathogenic factors by either location or function. 
 
 
Mitochondria and Parkinson´s disease are related but the sense of this 
relation remains unclear: amongst other facts, mitochondrial function is 
altered in patients although it is not clear whether it is cause or consequence 
of the malady, there is a close relation between some pathological genes and 
mitochondrial function or integrity, complex I is impaired in PD patients and, in 
addition, some PD patients have mutations in their mtDNA.  
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We decided to study the ARMCX gene family because the 6 members 
share some interesting characteristics that could shed light into this 
connection and imply a new pathological mechanism in Parkinson´s disease 
based on the mitochondria: at least in silico, the 6 proteins have a 
mitochondrial targeting signal100, in vitro studies have reported that human 
ARMCX1, 2, 3 and 6 are mitochondrial proteins [397], and moreover, ARMCX3 
is a member of the KIF5/Miro/Trak2 protein complex responsible for the 
mitochondrial transport along axons [397]. Thus, these proteins could 
regulate mitochondrial dynamics and trafficking, which are essential to supply 
appropriate energy to distal neuronal branches, and thus for the correct 
neurotransmission and neuronal viability. 
 
In addition, they are located at chromosome X and could be related to 
PARK12 (Xq21-25), and thus to the possibility that sex has some influence on 
PD susceptibility, despite that the studies that defined the locus ([215] first, 
and [216] although only when using broad criteria for inclusion of PD 
patients101) did not include the ARMCX cluster inside the region limited by the 
markers that showed the highest LOD scores. 
 
We obtained that, from the 8 markers located along the cluster that 
were analyzed, only rs2858162 (ARMCX6) gave some relevant results: the 
                                                          
100
 Four members of the family also have a nuclear localization signal. 
101
 In both studies, the major part of the association for this region in X chromosome was due 
to brother-brother pairs, with sister-sister pairs and mixed sex sibships having lower linkage 
values. 
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distribution of alleles and genotypes between healthy controls and PD cases 
was close to be statistically different (p≈0.070). That was observed when 
comparing cases and controls in overall, being the C allele and C-containing 
genotypes more frequent in affected individuals than in healthy people. The 
same tendency was observed when dividing by sex, for women and men, 
although there was not statistical significance, maybe due to the reduced size 
of those groups that had not enough statistical power (Table 74). 
Nevertheless, when we analyzed the relevance of haplotypes formed 
by the eight polymorphisms, we obtained a statistically significant result were 
the role of rs2858162 was decisive: the haplotype TACTAC only appeared in 
healthy controls, i.e. it was protective (p=0.034). Nevertheless, the haplotype 
TACCAC was more frequent in PD cases than in controls although the 
statistical significance was not enough to consider it a risk haplotype 
(p=0.077) (Table 76). Both haplotypes only differentiate in their fourth 
position, that corresponds to rs2858162 and, as observed for genotypes and 
alleles, the C variant was risky whereas the T variant was protective. 
 
 Therefore, although ARMCX genes were good candidates to represent 
new genetic susceptibility factors for their cellular localization, their structure, 
their expression pattern and their predicted function, our results did not point 
out to an effect of the ARMCX gene family, or any of its members, on PD 
pathogenesis and thus to a relation with the PARK12 locus. Moreover, we did 
not observe any influence of sex on PD pathogenesis, although this result 
could be influenced by the reduced size of those groups, i.e. the low statistical 
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power. Only the polymorphism rs2858162 (ARMCX6) should be more deeply 
studied to confirm the trend observed for its alleles and genotypes (and 
haplotypes). 
 
 And for our fourth objective we used an epigenetic perspective: we 
analyzed if the five genes responsible for the familial forms of Parkinson´s 
disease could be epigenetically related to PD pathogenesis. 
Our interest focused on DNA methylation levels around their 
transcription start site becuase variations of this epigenetic mark in this area 
can influence gene expression. 
For SNCA and LRRK2, overexpression is pathogenic and thus, lower 
DNA methylation levels that involve higher transcription and gene expression 
could be pathogenic too. However, for PRKN, PINK1 and DJ-1, the pathogenic 
factor is the lack of enough active protein; therefore, higher DNA methylation 
levels that involve transcription silencing could lead to decreased gene 
expression and thus, be pathogenic. 
 
Previous studies analyzed DNA methylation levels around the TSS after 
bisulfite treatment and PCR amplification in SNpc and cortex, even in 
putamen, from PD cases and healthy controls [471-474].  
There are two differences when comparing to our study: instead of 
cloning and sequencing or using mass spectroscopy to quantify the 
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methylation levels, we carried out pyrosequencing. Moreover, we analyzed 
the five genes mutated in familial PD whereas [471] and [472] studied loci that 
are relatively related to Parkinson´s disease, that is, MAPT which is one clear 
genetic susceptibility factor but also UCHL1, TNF, APP and PSEN1 that have 
no such clear relation with it. Those studies concluded that in any of the brain 
regions analyzed DNA methylation levels were different between cases and 
controls. 
With regard to [473] and [474], although the region that they analyzed 
in SNCA was not included in our study, it was close to the area in intron 1 that 
we studied. Those studies concluded that PD cases showed low methylation 
levels in SNpc, cortex and putamen when compared to controls, and that PD 
cases presented lower DNA methylation levels but only in SNpc (not in cortex 
or putamen), respectively. 
 
In our case, as expected for housekeeping genes, the promoters of DJ-
1, LRRK2, PINK1, PRKN and SNCA were poorly methylated in all the tissues to 
allow their ubiquitous expression. The range of our values was similar to the 
observed by [473] (the percentages observed by [474] were completely 
different). The major part of our most relevant (statistically significant or close 
to significance) results were obtained for specific CpG sites mainly located in 
PRKN and SNCA (for PINK1, LRRK2 and DJ-1 there were almost no relevant 
results). Most of them showed that DNA methylation levels were higher in 
controls than in cases but there was no overall tendency as [473] and [474] 
concluded (Tables 77 and 78). 
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We analyzed substantia nigra, parietal cortex and occipital cortex with 
special interest for the results in SN because, unlike parietal cortex and 
occipital cortex, that have not been described as affected early in PD and 
could be considered “control brain regions”, it is extensevely affected in PD 
[17]. Nevertheless, those CpG sites with statistically or almost statistically 
significant differences in DNA methylation levels were observed not only in 
SN, but also in parietal and occipital cortex and even, sometimes, were shared 
by more than one brain region (Tables 77 and 78). 
Unfortunately, there was no blood from any of the individuals, so we 
could not analyze if there was some change in methylation levels in this tissue 
due to the maladie and if, therefore, it could serve as a new biomarker to 
detect PD102. Furthermore, we did not compare the values between brain 
regions because, as [448] concluded, the DNA methylation pattern correlates 
much more strongly within a brain region across individuals than within an 
individual across brain regions. Moreover, our methodological approach was 
not able to differentiate 5hmC from 5mC but, although 5hmC has its highest 
levels in the central nervous system and its amount increases with age, the 
impact of that fact on methylation percentages is expected to be almost 
imperceptible. 
Due to the characteristics of our study, i.e. low number of individuals 
analyzed, low levels of DNA methylation observed, small differences and high 
standard deviation values, as well as presence of relevant results not only in 
                                                          
102
 This was one of our objectives in this epigenetic study, so we decided to include in Annex 
VI the results we observed in our second trial in blood from 10 PD cases to, at least, have an 
idea of how they could have been. 
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substantia nigra, our results could be considered as trends that should be 
replicated in a larger study. In addition, those methylation levels need to be 
correlated with gene expression levels. 
 
Subsequently, for the differentially methylated CpG sites, we 
conducted an in silico prediction to determine if they were target sites for 
transcription factor binding and that, consequently, could alter the binding of 
transcription factors and thus, gene expression.  
In each case some candidates were proposed, but due to their 
expression pattern, that did not include SN in the brain (that was the case for 
WT1, ELK1, ETS1, GATA-1, HOXA5, SPIB, FEV and ICSBP), and/or their targets, 
that did not include our genes (as was the case for NRF-1103, AP-2-alpha104, 
FOXC1105, HIF1106, GATA-1107, SPIB108 and ICSBP109), finally only Sp1 could be 
considered as a possible candidate: it is ubiquitous and binds to GC-rich motifs 
                                                          
103
 NRF-1 is implicated in the control of nuclear genes required for respiration, heme 
biosynthesis and mitochondrial DNA transcription and replication. 
104
 AP-2-alpha is involved in a large spectrum of biological functions including proper eye, 
face, body wall, limb and neural tube development. Therefore, defects in this gene are a 
cause of branchiooculofacial syndrome. 
105
 FOXC1 is an important regulator of cell viability and resistance to oxidative stress in the 
eye. Therefore, mutations in this gene cause some glaucoma phenotypes. 
106
 HIF1 functions as a master regulator of cellular and systemic homeostatic response to 
hypoxia. 
107
 GATA-1 plays an important role in erythroid development by regulating the switch of fetal 
hemoglobin to adult hemoglobin. Mutations in this gene have been associated with X-linked 
dyserythropoietic anemia and thrombocytopenia. 
108
 SPIB promotes the development of plasmacytoid dendritic cells, also known as natural 
interferon-producing cells. 
109
 ICSBP regulates the expression of genes stimulated by type I IFNs, namely IFN-alpha and 
IFN-beta. IFN=interferon. 
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(for that reason it was obtained as candidate for all our genes). Moreover, it is 
involved in many cellular processes, including cell differentiation, cell growth, 
apoptosis, immune responses, response to DNA damage, and chromatin 
remodeling. It can be an activator or a repressor and its activity is highly 
regulated by post-translational modifications. Amongst others it interacts with 
HDAC1 and DNMT1.  
In vitro studies should be conducted to confirm that Sp1 binds to the 
predicted sites and that its binding is altered by changes in methylation levels. 
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1. We have confirmed that, at least in non-Basque population, 
mutations in GBA and the H1H1 genotype in MAPT are clear genetic 
susceptibility factors that increase the risk to develop PD. Their effect 
in Basques is less important, pointing out that there might be genetic 
differences between the two Spanish groups regarding to PD risk.  
APOE remains as a controversial risk factor. 
 
2. Despite the limitations of our study, derived from the characteristics 
of the individuals analyzed, we have observed some trends for 
variants do not previously related to PD, or at least, not clearly, with 
regard to their influence on PD risk and/or cognitive status during the 
malady. They are important features to consider in future studies. 
 
3. Based on our results, we have concluded that the members of the 
ARMCX gene family cannot be considered genetic susceptibility 
factors on Parkinson´s disease. Only the polymorphism rs2858162 
(ARMCX6) showed some tendency that should be more deeply 
analyzed. 
 
4. And finally, in our pilot epigenetic study, we have reported that there 
are differences in DNA methylation levels between cases and controls 
in some specific CpG dinucleotides located in the predicted 
promoters of genes responsible for familial forms of Parkinson´s 
disease, although not only in substantia nigra. In addition, these CpG 
are part of predicted binding sites of transcription factor Sp1 and, 
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consequently, depending on their methylation level, could alter its 
binding and thus, gene expression. 
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La enfermedad de Parkinson (PD) es progresiva y neurodegenerativa. Se 
caracteriza clínicamente por bradiquinesia, temblor en reposo, rigidez e 
inestabilidad postural y anatomopatológicamente por degeneración 
nigral y por la presencia de numerosos cuerpos de Lewy (LB) en las 
neuronas supervivientes. 
 
La degeneración nigral hace referencia a la muerte de neuronas en la 
substantia nigra, concretamente a las que contienen dopamina en la 
substantia nigra pars compacta (SNpc). La substantia nigra se encuentra 
en el mesencéfalo y forma, junto a otros cuatro núcleos (caudado, 
putamen, globo pálido y núcleo subtalámico), los ganglios basales. Ellos, 
con el córtex y el tálamo, forman un circuito que se encarga de controlar 
la ejecución de los movimientos voluntarios. Concretamente afectan al 
inicio y la planificación.  
La degeneración nigral podría, por tanto, explicar el enlentecimiento en 
la ejecución de movimientos, o bradiquinesia, característico de la 
enfermedad. Sin embargo, no explicaría el resto de síntomas.  
 
Además de los cuatro rasgos motores típicos, los enfermos de PD pueden 
sufrir otros síntomas motores. Asimismo es muy común que también se 
vean afectados por síntomas no motores. 
Dicho síntomas se dividen en alteraciones sensoriales, cognitivas, 
disfunciones autónomas y desórdenes del sueño, y podrían deberse a 
daños en otras regiones del cerebro, que también se ven afectadas como 
consecuencia del progreso de la enfermedad. 
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Se han postulado factores genéticos y/o ambientales como responsables 
de la enfermedad de Parkinson. Además, procesos tales como el estrés 
oxidativo, la agregación de proteínas, la disfunción mitocondrial o la 
inflamación, entre otros, se encuentran alterados en los enfermos, 
aunque falta aclarar si ello es causa o consecuencia de la enfermedad. 
El 90% de los casos corresponden a formas esporádicas o idiopáticas de 
PD, de causa desconocida, mientras que el 10% restante, las 
denominadas formas familiares o monogénicas110, son causados por 
mutaciones en alguno de los siguientes cinco genes: 
1. SNCA (PARK1, PARK4), 4q22.1. Este gen codifica para la proteína 
-sinucleína, Syn, que no tiene estructura en su forma nativa y 
de la cual se desconoce su función. Dicha proteína es uno de los 
componentes de los LB.  
Cambios en su secuencia, actualmente sólo hay tres mutaciones 
descritas (p.A30P, p.E46K, p.A53T), o en su cantidad, se han 
descrito enfermos con duplicaciones o triplicaciones de regiones 
que contienen el gen, originan PD con herencia autosómica 
dominante. 
Además, existen dos polimorfismos ampliamente estudiados 
como posibles factores de susceptibilidad: Rep1, del que se 
desconoce qué alelo podría estar implicado, y rs356219, cuyo 
alelo G es considerado de riesgo. 
 
2. PRKN (PARK2), 6q26. Mutaciones, deleciones, duplicaciones y 
otros cambios en la secuencia del gen conllevan la pérdida de 
función de la proteína. Dichas alteraciones, presentes en 
homocigosis o en heterocigosis combinada, se han descrito en 
                                                          
110
 Las formas familiares de la enfermedad se diferencian de las esporádicas en que su inicio 
suele ser más temprano. 
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enfermos de PD siguiendo una herencia autosómica recesiva. Sin 
embargo, también hay portadores heterocigotos que han 
desarrollado la enfermedad, lo que sigue siendo un controvertido 
aspecto de estudio a día de hoy, así como la poca o nula presencia 
de LB en el cerebro de los enfermos.  
La proteína parkina participa en el mecanismo de degradación de 
proteínas por el proteasoma. Concretamente es una enzima E3 
que marca con ubiquitina a la proteína que debe ser degradada 
(K-48 poliubiquitinación). Además, participa en otros procesos, 
mediante monoubiquitinación o K-63 poliubiquitinación, como la 
regulación de la endocitosis o la formación del agregosoma.  
 
3. PINK1 (PARK6), 1p36.12. Los portadores homocigotos o 
heterocigotos combinados de mutaciones en este gen se ven 
afectados por la enfermedad de Parkinson, pero también algunos 
heterocigotos la han desarrollado, lo cual contradice la herencia 
autosómica recesiva observada en las familias. PINK1 es una 
quinasa que, junto con parkina, uno de sus sustratos, se encarga 
de marcar aquellas mitocondrias dañadas para que sean 
eliminadas por mitofagia. Cuando alguno de los dos genes está 
mutado, este proceso se ve bloqueado. 
 
4. DJ-1 (PARK7), 1p36.23. Son raras las mutaciones en este gen. A 
pesar de ello, hay familias en las que se han heredado en 
homocigosis o en heterocigosis combinada de forma autosómica 
recesiva. DJ-1 forma homodímeros y participa en mecanismos de 
protección frente a estrés oxidativo, posiblemente junto a Nrf2 
y/o SOD1. Todo ello se pierde cuando está mutado. 
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5. LRRK2 (PARK8), 12q12. Este gen codifica para una proteína, 
denominada dardarina, con varios dominios funcionales: uno 
GTPasa (ROC), otro quinasa y cuatro de interacción con proteínas 
como son ARM, ANK, LRR y WD40. Se desconoce la función de 
dardarina, pero se sabe que la actividad GTPasa controla la 
actividad quinasa, de modo que es necesario que se una GTP en 
ROC para que la proteína pueda fosforilar sus sustratos. La 
actividad GTPasa es independiente de la actividad quinasa. Si 
forma o no dímeros, así como las propiedades que puedan tener, 
es debatido a día de hoy. 
Solo mutaciones puntuales, ni deleciones ni duplicaciones, se han 
descrito en este gen. Más de 40 hasta el momento, pero solo 6 se 
consideran patogénicas y causantes de formas autosómicas 
dominantes de PD: p.N1437H, p.R1441C, p.R1441G, p.Y1699C, 
p.G2019S, p.I2020T. Las más comunes, y descritas tanto en casos 
familiares como en esporádicos, son p.R1441C y p. R1441G, que se 
localizan en el dominio ROC y disminuyen la actividad GTPasa de 
la proteína, y p.G2019S, que se localiza en el dominio quinasa y 
aumenta dicha actividad, tiene penetrancia incompleta y 
dependiente de la edad y es la mutación causante de PD más 
común. 
Además, hay dos polimorfismos, p.G2385R y p.R1628P, que son 
factores de riesgo en población asiática. 
 
 
Existen otros loci que también se han relacionado con la enfermedad de 
Parkinson, pero hay resultados controvertidos sobre su influencia: 
 PARK3 (2p13) se identificó en familias con posible herencia 
autosómica dominante pero penetrancia incompleta y fenotipo 
amplio y no pudo ser replicado en estudios posteriores. 
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 PARK5 (UCHL1; 4p14) participa en el mecanismo de degradación 
de proteínas por el proteasoma como enzima desubiquitinante. La 
mutación p.I93M, que causa una ganancia de función en la 
proteína, probablemente patogénica aunque rara, y el 
polimorfismo p.S18Y, posible factor de riesgo, se han estudiado 
sin llegar a conclusiones concluyentes. 
 PARK9 (ATP13A2; 1p36) ocasiona el síndrome de Kufor-Rakeb, de 
herencia autosómica recesiva y fenotipo solapante con la PD. Por 
ello se ha estudiado la frecuencia de mutaciones en enfermos de 
Parkinson familiares y esporádicos, obteniendo mayoritariamente 
resultados que descartan la relación entre ATP13A2 y PD. 
 PARK10 (1p32) fue identificado en el estudio de familias 
islandesas con PD de inicio tardío, pero estudios posteriores no 
han logrado esclarecer qué gen sería el responsable, si lo hubiera. 
 PARK11 (GIGYF2; 2q36-37) y PARK12 (Xq21-25) fueron 
postulados tras un extenso estudio de ligamiento, pero, como en 
el caso anterior, poco más se ha avanzado en su identificación. En 
el caso de PARK11, al obtenerse el valor más alto de ligamiento en 
el gen GIGYF2, éste ha sido estudiado en individuos con formas 
familiares de PD de diversas poblaciones, pero las conclusiones 
son contrapuestas y, como mucho, podría hablarse de causa rara 
de PD. 
 PARK13 (HtrA2; 2p13.1) codifica para una serín proteasa 
mitocondrial. Una mutación en dicho gen origina  parkinsonismo y 
neurodegeneración en un modelo murino y, por ello, se consideró 
como candidato a explicar la enfermedad de Parkinson. Sin 
embargo, los estudios genéticos llevados a cabo no apuntan en 
dicha dirección. 
 PARK14 (PLA2G6; 22q13.1) está relacionado con fenotipos más 
complejos que incluyen parkinsonismo y otros síntomas como 
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distonía o demencia. Pero también hay descritos individuos 
portadores de mutaciones en dicho gen asintomáticos o con 
formas típicas de PD, lo que ha conllevado controversia sobre su 
implicación en PD. 
 PARK15 (FBXO7; 22q12.3) se ha encontrado mutado en personas 
que presentan parkinsonismo pero también signos piramidales. 
El estudio a gran escala del genoma mediante GWAs ha supuesto la 
descripción de nuevos PARK loci: PARK16 (1q32), PARK17 (4p16.3; 
aunque también se propone 16q11.2) y PARK18 (6p21.3; aunque 
también se propone 3q27.1). Sin embargo, la replicación de las regiones 
implicadas así como la identificación de los genes que en ellas se 
localizan causantes de la enfermedad es complicada. 
 
Además, hay tres factores de susceptibilidad descritos en la enfermedad 
de Parkinson: 
o MAPT (17q21.31), codifica para la proteína tau, una proteína de 
unión a microtúbulos, que promueve su formación, estabiliza su 
estructura y colabora en el transporte axonal a través de ellos. En 
las enfermedades clasificadas como taupatías, como la 
enfermedad de Alzheimer, forma depósitos en el cerebro 
denominados ovillos neurofibrilares. 
Múltiples y diversos estudios (analizando pacientes con 
diferentes edades de inicio, etnias, con formas familiares o con 
formas esporádicas) han observado que en los enfermos de 
Parkinson, el porcentaje de individuos portadores homocigotos 
del haplotipo H1 es mayor que en población sana. 
o GBA (1q22) codifica para la enzima glucocerebrosidasa. Las 
personas que presentan mutaciones en homocigosis o en 
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heterocigosis compuesta, desarrollan una enfermedad lisosomal 
denominada de Gaucher. Algunos de los enfermos además 
presentan parkinsonismo. Se ha observado que el porcentaje de 
enfermos de PD entre sus parientes, que suelen ser portadores 
heterocigotos de mutaciones en el gen, es más elevado que en la 
población general y que los enfermos de PD tienen, con mayor 
frecuencia, mutaciones en GBA. De entre las múltiples mutaciones 
descritas, las más comunes son p.N370S y p.L444P. Por ello, 
mutaciones en este gen se consideran un factor de riesgo de PD. 
o NR4A2 (2q24.1) es un factor de transcripción esencial para el 
desarrollo y la supervivencia de las neuronas dopaminérgicas. 
Dada la imposibilidad de replicar los estudios que inicialmente 
concluyeron que c.-291delT y c.-245T>G eran causantes de la 
enfermedad y que 7048G7049 (c.1361+16insG) era un factor de 
susceptibilidad, en la actualidad, se duda de su relación con PD. 
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Nuestro objetivo principal en este trabajo ha sido la identificación de 
factores genéticos de susceptibilidad para la enfermedad de Parkinson 
en población española. Además de ello, analizamos la posible relación de 
una familia de genes poco estudiada (ARMCX) con el riesgo de padecer la 
enfermedad así como la posible influencia genética en la aparición de 
demencia en los enfermos de PD. 
 
Cabe destacar que en todo el proceso experimental llevamos a cabo 
controles de calidad y comprobaciones para confirmar la validez de los 
resultados. 
 
Para llevar a cabo estos tres estudios genéticos, empleamos diferentes 
técnicas de genotipado basadas en la amplificación del DNA:  
1. para detectar inserciones o deleciones, tras dicha amplificación 
solo era necesario observar el tamaño de la región amplificada 
mediante electroforesis horizontal en gel de agarosa; 
2. PCRs específicas de alelo (AS-PCR), en las que para analizar un 
polimorfismo se llevaban a cabo dos amplificaciones paralelas 
pero con diferente combinación de primers: se empleaba un 
primer común en ambos casos pero, la pareja, en la cadena 
opuesta, era complementaria en 3´, según el caso, a una de las dos 
variantes posibles del polimorfismo a analizar. Ambos productos 
de PCR eran posteriormente analizados mediante electroforesis 
horizontal en gel de agarosa para determinar si uno o las dos 
amplificaciones había tenido éxito y, determinar, por tanto, el 
genotipo. 
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3. RFLPs, o polimorfismos de longitud de fragmento de restricción, 
es decir, polimorfismos que crean o destruyen sitios de 
reconocimiento de enzimas de restricción y, por tanto, cuando 
regiones de DNA que los contienen son amplificadas y digeridas 
con dichas enzimas de restricción, muestran un patrón de bandas 
determinado, en geles de agarosa sometidos a electroforesis 
horizontal, según la variante del polimorfismo presente. 
4. finalmente, empleamos la pirosecuenciación en algunos casos 
concretos, así como electroforesis capilar en polimorfismos de 
longitud, es decir, en aquellos basados en el diferente número de 
repeticiones de determinadas secuencias, como dinucleótidos, u 
homopolímeros. 
A pesar de las condiciones específicas en cada técnica de genotipado, el 
diseño de primers siguió unas normas generales para aumentar la 
eficiencia de la reacción de amplificación: la longitud de los primers se 
mantuvo entre 18 y 25 nucleótidos, se intentó que terminaran en 3´en C 
o en G, así como que no hubiera estructuras secundarias intra- e 
intermoleculares, que tuvieran una temperatura de fusión inferior a 65⁰C 
y una diferencia inferior a 2⁰C en la temperatura de fusión entre los dos 
miembros de la pareja. 
 
En nuestro primer estudio, llevamos a cabo un análisis en población 
española de factores genéticos de susceptibilidad ampliamente 
reconocidos, como son el haplotipo H1/H2 de MAPT y la presencia de 
mutaciones en GBA, así como de otros que, a día de hoy, y tras múltiples 
estudios con conclusiones contradictorias, están en entredicho, como 
son el  polimorfismo p.S18Y en PARK5 y los cambios intrónicos en NR4A2 
(nosotros decidimos analizar uno no analizado previamente en el intrón 
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3). Además, también se determinó la posible influencia de dos variantes 
en el gen TOR1A, causante de la forma mayoritaria de distonía primaria 
hereditaria (la distonía es uno de los síntomas motores secundarios 
presentes en PD),  así como el efecto del genotipo en APOE (el alelo 4 
es factor de riesgo totalmente reconocido en la enfermedad de 
Alzheimer) o de la longitud del homopolímero recientemente descrito 
en TOMM40, que se sospecha es el auténtico factor de riesgo para la 
enfermedad de Alzheimer, y no el alelo 4. 
Al incluir en el estudio individuos vascos y de otros puntos de España 
(Sevilla, Barcelona y Valencia), decidimos analizarlos por separado, ya 
que dado el aislamiento que ha mantenido la población vasca y su alta 
tasa de endogamia, los factores genéticos de susceptibilidad podían ser 
diferentes entre individuos vascos y no vascos.  
A pesar de que en ninguna de las dos poblaciones estudiadas se 
obtuvieron resultados estadísticamente significativos (y, por tanto, se 
descartaron como factores genéticos de susceptibilidad para la 
enfermedad de Parkinson), para el polimorfismo p.S18Y (PARK5), el 
cambio intrónico en NR4A2, la longitud del homopolímero en TOMM40 
ni la mutación p.delE302/303 (TOR1A) (la cual ni siquiera se encontró en 
los individuos), observamos que sí había diferencias en el estudio 
genético entre ambas poblaciones en cuatro casos, para los que los 
resultados sí tuvieron significatividad estadística, indicando que los 
factores genéticos de susceptibilidad a la enfermedad podrían ser 
diferentes entre vascos y no vascos: 
 Por lo que respecta al haplotipo H1/H2 (MAPT), mientras que en 
población no vasca, el riesgo de padecer PD de los individuos 
H1H1 era claramente superior, al de los no portadores, alrededor 
de dos veces mayor, confirmando la amplia mayoría de estudios 
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previos, en población vasca, no se obtuvo dicho resultado sino 
que únicamente se encontró una tendencia del haplotipo H1 (y 
del genotipo H1H1) a incrementar el riesgo, pero sin llegar a 
adquirir significatividad estadística. 
 También se observó que las mutaciones p.N370S y p.L444P (GBA) 
eran muy frecuentes en población no vasca, confirmando los 
estudios previos en los que se considera un claro factor de riesgo. 
De hecho, alcanzaron valores estadísticamente significativos. Sin 
embargo, en población vasca, únicamente un enfermo presentó la 
mutación p.N370S, por lo que en dicha población no parece existir 
una influencia tan clara de estas mutaciones en el desarrollo de la 
enfermedad (en estos individuos puede ser que haya otras en 
este gen, que no fueron analizadas, que sean factores de riesgo).   
 Únicamente en población no vasca, el polimorfismo p.D216H 
(TOR1A) mostró tendencia a aumentar el riesgo de padecer la 
enfermedad, concretamente los portadores del genotipo CC eran 
más frecuentes entre los casos (6 individuos) que entre los 
controles (ninguno). Dado que el genotipo CC es de muy baja 
frecuencia, consideramos que, como mucho, representaría un 
factor de riesgo raro y que probablemente no tenga mayor 
relevancia en la susceptibilidad a PD. 
 Además, mientras que en población vasca, los portadores de un 
alelo 4 en APOE mostraron tener más riesgo de padecer PD, en 
población no vasca fueron los portadores de un alelo 2. Dichos 
resultados contradictorios son habituales en los estudios que 
pretenden determinar la relación existente entre APOE y PD: 
tanto el alelo 4 como el 2 han sido considerados factores de 
riesgo, e, incluso, algunos estudios han considerado que ninguno 
está relacionado con la enfermedad de Parkinson. Además, 
observamos que los individuos no vascos portadores del 
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genotipo H1H1 (MAPT) y a la vez de un alelo 2 en APOE eran 
tres veces más susceptibles de padecer la enfermedad de 
Parkinson que aquellos que no portaban ninguno de los dos 
factores. Es decir, había un efecto combinado de ambos factores. 
 
En el segundo estudio abordamos la determinación de factores 
genéticos de riesgo para el desarrollo de deterioro cognitivo. 
Prácticamente desde su comienzo, los enfermos de PD presentan un 
ligero deterioro cognitivo, el cual, tras décadas de padecer la 
enfermedad mayoritariamente evoluciona a demencia. 
Para ello analizamos casos de PD de Navarra, los cuales fueron 
clasificados, tras los tests cognitivos llevados a cabo, en cognitivamente 
normales, con deterioro cognitivo leve o con demencia. Estos dos últimos 
incluían individuos afectados por procesos diferentes pero conectados 
de algún modo, como son la demencia y el deterioro cognitivo leve, por 
lo que, dado que presentaban características demográficas y genéticas 
similares, los agrupamos en un solo grupo denominado deterioro 
cognitivo. 
También se incluyeron en el estudio individuos sanos. Por ello, se decidió 
investigar también factores genéticos de susceptibilidad a PD: el 
haplotipo H1/H2 (MAPT), el genotipo de APOE, la longitud del 
homopolímero en TOMM40, la presencia de mutaciones en GBA 
(p.N370S y p.L444P) y los polimorfismos Rep1 y rs356219 (SNCA). 
Nuevamente, se obtuvo que la longitud de la poly-T de TOMM40 no 
podía considerarse relacionada con la enfermedad de Parkinson y que, 
por el contrario, los portadores del haplotipo H1 tenían un riesgo 
elevado de padecer la enfermedad. No se observó que ningún alelo de 
APOE estuviera diferentemente distribuido en casos y en controles (otra 
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vez los resultados para el genotipo de APOE fueron controvertidos), ni 
tampoco los alelos del microsatélite Rep1. Tampoco las mutaciones de 
GBA se encontraron en una frecuencia suficiente como para ser 
consideradas factores de riesgo, pero, por el contrario, sí se vio que el 
alelo G en rs356219 incrementaba el riesgo de padecer PD, como ya se 
había visto previamente en otros estudios.  
En algunos casos, como GBA, podemos pensar que los resultados 
pudieron verse influenciados por únicamente estudiar 2 de las alrededor 
de 300 mutaciones descritas en el gen, por las diferencias que existían 
entre los grupos de casos con PD y de controles sanos en cuanto a edad 
media y porcentaje de hombres y mujeres, así como por su tamaño, 
aunque ello no fue inconveniente para que dos factores de riesgo 
ampliamente reconocidos (haplotipo H1 en MAPT y alelo G en rs356219, 
SNCA) originaran resultados estadísticamente significativos. Podemos 
pensar que el resto de factores o no influyen en la enfermedad o lo 
hacen de un modo menor y que, por tanto, dichas limitaciones alteraron 
la capacidad de determinar su riesgo. 
Por lo que respecta a la influencia de dichas variantes en el proceso de 
deterioro cognitivo, aunque algunos grupos han observado que el 
haplotipo H1 y las mutaciones en GBA también son más frecuentes en los 
enfermos de PD que desarrollan demencia que en aquellos que no la 
padecen, no fue eso lo que observamos. A excepción del genotipo de 
APOE, el resto de polimorfismos y mutaciones no se encontraron 
distribuidos diferentemente entre los enfermos de PD cognitivamente 
normales y aquellos con deterioro cognitivo.  
Otros estudios han observado que el alelo 4 de APOE aumenta también 
el riesgo de padecer demencia durante PD; en nuestro caso, observamos 
que era el alelo 2 el que aumentaba el riesgo de padecer deterioro 
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cognitivo. Nuevamente, en APOE obtenemos resultados contradictorios. 
Podemos considerar que las diferencias observadas podrían tener 
relación con el hecho de que nosotros no analizamos solo demencia sino 
deterioro cognitivo en general, aunque, como hemos anotado 
anteriormente, los grupos demencia y deterioro cognitivo leve no 
presentaban diferencias genéticas en estos factores. 
Finalmente, analizamos mutaciones y polimorfismos en genes 
relacionados con otras enfermedades que cursan con demencia (PSEN1, 
PSEN2, APP y CALHM1 en la enfermedad de Alzheimer; HTT en la 
enfermedad de Huntington; PRNP en la enfermedad de Creutzfeldt-
Jakob; TARDBP y GRN en demencia frontotemporal, ATP13A2 en el 
síndrome de Kufor-Rakeb), en aquellos que codifican para factores 
neurotróficos (CDNF, MANF -y DOCK3-, BDNF), en genes implicados en 
procesos relacionados con la patología de PD como el estrés oxidativo 
(NFE2L2 y KEAP1), la autofagia mediada por chaperonas (HSPA8 y 
LAMP-2A), el metabolismo de homocisteína (MTHFR, MTR y CBS) y 
GSK3. 
Encontramos que en algunos de ellos había diferencias estadísticamente 
significativas o casi, en las distribuciones alélicas, genotípicas o 
haplotípicas tanto cuando se compararon pacientes con controles como 
cuando se comparaban los pacientes de PD entre sí en función de su 
estado cognitivo, es decir, cognitivamente normales y con deterioro 
cognitivo. Incluso se vio que polimorfismos en el mismo gen mostraban 
significatividad en distintas comparaciones. 
Pero no se obtuvo una tendencia clara en los resultados. Ello, junto con 
las limitaciones ya descritas en cuanto a las características de los grupos 
analizados hace que los resultados observados deban considerarse como 
tendencias que deberían ser replicadas en otras poblaciones. 
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El tercer estudio, pretendía, a pequeña escala, analizar si los genes de la 
familia ARMCX (1 a 6) podrían estar implicados en la enfermedad de 
Parkinson. Dichos genes se localizan en el cromosoma X, dentro de la 
zona delimitada como PARK12, lo cual podría conllevar un efecto del 
sexo en la PD. Los 6 genes de la familia están poco descritos, aunque se 
sabe que comparten ciertas características, como que son cortos, con 
toda la parte codificante en un intrón y que originan proteínas 
mitocondriales. Se analizaron 8 polimorfismos distribuidos a lo largo de 
la región que comprendía el cluster. 
 
Se empleó en este ensayo, una subpoblación no vasca, de la previamente 
analizada, por lo que al igual que para la población no vasca global, 
nuevamente se concluyó que ni p.S18Y (PARK5), ni p.del302/303 (TOR1A), 
ni la longitud de la poly-T en TOMM40  ni el cambio intrónico 
c.864+246C>T (NR4A2) podían considerarse factores genéticos de 
susceptibilidad a PD. Además, los portadores H1H1 (MAPT) mostraron 
tener un riesgo elevado de desarrollar la enfermedad, pero, sin embargo, 
la presencia de mutaciones en GBA no alcanzó significatividad 
estadística: seguramente ello fue debido al reducido tamaño de muestra 
ya que sí eran más frecuentes en los casos que en los controles y al 
hecho de analizar únicamente dos mutaciones. Hubo otras dos 
diferencias: no se determinó ninguna influencia del polimorfismo 
p.D216H (TOR1A) en el riesgo de padecer la enfermedad, aunque esto 
era de esperar ya que el resultado obtenido en población no vasca 
global ya fue considerado un posible artefacto matemático y se observó 
que los portadores del genotipo 34 (APOE) tenían menor riesgo de PD. 
Nuevamente, los resultados para el genotipo de APOE fueron 
controvertidos. 
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Por lo que respecta a los polimorfismos analizados en los seis miembros 
del cluster ARMCX, únicamente se obtuvieron resultados casi 
estadísticamente significativos (p≈0.070) para uno de ellos, rs2858162, 
ARMCX6, para el cual el alelo C así como los genotipos que lo contenían 
eran más frecuentes en pacientes que en controles. Tanto en hombres 
como en mujeres se observó esa tendencia, aunque no alcanzó 
significatividad estadística, probablemente por el reducido tamaño de 
los grupos. Además, se identificó un haplotipo protector (p=0.034)  
frente a la enfermedad, TACTAC, y otro casi de riesgo (p=0.077), 
TACCAC, que se diferenciaban justamente en la posición 
correspondiente a rs2858162, poniendo de manifiesto la importancia de 
dicho polimorfismo. Al igual que lo observado en los genotipos y alelos, 
en el haplotipo, la variante C era de riesgo, mientras que la T era 
protectora. 
A pesar de que la familia de genes ARMCX eran a priori unos buenos 
candidatos como factores genéticos de susceptibilidad en PD, por su 
localización celular, su estructura, su patrón de expresión así como su 
función predicha, no encontramos resultados que apoyaran su 
implicación en el desarrollo de la enfermedad, más allá de los 
observados en uno de los marcadores. Nuestros resultados deberían ser 
replicados para, de ese modo, determinar y confirmar, si procede, la 
relevancia del polimorfismo rs2858162 en el desarrollo de PD así como la 
ausencia de la misma por parte de los otros miembros del cluster. 
Asimismo, dicha réplica determinaría si, al igual que se ha observado en 
nuestros resultados, el sexo no influye en el papel de rs2858162 ni en el 
de ninguno de los otros ARMCX. 
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Finalmente, abordamos el objetivo principal desde una perspectiva 
epigenética y estudiamos si los niveles de metilación de determinados 
genes podrían verse alterados por la enfermedad y las posibles 
consecuencias que ello tendría. 
 
La epigenética es el estudio de los cambios heredados mitóticamente o 
meióticamente que no pueden ser explicados por cambios en la 
secuencia de DNA. Explica, por ejemplo, porqué, teniendo el mismo 
genoma, existen diferentes tipos celulares en un individuo. Cada 
individuo posee un genoma pero cientos o incluso miles de epigenomas 
que varían con el tiempo y los factores ambientales. 
La epigenética incluye las modificaciones de histonas, la metilación del 
DNA y procesos mediados por RNA. 
La metilación del DNA está generalmente asociada con un estado 
inactivo de la cromatina y, por tanto, con represión transcripcional. Ello 
podría explicarse bien porque hay proteínas que reconocen el DNA 
metilado y se unen a él, y, posteriormente, reclutan modificadores de la 
cromatina para establecer un entorno reprimido, o por la imposibilidad 
de los factores de transcripción de unirse al DNA metilado lo que 
conllevaría que la transcripción se inhibiera. 
En los mamíferos, la metilación sucede siempre sobre los dinucleótidos 
CpG. Dichos dinucleótidos, se acumulan en las islas CpG, las cuales se 
definen por tener una longitud mínima de 200 nucleótidos, un contenido 
en C+G igual o superior a 0.5 y una relación de dinucleótidos 
observada/esperada del 0.6 o mayor. Sin embargo, la mayoría de 
dinucleótidos en las islas no están metilados y sí lo están aquellos 
distribuidos por el resto del genoma. 
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Según la presencia o no de islas CpG, los genes se clasifican en 
 GC rich: todos los genes housekeeping así como la mitad de los 
genes específicos de tejido tienen una isla CpG en su promotor y 
bajos niveles de metilación. 
 GC poor: la otra mitad de los genes específicos de tejido no tienen 
isla CpG en el promotor pero los dinucleótidos presentes están 
muy metilados. 
 
Para el estudio epigenético, se llevó a cabo inicialmente un estudio in 
silico de la posición de las islas CpG en los 5 genes a analizar. Dichos 
genes son aquellos involucrados en las formas familiares de la 
enfermedad de Parkinson: DJ-1, LRRK2, PINK1, PRKN, SNCA. Como era de 
esperar, dada la expresión ubicua de los 5 y ser, por tanto, genes CG rich, 
únicamente tenían una isla cada uno y localizada en su promotor. 
Tras su identificación procedimos a diseñar cebadores que amplificaran 
dichas islas, teniendo en cuenta los cambios que existirían en la 
secuencia de DNA tras su tratamiento con bisulfito.  
El tratamiento con bisulfito es la técnica más empleada para el estudio 
de los niveles de metilación de DNA ya que modifica las citosinas no 
metiladas convirtiéndolas en uracilos, que son reemplazados por timinas, 
mientras que las citosinas metiladas no se ven modificadas. Dichos 
cambios en la secuencia pueden ser posteriormente detectados por 
diferentes métodos, en nuestro caso, tras la amplificación, por 
pirosecuenciación. 
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Cabe destacar que el diseño de los primers tuvo en cuenta tanto los 
requisitos necesarios para amplificar DNA tratado con bisulfito111 como 
las limitaciones de la técnica de pirosecuenciación112. Todo ello, junto con 
la gran longitud de las islas CpG predichas, determinó que optáramos por 
estudiar regiones de la isla en vez de toda entera. Dichas regiones se 
encontraban antes, en y tras el punto de inicio de transcripción de cada 
gen. 
 
Antes de comenzar con el estudio de diferentes tejidos cerebrales de 
personas sanas y enfermas de Parkinson, llevamos a cabo dos pruebas: 
1. En primer lugar analizamos los niveles de metilación de DNA en 
distintos tejidos procedentes de un mismo individuo para conocer 
aproximadamente el rango en el que se encontrarían nuestros 
valores así como para probar todo el diseño experimental. Como 
era de esperar, se observaron bajos niveles de metilación. 
2. Posteriormente analizamos sangre de 10 enfermos de PD y los 
valores estuvieron en el mismo rango.  
 
A continuación estudiamos, en 5 individuos sanos y en 5 pacientes de PD, 
los niveles de metilación de DNA en substantia nigra, córtex parietal y 
córtex occipital. Se analizó, en cada ensayo tanto los valores individuales 
                                                          
111
 Longitud de los primers entre 18 y 30 nucleótidos; ausencia de estructuras secundarias 
intra- e intermoleculares; diferencia inferior a 2⁰C en la temperatura de fusión entre los dos 
miembros de la pareja; fragmento amplificado de entre 100 y 500 nucleótidos; inclusión de 
un número limitado de dinucleótidos CG, no más de 2, localizados lo más lejos posible del 
extremo 3´en la secuencia del primer; e inclusión de Ts procedentes de la conversión de Cs no 
metiladas en, o lo más cerca posible, del extremo 3´del primer. 
112
 Las reacciones no pueden ser más largas de 50 nucleótidos y no deben incluir 
homopolímeros de longitud mayor a 4. 
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por posición como globales y se obtuvieron diferencias estadísticamente 
significativas entre ambos grupos tras el análisis con tests no 
paramétricos (test de Mann-Whitney). Aunque la mayoría de los 
resultados estadísticamente significativos o casi mostraban que los 
niveles de metilación en enfermos eran menores que en controles, no se 
observó una tendencia general en los resultados en cuanto a los niveles 
de metilación. 
El hecho de haber analizado tan pocos individuos así como los bajos 
niveles de metilación obtenidos y la elevada desviación estándar nos 
hacen considerar estas diferencias como posibles indicios que deberían 
ser replicados en poblaciones mayores. Además, se debería analizar la 
relación existente entre los niveles de metilación observados y los 
niveles de expresión génica. 
Además, no solo se encontraron diferencias en la substantia nigra, sino 
también en córtex parietal y córtex occipital, los cuales no se han 
descrito hasta la fecha como regiones afectadas en la enfermedad de 
Parkinson. Incluso, en algunos casos, el resultado era compartido entre 
varios tejidos.  
Esto también se ha observado en alguno de los pocos estudios llevados a 
cabo sobre metilación de DNA en enfermos de PD. 
Nuestro estudio se diferencia de los previos principalmente en las 
regiones analizadas así como en la metodología de cuantificación de la 
metilación (pirosecuenciación) y en la no observación de niveles de 
metilación inferiores generalizados en los pacientes respecto a los 
controles. 
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Como parte final de este estudio, decidimos hacer una predicción in silico 
para determinar si dichas posiciones (elegimos aquellas en las que se 
observaron diferencias significativas así como aquellas con valores de 
p<0.1 en substantia nigra) eran puntos de unión de factores de 
transcripción. Las alteraciones en los niveles de metilación podrían 
conllevar cambios en la unión de determinados factores de transcripción 
y, consecuentemente, se podrían producir cambios en la expresión de 
dichos genes, lo que supondría un nuevo mecanismo patogénico en los 
enfermos de PD. 
De entre los candidatos propuestos, únicamente Sp1 parece adecuado 
ya que los demás, o no se expresaban en cerebro o no incluían a los 
genes de estudio entre sus dianas. Este factor de transcripción es ubicuo 
y se une a regiones ricas en GC. Por lo tanto, es habitual en las islas CpG. 
Además, participa en numerosos procesos celulares como diferenciación 
celular, apoptosis o remodelación de la cromatina. Interacciona, entre 
otros, con HDAC1 y DNMT1.  
Se deberían llevar a cabo estudios in vitro para confirmar si, 
efectivamente, Sp1 se une en las secuencias predichas y cuál es la 
influencia de los niveles de metilación en dicha unión. 
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1. Hemos confirmado que, al menos en población no vasca, 
mutaciones en GBA y el genotipo H1H1 en MAPT son claros 
factores genéticos de susceptibilidad que aumentan el riesgo de 
desarrollar la enfermedad de Parkinson. Su efecto en vascos es 
menos importante, indicando que puede haber diferencias 
genéticas entre los dos grupos de población española en cuanto 
a su riesgo de padecer PD.  
APOE permanece como un factor de riesgo controvertido. 
 
2. A pesar de las limitaciones de nuestro studio, derivadas de las 
características de los individuos analizados, hemos observado 
algunos indicios para variantes previamente no relacionadas 
con PD, o, al menos, no claramente, en relación con su 
influencia en el riesgo de padecer PD y/o el estado cognitivo 
durante la enfermedad. Representan importantes aspectos a 
considerar en futuros estudios. 
 
3. Basándonos en nuestros resultados, hemos concluido que los 
miembros de la familia génica ARMCX no pueden ser 
considerados factores genéticos de susceptibilidad para la 
enfermedad de Parkinson. Únicamente el polimorfismo 
rs2858162 (ARMCX6) mostró alguna tendencia que debería ser 
analizada con mayor profundidad. 
 
4. Y finalmente, en nuestro estudio piloto epigenético, hemos 
encontrado diferencias entre casos y controles en los niveles de 
metilación de DNA en algunos dinucleótidos CpG concretos 
localizados en los promotores (predichos in silico) de genes 
responsables de formas familiares de la enfermedad de 
Parkinson, aunque no solo en substantia nigra. Además, dichos 
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CpG forman parte de sitios de unión (también predichos in 
silico) del factor de transcripción Sp1 y, consecuentemente, 
dependiendo de su nivel de metilación, podrían alterar su unión 
y la expresión génica. 
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1 -0.5⁰C/cycle. i.e. TD60-50. The purpose of touchdown PCR is to improve the amplification efficiency in the first few cycles at a relatively high temperature without 
decreasing the yield of PCR amplification as the annealing temperature drops later. 
Gene Mutation or 
polymorphism  
Genic location 
(reference 
sequence) 
Primer sequences (5´→ 3´) Size of 
fragment (bp) 
Genotyping 
method 
% 
agarose 
Restriction 
enzyme 
APOE* 
(1) 
alleles 2, 3 
and 4 are 
determined by 
rs429358 and 
rs7412  
(in both cases 
C>T) 
Exon 4 
(NM_000041) 
F: GGCACGGCTGTCCAAGGA 
R: CGGGCCCCGGCCTGGTACAC 
231 RFLP 2 AflIII and 
HaeII  
PCR conditions: 95⁰C 5´; 5 cycles (95⁰C 30”, 60⁰C 30”, 72⁰C 45”); 20 cycles (95⁰C 30”, 60⁰C→50⁰C
1
 30”, 72⁰C 45”); 10 cycles (95⁰C 30”, 50⁰C 30”, 72⁰C 
45”); 72⁰C 5´; 4⁰C ∞ 
APP  
(2) 
rs463946  
(C>G) 
≈3000pb 
upstream 
from the 5´ 
(NM_000484) 
F: TACAACAGCATCCCCATCC 
R: GCAGAGTAGTGGGCAACATC 
433 
 
RFLP  
 
C: 250+180 
G:433 
1.5 XbaI 
PCR conditions: 95⁰C 10´; 40 cycles (95⁰C 30”, 62⁰C 1´, 72⁰C 45”); 72⁰C 10´; 4⁰C ∞ 
ARMCX1 
(4) 
rs6616255 
(A>G) 
Exon 4 
5´UTR 
(NM_016608) 
F: GTGGCAGGGAACTTTAACG 
R: GCTCCTTTCACAGTCTCAACC 
545 
 
RFLP  
 
A:545 
G:180+365 
1.5 PvuII 
PCR conditions: 95⁰C 10´; 38 cycles (95⁰C 30”, 52⁰C 30”, 72⁰C 1´); 72⁰C 10´; 4⁰C ∞ 
Table A. Description of the parameters used for the genetic analysis of mutations/polymorphisms. 
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Gene Mutation or 
polymorphism  
Genic location 
(reference 
sequence) 
Primer sequences (5´→ 3´) Size of 
fragment (bp) 
Genotyping 
method 
% 
agarose 
Restriction 
enzyme 
ARMCX1 
(4) 
rs1044275  
(C>T) 
p.G103G 
Exon 4 
(NM_016608) 
 
F: TCGGGTTAAGAGATTTGTCC 
R: ATCATTTGTTCGCTCCAGG 
687 
 
RFLP  
 
C:687 
T:340+350 
1.2 XbaI 
PCR conditions: 95⁰C 10´; 38 cycles (95⁰C 30”, 52⁰C 30”, 72⁰C 1´); 72⁰C 10´; 4⁰C ∞ 
ARMCX2 
(3) 
rs5951282  
(C>T) 
Intron 5 
(NM_177949) 
F: CCATGTCTGTACTGCCTCTCG 
R: GCCCCAACTACTGATTCGG 
776 
 
RFLP  
 
C:776 
T:175+600 
1.5 Tsp590I 
PCR conditions: 95⁰C 10´; 38 cycles (95⁰C 30”, 52⁰C 30”, 72⁰C 1´); 72⁰C 10´; 4⁰C ∞ 
ARMCX3 
(3) 
rs6995  
(A>G) 
Exon 5 
3´UTR 
(NM_177948) 
F: AATGAATATCACTACTTGTTCTG 
R: TTAACATACAATTTTATTGTTGA 
A mismatch (T instead of A) was 
introduced to create the recognition site. 
178 
 
RFLP  
 
A:178 
G:160+20 
2.5 HincII 
PCR conditions: 95⁰C 10´; 42 cycles (95⁰C 30”, 50⁰C 30”, 72⁰C 1´); 72⁰C 10´; 4⁰C ∞ 
ARMCX4
** 
(3) 
rs2179670  
(T>C) 
Intergenic 
region 
F: GGAGTGAAGGAGTTGGGTGTC 
R: ATCAGTGAATTAGGAAACACGGT 
A mismatch (G instead of T) was 
introduced to create the recognition site. 
219 
 
RFLP  
 
T:219 
C:35+185 
2.5 HphI 
PCR conditions: 95⁰C 10´; 42 cycles (95⁰C 30”, 50⁰C 30”, 72⁰C 1´); 72⁰C 10´; 4⁰C ∞ 
Table A. Description of the parameters used for the genetic analysis of mutations/polymorphisms. (Continued) 
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Gene Mutation or 
polymorphism  
Genic location 
(reference 
sequence) 
Primer sequences (5´→ 3´) Size of 
fragment (bp) 
Genotyping 
method 
% 
agarose 
Restriction 
enzyme 
ARMCX4
** 
(3) 
rs6523506  
(T>G) 
Intergenic 
region 
F: GGTTGGCATACTGGTAAGA 
R: CAGCTTTTTGTTATTCTTTTC 
A mismatch (G instead of A) was 
introduced to create the recognition site. 
150 
 
RFLP  
 
T:150 
G:140+10 
2.5 MnlI 
PCR conditions: 95⁰C 10´; 35 cycles (95⁰C 30”, 52⁰C 30”, 72⁰C 1´); 72⁰C 10´; 4⁰C ∞ 
ARMCX5 
(4) 
rs2235827  
(C>T) 
Intron 1 
(NM_022838) 
F: TTGTCTAGGCATTTCGTCCC 
R: CGTGAGAGCAGGACAAGCAG 
582 
 
RFLP 
 C:210+390 
T:582 
1.2 StyI 
(Eco130I) 
PCR conditions: 95⁰C 10´; 38 cycles (95⁰C 30”, 54⁰C 30”, 72⁰C 1´); 72⁰C 10´; 4⁰C ∞ 
ARMCX6 
(4) 
rs2858162  
(C>T) 
Promoter 
(NM_019007) 
F: TGAATGAAAGGCAGGCTAATC 
R: TTCTCCTGGCTGAACTCATAAT 
A mismatch (A instead of G) was 
introduced to create the recognition site. 
185 
 
RFLP  
 
C:185 
T:160+25 
2.5 SspI 
PCR conditions: 95⁰C 10´; 38 cycles (95⁰C 30”, 52⁰C 30”, 72⁰C 1´); 72⁰C 10´; 4⁰C ∞ 
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Gene Mutation or 
polymorphism  
Genic location 
(reference 
sequence) 
Primer sequences (5´→ 3´) Size of 
fragment (bp) 
Genotyping 
method 
% 
agarose 
Restriction 
enzyme 
ATP13A2 
(3) 
rs2871776  
(A>G) 
Intron 8 
(NM_022089) 
F: CTCCTCCTTCTGATGGCTTG 
R_T: TCTTTGCCTCCAATCCCTAT 
R_C: TCTTTGCCTCCAATCCCTAC 
A mismatch (T instead of G) was created 
to disrupt secondary structures. 
R:  GGACTGTTGGGAGCATGAAA 
356 
 
F+R for 
sequencing: 
457 
AS-PCR - - 
AS-PCR conditions: 95⁰C 10´; 40 cycles (95⁰C 30”, 63⁰C 30”, 72⁰C 45”); 72⁰C 10´; 4⁰C ∞ 
sequencing conditions:  95⁰C 10´; 35 cycles (95⁰C 30”, 63⁰C 30”, 72⁰C 45”); 72⁰C 10´; 4⁰C ∞ 
ATP13A2 
(3) 
rs6684770  
(C>T) 
Intron 11 
(NM_022089) 
F:   AGTTTCACTATGTTGCCCAGG  
R:   ATTTATGCTGCACCTCTCGC 
A mismatch (G instead of A) was 
introduced to create the recognition site. 
289 
 
RFLP  
 
C: 
100+170+20 
T: 100+190 
2.5 HhaI 
PCR conditions: 95⁰C 10´; 35 cycles (95⁰C 30”, 57⁰C 30”, 72⁰C 30”); 72⁰C 10´; 4⁰C ∞ 
ATP13A2 
(3) 
rs4920608  
(G>A) 
Intron 16 
(NM_022089) 
F: GGTGGTGCATGCCTGTAGTC  
R: AGGGAAGTTTGGTGTCTGGG  
768 
 
RFLP 
 
G: 30+130+ 
160+240+ 200 
A: 30+130+ 
160+440 
1.5 BbvCI 
PCR conditions: 95⁰C 10´; 40X (95⁰C 30”, 64⁰C 30”, 72⁰C 1´); 72⁰C 10´; 4⁰C ∞ 
Table A. Description of the parameters used for the genetic analysis of mutations/polymorphisms. (Continued) 
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2
 Despite that the insertion is located in an exon, it has no effect on protein sequence. 
Gene Mutation or 
polymorphism  
Genic location 
(reference 
sequence) 
Primer sequences (5´→ 3´) Size of 
fragment (bp) 
Genotyping 
method 
% 
agarose 
Restriction 
enzyme 
BDNF 
(1) 
rs6265  
(G>A) 
p.V66M 
Exon 2 
(NM_170731) 
F: AAAGAAGCAAACATCCGAGGACAAG 
R: ATTCCTCCAGCAGAAAGAGAAGAGG 
[1] 
274 
 
RFLP 
 
G:217+57 
A:140+77+57 
1.5 NlaIII 
PCR conditions: 94⁰C 2´; 35 cycles (94⁰C 1´, 55⁰C 2´, 72⁰C 2´); 72⁰C 4´; 4⁰C ∞ [1] 
CALHM1 
(2) 
rs2986017  
(C>T) 
p.P86L  
Exon 1 
(NM_0010014
12) 
F: GAAGAGTGGAAGCGGCCAC 
R:GACGGCCACCCAGACGACA 
A mismatch (A instead of G) was 
introduced to create the recognition site. 
114 RFLP  
 
C:114 
T:94+20 
2.5 BsrI 
PCR conditions: 95⁰C 10´; 40 cycles (95⁰C 30”, 65⁰C 1´, 72⁰C 45”); 72⁰C 10´; 4⁰C ∞ 
CBS
2
 
(1) 
c.844ins68 
68bp insertion 
Exon 10 
(NM_000071) 
F:ATAGAATATCGAGGCATGTCCAGGCG 
R:TGGGGCCCAGGGTCAGCCAGGCTCC 
282  
(350 with the 
insertion) 
PCR - - 
PCR conditions: 95⁰C 10´; 35 cycles (95⁰C 45”, 60⁰C 30”, 72⁰C 1´); 72⁰C 10´; 4⁰C ∞ 
CDNF 
(3) 
rs7094179  
(G>T) 
Intron 1 
(NM_0010299
54) 
F: GAAGAAGGGCACATAACTGA 
R: CTACTTTGCTCAGTGTCAAGG 
A mismatch (C instead of G) was 
introduced to create the recognition site. 
196 
 
RFLP  
 
G:166+20+10 
T:186+10 
2.5 DdeI 
(HpyF3I) 
PCR conditions: 95⁰C 10´; 38 cycles (95⁰C 30”, 51⁰C 30”, 72⁰C 30”); 72⁰C 10´; 4⁰C ∞ 
Table A. Description of the parameters used for the genetic analysis of mutations/polymorphisms. (Continued) 
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3
 Although their correct description is p.N409S and p.L483P, for tradition, they remain named as p.N370S and p.L444P. 
4
 -0.5⁰C/cycle. i.e. TD57-52. 
Gene Mutation or 
polymorphism  
Genic location 
(reference 
sequence) 
Primer sequences (5´→ 3´) Size of 
fragment (bp) 
Genotyping 
method 
% 
agarose 
Restriction 
enzyme 
CDNF 
(3) 
rs7099185  
(T>C) 
Intron 3 
(NM_0010299
54) 
F_T: CAGTGTATAGCTGACCCTCT 
F_C: AGTGTATAGCTGACCCTCC 
R: TAATCCCAGCATCTCAGG 
 
F: CCTTCAGCCTCTTATCTTG 
413 
 
F+R for 
sequencing: 
731 
AS-PCR - - 
AS-PCR conditions: 95⁰C 10´; 38 cycles (95⁰C 30”, 60⁰C 30”, 72⁰C 1´); 72⁰C 10´; 4⁰C ∞ 
sequencing conditions: 95⁰C 10´; 35 cycles (95⁰C 30”, 54⁰C 30”, 72⁰C 1´); 72⁰C 10´; 4⁰C ∞ 
DOCK3 
*** 
(3) 
rs4441646  
(A>C) 
Exon 53 
3´UTR region 
(NM_004947) 
F: ATGTGGTCAGGTTCAGCAGG 
R: ATCCTCAGCAGCCTTCCG 
730 RFLP  
A:387+343 
C:730 
1.2 TaqI 
PCR conditions: 95⁰C 10´; 40 cycles (95⁰C 30”, 66⁰C 30”, 72⁰C 1´); 72⁰C 10´; 4⁰C ∞ 
GBA
3
 
(1) 
p.N370S  
(A>G) 
Exon 9 
(NM_000157) 
F: GCCTTTGTCCTTACCCTCG 
R:GACAAAGTTACGCACCCAA 
[2]  
A mismatch (C instead of A) was 
introduced to create the recognition site. 
105 
 
RFLP  
 
A:105 
G:89+16 
2.5 XhoI 
PCR conditions: 94⁰C 10´; 5 cycles (94⁰C 30”, 57⁰C 30”, 72⁰C 1´); 11 cycles (94⁰C 30”, 57⁰C→52⁰C
4
 30”, 72⁰C 1´); 22 cycles (94⁰C 30”, 52⁰C 30”, 72⁰C 
1´); 72⁰C 10´; 4⁰C ∞ [2] 
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5
 -0.5⁰C/cycle. i.e. TD57-52. 
Gene Mutation or 
polymorphism  
Genic location 
(reference 
sequence) 
Primer sequences (5´→ 3´) Size of 
fragment (bp) 
Genotyping 
method 
% 
agarose 
Restriction 
enzyme 
GBA 
(1) 
p.L444P  
(T>C) 
Exon 10 
(NM_000157) 
F:CGTAACTTTGTCGACAGTCC 
R:TCCCAGACCTCACCATTG 
[2] 
600 
 
RFLP  
 
T:600 
C:518+82 
1.5 NciI 
PCR conditions: TD57-52: 94⁰C 10´; 5 cycles (94⁰C 30”, 57⁰C 30”, 72⁰C 1´); 11 cycles (94⁰C 30”, 57⁰C→52⁰C
5
 30”, 72⁰C 1´); 22 cycles (94⁰C 30”, 52⁰C 
30”, 72⁰C 1´); 72⁰C 10´; 4⁰C ∞  [2] 
GRN 
(5) 
rs11547442 
(T>C)  
p.L46P 
Exon 2 
(NM_002087) 
R:GCACCCTCCTATCCCCAG 
F: CTTGGTACTTTGCAGGCAGA 
 
788 
 
RFLP  
 
T:788 
C:630+160 
1.5 BsaWI 
PCR conditions: 95⁰C 10´; 40 cycles (95⁰C 30”, 62⁰C 30”, 72⁰C 1´); 72⁰C 10´; 4⁰C ∞ 
GRN 
(5) 
rs34975779 
(G>-) 
p.V452V 
but the frameshift 
originates a 
premature STOP 
codon 
downstream 
Exon 11 
(NM_002087) 
F: CCTTATCCCACCCCAGAG 
R: TTATGTTCCTGTCCCCTCAC 
174 
 
RFLP  
 
G:170 
-:150+20 
2.5 BglI 
PCR conditions: 95⁰C 10´; 40 cycles (95⁰C 30”, 59⁰C 1´, 72⁰C 45”); 72⁰C 10´; 4⁰C ∞ 
Table A. Description of the parameters used for the genetic analysis of mutations/polymorphisms. (Continued) 
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Gene Mutation or 
polymorphism  
Genic location 
(reference 
sequence) 
Primer sequences (5´→ 3´) Size of 
fragment (bp) 
Genotyping 
method 
% 
agarose 
Restriction 
enzyme 
GRN 
(5) 
rs1141754 
(C>A)  
p.Q479K 
Exon 12 
(NM_002087) 
F: GCTAAGCCCAGTGAGGGGAC 
R: CAGCCGGGCAGCAGTACT 
A mismatch (A instead of G) was 
introduced to create the recognition site. 
98 
 
RFLP  
 
C: 80+18 
A:98 
2.5 BsrI 
PCR conditions: 95⁰C 10´; 40 cycles (95⁰C 30”, 62⁰C 1´, 72⁰C 45”); 72⁰C 10´; 4⁰C ∞ 
GSK3
(2) 
rs334558  
(T>C) 
Promoter 
(NM_002093) 
F: TTTATAGACGCCCTCCCTTCGCTT 
R: TCCTTCCTTCCTTTGTCACTTGGC 
[3] 
721 
 
RFLP  
 
T:642+79 
C:721 
1.2 AluI 
PCR conditions: 95⁰C 10´; 40 cycles (95⁰C 30”, 63⁰C 30”, 72⁰C 1´); 72⁰C 10´; 4⁰C ∞ 
GSK3
(2) 
rs6438552  
(T>C) 
Intron 5 
(NM_002093) 
F: GCTTTTGGTGCCTTCTTAGGTGAC 
R: CGAAACATTGGGTTCTCCTCG 
[3] 
287 
 
RFLP  
 
T:267+20 
C:173+94+20 
1.5 Hpy188I 
PCR conditions: 95⁰C 10´; 40 cycles (95⁰C 30”, 50⁰C 30”, 72⁰C 30”); 72⁰C 10´; 4⁰C ∞ 
HSPA8 
(3) 
rs1461496  
(T>C) 
Intron 6 
(NM_006597) 
F: ATTGAAACTGCTGGTGGAG 
R: GACAGTGCCTCCTTACCC 
560 
 
RFLP  
 
T: 100+460 
C: 
100+200+260 
1.5 BspCNI 
PCR conditions: 95⁰C 10´; 40 cycles (95⁰C 30”, 58⁰C 30”, 72⁰C 1´); 72⁰C 10´; 4⁰C ∞ 
Table A. Description of the parameters used for the genetic analysis of mutations/polymorphisms. (Continued) 
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Gene Mutation or 
polymorphism  
Genic location 
(reference 
sequence) 
Primer sequences (5´→ 3´) Size of 
fragment (bp) 
Genotyping 
method 
% 
agarose 
Restriction 
enzyme 
HSPA8 
(3) 
rs4936770  
(G>A) 
Intron 8 
(NM_006597) 
F: AATTCACTTGAGTCCTATGCC 
R: TCTCCCTGACGCAATCTG 
414 
 
RFLP  
 
G:200+220 
A:414 
1.5 TspRI 
PCR conditions: 95⁰C 10´; 40 cycles (95⁰C 30”, 56⁰C 30”, 72⁰C 30”); 72⁰C 10´; 4⁰C ∞ 
HTT 
(3) 
rs10015979 
(A>G) 
Intron 6 
(NM_002111) 
F: TGCTGTGAGTGAGTCTGTG 
R: ATCTGATTCCACTCTACCC 
559 
 
RFLP  
 
A:260+300 
G:559 
1.2 MseI 
(Tru1I) 
PCR conditions: 95⁰C 10´; 40 cycles (95⁰C 30”, 56⁰C 30”, 72⁰C 1´); 72⁰C 10´; 4⁰C ∞ 
HTT 
(3) 
rs363066  
(T>G) 
Intron 18 
(NM_002111) 
F: TCCAGGTTTTCAGTCAGTTG 
R: CATCTACCTAAACCACTCGG 
848 
 
RFLP  
 
T:848 
G:400+430 
1.2 BsaXI 
PCR conditions: 95⁰C 10´; 40 cycles (95⁰C 30”, 56⁰C 30”, 72⁰C 1´); 72⁰C 10´; 4⁰C ∞ 
HTT 
(3) 
rs363096  
(T>C) 
Intron 34 
(NM_002111) 
F: CCTGTTAGCTTGATGTGTGC 
R: ATGATTGCCTCTGATTCACT 
A mismatch (A instead of C) was 
introduced to disrupt secondary 
structures. 
136 
 
RFLP  
 
T:136 
C:115+20 
2.5 BfaI 
PCR conditions: 95⁰C 10´; 40 cycles (95⁰C 30”, 54⁰C 30”, 72⁰C 30”); 72⁰C 10´; 4⁰C ∞ 
Table A. Description of the parameters used for the genetic analysis of mutations/polymorphisms. (Continued) 
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Gene Mutation or 
polymorphism  
Genic location 
(reference 
sequence) 
Primer sequences (5´→ 3´) Size of 
fragment (bp) 
Genotyping 
method 
% 
agarose 
Restriction 
enzyme 
HTT 
(3) 
rs2298969  
(A>G) 
Intron 37 
(NM_002111) 
F: GGGGAGGGAAGGGAGTGAG 
R: CATGCTGCCAAGGGGTGC 
A mismatch (G instead of A) was 
introduced to create the recognition site. 
211 
 
RFLP  
 
A:45+165 
G:45+145+20 
2 NlaIV 
PCR conditions: 95⁰C 10´; 40 cycles (95⁰C 30”, 56⁰C 30”, 72⁰C 1´); 72⁰C 10´; 4⁰C ∞ 
HTT 
(3) 
rs110501  
(T>C) 
Intron 55 
(NM_002111) 
F: AGAGGTGGTTGTGGGTGTC 
R: GTATTTAGCACCACAGCCTC 
912 
 
RFLP  
 
T:400+500 
C:912 
1.2 Tsp45I 
(NmuCI) 
PCR conditions: 95⁰C 10´; 40 cycles (95⁰C 30”, 57⁰C 30”, 72⁰C 1´); 72⁰C 10´; 4⁰C ∞ 
KEAP1 
(4) 
rs8113472  
(G>T) 
Intron 2 
(NM_203500) 
F: AGCACCATACCAACACCAG 
R: GGCACTCGTCTATGTAATCAG 
471 
 
RFLP  
 
G:230+240 
T:471 
1.5 KpnI 
PCR conditions: 95⁰C 10´; 40 cycles (95⁰C 30”, 57⁰C 30”, 72⁰C 1´); 72⁰C 10´; 4⁰C ∞ 
LAMP-
2A 
(3) 
rs7057652 
(G>T) 
Intron 1 
(NM_002294) 
F: TTCTTCTGTGGTTATTGATTC 
R: GGCTCACTGCAACTTCCAC 
564 
 
RFLP  
 
G: 564 
T: 460+100 
1.5 MlyI (SchI) 
PCR conditions: 95⁰C 10´; 40 cycles (95⁰C 30”, 58⁰C 30”, 72⁰C 30”); 72⁰C 10´; 4⁰C ∞ 
Table A. Description of the parameters used for the genetic analysis of mutations/polymorphisms. (Continued) 
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Gene Mutation or 
polymorphism  
Genic location 
(reference 
sequence) 
Primer sequences (5´→ 3´) Size of 
fragment (bp) 
Genotyping 
method 
% 
agarose 
Restriction 
enzyme 
LAMP-
2A 
(3) 
rs42897  
(A>G) 
Intron 1 
(NM_002294) 
F: GAGTAAAAGTGGTCCCTGTG 
R: ATATCTGAGCAATCCACTGTC 
802 
 
RFLP  
 
A:802 
G:430+370 
1.2 BseRI 
PCR conditions: 95⁰C 10´; 40 cycles (95⁰C 30”, 54⁰C 30”, 72⁰C 1´); 72⁰C 10´; 4⁰C ∞ 
LAMP-
2A 
(3) 
rs42895  
(C>A) 
Intron 3 
(NM_002294) 
F: TTGATGAATGAGAAAATGC 
R: ATCCCTTTGTCCAGTATATC 
494 
 
RFLP  
 
C:494 
A:350+150 
1.5 BsrI 
PCR conditions: 95⁰C 10´; 40 cycles (95⁰C 30”, 50⁰C 30”, 72⁰C 30”); 72⁰C 10´; 4⁰C ∞ 
LAMP-
2A 
(3) 
rs42890  
(T>G) 
Intron 6 
(NM_002294) 
F: TGGGTTATGGAGAAGAAAG 
R: TATACACCTTCCACAGTCCT 
A mismatch (C instead of A) was 
introduced to create the recognition site. 
160 
 
RFLP  
 
T:160 
G:140+20 
2.5 MnlI 
PCR conditions: 95⁰C 10´; 40 cycles (95⁰C 30”, 54⁰C 30”, 72⁰C 30”); 72⁰C 10´; 4⁰C ∞ 
LRRK2 
(1) 
rs33939927  
(C>G) 
p.R1441G 
 
 
Exon 31 
(NM_198578) 
F_C: GTGTCTTTCCCTCCAGGCTC 
F_G: GTGTCTTTCCCTCCAGGCTG 
R: CCCTTGTGATTGAATCACCAC 
569 AS-PCR - - 
Table A. Description of the parameters used for the genetic analysis of mutations/polymorphisms. (Continued) 
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6
 -0.5⁰C/cycle. i.e. TD60-50. 
7
 -0.5⁰C/cycle. i.e. TD60-50. 
8
 -0.5⁰C/cycle. i.e. TD60-50. 
AS-PCR conditions: 95⁰C 10´; 35 cycles (95⁰C 30”, 62⁰C 30”, 72⁰C 45”); 72⁰C 10´; 4⁰C ∞ 
Sequencing: F:TCAACAGGAATGTGAGCAGG and R:CCCACAATTTTAAGTGAGTTGC; fragment length: 386bp 
  PCR conditions: 95⁰C 5´; 5 cycles (95⁰C 30”, 60⁰C 30”, 72⁰C 45”); 20 cycles (95⁰C 30”, 60⁰C→50⁰C
6
 30”, 72⁰C 45”); 10 cycles (95⁰C 30”, 50⁰C 30”, 72⁰C 
45”); 72⁰C 5´; 4⁰C ∞ 
LRRK2 
(1) 
rs33939927  
(C>T) 
p.R1441C 
 
Exon 31 
(NM_198578) 
F_C: GTCTTTCCCTCCAGGCTC 
F_T: GTCTTTCCCTCCAGGCTT 
R: TGACATTTCTAGGCAGTTGAG 
291 AS-PCR - - 
AS-PCR conditions: 95⁰C 10´; 35 cycles (95⁰C 30”, 62⁰C 30”, 72⁰C 45”); 72⁰C 10´; 4⁰C ∞ 
Sequencing: F:TCAACAGGAATGTGAGCAGG and R:CCCACAATTTTAAGTGAGTTGC; fragment length: 386bp 
  PCR conditions: 95⁰C 5´; 5 cycles (95⁰C 30”, 60⁰C 30”, 72⁰C 45”); 20 cycles (95⁰C 30”, 60⁰C→50⁰C
7
 30”, 72⁰C 45”); 10 cycles (95⁰C 30”, 50⁰C 30”, 72⁰C 
45”); 72⁰C 5´; 4⁰C ∞ 
LRRK2 
(1) 
rs34637584 
(G>A)  
p.G2019S 
 
Exon 41 
(NM_198578) 
F_G: GCAAAGATTGCTGACTACG 
F_A: TGCAAAGATTGCTGACTACA 
R: ACAAGTGCCAACAATACCTAG 
420 AS-PCR - - 
AS-PCR conditions: 95⁰C 10´; 35 cycles (95⁰C 30”, 62⁰C 30”, 72⁰C 45”); 72⁰C 10´; 4⁰C ∞ 
Sequencing: F: TTTTGATGCTTGACATAGTGGAC and R: CACATCTGAGGTCAGTGGTTATC; fragment length: 329bp 
  PCR conditions: 95⁰C 5´; 5 cycles (95⁰C 30”, 60⁰C 30”, 72⁰C 45”); 20 cycles (95⁰C 30”, 60⁰C→50⁰C
8
 30”, 72⁰C 45”); 10 cycles (95⁰C 30”, 50⁰C 30”, 72⁰C 
45”); 72⁰C 5´; 4⁰C ∞ 
Table A. Description of the parameters used for the genetic analysis of mutations/polymorphisms. (Continued) 
Annex I. Primers genetics. 
13 
 
Gene Mutation or 
polymorphism  
Genic location 
(reference 
sequence) 
Primer sequences (5´→ 3´) Size of 
fragment (bp) 
Genotyping 
method 
% 
agarose 
Restriction 
enzyme 
MANF 
(5) 
rs11538558  
(A>G) 
 The STOP codon 
changes to W and 
thus a larger 
protein (90aa 
more) is 
synthesized 
Exon 4 
(NM_006010) 
F: TGCCTGTAAATGTGTCTGG 
R: CAGCATCATCAGGAAAGC 
472 
 
RFLP  
 
A:310+162 
G:310+150+12 
2.5 BslI 
PCR conditions: 95⁰C 10´; 40 cycles (95⁰C 30”, 54⁰C 30”, 72⁰C 1´); 72⁰C 10´; 4⁰C ∞ 
MAPT 
(1) 
H1/H2 
haplotype 
(238bp 
deletion) 
Intron  10 
(NM_016835) 
F: GGAAGACGTTCTCACTGATCTG 
R: AGGAGTCTGGCTTCAGTCTCTC 
[4] 
H1: 484 
H2: 246 
PCR - - 
PCR conditions: 95⁰C 10´; 35 cycles (95⁰C 30”, 66⁰C 30”, 72⁰C 1´); 72⁰C 10´; 4⁰C ∞ 
MTHFR 
(1) 
rs1801133 
(c.C677T) 
p.A222V 
Exon 5 
(NM_005957) 
F: TGAAGGAGAAGGTGTCTGCGGGA 
R:AGGACGGTGCGGTGAGAGTG 
[5] 
198 
 
RFLP  
C:198 
T:174+24 
2.5 HinfI 
PCR conditions: 95⁰C 10´; 35 cycles (95⁰C 45”, 60⁰C 30”, 72⁰C 1´); 72⁰C 10´; 4⁰C ∞ 
MTHFR 
(1) 
rs1801131 
(c.A1298C) 
p.E429A 
Exon 8 
(NM_005957) 
F: GTCTCCCAACTTACCCTTCTCCC 
R:ATGTGGGGGGAGGAGCTGAC 
241 
 
RFLP 
A:210+30 
C:241 
2.5 MboII 
PCR conditions: 95⁰C 10´; 35 cycles (95⁰C 45”, 60⁰C 30”, 72⁰C 1´); 72⁰C 10´; 4⁰C ∞ 
Table A. Description of the parameters used for the genetic analysis of mutations/polymorphisms. (Continued) 
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Gene Mutation or 
polymorphism  
Genic location 
(reference 
sequence) 
Primer sequences (5´→ 3´) Size of 
fragment (bp) 
Genotyping 
method 
% 
agarose 
Restriction 
enzyme 
MTR 
(1) 
rs1805087 
(c.A2756G) 
p.D519G 
Exon 26 
(NM_000254) 
F: TGTTCCCAGCTGTTAGATGAAAATC 
R: GATCCAAAGCCTTTTACACTCCTC 
211 
 
RFLP  
 
A:211 
G:131+80 
1.5 BsuRI 
PCR conditions: 95⁰C 10´; 35 cycles (95⁰C 45”, 60⁰C 30”, 72⁰C 1´); 72⁰C 10´; 4⁰C ∞ 
NFE2L2 
(3) 
rs1806649 
(G>A) 
Intron 1 
(NM_006164) 
F: GTATTGTTTATTTGAAGGGG 
R: AGTCACATTTTCTCATCTGC 
602 
 
RFLP  
G:400+200 
A: 602 
1.5 Bpu10I 
PCR conditions: 95⁰C 10´; 40 cycles (95⁰C 30”, 53⁰C 30”, 72⁰C 1´); 72⁰C 10´; 4⁰C ∞ 
NFE2L2 
(3) 
rs10183914  
(G>A) 
Intron 3 
(NM_006164) 
F: AATAGAAAAACTCCATCATAAC 
R: CCGAAGAAACCTAAAATTG 
653 
 
RFLP  
 
G: 300+353 
A: 653 
1.2 HphI 
PCR conditions: 95⁰C 10´; 40 cycles (95⁰C 30”, 52⁰C 30”, 72⁰C 1´); 72⁰C 10´; 4⁰C ∞ 
NR4A2 
**** 
(C>T) Intron 3 
(NM_006186) 
F: GCTGTGTGTGGGGACAACG 
R:AGTGGAACGTGATGCTGGAG 
1073 
 
RFLP  
C: 
120+290+300
+400 
T:120+290+30
0+360+30 
1.5 MvaI 
PCR conditions: 95⁰C 10´; 35 cycles (95⁰C 30”, 60⁰C 30”, 72⁰C 1´30”); 72⁰C 10´; 4⁰C ∞ 
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Gene Mutation or 
polymorphism  
Genic location 
(reference 
sequence) 
Primer sequences (5´→ 3´) Size of 
fragment (bp) 
Genotyping 
method 
% 
agarose 
Restriction 
enzyme 
PRNP 
(3) 
rs4815729  
(G>A) 
Intron 1 
(NM_000311) 
F: CTAAGTGAATAGTGTGTGCAGC 
R: CTTTTCACTGAAGGATTACGTC 
A mismatch (G instead of C) was 
introduced to create the recognition site. 
150 RFLP  
 
G: 150 
A: 130+20 
2.5 BsmAI 
(Alw26I) 
PCR conditions: 95⁰C 10´; 40 cycles (95⁰C 30”, 54⁰C 30”, 72⁰C 30”); 72⁰C 10´; 4⁰C ∞ 
PRNP 
(3) 
rs1799990  
(A>G) 
p.M129V 
Exon 2 
(NM_000311) 
F: CAGCTGATACCATTGCTATGC 
R: AGGGTATTGATTAGCCTATCCG 
1006 
 
RFLP  
 
A: 
70+440+490 
G: 440+560 
1.5 NspI (XceI) 
PCR conditions: 95⁰C 10´; 42 cycles (95⁰C 30”, 58⁰C 30”, 72⁰C 1´); 72⁰C 10´; 4⁰C ∞ 
PSEN1 
(3) 
rs165932  
(G>T) 
Intron 8 
(NM_000021) 
F: ATTTAGTGGCTGTTTTGTG 
R: CACTGATTACTAATTCAAGATC  
A mismatch (G instead of T) was 
introduced to create the recognition site. 
140 
 
RFLP  
 
G:115+25 
T:140 
2.5 BstYI 
PCR conditions: 95⁰C 10´; 40 cycles (95⁰C 30”, 56⁰C 1´, 72⁰C 45”); 72⁰C 10´; 4⁰C ∞ 
PSEN2 
(3) 
rs6426554  
(A>G) 
Intron 12 
(NM_000447) 
F: TCCTGCCGTGACTTCATCTC 
R: GGATGGTAAGATGCCCTCAG 
452 
 
RFLP  
A: 452 
G: 70+380 
1.5 BsaHI 
PCR conditions: 95⁰C 10´; 40 cycles (95⁰C 30”, 65⁰C 1´, 72⁰C 45”); 72⁰C 10´; 4⁰C ∞ 
Table A. Description of the parameters used for the genetic analysis of mutations/polymorphisms. (Continued) 
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9
 This primer was modified in 5´ with 6FAM. 
10
 This primer was modified in 5´ with 6FAM. 
Gene Mutation or 
polymorphism  
Genic location 
(reference 
sequence) 
Primer sequences (5´→ 3´) Size of 
fragment (bp) 
Genotyping 
method 
% 
agarose 
Restriction 
enzyme 
SNCA 
(1) 
Rep1 
microsatellite 
10kb 
upstream 
(NM_000345) 
F: 
9
CCTGGCATATTTGATTGCAA 
R: GACTGGCCCAAGATTAACCA 
[6] 
267/269/271 
are the most 
frequent 
Fragment 
analysis 
- - 
PCR conditions: 95⁰C 10´; 10 cycles (94⁰C 15”, 55⁰C 15”, 72⁰C 30”); 30 cycles (89⁰C 15”, 55⁰C 15”, 72⁰C 30”); 72⁰C 10´; 4⁰C ∞ 
SNCA 
(1) 
rs356219 
(A>G) 
9kb downstream 
(NM_000345) 
F: AATGTGAGGGCTCAAAAAC 
R: AAAACAAACACAAAATTCGA 
A mismatch (G instead of C) was 
introduced to create the recognition site. 
140  
 
RFLP  
 
A: 140. 
G: 120 + 20. 
2.5 BsaHI 
PCR conditions: 95⁰C 10´; 40 cycles (95⁰C 30”, 50⁰C 1´, 72⁰C 45”); 72⁰C 10´; 4⁰C ∞ 
TARDBP 
or TDP-
43 
(5) 
rs11547736  
(C>A) 
p.S92X 
Exon 3 
(NM_007375) 
F: GGATGAGACAGATGCTTGAT 
R: ACCTGCACCATAAGAACTTC 
A mismatch (G instead of C) was 
introduced to create the recognition site. 
150 
 
RFLP  
 
C:130+20 
A:150 
2.5 MboI 
PCR conditions: 95⁰C 10´; 40 cycles (95⁰C 30”, 61⁰C 1´, 72⁰C 45”); 72⁰C 10´; 4⁰C ∞ 
TOMM40 
***** 
(2) 
rs10524523 
Poly-T 
Intron 6 
(NM_006114) 
F: CTCCAACTGCTGACCTCAAG 
R: 
10
GCTGAGAAGGGAGGATTGC 
 
from 165 
(12T) to 188 
(35T) 
Fragment 
analysis 
- - 
PCR conditions: 95⁰C 10´; 40 cycles (95⁰C 30”, 65⁰C 30”, 72⁰C 30”); 72⁰C 10´; 4⁰C ∞ 
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11 This primer was biotinylated in 5´. 
12 This primer was biotinylated in 5´. 
13  -0.2⁰C/cycle. i.e. TD55-50. 
Gene Mutation or 
polymorphism  
Genic location 
(reference 
sequence) 
Primer sequences (5´→ 3´) Size of 
fragment (bp) 
Genotyping 
method 
% 
agarose 
Restriction 
enzyme 
TOR1A 
(1) 
rs1801968  
(G>C) 
p.D216H 
Exon 4 
(NM_000113) 
 
F:
11
AACCCTGTCCTTACCCACTG 
R: TCTGCTTTCCACTCCTCCAG 
Pyroseq (R): GAAATCCAAAGCCACA 
[7]  
97 Pyrosequencing - - 
PCR conditions: 95⁰C 10´; 40 cycles (95⁰C 30”, 57⁰C 30”, 72⁰C 30”); 72⁰C 10´; 4⁰C ∞ 
TOR1A 
(1) 
p.delE302/303  
(GAG/-) 
 
Exon 5 
(NM_000113) 
F: CCTGGAATACAAACACCTA 
R: 
12
GGCTGCCAATCATGACTGTC 
[8] 
Pyroseq (F): ATTGTAAGCAGAGTGGC 
225 Pyrosequencing - - 
PCR conditions: 94⁰C 2´; 40 cycles (94⁰C 1´, 55⁰C 1´, 72⁰C 1´30”); 72⁰C 10´; 4⁰C ∞ [8] 
UCHL1 
(1) 
rs5030732  
(C>A) 
p.S18Y 
Exon 3 
(NM_004181) 
F_A: CTCTCCGCAGGTGCTGTA 
F_C: CTCTCCGCAGGTGCTGTC 
R: AGCCCAGGGAGTAGGTACC  
 
F: CTTTGTGCTGTGTCATTGC 
303 
 
F+R for 
sequencing: 
465 
AS-PCR - - 
AS-PCR conditions: 95⁰C 10´; 40 cycles (95⁰C 30”, 60⁰C 30”, 72⁰C 45”); 72⁰C 10´; 4⁰C ∞ 
sequencing conditions: 95⁰C 10´; 5 cycles (95⁰C 30”, 55⁰C 30”, 72⁰C 45”); 25 cycles (95⁰C 30”, 55⁰C→50⁰C
13
 30”, 72⁰C 45”); 5 cycles (95⁰C 30”, 50⁰C 
30”, 72⁰C 45”); 72⁰C 10´; 4⁰C ∞ 
Table A. Description of the parameters used for the genetic analysis of mutations/polymorphisms. (Continued) 
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For each gene, we decided to study (1) mutations or polymorphisms that were relevant and had been extensively 
analyzed in genetics of Parkinson´s disease. However, in some cases, that was not possible and we focused on (2) 
variants reported in some article about genetics in PD or AD. When even that was not possible, we considered that, in 
order of priority, (3) tag SNPs, (4) common polymorphisms or even (5) mutations, could be part of our study. 
 
Tag SNPs were selected by using the data released by the HapMap (Haplotype Map) project14 which was launched in 
2002 to describe the common patterns of genetic variation in humans. By the global analysis of SNPs15 and of patterns 
of linkage disequilibrium16 in worldwide population, this study highlighted haplotypes17 and, therefore, the possibility to 
select tSNPs18, thus reducing the need for genotyping, with little loss of information, in association studies [9]. With this 
information it was possible to analyze larger genomic regions with the minimum number of SNPs (Figure I) [10]19.  
                                                          
14
 The information is freely available in http://hapmap.ncbi.nlm.nih.gov/. 
15
 SNP or single nucleotide polymorphism is a site in the genome where individuals differ by a single base. 
16
 Linkage disequilibrium (LD) refers to the phenomenon that alleles that are close together in the genome tend to be inherited together. 
17
 Haplotype is a combination of alleles at multiple linked sites on a single chromosome, all of which are transmitted together. 
18
 tSNP or tag SNP is a representative SNP in a region of the genome with high LD to other variants. 
19
 It is noteworthy that there is no clinical information about any of the individuals that enrolled in the HapMap project. The only available data 
about people are their sex and their origin. 
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HapMap project has developed during the time we 
have been conducting our study and thus new 
data have been released. For this reason, 
nowadays, some of our selected tag SNPs20 could 
have lost their category and just be SNPs. If any of 
the tSNPs gives significant results, we will take this 
fact into account in order to give the appropriate 
interpretation to results. 
 
Common polymorphisms and mutations were 
chosen among those described by the HapMap 
project or the Single Nucleotide Polymorphism 
database, dbSNP 
(http://www.ncbi.nlm.nih.gov/projects/SNP/). 
 
Taken from [10] 
                                                          
20
 Cut off values defined for tSNP selection: r
2
≥ 0.8; MAF≥ 0.05. 
Fig. I. SNPs, haplotypes and tag SNPs.  
Most of the DNA sequence is identical but there are bases that differ. Here, 
there are three SNPs in the four chromosomes. These and other SNPs define 
haplotypes: combinations of alleles. However, due to the strong association 
among the SNPs in most chromosomal regions, only a few carefully chosen 
SNPs (known as tag SNPs) need to be typed to predict the likely variants at the 
rest of the SNPs in each region. In this example, the four haplotypes can be 
differentiated just by genotyping the three marked tSNPs. 
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APOE*: two restrictions (one with AflIII and other with HaeII) were conducted and the genotype was determined by the 
combined restriction fragments pattern obtained visualized in an electrophoresis (Table B). 
 
ARMCX4**: when we started our genetic analysis, ARMCX4 had been 
considered a big pseudogene (≈115 kb) by in silico predictions and comparison 
with murine genome, so we decided to analyze the three tag SNPSs that 
covered the region. However, it has been recently described and considered a 
functional gene that only covers ≈8kb. Under these new circumstances, tag 
SNP rs5951332 should have been analyzed instead of our tag SNPSs which are 
located far from the gene: rs2179670 is ≈60kb upstream, whereas rs6523506 
is ≈10kb downstream.  
 
DOCK3***: this gene is upstream MANF and has a tag SNP (rs4441646) in 
high linkage disequilibrium with it. Moreover, DOCK3 presents some 
promising features: it is expressed in brain and in vitro experiments have 
concluded that it binds PSEN1 [11], it decreases the activity of GSK3 on tau 
 AflIII HaeII 
Genotype 171 231 205 231 
2/2 + - - + 
2/3 + - + + 
2/4 + + + + 
3/3 + - + - 
3/4 + + + - 
4/4 - + + - 
Table B. APOE restriction fragments 
pattern. 
The assay with AflIII determined the 
nucleotide sequence in rs429358 (T>C) and 
thus the codon 112: CGC (R)→TGC (C) [C: 
231; T: 171+62].  
Whereas, the assay with HaeII determined 
the nucleotide sequence in rs7412 (C>T) and 
thus the codon 158: CGC (R)→TGC (C) [C: 
205+26; T: 231] 
                  +: presence; -: absence. 
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but increases its phosphorylation by other kinases [12] and, moreover, DOCK3 modulates the neurite growth due to its 
important role downstream of BDNF signaling (it works as a guanine nucleotide exchange factor -GEF- in the 
cytoskeleton network) by stimulating dual pathways: actin polymerization and microtubule assembly  [13, 14]. 
 
NR4A2****: its intron 3 is highly conserved in mammals (data obtained from the UCSC genome browser) and, for that 
reason we thought it could be interesting to analyze it rather than to focus on previously described and studied variants. 
Initially, we sequenced few healthy controls without finding any change. Nevertheless, when we analyzed 48 randomly 
chosen PD patients (16 from Donosti,  16 from Barcelona and 16 from Sevilla) one of them presented a new mutation 
that we decided to study in more detail. Its correct description is c.864+246C>T (or IVS3+246C>T). 
 
TOMM40*****: we classified the homopolymers in three groups as [15] did, i.e. short (s; T≤19), long (l; 20≤T≤29) and 
very long (vl; T≥30) alleles. Mostly of 4 carriers (APOE) presented long alleles, whereas 3 (and 2) carriers presented 
short and very long alleles. 
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Gene Assay Primers sequence (5´→ 3´) Amplicon 
(bp) 
CpGs 
analyzed 
Number of 
PCR cycles 
(X) 
Annealing 
temperature 
(Y; ⁰C) 
Target 
DJ-1 1 F: GGGAGGTTTGGATTAGAGTTT 
R: *ACCCCCCACCAATAACACAATCC 
Pyroseq (F): 
GGTTTGGATTAGAGTTTTAATAG 
229 6 38 61 “Promoter” 
DJ-1 2 F: GGTGGAGGTAGAGATTGTTAAGTTT 
R: *CACCCCACACCAAACTAA 
Pyroseq (F): TGTGGGGTTGAGGGA 
273 8 45 60 Exon 1 • 
DJ-1 3; 3.1 F: GTGTGGGGTGAGTGGTAT 
R: *ATCAACCCAACTACATCTATCTCT 
Pyroseq (F; 3): GGTGTTTAGTTGGTTTAG 
Pyroseq (F; 3.1): 
TTGGAGTTGGATTTGATTGA 
465 5; 4 45 65 Intron 1  
(• only for 3, 
not for 3.1)  
LRRK2 1 F: GGGGTTTAGGGTTTGTGGAT 
R: *TCCCTCTCCCAAACCCTCCTAC 
Pyroseq (F): AGTTAGGTTAGGTTTTAGTAGT 
307 9 45 65 “Promoter” 
LRRK2 2 F: TTTGAGTGGGGGAGGAGGAA 
R: *ACCACTAACCATAATAACACCTACTTC 
Pyroseq (F): 
AGTTGTTTTTTTTTTTATAAATAGG 
254 9 45 63 Exon 1 
PINK1 1 F: GTGTAAAGGGAAAGTTATTGTTAGAG 
R: *ATCCTACCACCCAACCTAAAC 
Pyroseq (F): GGGTAGAGGTTTGTAGTTGG 
358 7 45 61 Exon 1 
Table C. Description of the parameters used for the epigenetic analysis of DNA methylation levels by pyrosequencing. 
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Gene Assay Primers sequence (5´→ 3´) Amplicon 
(bp) 
CpGs 
analyzed 
Number of 
PCR cycles 
(X) 
Annealing 
temperature 
(Y; ⁰C) 
Target 
PINK1 2 F: TGGTGAGGGTTTGGGGTTG 
R: *ACCCCCCTCACCTAAATCTCCTAAC 
Pyroseq (F): 
TTGGGTTTTATAGAGGAAAAATAG 
142 5 38 61 Exon 1 • 
PRKN 1 F: AGAGTTGTAATAAGTTTTTAAAGGTAAGT 
R: *CTCCCACCAACCACTCTCCTAAATTA 
Pyroseq (F): GGGGGGTTGGGGGTA 
284 4 45 60 “Promoter” 
PRKN 2 F: 
GATAGGTAAGTGGGTATTTGTTAGGTATAG 
R: 
*ACTTTAACCCCCTCATTAACAATTAACACC 
Pyroseq (F): ATTTGTTAGGTATAGTTTTTTTG 
124 9 38 58 Intron 1  
(• partially 
overlaps) 
SNCA 1 F: GGGGAAAGAGGAAGAGGT 
R: *CCCTCTCTTAAACCCCTTCTA 
Pyroseq (F): 
GGAGTAAGTTGTAGGGAAAGTA 
340 6 45 63 “Promoter” 
SNCA 2 F: AGGTAGGAGGTTGGAGTTGAT 
R: *TAACCACTCCCAATTCTCC 
Pyroseq (F): GGGTTTAAGAGAGGGGG 
380 8 38 61 Exon 1
1   
(• partially 
overlaps) 
        
                                                          
1
 In isoform NM_000345. 
Table C. Description of the parameters used for the epigenetic analysis of DNA methylation levels by pyrosequencing. (Continued) 
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Gene Assay Primers sequence (5´→ 3´) Amplicon 
(bp) 
CpGs 
analyzed 
Number of 
PCR cycles 
(X) 
Annealing 
temperature 
(Y; ⁰C) 
Target 
SNCA 3 F: GGAGAATTGGGAGTGGTTAT 
R: *CACAAATACTTACCTAAATCCCTCTAC 
Pyroseq (F): GGGTTTGTTTTTTATTTTTTTAG 
262 5 45 60 Exon 1
2
  
SNCA 4 F: GAGAAGTAGAGGGATTTAGGTAAGTAT 
R: *ACCTAACCCAACCAATCCTCATAACA 
Pyroseq (F): 
GGGAGTTTTTGGAAATTTTGGAG 
139 5 38 58 Intron 1 
*All the reverse primers were biotinylated in 5´. 
T (in forward primers) and A (in reverse primers) denote the converted unmethylated cytosines whereas A (in forward 
primers) and C (in reverse primers) correspond to cytosines in CpG dinucleotides and are thus introduced as mismatches 
to overpass those variable positions. 
PCR conditions: 95⁰C 15´; X cycles (94⁰C 30”, Y⁰C 30”, 72⁰C 30”); 72⁰C 10´; 4⁰C ∞ 
PCR mix3 per one reaction (1X) for a final volume of 25µL: 17.25µL Milli-Q water + 2.5µL 10X buffer + 1µL dNTPs 5mM 
each + 2.5µL MgCl2 25mM + 0.5µL primerF 10 µM + 0.5µL primerR 10 µM + 0.25µL Maxima Hot Start Taq DNA 
polymerase (Thermo Scientific) 5U/µL + 0.5µL bisulfite treated DNA 50ng/µL. 
                                                          
2
 In isoforms NM_007308 and NM_001146054. 
Table C. Description of the parameters used for the epigenetic analysis of DNA methylation levels by pyrosequencing. (Continued) 
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“Promoter” indicates that our trial predictions located it in this area. However, in some assays, the predicted promoter 
overlapped with exons or introns (marked with a  •).  
Assays DJ-1 3, DJ-1 3.1, PINK1 1 and SNCA 4 were finally discarded because it was not possible to obtain methylation 
values that passed the quality controls established by the program. PCR amplifications were successful but the 
pyrosequencing reactions did not work. We do not know the reason because their features were similar to the other 
assays. 
                                                                                                                                                                                                                       
3
 When trying to amplify bisulfite treated DNA it is essential to use Hot Start polymerase and MgCl2. In addition, because biotinylated template 
strands as well as unincorporated biotinylated primers will be captured on streptavidin-coated beads, only a small amount of primer is used in the 
PCR amplification and a large number of amplification cycles is performed to exhaust the primers. These amplification conditions are necessary; 
otherwise, the unincorporated biotinylated primer will compite with the amplicons for the streptavidin sites, reducing the amount of template 
bound to the beads and, therefore, the number of molecules being sequenced, lessening the strength of the results. 
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Basque population: 
 
 
 
 
 
 
 
 
 
With regard to the mutation c.864+246C>T in NR4A2, any of the 
individuals, neither cases nor controls, carried it. 
 
 
 
 
 
Gene and polymorphism Genotypes 
MAPT, H1/H2 haplotype H1H1 H1H2 H2H2 
Controls 36 41 9 
PD cases 81 58 11 
 X2 = 3.315; 2df; p=0.191 
Gene and polymorphism Genotypes Alleles 
UCHL1, rs5030732 (p.S18Y) SS SY YY S Y 
Controls 61 21 4 143 29 
PD cases 103 43 4 249 51 
 X2 = 1.039; 2df; p=0.595 X2 = 0.002; 1df; p=0.969 
TOR1A, rs1801968 (p.D216H) GG GC CC G C 
Controls 74 12 0 160 12 
PD cases 129 21 0 279 21 
 X2 = 0; 1df; p=0.992 X2 = 0; 1df; p=0.992 
Table D. Genotypic frequency of H1/H2 haplotype (MAPT). 
Table E. Genotypic and allelic frequency of p.S18Y (UCHL1) and p.D216H (TOR1A). 
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Gene and 
polymorphism 
Genotypes Alleles 
APOE, 
genotype 
22 23 33 34 44 24 2 3 4 
Controls 3 17 54 8 0 4 27 133 12 
PD cases 5 24 83 24 0 14 48 214 38 
 X2 = 4.354; 4df; p=0.360 X2 = 3.881; 2df; p=0.144 
APOE, 
genotype 
2 +/+ 2 +/- 2 -/- 2 + 2 - 
Controls 3 21 62 24 62 
PD cases 5 38 107 43 107 
 X2 = 0.027; 2df; p=0.987 X2 = 0.016; 1df; p=0.901 
Gene and 
polymorphism 
Genotypes Alleles 
TOMM40, 
rs10524523 
ss sl ll vll vlvl svl s l vl 
Controls 19 3 5 2 17 40 81 15 76 
PD cases 45 14 3 3 22 63 167 23 110 
 X2 = 7.341; 5df; p=0.196 X2 = 3.249; 2df; p=0.197 
Table F. Genotypic and allelic frequency of APOE genotype. 
Table G. Frequency of APOE genotype when considering the number of 2 alleles. 
Table H. Genotypic and allelic frequency of poly-T homopolymer (TOMM40). 
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Non-Basque population:  
 
With regard to the mutation c.864+246C>T in NR4A2, there were 3 
heterozygous controls and 2 heterozygous cases (Fisher´s exact test, p=0.673). 
Therefore, there was no statistical significance. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene and polymorphism Genotypes Alleles 
UCHL1, rs5030732 (p.S18Y) SS SY YY S Y 
Controls 201 86 14 488 114 
PD cases 234 86 12 554 110 
 X2 = 1.142; 2df; p=0.565 X2 = 1.218; 1df; p=0.270 
Gene and polymorphism Alleles 
TOR1A, rs1801968 (p.D216H) G C 
Controls 550 52 
PD cases 595 69 
 X2 = 1.123; 1df; p=0.289 
Table I. Genotypic and allelic frequency of p.S18Y (UCHL1). 
Table J. Allelic frequency of p.D216H (TOR1A). 
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APOE, 
genotype 
 +/+ 4 +/-  -/- 4 +  - 
Controls 2 73 226 75 226 
PD cases 4 79 249 83 249 
 X2 = 0.500; 2df; p=0.779 X2 = 0.001; 1df; p=0.981 
Gene and 
polymorphism 
Genotypes Alleles 
TOMM40, 
rs10524523 
ss sl ll vll vlvl svl s l vl 
Controls 64 25 11 25 59 117 270 72 260 
PD cases 61 30 15 19 73 134 286 79 299 
 X2 = 3.086; 5df; p=0.687 X2 = 0.471; 2df; p=0.790 
Table L. Genotypic and allelic frequency of poly-T homopolymer (TOMM40). 
Table K. Frequency of APOE genotype when considering the number of 4 alleles. 
Annex IVa. Analysis of genetic determinants in cognitive status in Parkinson´s 
disease. PD risk. 
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Navarrese healthy controls and PD patients. 
 
i. Possible genetic susceptibility factors 
a. in PD: 
 
 
 
b. in AD: 
 
 
Gene and 
polymorphism 
Genotypes Alleles 
SNCA, Rep1 
microsatellite 
267-
267 
267-
269 
269-
269 
269-
271 
271-
271 
267-
271 
267 269 271 
Controls 5 26 25 2 0 0 36 78 2 
PD cases 13 42 49 5 0 2 70 145 7 
 X2 = 1.961; 4df; p=0.743 X2 = 0.633; 2df; p=0.729 
Gene and 
polymorphism 
Genotypes Alleles 
APOE, 
genotype 
22 23 33 34 44 24 2 3 4 
Controls 0 6 43 8 0 1 7 100 9 
PD cases 1 14 75 19 1 1 17 183 22 
 X2 = 1.928; 5df; p=0.859 X2 = 0.797; 2df;  p=0.671 
Table N. Genotypic and allelic frequency of APOE genotype. 
Table M. Genotypic and allelic frequency of Rep1 microsatellite (SNCA). 
Annex IVa. Analysis of genetic determinants in cognitive status in Parkinson´s 
disease. PD risk. 
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 2 +/+ 2 +/- 2 -/- 2 + 2 - 
Controls 0 7 51 7 51 
PD cases 1 15 95 16 95 
 X2 = 0.608; 2df;  p=0.738 X2 = 0.178; 1df;  p=0.673 
  +/+ 4 +/-  -/- 4 +  - 
Controls 0 9 49 9 49 
PD cases 1 20 90 21 90 
 X2 = 0.715; 2df; p=0.699 X2 = 0.302; 1df; p=0.583 
Gene and 
polymorphism 
Genotypes Alleles 
TOMM40, 
rs10524523 
ss sl ll vll vlvl svl s l vl 
Controls 15 5 2 4 9 23 58 13 45 
PD cases 24 15 3 4 22 43 106 25 91 
 X2 = 2.404; 5df; p=0.791 X2 = 0.171; 2df; p=0.918 
Table O. Frequency of APOE genotype when considering the number of 2 or 4 alleles. 
Table P. Genotypic and allelic frequency of poly-T homopolymer (TOMM40). 
Annex IVa. Analysis of genetic determinants in cognitive status in Parkinson´s 
disease. PD risk. 
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ii. Genes related to other diseases where dementia is consubstantial 
such as 
a. AD: 
 
 
Only one healthy control and one PD case were heterozygous for the SNP 
rs463946 (APP). The rest of individuals were CC. Therefore, there was no 
statistical significance (Fisher´s exact test, p=1).  
 
 
 
 
Gene and polymorphism Genotypes Alleles 
PSEN1, rs165932 TT TG GG T G 
Controls 21 22 15 64 52 
PD cases 34 54 23 122 100 
 X2 = 1.785; 2df; p=0.410 X2 = 0.001; 1df; p=0.970 
PSEN2, rs6426554 AA AG GG A G 
Controls 40 17 1 97 19 
PD cases 68 40 3 176 46 
 X2 = 1.019; 2df; p=0.601 X2 = 0.925; 1df; p=0.336 
CALHM1, rs2986017 (p.P86L) TT TC CC T C 
Controls 3 17 38 23 93 
PD cases 9 21 81 39 183 
 X2 = 2.593; 2df; p=0.274 X2 = 0.260; 1df; p=0.610 
Table Q. Genotypic and allelic frequencies of PSEN1, PSEN2 and CALHM1 variants. 
Annex IVa. Analysis of genetic determinants in cognitive status in Parkinson´s 
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b. HD: 
 
 
 
 
 
 
 
Gene and polymorphism Genotypes Alleles 
HTT, rs10015979 AA AG GG A G 
Controls 27 25 6 79 37 
PD cases 44 47 20 135 87 
 X2 = 1.896; 2df; p=0.387 X2 = 1.744; 1df; p=0.187 
HTT, rs363066 TT TG GG T G 
Controls 39 19 0 97 19 
PD cases 72 37 2 181 41 
 X2 = 1.082; 2df; p=0.582 X2 = 0.228; 1df; p=0.633 
HTT, rs2298969 AA AG GG A G 
Controls 30 21 7 81 35 
PD cases 39 57 15 135 87 
 X2 = 4.522; 2df; p=0.104 X2 = 2.685; 1df; p=0.101 
HTT, rs110501 TT TC CC T C 
Controls 29 23 6 81 35 
PD cases 46 51 14 143 79 
 X2 = 1.139; 2df; p=0.566 X2 = 0.999; 1df; p=0.318 
Table R. Genotypic and allelic frequencies of HTT polymorphisms. 
Annex IVa. Analysis of genetic determinants in cognitive status in Parkinson´s 
disease. PD risk. 
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c. CJD: 
 
 
 
 
There were not statistically or almost statistically significant results either for 
genotypes or for alleles (Table S). The result was the same when considering 
haplotypes (Table T):  
 
 
 
 
The order of the markers at the haplotype is: rs4815729 – rs1799990. 
 
Gene and polymorphism Genotypes Alleles 
PRNP, rs4815729 AA AG GG A G 
Controls 6 23 29 35 81 
PD cases 10 48 53 68 154 
 X2 = 0.228; 2df; p=0.892 X2 = 0.008; 1df; p=0.931 
PRNP, rs1799990 (p.M129V) AA AG GG A G 
Controls 19 29 10 67 49 
PD cases 33 62 16 128 94 
 X2 = 0.554; 2df; p=0.758 X2 =0.0003; 1df; p=0.986 
Haplotype Overall 
frequency 
Frequencies: 
Case, Control 
Chi square 
(X2) 
p-value 
GA 0.570 0.567, 0.577 0.031 0.859 
AG 0.298 0.296, 0.301 0.007 0.932 
GG 0.125 0.127, 0.122 0.021 0.885 
Table S. Genotypic and allelic frequencies of PRNP polymorphisms. 
Table T. Haplotypes in PRNP. 
Annex IVa. Analysis of genetic determinants in cognitive status in Parkinson´s 
disease. PD risk. 
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d. Kufor-Rakeb syndrome, that is also characterized by 
parkinsonism: 
 
 
 
iii. Genes that encode neurotrophic factors: 
 
Gene and polymorphism Genotypes Alleles 
ATP13A2, rs2871776 AA AG GG A G 
Controls 10 21 27 41 75 
PD cases 29 31 51 89 133 
 X2 = 2.155; 2df; p=0.340 X2 = 0.725; 1df; p=0.395 
ATP13A2, rs4920608 AA AG GG A G 
Controls 21 28 9 70 46 
PD cases 44 57 10 145 77 
 X2 = 1.624; 2df; p=0.444 X2 = 0.813; 1df; p=0.367 
Gene and polymorphism Genotypes Alleles 
CDNF, rs7094179 GG GT TT G T 
Controls 28 28 2 84 32 
PD cases 46 52 13 144 78 
 X2 = 3.354; 2df; p=0.187 X2 = 1.978; 1df; p=0.160 
BDNF, rs6265 (p.V66M) AA AG GG A G 
Controls 4 17 37 25 91 
PD cases 6 47 58 59 163 
 X2 = 2.754; 2df; p=0.252 X2 = 1.030; 1df; p=0.310 
Table U. Genotypic and allelic frequencies of ATP13A2 polymorphisms. 
Table V. Genotypic and allelic frequencies of CDNF and BDNF polymorphisms. 
Annex IVa. Analysis of genetic determinants in cognitive status in Parkinson´s 
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iv. Genes involved in processes that are related to PD such as 
a. homocysteine metabolism: 
 
 
 
b. protection against oxidative stress: 
 
 
Gene and polymorphism Genotypes Alleles 
CBS, c.844ins68 ins/ins ins/- -/- ins - 
Controls 0 9 49 9 107 
PD cases 1 17 93 19 203 
 X2 = 0.526; 2df; p=0.769 X2 = 0.064; 1df; p=0.800 
MTR, rs1805087 (c.A2756G) AA AG GG A G 
Controls 38 18 2 94 22 
PD cases 79 28 4 186 36 
 X2 = 0.651; 2df; p=0.722 X2 = 0.405; 1df; p=0.524 
Gene and polymorphism Genotypes Alleles 
NFE2L2, rs1806649 AA AG GG A G 
Controls 5 22 31 32 84 
PD cases 6 53 52 65 157 
 X2 = 1.770; 2df; p=0.413 X2 = 0.107; 1df; p=0.744 
NFE2L2, rs10183914 AA AG GG A G 
Controls 8 20 30 36 80 
PD cases 16 55 40 87 135 
 X2 = 4.223; 2df; p=0.121 X2 = 2.189; 1df; p=0.139 
Table X. Genotypic and allelic frequencies of NFE2L2 polymorphisms. 
Table W. Genotypic and allelic frequencies of CBS and MTR variants. 
Annex IVa. Analysis of genetic determinants in cognitive status in Parkinson´s 
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There were not statistically or almost statistically significant results either for 
genotypes or for alleles (Table X). The result was the same even when 
considering haplotypes (Table Y): 
 
 
 
 
The order of the markers at the haplotype is: rs1806649 – rs10183914. 
 
 
c. chaperone-mediated autophagy: 
 
 
Haplotype Overall 
frequency 
Frequencies: 
Case, Control 
Chi square 
(X2) 
p-value 
GG 0.592 0.566, 0.642 1.828 0.176 
AA 0.243 0.251, 0.228 0.207 0.649 
GA 0.121 0.141, 0.082 2.513 0.113 
AG 0.044 0.042, 0.047 0.054 0.817 
Gene and polymorphism Genotypes Alleles 
KEAP1, rs8113472 GG GT TT G T 
Controls 49 9 0 107 9 
PD cases 96 14 1 206 16 
 X2 = 0.777; 2df; p=0.678 X2 = 0.034; 1df; p=0.854 
Gene and polymorphism Genotypes Alleles 
HSPA8, rs4936770 AA AG GG A G 
Controls 3 18 37 24 92 
PD cases 7 35 69 49 173 
 X2 = 0.102; 2df; p=0.950 X2 = 0.086; 1df; p=0.769 
Table Z. Genotypic and allelic frequency of KEAP1 polymorphism. 
Table AA. Genotypic and allelic frequency of HSPA8 polymorphism. 
Table Y. Haplotypes in NFE2L2. 
Annex IVa. Analysis of genetic determinants in cognitive status in Parkinson´s 
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1
 As the result obtained with the parameter ZfG
2
, which is more appropriate to analyze 
markers at chromosome X, was not even almost statistically significant, we did not consider 
that there were relevant results to our study in this polymorphism and thus, we did not 
include it in the subsequent analysis. The p-value observed in the X
2
 test may be originated by 
the absence of homozygous GG female patients. 
Gene and 
polymorphism 
Genotypes Alleles 
LAMP-2A, rs42897 AA AG GG A G 
Controls, overall 52 2 4 81 9 
PD cases, overall 97 7 7 138 14 
 X2 = 0.627; 2df; p=0.731 
ZmfG
2 = 1.384; 1df; p=0.239 
ZC
2 = 1.400; 2df; p=0.497 
X2 = ZA
2 = 0.041; 1df; p=0.840 
ZmfA
2 = 1.485; 1df; p=0.223 
Controls, women 27 2 3 56 8 
PD cases, women 34 7 0 75 7 
 X2 = 5.556; 2df; p=0.0621 
ZfG
2 = 0.460; 1df; p=0.498 
X2 = ZfA
2 = 0.613; 1df; p=0.433 
Controls, men - - - 25 1 
PD cases, men - - - 63 7 
 - X2 = Zm
2 = 0.940; 1df; p=0.332 
Table AB. Genotypic and allelic frequencies of LAMP-2A polymorphisms. 
Annex IVa. Analysis of genetic determinants in cognitive status in Parkinson´s 
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It is noteworthy that the gene LAMP-2A is located at chromosome X and, 
therefore, males present only one allele whereas females present two. 
Pearson´s X2 may not be appropriate to test for association of X chromosome 
markers but there are not standardized association tests. We decided to 
calculate the statistical tests proposed by [1]2. 
 
                                                          
2
 ZmfA
2
 and ZmfG
2
 are the weighted sum of Zm
2
 plus ZfA
2
 or ZfG
2
, respectively. Both are modified 
tests to allow the differential allele effects in males and females. ZC
2
 is a genotype-based test 
where allele frequencies are estimated separately for males and females. 
Gene and 
polymorphism 
Genotypes Alleles 
LAMP-2A, rs42895 AA AC CC A C 
Controls, overall 29 14 15 55 35 
PD cases, overall 62 14 35 93 59 
 X2 = 3.711; 2df; p=0.156 
ZmfG
2 = 0.019; 1df; p=0.891 
ZC
2 = 0.019; 2df; p=0.991 
X2 = ZA
2 = 0.0001; 1df; p=0.991 
ZmfA
2 = 0.020; 1df; p=0.887 
Controls, women 12 14 6 38 26 
PD cases, women 17 14 10 48 34 
 X2 = 0.764; 2df; p=0.682 
ZfG
2 = 0.009; 1df; p=0.926 
X2 = ZfA
2 = 0.010; 1df; p=0.919 
Controls, men - - - 17 9 
PD cases, men - - - 45 25 
 - X2 = Zm
2 = 0.010; 1df; p=0.920 
Table AC. Genotypic and allelic frequencies of LAMP-2A polymorphisms. (Continued) 
Annex IVa. Analysis of genetic determinants in cognitive status in Parkinson´s 
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d. and GSK3which is mainly associated with tauopathies, but 
also with PD. 
 
 
 
 
There were not statistically or almost statistically significant results either for 
genotypes or for alleles (Table AD). The result was the same when considering 
haplotypes (Table AE):  
 
 
 
 
 
The order of the markers at the haplotype is: rs334558 – rs6438552. 
Gene and polymorphism Genotypes Alleles 
GSK3, rs334558 TT TC CC T C 
Controls 21 30 7 72 44 
PD cases 48 54 9 150 72 
 X2 = 1.166; 2df; p=0.558 X2 = 1.022; 1df; p=0.312 
GSK3, rs6438552 TT TC CC T C 
Controls 22 24 12 68 48 
PD cases 50 49 12 149 73 
 X2 = 3.138; 2df; p=0.208 X2 = 2.393; 1df; p=0.121 
Haplotype Overall 
frequency 
Frequencies: 
Case, Control 
Chi square 
(X2) 
p-value 
TT 0.584 0.604, 0.547 1.017 0.313 
CC 0.285 0.257, 0.340 2.574 0.109 
TC 0.073 0.072, 0.074 0.004 0.948 
CT 0.058 0.067, 0.039 1.100 0.294 
Table AD. Genotypic and allelic frequencies of GSK3 polymorphisms. 
Table AE. Haplotypes in GSK3. 
Annex IVa. Analysis of genetic determinants in cognitive status in Parkinson´s 
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Parkinson´s disease patients:  
normal cognition (N.C.) – cognitive impairment (C.I.). 
i. Possible genetic susceptibility factors 
a. in PD: 
 
 
Gene and polymorphism Genotypes Alleles 
MAPT, H1/H2 haplotype H1H1 H1H2 H2H2 H1 H2 
N.C. 27 15 8 69 31 
C.I. 42 11 8 95 27 
 X2 = 2.814; 2df; p=0.245 X2 = 2.240; 1df; p=0.135 
SNCA, rs356219 AA AG GG A G 
N.C. 17 26 7 60 40 
C.I. 21 32 8 74 48 
 X2 = 0.019; 2df; p=0.991 X2 = 0.010; 1df; p=0.921 
Gene and 
polymorphism 
Genotypes Alleles 
SNCA, Rep1 
microsatellite 
267-
267 
267-
269 
269-
269 
269-
271 
271-
271 
267-
271 
267 269 271 
N.C. 4 21 21 3 0 1 30 66 4 
C.I. 9 21 28 2 0 1 40 79 3 
 X2 = 2.053; 4df; p=0.726 X2 = 0.562; 2df; p=0.755 
Table AF. Genotypic and allelic frequencies of H1/H2 haplotype (MAPT) and rs356219 (SNCA). 
Table AG. Genotypic and allelic frequency of Rep1 microsatellite (SNCA). 
Annex IVb. Analysis of genetic determinants in cognitive status in Parkinson´s 
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b. in AD: 
 
 
 
 
 
 
 
 
 
Gene and 
polymorphism 
Genotypes Alleles 
APOE, 
genotype 
22 23 33 34 44 24 2 3 4 
N.C. 1 3 34 11 1 0 5 82 13 
C.I. 0 11 41 8 0 1 12 101 9 
 X2 = 7.684; 5df; p=0.175 X2 = 3.436; 2df;  p=0.179 
  +/+ 4 +/-  -/- 4 +  - 
N.C. 1 11 38 12 38 
C.I. 0 9 52 9 52 
 X2 = 2.310; 2df; p=0.315 X2 = 1.531; 1df; p=0.216 
Gene and 
polymorphism 
Genotypes Alleles 
TOMM40, 
rs10524523 
ss sl ll vll vlvl svl s l vl 
N.C. 11 5 2 2 11 19 46 11 43 
C.I. 13 10 1 2 11 24 60 14 48 
 X2 = 1.674; 5df; p=0.892 X2 = 0.307; 2df; p=0.858 
Table AH. Genotypic and allelic frequency of APOE genotype. 
Table AI. Frequency of APOE genotype when considering the number of 4 alleles. 
Table AJ. Genotypic and allelic frequency of poly-T homopolymer (TOMM40). 
Annex IVb. Analysis of genetic determinants in cognitive status in Parkinson´s 
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ii. Genes related to other diseases where dementia is consubstantial 
such as 
a. AD:  
 
Only one patient with cognitive impairment was heterozygous for the SNP 
rs463946 (APP). The rest of individuals were CC. Therefore, there was no 
statistical significance (Fisher´s exact test, p=1). 
 
 
 
Gene and polymorphism Genotypes Alleles 
PSEN1, rs165932 TT TG GG T G 
N.C. 15 22 13 52 48 
C.I. 19 32 10 70 52 
 X2 = 1.640; 2df; p=0.440 X2 = 0.642; 1df; p=0.423 
PSEN2, rs6426554 AA AG GG A G 
N.C. 34 15 1 83 17 
C.I. 34 25 2 93 29 
 X2 = 1.761; 2df; p=0.415 X2 = 1.533; 1df; p=0.216 
CALHM1, rs2986017 
(p.P86L) 
TT TC CC T C 
N.C. 4 10 36 18 82 
C.I. 5 11 45 21 101 
 X2 = 0.069; 2df; p=0.966 X2 = 0.023; 1df; p=0.878 
Table AK. Genotypic and allelic frequencies of PSEN1, PSEN2 and CALHM1 variants. 
Annex IVb. Analysis of genetic determinants in cognitive status in Parkinson´s 
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b. HD: 
 
 
 
 
Gene and polymorphism Genotypes Alleles 
HTT, rs10015979 AA AG GG A G 
N.C. 23 18 9 64 36 
C.I. 21 29 11 71 51 
 X2 = 1.793; 2df; p=0.408 X2 = 0.777; 1df; p=0.378 
HTT, rs363066 TT TG GG T G 
N.C. 30 19 1 79 21 
C.I. 42 18 1 102 20 
 X2 = 0.946; 2df; p=0.623 X2 = 0.774; 1df; p=0.379 
HTT, rs363096 TT TC CC T C 
N.C. 10 24 16 44 56 
C.I. 12 30 19 54 68 
 X2 = 0.016; 2df; p=0.992 X2 = 0.002; 1df; p=0.969 
HTT, rs2298969 AA AG GG A G 
N.C. 18 26 6 62 38 
C.I. 21 31 9 73 49 
 X2 = 0.181; 2df; p=0.913 X2 = 0.108; 1df; p=0.742 
HTT, rs110501 TT TC CC T C 
N.C. 21 22 7 64 36 
C.I. 25 29 7 79 43 
 X2 = 0.221; 2df; p=0.896 X2 = 0.014; 1df; p=0.907 
Table AL. Genotypic and allelic frequencies of HTT polymorphisms. 
Annex IVb. Analysis of genetic determinants in cognitive status in Parkinson´s 
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There were not statistically or almost statistically significant results either for 
genotypes or for alleles or for haplotypes (Tables AL and AM and Figure II, 
which shows the high linkage disequilibrium observed across the gene). 
 
 
 
 
 
 
The order of the markers at the haplotype is: rs10015979 – rs363066 – rs363096 – rs2298969 
– rs110501. 
 
 
 
 
 
 
 
 
 
 
 
 
Haplotype Frequency Frequencies: 
C.I., N.C. 
Chi square 
(X2) 
p-value 
GTTAT 0.346 0.367, 0.319 0.573 0.449 
ATCAT 0.208 0.200, 0.218 0.107 0.744 
AGCGC 0.168 0.141, 0.201 1.424 0.233 
ATCGC 0.153 0.188, 0.110 2.611 0.106 
ATTGT 0.037 0.026, 0.050 0.837 0.360 
ATTAT 0.027 0.018, 0.039 0.948 0.330 
GTTGT 0.017 0.023, 0.010 0.504 0.478 
GGCGC 0.011 0.014, 0.006 0.326 0.568 
Fig. II. Linkage disequilibrium map in HTT. 
Table AM. Haplotypes in HTT. 
Annex IVb. Analysis of genetic determinants in cognitive status in Parkinson´s 
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c. CJD: 
 
 
There were not statistically or almost statistically significant results either for 
genotypes or for alleles (Table AN). There was not any effect for the 
haplotypes either (Table AO). 
 
 
 
 
 
 
The order of the markers at the haplotype is: rs4815729 – rs1799990. 
 
 
Gene and polymorphism Genotypes Alleles 
PRNP, rs4815729 AA AG GG A G 
N.C. 4 23 23 31 69 
C.I. 6 25 30 37 85 
 X2 = 0.321; 2df; p=0.852 X2 = 0.012; 1df; p=0.914 
PRNP, rs1799990 (p.M129V) AA AG GG A G 
N.C. 15 28 7 58 42 
C.I. 18 34 9 70 52 
 X2 = 0.013; 2df; p=0.993 X2 = 0.009; 1df; p=0.926 
Haplotype Overall 
frequency 
Frequencies: 
C.I., N.C. 
Chi square 
(X2) 
p-value 
GA 0.566 0.564, 0.569 0.004 0.949 
AG 0.296 0.294, 0.299 0.006 0.938 
GG 0.128 0.133, 0.121 0.060 0.807 
AA 0.010 0.010, 0.011 0.020 0.887 
Table AN. Genotypic and allelic frequencies of PRNP polymorphisms. 
Table AO. Haplotypes in PRNP. 
Annex IVb. Analysis of genetic determinants in cognitive status in Parkinson´s 
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d. Kufor-Rakeb syndrome, that is also characterized by 
parkinsonism: 
 
 
 
 
 
 
 
 
 
 
The order of the markers at the haplotype is: rs4920608 – rs6684770 – rs2871776. 
Gene and polymorphism Genotypes Alleles 
ATP13A2, rs2871776 AA AG GG A G 
N.C. 13 17 20 43 57 
C.I. 16 14 31 46 76 
 X2 = 1.902; 2df; p=0.386 X2 = 0.642; 1df; p=0.423 
ATP13A2, rs6684770 TT TC CC T C 
N.C. 8 22 20 38 62 
C.I. 3 32 26 38 84 
 X2 = 3.855; 2df; p=0.146 X2 = 1.146; 1df; p=0.284 
ATP13A2, rs4920608 AA AG GG A G 
N.C. 24 22 4 70 30 
C.I. 20 35 6 75 47 
 X2 = 2.665; 2df; p=0.264 X2 = 1.763; 1df; p=0.184 
Haplotype Overall 
frequency 
Frequencies: 
C.I., N.C. 
Chi square 
(X2) 
p-value 
ACA 0.300 0.302, 0.299 0.002 0.961 
ATG 0.191 0.168, 0.217 0.858 0.354 
GCG 0.189 0.226, 0.144 2.423 0.120 
ACG 0.122 0.122, 0.123 0.001 0.978 
GTG 0.098 0.107, 0.086 0.277 0.599 
GCA 0.046 0.040, 0.055 0.296 0.586 
ATA 0.040 0.023, 0.061 2.060 0.151 
GTA 0.014 0.013, 0.015 0.025 0.874 
Table AP. Genotypic and allelic frequencies of ATP13A2 polymorphisms. 
Table AQ. Haplotypes in ATP13A2. 
Annex IVb. Analysis of genetic determinants in cognitive status in Parkinson´s 
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There were not statistically or almost statistically 
significant results either for genotypes or for alleles 
(Table AP). There was not any effect for the haplotypes 
either (Table AQ, Figure III). 
 
The linkage disequilibrium was low across the region. 
 
 
 
iii. Genes that encode neurotrophic factors: 
 
 
Gene and polymorphism Genotypes Alleles 
CDNF, rs7099185 TT TC CC T C 
N.C. 35 15 0 85 15 
C.I. 38 23 0 99 23 
 X2 = 0.725; 1df; p=0.395 X2 = 0.575; 1df; p=0.448 
DOCK3, rs4441646 AA AC CC A C 
N.C. 33 11 6 77 23 
C.I. 42 16 3 100 22 
 X2 = 1.935; 2df; p=0.380 X2 = 0.839; 1df; p=0.360 
BDNF, rs6265 (p.V66M) AA AG GG A G 
N.C. 3 22 25 28 72 
C.I. 3 25 33 31 91 
 X2 = 0.207; 2df; p=0.902 X2 = 0.189; 1df; p=0.664 
Fig. III. Linkage 
disequilibrium 
map in ATP13A2. 
Table AR. Genotypic and allelic frequencies of CDNF, DOCK3 and BDNF variants. 
Annex IVb. Analysis of genetic determinants in cognitive status in Parkinson´s 
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iv. Genes involved in processes that are related to PD such as 
a. homocysteine metabolism: 
 
 
 
 
Any of the polymorphisms analyzed showed statistically or almost statistically 
significant results neither for genotypes nor for alleles (Table AS). The study of 
haplotypes reported again no statistical significance (Table AT). 
 
 
 
 
The order of the markers at the haplotype is: rs1801133 (c.C677T) – rs1801131 (c.A1298C). 
 
Gene and polymorphism Genotypes Alleles 
MTHFR, rs1801133 (c.C677T) CC CT TT C T 
N.C. 23 21 6 67 33 
C.I. 23 34 4 80 42 
 X2 = 2.406; 2df; p=0.300 X2 = 0.050; 1df; p=0.823 
MTHFR, rs1801131 (c.A1298C) AA AC CC A C 
N.C. 22 24 4 68 32 
C.I. 31 22 8 84 38 
 X2 = 1.877; 2df; p=0.391 X2 = 0.018; 1df; p=0.892 
Haplotype Overall 
frequency 
Frequencies: 
C.I., N.C. 
Chi square 
(X2) 
p-value 
CA 0.354 0.347, 0.363 0.060 0.806 
TA 0.331 0.342, 0.317 0.147 0.701 
CC 0.308 0.309, 0.307 0.001 0.980 
Table AS. Genotypic and allelic frequencies of MTHFR polymorphisms. 
Table AT. Haplotypes in MTHFR. 
Annex IVb. Analysis of genetic determinants in cognitive status in Parkinson´s 
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b. protection against oxidative stress: 
 
 
 
 
 
c. chaperone-mediated autophagy: 
 
 
 
 
 
Gene and polymorphism Genotypes Alleles 
NFE2L2, rs1806649 AA AG GG A G 
N.C. 3 28 19 34 66 
C.I. 3 25 33 31 91 
 X2 = 2.877; 2df; p=0.237 X2 = 1.958; 1df; p=0.162 
NFE2L2, rs10183914 AA AG GG A G 
N.C. 10 25 15 45 55 
C.I. 6 30 25 42 80 
 X2 = 2.893; 2df; p=0.235 X2 = 2.578; 1df; p=0.108 
Gene and polymorphism Genotypes Alleles 
HSPA8, rs1461496 TT TC CC T C 
N.C. 9 16 25 34 66 
C.I. 11 14 36 36 86 
 X2 = 1.239; 2df; p=0.538 X2 = 0.514; 1df; p=0.474 
Table AU. Genotypic and allelic frequencies of NFE2L2 polymorphisms. 
Table AV. Genotypic and allelic frequency of HSPA8 polymorphism. 
Annex IVb. Analysis of genetic determinants in cognitive status in Parkinson´s 
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Gene and 
polymorphism 
Genotypes Alleles 
LAMP-2A, rs7057652 TT TG GG T G 
N.C., overall 21 8 21 33 33 
C.I., overall 27 9 25 44 42 
 X2 = 0.067; 2df; p=0.967 
ZmfG
2 = 0.034; 1df; p=0.854 
ZC
2 = 0.054; 2df; p=0.973 
X2 = ZA
2 = 0.020; 1df; p=0.887 
ZmfA
2 = 0.025; 1df; p=0.875 
N.C., women 4 8 4 16 16 
C.I., women 8 9 8 25 25 
 X2 = 0.788; 2df; p=0.674 
ZfG
2 = 0; 1df; p=1.000 
X2 = ZfA
2 = 0; 1df; p=1.000 
N.C., men - - - 17 17 
C.I., men - - - 19 17 
 - X2 = Zm
2 = 0.054; 1df; p=0.816 
Table AW. Genotypic and allelic frequencies of LAMP-2A polymorphisms. 
Annex IVb. Analysis of genetic determinants in cognitive status in Parkinson´s 
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1
 As the result obtained with the parameter ZfG
2
, which is more appropriate to analyze 
markers at chromosome X, was not even almost statistically significant, and there were 
opposite results for the ZA
2
 and ZfmA
2
, we did not consider that there were relevant results to 
our study in this polymorphism and thus, we did not include it in the subsequent analysis. 
Gene and 
polymorphism 
Genotypes Alleles 
LAMP-2A, rs428951 AA AC CC A C 
N.C., overall 27 8 15 42 24 
C.I., overall 35 6 20 51 35 
 X2 = 0.952; 2df; p=0.621 
ZmfG
2 = 2.364; 1df; p=0.124 
ZC
2 = 2.599; 2df; p=0.273 
X2 = ZA
2 = 0.295; 1df; p=0.587 
ZmfA
2 = 3.000; 1df; p=0.083 
OR: 0.83,  CI95%=[0.43-1.61] 
N.C., women 7 8 1 22 10 
C.I., women 10 6 9 26 24 
 X2 = 5.505; 2df; p=0.064 
ZfG
2 = 1.740; 1df; p=0.187 
X2 = ZfA
2 = 2.256; 1df; p=0.133 
N.C., men - - - 20 14 
C.I., men - - - 25 11 
 - X2 = Zm
2 = 0.859; 1df; p=0.354 
Table AX. Genotypic and allelic frequencies of LAMP-2A polymorphisms. (Continued) 
Annex IVb. Analysis of genetic determinants in cognitive status in Parkinson´s 
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It is noteworthy that LAMP-2A is located at chromosome X and, therefore, 
males present only one allele whereas females present two. Pearson´s X2 may 
not be appropriate to test for association of X chromosome markers but there 
are not standardized association tests. We decided to calculate the statistical 
tests proposed by [1]3. 
 
                                                          
2
 The opposite results observed for the different parameters calculated in the overall 
genotype and allele distribution made us consider that there were not relevant results to our 
study in this polymorphism and thus, we did not include it in the subsequent analysis. 
3
 ZmfA
2
 and ZmfG
2
 are the weighted sum of Zm
2
 plus ZfA
2
 or ZfG
2
, respectively. Both are modified 
tests to allow the differential allele effects in males and females. ZC
2
 is a genotype-based test 
where allele frequencies are estimated separately for males and females. 
Gene and 
polymorphism 
Genotypes Alleles 
LAMP-2A, rs428902 GG GT TT G T 
N.C., overall 27 7 16 42 24 
C.I., overall 34 9 18 52 34 
 X2 = 0.082; 2df; p=0.960 
ZmfG
2 = 3.377; 1df; p=0.066 
ZC
2 = 3.598; 2df; p=0.165 
X2 = ZA
2 = 0.159; 1df; p=0.690 
ZmfA
2 = 3.942; 1df; p=0.047 
OR: 0.87,  CI95%=[0.45-1.69] 
N.C., women 8 7 1 23 9 
C.I., men 9 9 7 27 23 
 X2 = 2.977; 2df; p=0.226 
ZfG
2 = 2.220; 1df; p=0.136 
X2 = ZfA
2 = 2.620; 1df; p=0.106 
N.C., men - - - 19 15 
C.I., men - - - 25 11 
 - X2 = Zm
2 = 1.378; 1df; p=0.241 
Table AY. Genotypic and allelic frequencies of LAMP-2A polymorphisms. (Continued) 
Annex IVb. Analysis of genetic determinants in cognitive status in Parkinson´s 
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d. and GSK3which is mainly associated with tauopathies, but 
also with PD. 
 
There were not relevant results either for genotypes or for alleles (Table AZ). 
There was not any effect for the haplotypes either (Table BA). 
 
 
 
 
The order of the markers at the haplotype is: rs334558 – rs6438552. 
 
Bibliography: 
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Genet Epidemiol, 2007. 31(8): p. 834-43. 
Gene and polymorphism Genotypes Alleles 
GSK3, rs334558 TT TC CC T C 
N.C. 21 24 5 66 34 
C.I. 27 30 4 84 38 
 X2 = 0.442; 2df; p=0.802 X2 = 0.204; 1df; p=0.651 
GSK3, rs6438552 TT TC CC T C 
N.C. 24 18 8 66 34 
C.I. 26 31 4 83 39 
 X2 = 3.810; 2df; p=0.149 X2 = 0.103; 1df; p=0.748 
Haplotype Overall 
frequency 
Frequencies: 
C.I., N.C. 
Chi square 
(X2) 
p-value 
TT 0.603 0.617, 0.585 0.227 0.634 
CC 0.256 0.248, 0.265 0.087 0.768 
TC 0.073 0.072, 0.075 0.007 0.933 
CT 0.069 0.064, 0.075 0.107 0.744 
Table AZ. Genotypic and allelic frequencies of GSK3 polymorphisms. 
Table BA. Haplotypes in GSK3. 
Annex IVc. Analysis of genetic determinants in cognitive status in Parkinson´s 
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We considered the genotypes, neither the alleles nor the haplotypes, 
that reported relevant results, i.e. p-value < 0.05 (X2 test) to find a 
mathematical model to quantify the contribution of the variants on the risk to 
develop dementia1: 
 
3. Risk of developing dementia during PD (61 PD patients: 36 mild 
cognitive impairment (M.C.I.) and 25 dementia (PDD))2: 
A. rs6426554 (PSEN2): AA vs AG+GG, p=0.039. 
B. rs2986017 (p.P86L, CALHM1): CC vs TT+CT, p=0.042. 
 
Again, we employed a binary logistic regression model to quantify the 
influence of these two variables on the risk to develop dementia during PD. 
The following equation explains what a binary logistic regression is: 
 
   
                          
                                
In our case,  
 P is the probability that an individual presents dementia (to belong to 
the PDD group), whereas 1-P is the probability that an individual 
presents mild cognitive impairment (to be part of the M.C.I. group).  
                                                          
1
 Due to the small number of individuals analyzed, the relevance of this model is 
compromised. 
2
 The risk variants are underlined. 
Annex IVc. Analysis of genetic determinants in cognitive status in Parkinson´s 
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 The term P / (1-P) is the odds ratio, i.e. the increase or decrease in the 
risk to evolve from M.C.I. to dementia during PD. 
 Each Xi represents a variable (genotype) that influences on the risk 
(value 1 for the underlined risk variants and 0 for the others) and a, b1, 
b2… are numerical coefficients. 
 
Table BB shows how many subjects were correctly assigned by the model. 
 
 
 
 
 
 
The results we obtained were4 (Table BC): 
 
                                                          
3
 Sensitivity can be defined as the proportion of PDD cases that are correctly assigned by the 
model, that is, capacity to identify positives. Specificity is defined as the proportion of M.C.I. 
patients that are correctly assigned by the model, i.e. capacity to identify negatives.  
The values obtained were low.  
As there were two subjects from the PDD group with unknown age at onset, they were not 
included in the model. 
4
 Sex distribution and mean age at onset were similar between both groups and were, 
therefore, considered in the model but the model did not include them. PSEN2 was excluded 
too because was not useful either. 
Observed 
Predicted 
cognitive status Percentage Correct 
M.C.I. PDD 
cognitive 
status 
M.C.I. 30 6 83.3 (specificity)3 
PDD 14 9 39.1 (sensitivity) 
Overall Percentage   66.1 
Table BB. Classification of the subjects analyzed under the binary logistic regression model. 
Annex IVc. Analysis of genetic determinants in cognitive status in Parkinson´s 
disease. M.C.I. vs PDD. 
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 What would happen if a person carries the risk variant in variable B 
(X1)? 
                                     =        = 1.50 
 
   
               
This person would have 1.50 times more possibilities to develop 
dementia or would develop it with a probability of 60%.  
 
Finally, we analyzed the distribution of the two variables in patients 
with mild cognitive impairment (M.C.I.) and with dementia (PDD)5 (Table BD 
and Figure IV): 
 
 
                                                          
5
 We also tried to determine if there was some correlation between them, but we observed 
that there was not any. There was not any correlation between these two with the nine PD 
risk variants or with the three cognitive impairment risk variants either. 
 b df p-value OR (eb) CI95% 
Lower Upper 
rs2986017 (p.P86L, CALHM1) X1 1.168 b1 1 0.059 3.214 e
b1 0.956 10.803 
constant -0.762 a 1 0.019 0.467   
Table BC. Results of the binary logistic regression model to determine the risk of developing 
dementia. 
Annex IVc. Analysis of genetic determinants in cognitive status in Parkinson´s 
disease. M.C.I. vs PDD. 
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Furthermore, we studied how many variants affecting PD (Figure V and 
Table BE) or cognitive impairment (Figure VI and Table BF) presented 
individuals of both groups.  
Number of dementia 
risk variants carried 
0 1 2 mean median 
M.C.I. 58.33 (21) 33.33 (12) 8.33 (3) 0.50 1 
PDD 24.00 (6) 52.00 (13) 24.00 (6) 1.00 1 
Table BD. Percentage of M.C.I. and PDD subjects that carry each number of dementia risk variants. 
Number of individuals are in parenthesis. 
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Fig. IV. Distribution of the number of dementia risk variants carried by M.C.I. and PDD 
groups. 
Annex IVc. Analysis of genetic determinants in cognitive status in Parkinson´s 
disease. M.C.I. vs PDD. 
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The mean number of PD risk variants carried by the subjects from the 
M.C.I. group was 4.86, whereas for PDD was 5.32. Medians were 5 and 5, 
respectively. 
Number of PD risk 
variants carried 
0 1 2 3 4 5 6 7 8 9 
M.C.I. 
0 
(0) 
0 
(0) 
8.33 
(3) 
8.33 
(3) 
19.44 
(7) 
36.11 
(13) 
13.89 
(5) 
8.33 
(3) 
5.56 
 (2) 
0 
(0) 
PDD 
0 
(0) 
0 
(0) 
0 
(0) 
12.00 
(3) 
16.00 
(4) 
32.00 
(8) 
16.00 
(4) 
16.00 
(4) 
8.00 
(2) 
0 
(0) 
Fig. V. Distribution of the number of PD risk variants carried by M.C.I. and PDD 
groups. 
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Table BE. Percentage of M.C.I. and PDD cases that carry each number of PD risk variants. 
Number of individuals are in parenthesis. 
Annex IVc. Analysis of genetic determinants in cognitive status in Parkinson´s 
disease. M.C.I. vs PDD. 
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The mean number of cognitive impairment risk variants carried by the 
cases with mild cognitive impairment was 1.78, whereas for those with 
dementia was 1.68. Medians were 2 and 2, respectively. 
Number of cognitive 
impairment risk variants carried 
0 1 2 3 
M.C.I. 
5.56  
(2) 
16.67  
(6) 
72.22  
(26) 
5.56  
(2) 
PDD 
4.00  
(1) 
36.00  
(9) 
48.00  
(12) 
12.00 
(3) 
Fig. VI. Distribution of the number of cognitive impairment risk variants carried by 
M.C.I. and PDD groups. 
Table BF. Percentage of M.C.I. and PDD cases that carry each number of cognitive impairment risk variants. 
Number of individuals are in parenthesis. 
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Annex V. Analysis of genetic variability in the ARMCX gene family in PD. 
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 2 +/+ 2 +/- 2 -/- 2 + 2 - 
Controls 0  8  87  8 87 
PD cases 3  10  79  13 79 
 X2 = 3.561; 2df; p=0.169 X2 = 1.528; 1df; p=0.216 
Gene and 
polymorphism 
Genotypes Alleles 
TOMM40, 
rs10524523 
ss sl ll vll vlvl svl s l vl 
Controls 20 7 2 10 21 35 82 21 87 
PD cases 21 6 1 6 16 42 90 14 80 
 X2 = 2.699; 5df; p=0.746 X2 = 1.970; 2df; p=0.373 
Gene and polymorphism Genotypes Alleles 
UCHL1, rs5030732 (p.S18Y) SS SY YY S Y 
Controls 62 29 4 153 37 
PD cases 66 23 3 155 29 
 X2 = 0.912; 2df; p=0.634 X2 = 0.887; 1df; p=0.346 
TOR1A, rs1801968 (p.D216H) GG GC CC G C 
Controls 78 17 0 173 17 
PD cases 69 21 2 159 25 
 X2 = 2.925; 2df; p=0.232 X2 = 2.018; 1df; p=0.155 
Table BG. Frequency of APOE genotype when considering the number of 2 alleles. 
Table BI. Genotypic and allelic frequencies of p.S18Y (UCHL1) and p.D216H (TOR1A). 
Table BH. Genotypic and allelic frequency of poly-T homopolymer (TOMM40). 
Annex V. Analysis of genetic variability in the ARMCX gene family in PD. 
 
66 
 
With regard to the mutation c.864+246C>T in NR4A2, 2 controls were 
heterozygous: there was no statistical significance (Fisher´s exact test, p=0.497). 
 
 
 
 
 
 
 
 
Gene and 
polymorphism 
Genotypes Alleles 
ARMCX1, 
rs6616255 
AA AG GG A G 
Controls, overall 72 13 10 110 23 
PD cases, overall 75 9 8 109 19 
 X2 = 0.963; 2df; p=0.618 
ZmfG
2 = 0.821; 1df; p=0.365 
ZC
2 = 1.108; 2df; p=0.575 
X2 = ZA
2 = 0.289; 1df; p=0.590 
ZmfA
2 = 0.639; 1df; p=0.424 
Controls, women 25 13 0 63 13 
PD cases, women 25 9 2 59 13 
 X2 = 2.675; 2df; p=0.262 
ZfG
2 = 0.024; 1df; p=0.878 
X2 = ZfA
2 = 0.023; 1df; p=0.879 
Controls, men - - - 47 10 
PD cases, men - - - 50 6 
 - X2 = Zm
2 =1.084; 1df; p=0.298 
Table BJ. Genotypic and allelic frequency of rs6616255 (ARMCX1). 
Annex V. Analysis of genetic variability in the ARMCX gene family in PD. 
 
67 
 
 
 
 
 
 
 
 
 
 
 
Gene and 
polymorphism 
Genotypes Alleles 
ARMCX1, 
rs1044275 
CC CT TT C T 
Controls, overall 83 10 2 121 12 
PD cases, overall 78 8 6 114 14 
 X2 = 2.330; 2df; p=0.312 
ZmfG
2 = 2.013; 1df; p=0.156 
ZC
2 = 2.398; 2df; p=0.302 
X2 = ZA
2 = 0.267; 1df; p=0.606 
ZmfA
2 = 1.611; 1df; p=0.204 
Controls, women 28 10 0 66 10 
PD cases, women 28 8 0 64 8 
 X2 = 0.168; 1df; p=0.682 
ZfG
2 = 0.168; 1df; p=0.681 
X2 = ZfA
2 = 0.145; 1df; p=0.703 
Controls, men - - - 55 2 
PD cases, men - - - 50 6 
  X2 = Zm
2 = 2.229; 1df; p=0.135 
Table BK. Genotypic and allelic frequency of rs1044275 (ARMCX1). 
Annex V. Analysis of genetic variability in the ARMCX gene family in PD. 
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Gene and 
polymorphism 
Genotypes Alleles 
ARMCX2, 
rs5951282 
CC CT TT C T 
Controls, overall 49 22 24 85 48 
PD cases, overall 55 20 17 90 38 
 X2 = 1.589; 2df; p=0.452 
ZmfG
2 = 1.519; 1df; p=0.218 
ZC
2 = 1.592; 2df; p=0.451 
X2 = ZA
2 = 1.210; 1df; p=0.271 
ZmfA
2 = 1.209; 1df; p=0.272 
Controls, women 14 22 2 50 26 
PD cases, women 15 20 1 50 22 
 X2 = 0.409; 2df; p=0.815 
ZfG
2 = 0.320; 1df; p=0.572 
X2 = ZfA
2 = 0.225; 1df; p=0.635 
Controls, men - - - 35 22 
PD cases, men - - - 40 16 
 - X2 = Zm
2 = 1.272; 1df; p=0.259 
Table BL. Genotypic and allelic frequency of rs5951282 (ARMCX2). 
Annex V. Analysis of genetic variability in the ARMCX gene family in PD. 
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Gene and 
polymorphism 
Genotypes Alleles 
ARMCX3, rs6995 AA AG GG A G 
Controls, overall 75 13 7 112 21 
PD cases, overall 68 10 14 102 26 
 X2 = 3.020; 2df; p=0.221 
ZmfG
2 = 1.585; 1df; p=0.208 
ZC
2 = 2.509; 2df; p=0.285 
X2 = ZA
2 = 0.904; 1df; p=0.341 
ZmfA
2 = 1.157; 1df; p=0.282 
Controls, women 24 13 1 61 15 
PD cases, women 24 10 2 58 14 
 X2 = 0.671; 2df; p=0.715 
ZfG
2 = 0.002; 1df; p=0.965 
X2 = ZfA
2 = 0.002; 1df; p=0.964 
Controls, men - - - 51 6 
PD cases, men - - - 44 12 
 - X2 = Zm
2 = 2.507; 1df; p=0.113 
Table BM. Genotypic and allelic frequency of rs6995 (ARMCX3). 
Annex V. Analysis of genetic variability in the ARMCX gene family in PD. 
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Gene and 
polymorphism 
Genotypes Alleles 
 ARMCX4, 
rs2179670 
CC CT TT C T 
Controls, overall 65 14 16 99 34 
PD cases, overall 59 15 18 89 39 
 X2 = 0.394; 2df; p=0.821 
ZmfG
2 = 0.485; 1df; p=0.486 
ZC
2 = 1.097; 2df; p=0.578 
X2 = ZA
2 = 0.779; 1df; p=0.377 
ZmfA
2 = 0.747; 1df; p=0.387 
Controls, women 20 14 4 54 22 
PD cases, women 15 15 6 45 27 
 X2 = 1.096; 2df; p=0.578 
ZfG
2 = 1.095; 1df; p=0.295 
X2 = ZfA
2 = 1.221; 1df; p=0.269 
Controls, men - - - 45 12 
PD cases, men - - - 44 12 
 - X2 = Zm
2 = 0.002; 1df; p=0.961 
Table BN. Genotypic and allelic frequency of rs2179670 (ARMCX4). 
Annex V. Analysis of genetic variability in the ARMCX gene family in PD. 
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It is noteworthy that the ARMCX genes are located at chromosome X and, 
therefore, males present only one allele whereas females present two. 
Pearson´s X2 may not be appropriate to test for association of X chromosome 
markers but there are not standardized association tests. We decided to 
calculate the statistical tests proposed by [1]1. 
                                                          
1
 ZmfA
2
 and ZmfG
2
 are the weighted sum of Zm
2
 plus ZfA
2
 or ZfG
2
, respectively. Both are modified 
tests to allow the differential allele effects in males and females. ZC
2
 is a genotype-based test 
where allele frequencies are estimated separately for males and females. 
Gene and 
polymorphism 
Genotypes Alleles 
ARMCX4, 
rs6523506 
GG TG TT G T 
Controls, overall 72 14 9 110 23 
PD cases, overall 65 14 13 99 29 
 X2 = 1.037; 2df; p=0.595 
ZmfG
2 = 1.139; 1df; p=0.286 
ZC
2 = 1.357; 2df; p=0.507 
X2 = ZA
2 = 1.176; 1df; p=0.278 
ZmfA
2 = 1.177; 1df; p=0.278 
Controls, women 24 14 0 62 14 
PD cases, women 20 14 2 54 18 
 X2 = 2.311; 2df; p=0.315 
ZfG
2 = 1.069; 1df; p=0.301 
X2 = ZfA
2 = 0.944; 1df; p=0.331 
Controls, men - - - 48 9 
PD cases, men - - - 45 11 
 - X2 = Zm
2 = 0.288; 1df; p=0.592 
Table BO. Genotypic and allelic frequency of rs6523506 (ARMCX4). 
Annex V. Analysis of genetic variability in the ARMCX gene family in PD. 
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Gene and 
polymorphism 
Genotypes Alleles 
ARMCX5, 
rs2235827 
CC CT TT C T 
Controls, overall 85 6 4 123 10 
PD cases, overall 76 9 7 112 16 
 X2 = 1.874; 2df; p=0.392 
ZmfG
2 = 1.915; 1df; p=0.166 
ZC
2 = 1.937; 2df; p=0.380 
X2 = ZA
2 = 1.804; 1df; p=0.179 
ZmfA
2 = 1.810; 1df; p=0.178 
Controls, women 32 6 0 70 6 
PD cases, women 27 9 0 63 9 
 X2 = 0.970; 1df; p=0.325 
ZfG
2 = 0.970; 1df; p=0.325 
X2 = ZfA
2 = 0.861; 1df; p=0.353 
Controls, men - - - 53 4 
PD cases, men - - - 49 7 
 - X2 = Zm
2 = 0.966; 1df; p=0.326 
Table BP. Genotypic and allelic frequency of rs2235827 (ARMCX5). 
Annex VI. Quantitation of DNA methylation levels in promoters of genes responsible for familial Parkinson´s disease. Pilot analysis.
DJ-1  1
Parietal cortex
Table BQ. Mean percentages of DNA methylation (and the standard deviation) per position and group. The statistical results are also described.
Position 1 2 3 4 5 6 Overall
Healthy controls 0,43 (0,73) 0,44 (0,95) 0,85 (1,15) 0,51 (0,74) 0,84 (1,01) 0,51 (1,08) 0,60 (0,90)
PD cases 0,31 (0,48) 0,80 (0,89) 0,47 (0,71) 0,63 (0,61) 1,53 (1,71) 1,20 (1,25) 0,82 (0,72)
p-value 0,841 0,841 0,841 0,841 0,421 0,548 0,548
Figure VII. Graphical representation of the results detailed in Table BQ.
Blood
Table BR. Mean percentages of DNA methylation (and the standard deviation) per position.
Position 1 2 3 4 5 6 Overall
Other PD cases 1,14 (1,34) 0,58 (0,76) 1,10 (0,97) 0,54 (0,75) 1,21 (1,55) 0,70 (0,99) 0,88 (1,00)
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Annex VI. Quantitation of DNA methylation levels in promoters of genes responsible for familial Parkinson´s disease. Pilot analysis.
DJ-1 1
Occipital cortex
Table BS. Mean percentages of DNA methylation (and the standard deviation) per position and group. The statistical results are also described.
Position 1 2 3 4 5 6 Overall
Healthy controls 0,62 (1,38) 0,62 (0,94) 0,79 (1,04) 0,38 (0,46) 0,65 (1,36) 0,66 (1,09) 0,62 (1,02)
PD cases 0 0,10 (0,14) 0,08 (0,11) 0,32 (0,35) 0,34 (0,50) 0 0,14 (0,15)
p-value 0,690 0,548 0,310 0,841 0,841 0,310 0,690
Figure VIII. Graphical representation of the results detailed in Table BS.
Blood
Table BT. Mean percentages of DNA methylation (and the standard deviation) per position.
Position 1 2 3 4 5 6 Overall
Other PD cases 1,14 (1,34) 0,58 (0,76) 1,10 (0,97) 0,54 (0,75) 1,21 (1,55) 0,70 (0,99) 0,88 (1,00)
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Annex VI. Quantitation of DNA methylation levels in promoters of genes responsible for familial Parkinson´s disease. Pilot analysis.
DJ-1 1
Substantia nigra
Table BU. Mean percentages of DNA methylation (and the standard deviation) per position and group. The statistical results are also described.
Position 1 2 3 4 5 6 Overall
Healthy controls 0,55 (1,11) 0,03 (0,03) 0,35 (0,42) 0,63 (0,71) 0,34 (0,38) 0,15 (0,29) 0,34 (0,39)
PD cases 0,63 (0,68) 0,51 (0,34) 0,40 (0,48) 0,85 (0,61) 0,09 (0,17) 0,43 (0,39) 0,49 (0,26)
p-value 0,730 0,111 1,000 0,556 0,190 0,111 0,556
Figure IX. Graphical representation of the results detailed in Table BU.
Blood
Table BV. Mean percentages of DNA methylation (and the standard deviation) per position.
Position 1 2 3 4 5 6 Overall
Other PD cases 1,14 (1,34) 0,58 (0,76) 1,10 (0,97) 0,54 (0,75) 1,21 (1,55) 0,70 (0,99) 0,88 (1,00)
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Annex VI. Quantitation of DNA methylation levels in promoters of genes responsible for familial Parkinson´s disease. Pilot analysis.
DJ-1  2
Parietal cortex
Table BW. Mean percentages of DNA methylation (and the standard deviation) per position and group. The statistical results are also described.
Position 1 2 3 4 5 6 7 8 Overall
Healthy controls 1,64 (0,30) 1,73 (0,76) 0,39 (0,87) 0,25 (0,57) 0,82 (1,35) 1,19 (1,68) 0,78 (1,04) 0,33 (0,43) 0,89 (0,81)
PD cases 0,88 (0,86) 1,58 (0,88) 0,31 (0,46) 0 0,28 (0,62) 0,29 (0,40) 0,30 (0,09) 0,68 (0,83) 0,54 (0,19)
p-value 0,151 0,841 0,841 0,690 0,421 0,548 0,690 0,690 0,690
Figure X. Graphical representation of the results detailed in Table BW.
Blood
Table BX. Mean percentages of DNA methylation (and the standard deviation) per position.
Position 1 2 3 4 5 6 7 8 Overall
Other PD cases 0,63 (1,28) 2,16 (1,71) 1,20 (1,15) 0,63 (1,35) 0,71 (0,72) 0,09 (0,24) 0,73 (0,99) 1,32 (1,17) 0,93 (0,52)
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Annex VI. Quantitation of DNA methylation levels in promoters of genes responsible for familial Parkinson´s disease. Pilot analysis.
DJ-1  2
Occipital cortex
Table BY. Mean percentages of DNA methylation (and the standard deviation) per position and group. The statistical results are also described.
Position 1 2 3 4 5 6 7 8 Overall
Healthy controls 0,72 (0,78) 2,60 (1,82) 0,11 (0,24) 0 0,12 (0,24) 0,44 (0,67) 0,12 (0,18) 0,45 (0,27) 0,57 (0,20)
PD cases 0,40 (0,51) 0,87 (0,50) 0,48 (0,66) 0,56 (0,61) 0,40 (0,82) 0,72 (0,83) 0,58 (0,65) 0,65 (0,64) 0,58 (0,43)
p-value 0,548 0,095 0,548 0,151 0,841 0,548 0,222 0,841 0,690
Figure XI. Graphical representation of the results detailed in Table BY.
Blood
Table BZ. Mean percentages of DNA methylation (and the standard deviation) per position.
Position 1 2 3 4 5 6 7 8 Overall
Other PD cases 0,63 (1,28) 2,16 (1,71) 1,20 (1,15) 0,63 (1,35) 0,71 (0,72) 0,09 (0,24) 0,73 (0,99) 1,32 (1,17) 0,93 (0,52)
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Annex VI. Quantitation of DNA methylation levels in promoters of genes responsible for familial Parkinson´s disease. Pilot analysis.
DJ-1  2
Substantia nigra
Table CA. Mean percentages of DNA methylation (and the standard deviation) per position and group. The statistical results are also described.
Position 1 2 3 4 5 6 7 8 Overall
Healthy controls 1,56 (1,02) 1,56 (1,09) 1,05 (0,52) 1,22 (0,96) 0,67 (0,77) 1,69 (1,04) 0,24 (0,30) 0,39 (0,18) 1,05 (0,51)
PD cases 0,56 (0,53) 1,49 (0,77) 0,28 (0,39) 0,10 (0,21) 0 0,73 (0,55) 1,95 (3,87) 0,56 (0,41) 0,71 (0,63)
p-value 0,190 1,000 0,063 0,111 0,286 0,286 1,000 0,556 0,413
Figure XII. Graphical representation of the results detailed in Table CA.
Blood
Table CB. Mean percentages of DNA methylation (and the standard deviation) per position.
Position 1 2 3 4 5 6 7 8 Overall
Other PD cases 0,63 (1,28) 2,16 (1,71) 1,20 (1,15) 0,63 (1,35) 0,71 (0,72) 0,09 (0,24) 0,73 (0,99) 1,32 (1,17) 0,93 (0,52)
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Annex VI. Quantitation of DNA methylation levels in promoters of genes responsible for familial Parkinson´s disease. Pilot analysis.
LRRK2  1
Parietal cortex
Table CC. Mean percentages of DNA methylation (and the standard deviation) per position and group. The statistical results are also described.
Position 1 2 3 4 5 6 7 8 9 Overall
Healthy controls 0,97 (0,83) 4,73 (1,04) 3,06 (1,52) 2,55 (1,37) 2,23 (1,67) 1,87 (1,72) 1,97 (1,99) 0 2,67 (1,40) 2,23 (0,73)
PD cases 2,89 (2,46) 4,50 (2,10) 2,68 (1,91) 3,31 (1,90) 2,46 (2,26) 2,50 (2,56) 1,68 (1,53) 0,62 (1,39) 2,09 (2,01) 2,53 (1,44)
p-value 0,222 1,000 0,690 0,690 0,841 0,841 0,690 0,690 0,690 0,841
Figure XIII. Graphical representation of the results detailed in Table CC.
Blood
Table CD. Mean percentages of DNA methylation (and the standard deviation) per position.
Position 1 2 3 4 5 6 7 8 9 Overall
Other PD cases 3,76 (2,82) 2,71 (1,72) 3,57 (2,27) 3,74 (3,09) 2,15 (1,83) 3,63 (2,66) 2,87 (1,74) 2,65 (1,85) 3,30 (3,14) 3,15 (1,54)
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Annex VI. Quantitation of DNA methylation levels in promoters of genes responsible for familial Parkinson´s disease. Pilot analysis.
LRRK2  1
Occipital cortex
Table CE. Mean percentages of DNA methylation (and the standard deviation) per position and group. The statistical results are also described.
Position 1 2 3 4 5 6 7 8 9 Overall
Healthy controls 0,59 (0,50) 1,07 (1,00) 2,58 (0,60) 1,18 (0,79) 0,56 (1,08) 1,52 (1,04) 0,48 (0,65) 0 0,42 (0,60) 0,94 (0,29)
PD cases 1,12 (1,56) 1,78 (0,83) 1,86 (1,46) 0,97 (0,38) 0,86 (0,64) 1,31 (1,32) 0,56 (0,56) 0,01 (0,02) 0,38 (0,41) 0,98 (0,44)
p-value 0,841 0,310 0,310 0,548 0,310 1,000 1,000 0,690 1,000 1,000
Figure XIV. Graphical representation of the results detailed in Table CE.
Blood
Table CF. Mean percentages of DNA methylation (and the standard deviation) per position.
Position 1 2 3 4 5 6 7 8 9 Overall
Other PD cases 3,76 (2,82) 2,71 (1,72) 3,57 (2,27) 3,74 (3,09) 2,15 (1,83) 3,63 (2,66) 2,87 (1,74) 2,65 (1,85) 3,30 (3,14) 3,15 (1,54)
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Annex VI. Quantitation of DNA methylation levels in promoters of genes responsible for familial Parkinson´s disease. Pilot analysis.
LRRK2  1
Substantia nigra
Table CG. Mean percentages of DNA methylation (and the standard deviation) per position and group. The statistical results are also described.
Position 1 2 3 4 5 6 7 8 9 Overall
Healthy controls 2,31 (1,70) 1,73 (0,64) 2,47 (1,21) 1,75 (1,59) 0,79 (0,76) 3,11 (2,00) 1,28 (1,55) 1,16 (2,31) 1,07 (1,34) 1,74 (0,60)
PD cases 1,37 (1,28) 1,50 (1,17) 1,89 (0,89) 1,62 (1,64) 0,93 (1,30) 1,70 (0,58) 056 (0,75) 0,33 (0,31) 0,21 (0,59) 1,12 (0,39)
p-value 0,413 0,905 0,556 0,905 0,905 0,286 0,730 0,413 0,556 0,111
Figure XV. Graphical representation of the results detailed in Table CG.
Blood
Table CH. Mean percentages of DNA methylation (and the standard deviation) per position.
Position 1 2 3 4 5 6 7 8 9 Overall
Other PD cases 3,76 (2,82) 2,71 (1,72) 3,57 (2,27) 3,74 (3,09) 2,15 (1,83) 3,63 (2,66) 2,87 (1,74) 2,65 (1,85) 3,30 (3,14) 3,15 (1,54)
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Annex VI. Quantitation of DNA methylation levels in promoters of genes responsible for familial Parkinson´s disease. Pilot analysis.
LRRK2  2
Parietal cortex
Table CI. Mean percentages of DNA methylation (and the standard deviation) per position and group. The statistical results are also described.
Position 1 2 3 4 5 6 7 8 9 Overall
Healthy controls 0,10 (0,15) 1,09 (0,96) 1,03 (1,49) 1,08 (1,40) 0,49 (0,53) 0,25 (0,55) 0,27 (0,52) 0,31 (0,68) 0,10 (0,16) 0,52 (0,39)
PD cases 0,07 (0,16) 0,91 (0,92) 0,96 (1,04) 1,46 (1,12) 0,33 (0,44) 0,91 (1,03) 0,94 (0,90) 0,41 (0,49) 1,21 (1,24) 0,80 (0,54)
p-value 0,841 0,841 0,841 0,421 0,841 0,310 0,151 0,548 0,095 0,421
Figure XVI. Graphical representation of the results detailed in Table CI.
Blood
Table CJ. Mean percentages of DNA methylation (and the standard deviation) per position.
Position 1 2 3 4 5 6 7 8 9 Overall
Other PD cases 1,57 (0,82) 1,31 (1,00) 0,71 (0,71) 0,57 (0,54) 1,34 (0,52) 1,05 (0,62) 0,77 (0,49) 3,31 (1,74) 1,13 (0,79) 1,31 (0,45)
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Annex VI. Quantitation of DNA methylation levels in promoters of genes responsible for familial Parkinson´s disease. Pilot analysis.
LRRK2  2
Occipital cortex
Table CK. Mean percentages of DNA methylation (and the standard deviation) per position and group. The statistical results are also described.
Position 1 2 3 4 5 6 7 8 9 Overall
Healthy controls 0,11 (0,16) 1,20 (1,58) 0,75 (0,61) 0,72 (1,08) 0,28 (0,62) 1,44 (3,02) 1,01 (1,10) 0,69 (0,59) 0,51 (0,75) 0,75 (0,83)
PD cases 0,33 (0,38) 0,63 (0,70) 1,24 (1,12) 0,60 (0,76) 1,29 (1,87) 0,65 (0,77) 0,44 (0,59) 1,57 (2,42) 0,20 (0,37) 0,77 (0,67)
p-value 0,421 0,690 0,421 0,690 0,222 0,421 0,841 1,000 0,690 0,690
Figure XVII. Graphical representation of the results detailed in Table CK.
Blood
Table CL. Mean percentages of DNA methylation (and the standard deviation) per position.
Position 1 2 3 4 5 6 7 8 9 Overall
Other PD cases 1,57 (0,82) 1,31 (1,00) 0,71 (0,71) 0,57 (0,54) 1,34 (0,52) 1,05 (0,62) 0,77 (0,49) 3,31 (1,74) 1,13 (0,79) 1,31 (0,45)
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Annex VI. Quantitation of DNA methylation levels in promoters of genes responsible for familial Parkinson´s disease. Pilot analysis.
LRRK2  2
Substantia nigra
Table CM. Mean percentages of DNA methylation (and the standard deviation) per position and group. The statistical results are also described.
Position 1 2 3 4 5 6 7 8 9 Overall
Healthy controls 0,32 (0,21) 0,44 (0,67) 0,27 (0,32) 0,80 (0,76) 0,38 (0,49) 0,74 (0,80) 1,41 (0,42) 1,08 (0,18) 1,36 (0,99) 0,76 (0,25)
PD cases 0,61 (0,44) 0,27 (0,43) 0,29 (0,64) 0,48 (0,29) 0,35 (0,34) 0,78 (0,33) 0,94 (0,35) 0,97 (0,57) 0,49 (0,80) 0,58 (0,17)
p-value 0,413 0,905 0,905 0,556 1,000 0,556 0,190 0,730 0,286 0,190
Figure XVIII. Graphical representation of the results detailed in Table CM.
Blood
Table CN. Mean percentages of DNA methylation (and the standard deviation) per position.
Position 1 2 3 4 5 6 7 8 9 Overall
Other PD cases 1,57 (0,82) 1,31 (1,00) 0,71 (0,71) 0,57 (0,54) 1,34 (0,52) 1,05 (0,62) 0,77 (0,49) 3,31 (1,74) 1,13 (0,79) 1,31 (0,45)
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Annex VI. Quantitation of DNA methylation levels in promoters of genes responsible for familial Parkinson´s disease. Pilot analysis.
PINK1  2
Parietal cortex
Table CO. Mean percentages of DNA methylation (and the standard deviation) per position and group. The statistical results are also described.
Position 1 2 3 4 5 Overall
Healthy controls 0,03 (0,08) 0,14 (0,16) 0,24 (0,33) 0 0 0,08 (0,07)
PD cases 0 0,14 (0,18) 0,14 (0,31) 0 0,08 (0,18) 0,07 (0,08)
p-value 0,690 1,000 0,690 1,000 0,690 0,841
Figure XIX. Graphical representation of the results detailed in Table CO.
Blood
Table CP. Mean percentages of DNA methylation (and the standard deviation) per position.
Position 1 2 3 4 5 Overall
Other PD cases 0,72 (1,07) 0,09 (0,24) 0,04 (0,10) 0,14 (0,25) 0,01 (0,05) 0,20 (0,30)
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Annex VI. Quantitation of DNA methylation levels in promoters of genes responsible for familial Parkinson´s disease. Pilot analysis.
PINK1  2
Occipital cortex
Table CQ. Mean percentages of DNA methylation (and the standard deviation) per position and group. The statistical results are also described.
Position 1 2 3 4 5 Overall
Healthy controls 0 0,03 (0,04) 0,58 (0,57) 0,06 (0,14) 0 0,13 (0,14)
PD cases 0,21 (0,47) 0,11 (0,19) 0 0,01 (0,03) 0 0,07 (0,10)
p-value 0,690 0,690 0,222 1,000 1,000 0,421
Figure XX. Graphical representation of the results detailed in Table CQ.
Blood
Table CR. Mean percentages of DNA methylation (and the standard deviation) per position.
Position 1 2 3 4 5 Overall
Other PD cases 0,72 (1,07) 0,09 (0,24) 0,04 (0,10) 0,14 (0,25) 0,01 (0,05) 0,20 (0,30)
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Annex VI. Quantitation of DNA methylation levels in promoters of genes responsible for familial Parkinson´s disease. Pilot analysis.
PINK1  2
Substantia nigra
Table CS. Mean percentages of DNA methylation (and the standard deviation) per position and group. The statistical results are also described.
Position 1 2 3 4 5 Overall
Healthy controls 0,18 (0,21) 0,28 (0,20) 0,64 (0,18) 0 0 0,22 (0,07)
PD cases 0 0,04 (0,06) 0,79 (0,32) 0 0 0,17 (0,06)
p-value 0,286 0,016 0,556 1,000 1,000 0,286
Figure XXI. Graphical representation of the results detailed in Table CS.
Blood
Table CT. Mean percentages of DNA methylation (and the standard deviation) per position.
Position 1 2 3 4 5 Overall
Other PD cases 0,72 (1,07) 0,09 (0,24) 0,04 (0,10) 0,14 (0,25) 0,01 (0,05) 0,20 (0,30)
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Annex VI. Quantitation of DNA methylation levels in promoters of genes responsible for familial Parkinson´s disease. Pilot analysis.
PRKN  1
Parietal cortex
Table CU. Mean percentages of DNA methylation (and the standard deviation) per position and group. The statistical results are also described.
Position 1 2 3 4 Overall
Healthy controls 1,77 (1,39) 0,49 (0,45) 0,95 (1,39) 0,57 (0,79) 0,94 (0,68)
PD cases 1,83 (2,22) 0,22 (0,16) 0,39 (0,78) 0,45 (0,63) 0,72 (0,68)
p-value 0,841 0,421 0,841 0,841 0,548
Figure XXII. Graphical representation of the results detailed in Table CU.
Blood
Table CV. Mean percentages of DNA methylation (and the standard deviation) per position.
Position 1 2 3 4 Overall
Other PD cases 0,65 (0,41) 0,26 (0,26) 1,15 (2,09) 0,46 (0,39) 0,63 (0,59)
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Annex VI. Quantitation of DNA methylation levels in promoters of genes responsible for familial Parkinson´s disease. Pilot analysis.
PRKN  1
Occipital cortex
Table CW. Mean percentages of DNA methylation (and the standard deviation) per position and group. The statistical results are also described.
Position 1 2 3 4 Overall
Healthy controls 1,17 (1,04) 0,48 (0,63) 0,30 (0,60) 0,26 (0,51) 0,55 (0,51)
PD cases 1,61 (1,41) 0,59 (0,68) 0,57 (1,27) 0,60 (0,95) 0,84 (0,78)
p-value 0,690 0,548 0,841 0,690 0,548
Figure XXIII. Graphical representation of the results detailed in Table CW.
Blood
Table CX. Mean percentages of DNA methylation (and the standard deviation) per position.
Position 1 2 3 4 Overall
Other PD cases 0,65 (0,41) 0,26 (0,26) 1,15 (2,09) 0,46 (0,39) 0,63 (0,59)
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Annex VI. Quantitation of DNA methylation levels in promoters of genes responsible for familial Parkinson´s disease. Pilot analysis.
PRKN  1
Substantia nigra
Table CY. Mean percentages of DNA methylation (and the standard deviation) per position and group. The statistical results are also described.
Position 1 2 3 4 Overall
Healthy controls 1,06 (0,76) 0,34 (0,64) 1,50 (0,40) 0,15 (0,30) 0,76 (0,18)
PD cases 1,54 (1,01) 0,51 (0,28) 0,29 (0,41) 0,40 (0,56) 0,68 (0,24)
p-value 0,556 0,286 0,016 0,556 0,730
Figure XXIV. Graphical representation of the results detailed in Table CY.
Blood
Table CZ. Mean percentages of DNA methylation (and the standard deviation) per position.
Position 1 2 3 4 Overall
Other PD cases 0,65 (0,41) 0,26 (0,26) 1,15 (2,09) 0,46 (0,39) 0,63 (0,59)
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Annex VI. Quantitation of DNA methylation levels in promoters of genes responsible for familial Parkinson´s disease. Pilot analysis.
PRKN  2
Parietal cortex
Table DA. Mean percentages of DNA methylation (and the standard deviation) per position and group. The statistical results are also described.
Position 1 2 3 4 5 6 7 8 9 Overall
Healthy controls 0,59 (0,60) 0,99 (0,44) 0,08 (0,18) 0,68 (0,26) 0,48 (0,27) 0,39 (0,35) 0,81  (0,26) 0,70 (0,12) 0,78 (0,43) 0,61 (0,20)
PD cases 0,16 (0,18) 0,67 (0,10) 0,10 (0,09) 0,71 (0,11) 0,55 (0,21) 0,05 (0,11) 0,71 (0,04) 0,65 (0,09) 0,56 (0,07) 0,46 (0,02)
p-value 0,222 0,222 0,151 0,841 0,690 0,032 0,421 0,310 0,548 0,151
Figure XXV. Graphical representation of the results detailed in Table DA.
Blood
Table DB. Mean percentages of DNA methylation (and the standard deviation) per position.
Position 1 2 3 4 5 6 7 8 9 Overall
Other PD cases 0,09 (0,16) 0,71 (0,30) 0 0 0,40 (0,25) 0,01 (0,04) 0,69 (0,30) 0,59 (0,25) 0,00 0,28 (0,12)
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Annex VI. Quantitation of DNA methylation levels in promoters of genes responsible for familial Parkinson´s disease. Pilot analysis.
PRKN  2
Occipital cortex
Table DC. Mean percentages of DNA methylation (and the standard deviation) per position and group. The statistical results are also described.
Position 1 2 3 4 5 6 7 8 9 Overall
Healthy controls 0,36 (0,35) 0,44 (0,31) 0,16 (0,23) 0,33 (0,33) 0,27 (0,22) 0,31 (0,30) 0,60 (0,16) 0,47 (0,36) 0,22 (0,31) 0,35 (0,16)
PD cases 0,26 (0,17) 0,05 (0,10) 0 0,33 (0,19) 0,26 (0,28) 0 0,25 (0,34) 0,25 (0,34) 0,30 (0,41) 0,19 (0,15)
p-value 0,690 0,032 0,310 1,000 1,000 0,056 0,151 0,310 0,841 0,222
Figure XXVI. Graphical representation of the results detailed in Table DC.
Blood
Table DD. Mean percentages of DNA methylation (and the standard deviation) per position.
Position 1 2 3 4 5 6 7 8 9 Overall
Other PD cases 0,09 (0,16) 0,71 (0,30) 0 0 0,40 (0,25) 0,01 (0,04) 0,69 (0,30) 0,59 (0,25) 0,00 0,28 (0,12)
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Annex VI. Quantitation of DNA methylation levels in promoters of genes responsible for familial Parkinson´s disease. Pilot analysis.
PRKN  2
Substantia nigra
Table DE. Mean percentages of DNA methylation (and the standard deviation) per position and group. The statistical results are also described.
Position 1 2 3 4 5 6 7 8 9 Overall
Healthy controls 0,88 (0,51) 1,97 (1,35) 0,56 (0,49) 0,86 (0,71) 1,19 (0,88) 0,76 (0,57) 0,98 (0,86) 0,72 (0,53) 0,70 (0,24) 0,95 (0,25)
PD cases 0,32 (0,25) 0,68 (0,45) 0,10 (0,22) 0,76 (0,54) 0,81 (0,55) 0,29 (0,34) 0,72 (0,15) 0,64 (0,18) 0,43 (0,36) 0,53 (0,22)
p-value 0,111 0,063 0,063 0,730 0,905 0,286 0,905 0,730 0,286 0,063
Figure XXVII. Graphical representation of the results detailed in Table DE.
Blood
Table DF. Mean percentages of DNA methylation (and the standard deviation) per position.
Position 1 2 3 4 5 6 7 8 9 Overall
Other PD cases 0,09 (0,16) 0,71 (0,30) 0 0 0,40 (0,25) 0,01 (0,04) 0,69 (0,30) 0,59 (0,25) 0,00 0,28 (0,12)
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Annex VI. Quantitation of DNA methylation levels in promoters of genes responsible for familial Parkinson´s disease. Pilot analysis.
SNCA  1
Parietal cortex
Table DG. Mean percentages of DNA methylation (and the standard deviation) per position and group. The statistical results are also described.
Position 1 2 3 4 5 6 Overall
Healthy controls 0,21 (0,47) 0,11 (0,17) 0,56 (0,41) 0,37 (0,82) 0,74 (1,06) 0,72 (0,54) 0,45 (0,25)
PD cases 0,29 (0,31) 0,09 (0,13) 1,44 (0,18) 0,11 (0,17) 0,17 (0,19) 2,13 (0,65) 0,70 (0,16)
p-value 0,310 1,000 0,008 0,548 0,310 0,016 0,095
Figure XXVIII. Graphical representation of the results detailed in Table DG.
Blood
Table DH. Mean percentages of DNA methylation (and the standard deviation) per position.
Position 1 2 3 4 5 6 Overall
Other PD cases 3,62 (3,01) 2,49 (2,31) 2,20 (2,53) 1,77 (1,31) 1,44 (1,08) 1,56 (1,13) 2,18 (1,76)
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Annex VI. Quantitation of DNA methylation levels in promoters of genes responsible for familial Parkinson´s disease. Pilot analysis.
SNCA  1
Occipital cortex
Table DI. Mean percentages of DNA methylation (and the standard deviation) per position and group. The statistical results are also described.
Position 1 2 3 4 5 6 Overall
Healthy controls 1,25 (1,45) 0,71 (0,70) 1,08 (0,91) 0,83 (0,99) 0,32 (0,55) 1,25 (0,78) 0,91 (0,81)
PD cases 0,73 (1,04) 0,53 (0,73) 0,90 (0,59) 0,20 (0,42) 0,51 (0,68) 0,62 (0,79) 0,58 (0,56)
p-value 0,841 1,000 1,000 0,151 0,690 0,421 0,548
Figure XXIX. Graphical representation of the results detailed in Table DI.
Blood
Table DJ. Mean percentages of DNA methylation (and the standard deviation) per position.
Position 1 2 3 4 5 6 Overall
Other PD cases 3,62 (3,01) 2,49 (2,31) 2,20 (2,53) 1,77 (1,31) 1,44 (1,08) 1,56 (1,13) 2,18 (1,76)
95
0
0,5
1
1,5
2
2,5
3
1 2 3 4 5 6 Overall
%
 m
e
th
yl
at
io
n
 
Position 
Healthy controls
PD cases
 
Annex VI. Quantitation of DNA methylation levels in promoters of genes responsible for familial Parkinson´s disease. Pilot analysis.
SNCA  1
Substantia nigra
Table DK. Mean percentages of DNA methylation (and the standard deviation) per position and group. The statistical results are also described.
Position 1 2 3 4 5 6 Overall
Healthy controls 2,59 (1,85) 1,69 (1,75) 2,18 (1,87) 2,45 (2,51) 0,80 (0,82) 1,98 (1,78) 1,95 (1,69)
PD cases 1,25 (1,49) 0,93 (1,00) 0,22 (0,34) 0,67 (0,87) 0,39 (0,62) 0 0,58 (0,66)
p-value 0,286 0,730 0,190 0,413 0,556 0,016 0,190
Figure XXX. Graphical representation of the results detailed in Table DK.
Blood
Table DL. Mean percentages of DNA methylation (and the standard deviation) per position.
Position 1 2 3 4 5 6 Overall
Other PD cases 3,62 (3,01) 2,49 (2,31) 2,20 (2,53) 1,77 (1,31) 1,44 (1,08) 1,56 (1,13) 2,18 (1,76)
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Annex VI. Quantitation of DNA methylation levels in promoters of genes responsible for familial Parkinson´s disease. Pilot analysis.
SNCA  2
Parietal cortex
Table DM. Mean percentages of DNA methylation (and the standard deviation) per position and group. The statistical results are also described.
Position 1 2 3 4 5 6 7 8 Overall
Healthy controls 2,24 (1,62) 2,36 (0,98) 2,67 (1,21) 0,70 (0,72) 2,60 (1,19) 1,70 (1,67) 2,06 (1,42) 0,59 (0,79) 1,87 (0,77)
PD cases 1,47 (0,73) 1,74 (0,99) 1,45 (0,45) 0,11 (0,24) 1,41 (0,83) 0,85 (0,92) 2,23 (1,06) 0,05 (0,10) 1,16 (0,44)
p-value 0,548 0,310 0,151 0,222 0,421 0,548 1,000 0,310 0,151
Figure XXXI. Graphical representation of the results detailed in Table DM.
Blood
Table DN. Mean percentages of DNA methylation (and the standard deviation) per position.
Position 1 2 3 4 5 6 7 8 Overall
Other PD cases 3,21 (2,03) 5,77 (3,29) 5,48 (3,43) 1,39 (1,83) 2,86 (2,16) 3,11 (2,58) 3,24 (2,10) 0,34 (0,36) 3,17 (1,65)
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Annex VI. Quantitation of DNA methylation levels in promoters of genes responsible for familial Parkinson´s disease. Pilot analysis.
SNCA  2
Occipital cortex
Table DO. Mean percentages of DNA methylation (and the standard deviation) per position and group. The statistical results are also described.
Position 1 2 3 4 5 6 7 8 Overall
Healthy controls 3,32 (3,26) 3,53 (1,45) 5,29 (4,52) 1,72 (1,69) 2,20 (1,36) 0,74 (1,02) 2,74 (1,07) 0,85 (1,01) 2,55 (1,53)
PD cases 1,69 (1,58) 1,15 (1,35) 1,11 (0,77) 0,19 (0,35) 1,57 (0,61) 0,43 (0,63) 1,44 (0,27) 0,01 (0,02) 0,95 (0,35)
p-value 0,548 0,032 0,095 0,310 0,421 0,841 0,008 0,222 0,095
Figure XXXII. Graphical representation of the results detailed in Table DO.
Blood
Table DP. Mean percentages of DNA methylation (and the standard deviation) per position.
Position 1 2 3 4 5 6 7 8 Overall
Other PD cases 3,21 (2,03) 5,77 (3,29) 5,48 (3,43) 1,39 (1,83) 2,86 (2,16) 3,11 (2,58) 3,24 (2,10) 0,34 (0,36) 3,17 (1,65)
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Annex VI. Quantitation of DNA methylation levels in promoters of genes responsible for familial Parkinson´s disease. Pilot analysis.
SNCA  2
Substantia nigra
Table DQ. Mean percentages of DNA methylation (and the standard deviation) per position and group. The statistical results are also described.
Position 1 2 3 4 5 6 7 8 Overall
Healthy controls 3,05 (1,36) 1,95 (1,94) 3,51 (3,32) 2,07 (2,30) 1,06 (0,87) 1,72 (1,32) 2,88 (2,73) 3,01 (2,88) 2,40 (0,77)
PD cases 0,60 (1,35) 1,94 (1,30) 2,25 (1,60) 0,45 (0,42) 2,29 (2,04) 2,65 (1,97) 3,09 (2,47) 0,10 (0,20) 1,67 (0,34)
p-value 0,111 1,000 0,556 0,190 0,413 0,556 1,000 0,016 0,111
Figure XXXIII. Graphical representation of the results detailed in Table DQ.
Blood
Table DR. Mean percentages of DNA methylation (and the standard deviation) per position.
Position 1 2 3 4 5 6 7 8 Overall
Other PD cases 3,21 (2,03) 5,77 (3,29) 5,48 (3,43) 1,39 (1,83) 2,86 (2,16) 3,11 (2,58) 3,24 (2,10) 0,34 (0,36) 3,17 (1,65)
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Annex VI. Quantitation of DNA methylation levels in promoters of genes responsible for familial Parkinson´s disease. Pilot analysis.
SNCA  3
Parietal cortex
Table DS. Mean percentages of DNA methylation (and the standard deviation) per position and group. The statistical results are also described.
Position 1 2 3 4 5 Overall
Healthy controls 2,46 (1,53) 1,09 (0,93) 1,72 (0,95) 0,77 (0,31) 1,50 (0,57) 1,51 (0,71)
PD cases 2,70 (3,03) 1,21 (1,35) 1,08 (1,25) 0,67 (0,42) 1,09 (0,86) 1,35 (1,36)
p-value 0,841 0,841 0,310 1,000 0,421 0,841
Figure XXXIV. Graphical representation of the results detailed in Table DS.
Blood
Table DT. Mean percentages of DNA methylation (and the standard deviation) per position.
Position 1 2 3 4 5 Overall
Other PD cases 2,03 (1,12) 2,36 (1,48) 2,20 (0,97) 2,46 (1,20) 2,45 (1,24) 2,30 (0,74)
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Annex VI. Quantitation of DNA methylation levels in promoters of genes responsible for familial Parkinson´s disease. Pilot analysis.
SNCA  3
Occipital cortex
Table DU. Mean percentages of DNA methylation (and the standard deviation) per position and group. The statistical results are also described.
Position 1 2 3 4 5 Overall
Healthy controls 1,43 (1,42) 1,41 (1,23) 1,27 (1,19) 0,69 (0,80) 1,38 (1,02) 1,24 (1,00)
PD cases 4,76 (2,62) 2,73 (1,50) 1,73 (1,27) 1,24 (0,71) 1,03 (0,99) 2,30 (1,31)
p-value 0,095 0,222 0,548 0,548 0,421 0,310
Figure XXXV. Graphical representation of the results detailed in Table DU.
Blood
Table DV. Mean percentages of DNA methylation (and the standard deviation) per position.
Position 1 2 3 4 5 Overall
Other PD cases 2,03 (1,12) 2,36 (1,48) 2,20 (0,97) 2,46 (1,20) 2,45 (1,24) 2,30 (0,74)
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Annex VI. Quantitation of DNA methylation levels in promoters of genes responsible for familial Parkinson´s disease. Pilot analysis.
SNCA  3
Substantia nigra
Table DW. Mean percentages of DNA methylation (and the standard deviation) per position and group. The statistical results are also described.
Position 1 2 3 4 5 Overall
Healthy controls 1,76 (1,42) 3,89 (1,35) 2,73 (0,96) 2,57 (0,97) 1,75 (0,29) 2,54 (0,69)
PD cases 3,44 (4,30) 4,55 (1,68) 3,64 (1,82) 2,02 (0,88) 1,99 (1,16) 3,13 (1,89)
p-value 1,000 0,730 0,413 0,556 0,730 1,000
Figure XXXVI. Graphical representation of the results detailed in Table DW.
Blood
Table DX. Mean percentages of DNA methylation (and the standard deviation) per position.
Position 1 2 3 4 5 Overall
Other PD cases 2,03 (1,12) 2,36 (1,48) 2,20 (0,97) 2,46 (1,20) 2,45 (1,24) 2,30 (0,74)
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